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both at the Department of Chemistry, DTU and during a nine months external stay in the Stoltz 
group at the California Institute of Technology (Caltech).   
 
The dissertation is divided into six chapters (excluding appendices etc.) detailing subjects related to 
the intertwined fields of method development and organic synthesis. Chapters one to four are 
concerned with projects conducted at DTU, while chapter five describes work carried out at Caltech. 
Finally, chapter six provides a brief summary. The chapters can be read independently, however, the 
first chapter describing previous synthetic efforts toward (+)-castanospermine can be read as a 
prelude to chapter two featuring our synthetic endeavors on (+)-castanospermine. Chapter three 
provides a brief introduction to natural product inspired drug discovery, covers the biology of 
pladienolide B, and details our development of a synthetic strategy to the macrocyclic core of (−)-
pladienolide B. Chapter four is concerned with the development of a ruthenium-catalyzed method to 
alkylate the 3-position of oxindoles. Chapter five describes our studies toward an asymmetric total 
synthesis of the sesterterpenoid variecolin.      
 
Several people have had a significant impact on the projects described in this dissertation. First I 
would like to express my gratitude to my supervisor Professor Robert Madsen for always taking the 
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techniques of method development in transition-metal catalyzed organic reactions, and for giving 
me great advice over the years. Additionally, I would like to thank Dr. Philip R Skaanderup for 
providing me with an opportunity to work on the pladienolides and for his support through out 
critical stages of the project. Special thanks go to Johan H. Dam for sharing the lab, for numerous 
discussions on mechanistic problems and the latest developments in chemistry, and for great 
company. Assistant Professor Peter Fristrup is thanked for great collaborations and for the 
occasional burger at Hamburger Hamlet during the Caltech times. Finally, the entire Madsen group, 
as well as people at the Department of Chemistry building 201, is acknowledged for invaluable help 
and for creating a great working atmosphere. 
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gifted chemist and great guy, who was my partner on the variecolin project. The entire Stoltz group 
is thanked for making the stay memorable and fruitful. I really enjoyed sharing the lab with Jenn 
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Abstract 
Project 1: The Total Synthesis of (+)-Castanospermine 
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2 steps 4 steps 3 steps
(22% yield, 9 steps)  
A novel synthesis of (+)-castanospermine has been achieved starting from methyl α-D-
glucopyranoside. The powerful α- and β-glucosidase inhibitor was synthesized in 9 steps with 22% 
overall yield, which constitutes the shortest chiral pool approach to this target. The 
octahydroindolizidine skeleton of (+)-castanospermine was constructed by the sequential use of a 
medium ring metathesis reaction, a diastereoselective epoxidation, and a strain-releasing 
transannular cyclization. The prerequisite diene was available from a zinc-mediated reductive 
fragmentation of methyl 6-deoxy-6-iodo-α-D-glucopyranoside followed by reductive amination.  
 
Project 2: Synthesis of the Macrocyclic Core of (−)-Pladienolide B 
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macrocyclic core of
(−)-Pladienolide Bnerol
8 steps5 steps 3 steps
(6.5% yield, 16 steps)  
An efficient synthesis of the macrocyclic core of (−)-pladienolide B was achieved. The concise route 
relied on chiral auxiliary-mediated asymmetric aldol addition and Sharpless asymmetric 
dihydroxylation to install the three oxygen substituted stereocenters of the macrocycle. (E)-Selective 
cross metathesis followed by Yamaguchi-macrolactonization was implemented to install the 12-
membered lactone and orthoester ring-opening was strategically applied to complete the synthesis. 
This purely reagent controlled and flexible strategy provides an excellent starting point for analog 
syntheses and structure activity relationship plotting of the appealing anticancer lead structure 
pladienolide B.  
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Project 3: Ruthenium-Catalyzed 3-Alkylation of Oxindoles 
R1OH (1.1 equiv)
[RuCl3  xH2O] (2.0 mol%) 
PPh3 (4.0 mol%)
NaOH (10 mol%)
110 oC, 20 h
21 examples, 71-92% yield
N
O
R2
R2 = H, Bn, PMB
N
O
R2
R1
 
A highly efficient protocol based on a hydrogen autotransfer process to directly alkylate the C(3) 
position of oxindole utilizing alcohols has been developed. The reaction required in general 2.0 
mol% of [RuCl3·xH2O], 4.0 mol% PPh3 and 10 mol% sodium hydroxide to afford full conversion at 
110 oC under neat reaction conditions. Importantly, this reaction provides a simple and highly atom-
economical protocol to alkylate oxindoles. The reaction was highly selective for the formation of 
C(3) substituted oxindoles. This transformation was tolerant toward a relatively wide range of 
functional groups and could be applied to o-, m-, and p-substituted benzyl alcohols, several aromatic 
heterocycles, primary and secondary aliphatic alcohols.  
 
Project 4: Studies Toward the Asymmetric Total Synthesis of Variecolin 
O
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I
OO
D-ring fragment
33% yield, 9 steps
88% ee
AB-ring fragment
2.9% yield, 12 steps
99% ee
O
O 5 steps
Variecolin model
34% yield, 5 steps
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H
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Efficient synthetic routes to an enantiopure AB-ring fragment and an enantioenriched D-ring 
fragment for the total synthesis of the sesterterpenoid variecolin has been developed. The central 
eight-membered ring of the AB fragment was constructed implementing the tandem Wolff-Cope 
rearrangement. Synthesis of the D-ring fragment was achieved utilizing the enantioselective 
decarboxylative allylation to construct the all-carbon quaternary stereocenter and a retro-aldol-aldol 
ring contraction to form the five-membered ring. Synthetic studies on the late stage coupling of a 
model AB-ring fragment and the D-ring fragment have revealed that these fragments can be 
convergently combined through a 1,4-hydrosilylation-alkylation sequence followed by conjugate 
radical cyclization. 
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Projekt 1: Totalsyntese af (+)-Castanospermine 
O
OMe
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F3C
O
2 trin 4 trin 3 trin
(22% udbytte, 9 trin)  
 
En ny syntese til fremstilling af (+)-castanospermine med methyl α-D-glukopyranosid som 
udgangsstof er blevet udviklet. Denne potente α- og β-glukosidase inhibitor er blevet syntetiseret i 9 
trin og 22% overordnet udbytte, hvilket udgør den hidtil korteste syntese af (+)-castanospermine 
startende fra chiralt materiale. Octahydroindolizidinskellet af (+)-castanospermine blev bygget vha. 
medium ringslutningsmetatese, diastereoselektiv epoxidering og transannular cyklisering. Dienen til 
ringslutningsmetatesen blev fremstillet vha. zink-medieret reduktiv fragmentering af methyl 6-
deoxy-6-iod-α-D-glukopyranosid og efterfølgende reduktiv aminering.  
 
Projekt 2: Syntese af den Makrocykliske Kerne af (−)-Pladienolide B 
OTBSN
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makrocyklisk kerne af
(−)-Pladienolide Bnerol
8 trin5 trin 3 trin
(6.5% udbytte, 16 trin)  
En effektiv syntese af den makrocyklisk kerne af (−)-pladienolide B er blevet udviklet. Syntesen 
anvendte en auxiliary-medieret asymmetrisk aldolkondensation og Sharpless asymmetrisk 
dihydroxylering til at installere de tre oxygen-substituerede stereocentre på makrocyklen. (E)-
Selektiv krydsmetatese efterfulgt af Yamaguchi-makrolaktonisering blev benyttet til at konstruere 
den 12-leddede lakton, og endelig blev regioselektiv ortho-ester-åbning anvendt til at fuldføre 
syntesen. Denne reagens-kontrollerede og fleksible syntesestrategi udgør et glimrende udgangspunkt 
for syntese af analoger og struktur-aktivitets studier af det lovende anticancerstof pladienolide B.    
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Projekt 3: Ruthenium-Katalyseret 3-Alkylering af Oxindoler 
R1OH (1.1 ækvivalenter)
[RuCl3  xH2O] (2.0 mol%) 
PPh3 (4.0 mol%)
NaOH (10 mol%)
110 oC, 20 h
21 eksempler, 71-92% udbytte
N
O
R2
R2 = H, Bn, PMB
N
O
R2
R1
 
En effektiv ny metode til at alkylere C(3)-positionen af oxindoler baseret på overgangsmetal-
katallyseret hydrogenoverførsel er blevet udviklet. Generelt krævede reaktionen 2.0 mol% 
[RuCl3·xH2O], 4.0 mol% PPh3 og 10 mol% natriumhydroxid  for at opnå fuld omsætning. 
Reaktionen udgør en simple og atomøkonomisk metode til at alkylere oxindoler. Denne reaktion er 
kompatibel med en relativt bred vifte af funktionelle grupper og kunne udføres med o-, m-, og p-
substituerede benzylalkoholer, adskillige heteroaromatiske alcoholer, samt primære og sekundære 
alifatiske alkoholer. 
  
Projekt 4: Syntesestudier mod en Asymmetrisk Totalsyntese af Variecolin 
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Der er blevet udviklet effektive synteseveje til et enantiomerisk rent AB-fragment og et D-fragment 
beriget i den ene enantiomer, som en del af totalsyntesen imod sesterterpenoidet variecolin. Den 
centrale otte-leddede ring i AB-fragmentet blev bygget vha. en tandem Wolff-Cope-omlejring. 
Syntesen af D-fragmentet blev gennemført ved brug af en enantioselektiv decarboxylativ allylering 
til at installere det kvarternære stereocenter og en retro-aldol-aldol sekvens til at danne den fem-
leddede ring. Studier af koblingen mellem en model for AB-fragmentet og D-fragmentet viste, at 
disse kunne kombineres konvergent ved anvendelse af en 1,4-hydrosilylering-alkyleringssekevens, 
efterfulgt af en konjugeret radikalcyklisering 
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1 Biology and Synthetic Approaches to (+)-Castanospermine 
Due to its highly interesting biological profile and intriguing structural complexity, (+)-
castanospermine has been the subject of numerous total syntheses since the original isolation in 
1981. These syntheses commence from either a carbohydrate,1-13 tartaric/malic acid14-16 or an achiral 
material employing an enantioselective strategy.17-22 The synthetic approaches to stereoisomers and 
analogs of (+)-castanospermine before 1996 have been subject to excellent reviews by Burgess and 
Henderson23 and Tyler and Winchester.24 Later approaches have been summarized in general 
reviews on indolizidine and quinolizidine alkaloids by Michael.25-36 Therefore the scope of the 
present chapter is to provide an overview of the syntheses reported since 1996 focusing exclusively 
on approaches to (+)-castanospermine. Moreover, the purpose of this review is to provide a brief 
introduction to the biology of (+)-castanospermine and to analyze the syntheses critically in a 
chronological order with particular focus on how the characteristic indolizidine skeleton was 
constructed. Initially, “chiral pool” syntheses starting from carbohydrates will be analyzed, and then 
syntheses starting from (−)-malic acid. Finally, this review describes the enantioselective syntheses 
starting from achiral materials.    
 
1.1 Isolation and Biological Background 
(+)-Castanospermine (1.1) was first isolated in 1981 from the seeds of the Moreton Bay chestnut 
Castanospermum australe by Hohenschutz and co-workers37 and later from the dry pods of Alexa 
leiopetala.38 In the original report, the absolute stereochemistry of (+)-castanospermine (1.1) was 
arbitrarily chosen as one enantiomer, however, the total synthesis by Ganem and Bernotas1 
unambiguously established the absolute stereochemistry as depicted in 1.1. (+)-Castanospermine 
(1.1) belongs to a family of naturally occurring polyhydroxylated indolizidine alkaloids (Figure 1.1) 
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Figure 1.1 A selection of naturally occurring indolizidine alkaloids. 
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(+)-Castanospermine (1.1) has been shown to be a potent inhibitor of several glycosidases.39-41 
Furthermore, studies have demonstrated that (+)-castanospermine (1.1) has potential for treatment of 
viral infections,42 various cancer types,43 and diabetes.44 Additionally, 1.1 has displayed anti-
inflammatory45 and immunosuppressant properties.46 The source of this remarkable plethora of 
biological activity has been ascribed to (+)-castanospermine’s glycosidase inhibitory properties. 
Glycosidases are enzymes recruited to catalyze the hydrolysis of glycosidic bonds. The hydrolysis 
of glycosidic bonds is of crucial importance, since many fundamental processes are governed by 
carbohydrate-mediated information e.g. quality control of protein folding, modulation of cell-cell 
adhesion, and signalling.47 
 
Recent studies have revealed that (+)-castanospermine (1.1) is a potent inhibitor of dengue virus 
infection in vitro and in vivo. Importantly, Diamond and co-workers48 demonstrated that 1.1 
prevented mortality in mice infected with dengue virus, and in vitro studies showed that all four 
serotypes of dengue virus were inhibited. It is believed that 1.1 inhibits the viral infection by 
disrupting the folding of several viral proteins of structural importance. This has been ascribed to 
(+)-castanospermine’s ability to prevent removal of terminal glucose residues on N-linked 
oligosaccharides, which may interrupt interaction with protein folding enzymes.49  
 
In 2004 (+)-castanospermine (1.1) and the ester derivative celgosivir (1.2) were tested as treatment 
for hepatitis C virus (HCV), the major cause of acute hepatitis and chronic liver disease (Figure 1.2). 
Utilizing a plague assay and a cytopathic effect assay Whitby and co-workers50 found that celgosivir 
(IC50 = 16 and 47 μm, respectively) was a more potent inhibitor than (+)-castanospermine (1.1) 
(IC50 = 110 and 367 μm, respectively). Currently, celgosivir in combination with interferon-α and 
ribavirin (two licensed agents for treatment of HCV) is undergoing phase II clinical trials.51 
N
H OH
HO
O
HO
O
Celgosivir (1.2)  
Figure 1.2 (+)-Castanospermine derivative in phase II clinical trials for treatment of chronic HCV. 
 
 
1 Biology and Synthetic Approaches to (+)-Castanospermine 
 3
1.2 Syntheses of (+)-Castanospermine from Carbohydrate Starting Materials 
1.2.1 Mootoo’s Approach 
In a preliminary communication in 1996 and a full paper in 2001, Mootoo and co-workers9,52 
described the total synthesis of (+)-castanospermine starting from aldehyde 1.3 which is available in 
4 steps from methyl α-D-glucopyranoside (Scheme 1.1). The octahydroindolizidine skeleton of (+)-
castanospermine was effectively constructed using a triple reductive amination cascade. The 
stereocenters at C(6), C(7), and C(8) were all derived from methyl α-D-glucopyranoside, while the 
stereocenter at C(1) was forged using a tin-mediated allylation under Barbier conditions.  
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Scheme 1.1 Mootoo’s reductive amination approach to 1.1. 
 
Aldehyde 1.3 was treated with allyl bromide and tin metal under conditions developed by 
Whitesides53 affording the requisite allylated pyranoside 1.4 upon benzyl ether protection.a When 
1.4 was treated with iodonium dicollidine perchlorate (IDCP), a mixture of iodo-tetrahydrofurans 
was obtained,54 which upon exposure to zinc metal and subsequent Swern oxidation afforded 
methoxy acetal 1.5. Ozonolytic cleavage and acetal hydrolysis provided the tricarbonyl species 1.6 
existing as a mixture of lactol isomers 1.7. Fortunately, treating 1.7 with ammonium formate and 
sodium cyanoborohydride followed by global deprotection afforded 1.1 in good yield. The high 
stereoselectivity observed during the reductive amination can be ascribed to preferential α-face 
                                                 
a The allylation led to a 9:1 mixture of alcohol epimers, these were easily separated using silica-gel chromatography. 
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hydride delivery on putative mono- or bicyclic iminium ion intermediates.  In summary, the 
synthesis of 1.1 took place in 9 steps from aldehyde 1.3 with an overall yield of 25% yield. The key 
to this successful and concise synthesis was the realization of a triple reductive amination cascade 
providing the entire indolizidine skeleton in one-pot. 
1.2.2 Pandit’s Approach 
As part of a research program directed toward the synthesis of bicyclic azasugars, Pandit and co-
workers55,56 developed an efficient synthetic route to monocyclic sugar lactams such as 1.8 derived 
from D-glucose (Scheme 1.2). In 1996 this material served as platform for Overkleeft and Pandit’s 
formal total synthesis of 1.1.8 Having already the six-membered moiety of the indolizidine skeleton 
in place, Pandit sought to implement a ring-closing metathesis strategy to forge the five-membered 
ring onto the sugar lactam 1.8. The stereogenic center at C(1) was build utilizing a diastereoselective 
dihydroxylation. 
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1.10 (10 mol%)
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(70% yield)
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2. SOCl2, Et3N
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NaBH4, DMAC
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(98% yield)
1. BH3 DMS
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18a
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1.11
1.12 1.13
1.8
O
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Scheme 1.2 Pandit’s formal total synthesis of 1.1. 
 
Lactam 1.8 was transformed into the RCM precursor 1.9 through a five step sequence. This diene 
was treated with the ruthenium carbene catalyst 1.10 developed by Grubbs57 affording the desired 
bicyclic  lactam 1.11 in good yield. En route to the formal total synthesis, the newly formed double 
bond was oxidized using osmium tetraoxide and N-methylmorpholine N-oxide affording a 
diastereomeric mixture of diols. This mixture was converted into cyclic sulphates via the 
corresponding sulphites. Separation of these sulphates provided the desired product 1.12 in 45% 
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yield along with 9% of the undesired diastereomer (not shown). While the authors did not provide 
an explanation for the stereochemical outcome, it seems reasonable that the C(8a) proton disfavors 
attack at the α-face of the bicyclic lactam due to steric interactions. The resulting sulphate was 
exposed to sodium borohydride which upon hydrolysis gave lactam 1.13. The exquisite 
regioselectivity of the nucleophilic attack was ascribed to exclusive attack at the sterically least 
congested site.  In summary, Pandit has provided a formal total synthesis of 1.1 affording lactam 
1.13 in 11 steps from 1.8 in a 19% overall yield. 
1.2.3 Park’s Approach 
In 2003 Park and co-workers10 disclosed a total synthesis of 1.1 commencing from aminoaldehyde 
1.14 which is available from D-glucono-δ-lactone using methodology developed by the laboratories 
of Vasella58 and Rapoport59 (Scheme 1.3). With 1.14 as entry point for their synthesis, the 
stereogenic centers at C(7), C(8), and C(8a) were already installed with the correct absolute 
configuration, whereas the C(6) stereocenter had to be inverted. Diastereoselective indium-mediated 
allylation was recruited to provide the final stereocenter at C(1). The indolizidine system was build 
in two separate steps employing intramolecular reductive amination to build the five-membered 
ring, and similar to Kang’s approach (cf. chapter 1.3.1) a strain-releasing cyclization of epoxide 1.17 
was deployed to append the six-membered ring.  
O
O
OHHO
HO
HO
NHPf
O
H
H
O
O
O
O
1. allyl bromide, In
    (+)-cinchonine
2. TBSCl, imidazole NHPf
H
O
O
O
O
OTBS 1. O3, DMS
2. H2, Pd(OH)2 (cat.)
3. CbzCl, K2CO3
H
O
O
O
O
N
OTBS
Cbz
N
O
O
O Cbz
H OH
1. Dowex, 50W-X8
    MeOH
2. TBSCl, imidazole
3. MsCl, Et3N
4 TBAF
   then K2CO3
1. H2, Pd/C, NaOAc
2. Dowex 50W-X8 NHO
HO
HO
H OH
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7 steps
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1
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Scheme 1.3 Park’s total synthesis of 1.1. 
 
When aldehyde 1.14 was treated with a preformed allylindium reagent in the presence of (+)-
cinchonine at low temperature, 1.15 was smoothly obtained after TBS-protection. The allylation 
almost exclusively provided the desired diastereomer (dr = 50:1). This exquisite syn diastereo-
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selectivity can be explained invoking the chelation control model described by Cram.60 Ozonolysis 
of the terminal alkene followed by catalytic hydrogenation facilitated one-carbon shortening, 
deprotection and cyclization. After Cbz-protection, the desired pyrrolidine 1.16 was obtained in 
good yield. A deprotection-protection sequence followed by mesylation and silylether cleavage 
furnished epoxide 1.17. Hydrogenolysis of the N-Cbz protecting group was accompanied by ring-
closure to a protected indolizidine, which upon exposure to an acidic ion-exchange resin gave 1.1. 
To summarize, Park attained the total synthesis of 1.1 in 11 steps and 26% overall yield starting 
from aminoaldehyde 1.14.  
1.2.4 Murphy’s Approach 
In 2005 Cronin and Murphy11 disclosed a total synthesis of (+)-castanospermine (1.1) commencing 
from azide 1.18,61,62 which is available in five steps from methyl α-D-glucopyranoside (Scheme 
1.4). The central features of the synthesis were incorporation of an aldol reaction to afford the C(1) 
stereogenic center and a reductive amination cascade to generate the indolizidine ring system and 
concomitantly provide the correct stereochemistry at C(8a). 
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Scheme 1.4 Murphy’s total synthesis of 1.1. 
 
Initially, the alkene 1.19 was generated from azide 1.18. Subsequent epoxidation, acid induced 
methanolysis and Ley oxidation afforded aldehyde 1.20 in 46% yield along with 12% of the epimer 
(not shown). When aldehyde 1.20 was condensed with the lithium enolate of ethyl acetate the β-
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hydroxy esters 1.21 and 1.22 were obtained in 35% and 16% yield, respectively. The minor isomer 
1.22 was carried on to the key amination cascade, which was mediated by hydrogenation over 
Pearlman’s catalyst. The cascade involved reduction of the azide moiety, intramolecular reductive 
amination, debenzylation, and lactam formation providing 1.23 in 62% yield. Furthermore the 
cascade succeeded in installing the correct bridgehead stereochemistry for the target alkaloid. (+)-
Castanospermine (1.1) was obtained from 1.23 via silylation of the free alcohol followed by 
reduction and acidic work-up. In summary, Cronin and Murphy have accessed 1.1 in 9 steps with a 
1.5% overall yield starting from azide 1.18. The relatively low overall yield was primarily caused by 
poor selectivity in the aldol reaction, however, the undesired (major) diastereomer from this step 
could be funneled into a synthesis of 1-epicastanospermine.  
1.2.5 Dhavale’s Approach 
In 1997 Dhavale and co-workers63,64 revealed interest in azasugars exploiting sugar-derived nitrones 
as starting point for their synthetic endeavors. Nine years later, in 2006, these explorations 
culminated in the total synthesis of (+)-castanospermine (1.1).12 The synthesis initiated from nitrone 
1.24 which is available in 5 steps from D-glucose (Scheme 1.5).63,65,66 Three of the five stereocenters 
were attained from D-glucose, while the stereocenters at C(8a) and C(1) were installed using 
diastereoselective vinylmagnesium bromide addition. The octahydroindolizidine skeleton was 
constructed through a mercury-mediated 5-endo-trig cyclization and an intramolecular reductive 
amination. 
 
The synthesis commenced with vinylmagnesium bromide addition to nitrone 1.24 in the presence of 
trimethylsilyl triflate. Two separable isomers were formed in a 13:87 ratio, and the major 
diastereomer was converted into aldehyde 1.25 through an additional three steps. The observed 
selectivity could be explained by invoking the Felkin-Anh selectivity model.67,68 A second 
vinylmagnesium bromide addition afforded a diastereomeric mixture of two vinyloxazolidinones 
1.26 and 1.27 in a 3:1 ratio. Unfortunately, it was the minor isomer 1.27 that possessed the requisite 
stereochemistry. However, the major isomer could be applied in a total synthesis of 1-epi-
castanospermine. Again the selectivity was explained in terms of Felkin-Anh-like transition states. 
Hydrolysis of the minor product 1.27 followed by an aminomercuration-demercuration sequence 
and benzyl protection furnished 1.28 in good yield. Hydrogenolysis of the three benzyl groups 
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followed by Cbz-protection of the amine afforded 1.29, which was poised to undergo intramolecular 
reductive amination to construct the six-membered ring of 1.1. 
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Scheme 1.5 Dhavale’s nitrone based approach to 1.1. 
 
Ultimately, deprotection of the acetonide functionality utilizing trifluoroacetic acid and water 
followed by hydrogenation over palladium on charcoal gave (+)-castanospermine (1.1) in excellent 
yield. To summarize, Dhavale has obtained access to 1.1 in 0.68% overall yield in 12 steps. The 
relatively low overall yield was primarily caused by poor selectivity in the two vinylmagnesium 
bromide additions to 1.24 and 1.25.    
1.2.6 Pyne’s Approach 
In 2004 Pyne and co-workers disclosed a novel strategy for targeting indolizidine alkaloids.69 
Recently, this strategy relying on the diastereoselective Petasis borono-Mannich70 reaction between 
L-xylose, allyl amine and (E)-styrene boronic acid has been implemented in the total synthesis of 
(+)-castanospermine (1.1) (Scheme 1.6).13 The borono-Mannich reaction provided the correct 
stereochemistry at C(8a). The five-membered ring of the indolizidine skeleton was formed in 
analogy with Pandit’s approach (cf. Chapter 1.2.2) using RCM, while the six-membered ring was 
constructed using a Mitsunobu displacement.  
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Scheme 1.6 Pyne’s total synthesis of 1.1. 
 
The amino-tetraol 1.30 attained from the borono-Mannich reaction was converted into oxazolidin-2-
one 1.31 by treatment with triphosgene under basic conditions and subsequent tritylation followed 
by benzylation. From intermediate 1.31, the five-membered ring of the indolizidine structure was 
formed via ring-closing metathesis. syn-Dihydroxylation of 1.33 furnished the desired diol along 
with minor amounts of the undesired diastereomer resulting from α-face dihydroxylation. The diol 
was converted into sulphate 1.34, which in analogy to Pandit's approach (cf. Chapter 1.2.2) afforded 
1.35 upon regioselective reductive ring-opening of the cyclic sulphate and basic hydrolysis of the 
oxazolidinone ring. Triol 1.35 was subjected to Mitsunobu cyclization conditions affording the 
desired amine only in low yield due to competing cyclizations to the free hydroxy groups. 
Ultimately, debenzylation afforded 1.1 in 24% yield. In summary, Pyne have arrived at 1.1 in 11 
steps from L-xylose and 0.9% overall yield. The synthesis rapidly constructs four of the five 
contiguous stereocenters of 1.1, however, the overall efficiency is hampered by unselective 
protecting group manipulations and lack of control during the final cyclization. 
 
1 Biology and Synthetic Approaches to (+)-Castanospermine 
 10
1.3 Synthesis of (+)-Castanospermine from Malic Acid 
1.3.1 Kang’s Approach 
In 1998 Kang and Kim16 disclosed their total synthesis of 1.1. Unlike the majority of the chiral pool 
approaches to (+)-castanospermine (1.1), Kang commenced the synthesis from the triol 1.36, which 
is commercially available or can be synthesized in one step from L-(−)-malic acid (Scheme 1.7). The 
stereogenic centers at C(6) and C(1) were obtained from the chiral triol, whereas the remaining 
stereocenters were installed using a diastereoselective dihydroxylation and a phenylselenyl chloride-
mediated cyclization. The five-membered ring of the octahydroindolizidine system was formed via 
an intramolecular Mitsunobu displacement, and the six-membered ring was constructed employing a 
strain-releasing 6-endo cyclization. 
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Scheme 1.7 Kang’s malic acid based synthesis of 1.1. 
 
Triol 1.36 was transformed into diacetal 1.37 through reaction with p-anisaldehyde in the presence 
of PPTS, Swern oxidation, and Wittig olefination. The p-methoxybenzylidene group was 
chemoselectively hydrolyzed using PPTS in methanol. Subsequent regioselective silylether 
formation, treatment with 2,2,2-trichloacetimdate, and phenylselenyl chloride-mediated cyclization 
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favored the construction of trans-oxazoline 1.38 (trans:cis = 15:1). The high degree of stereocontrol 
during the cyclization was not addressed by the authors, however, a likely explanation is that the 
stereocenter at C(1) induces diastereoselectivity through minimization of A1,3-strain.71 Oxazoline 
1.38 was partially hydrolyzed to the corresponding hydroxy trichloroacetamide, which upon 
oxidative elimination furnished 1.39. Desilylation, Mitsunobu cyclization, and treatment with 
NaOBn afforded pyrrolidine 1.40. Three standard protection group manipulations followed by a 
diastereoselective dihydroxylation gave triol 1.41 in high yield along with minor amounts of the 
isomeric triol (15:1 ratio). The observed diastereoselectivity was in accordance with selectivity 
models proposed by Kishi72,73 and Stork.74 After conversion into epoxide 1.42 removal of the Cbz-
group induced 6-endo cyclization rather than 5-exo cyclization, this was attributed to the anti 
arrangement of the dioxolane ring. Ultimately, HCl-promoted methanolysis afforded 1.1. In 
summary, Kang and Kim have attained 1.1 in 21 steps and 8.1% overall yield. A phenylselenyl 
chloride-mediated cyclization was employed to install the stereocenter at C(8a) constituting a novel 
solution to this synthetic challenge.  
 
1.4 Enantioselective Syntheses of (+)-Castanospermine from Achiral Materials   
1.4.1 Denmark’s Approach 
During the last part of the 1990’s, Denmark and co-workers75-80 investigated the tandem asymmetric 
[4 + 2]/[3 + 2] cycloaddition of nitroalkenes as a general method to synthesize pyrrolidine- and 
pyrrolizidine-containing compounds. In 1999 this tandem reaction was employed in the total 
synthesis of 1.1. (Scheme 1.8)19 A key intermediate in this approach was the nitroso acetal 1.45, 
which also served as entry point to the total synthesis of (+)-6-epicastanospermine, (+)-australine 
and (+)-3-epiaustraline emphasizing the generality of this strategy. The tandem asymmetric             
[4 + 2]/[3 + 2] cycloaddition afforded four of the five contiguous stereocenters. The octahydro-
indolizidine framework was assembled in one step combining hydrogenolytic unmasking of the 
nitroso acetal 1.46, N-alkylation, and reductive amination. 
 
The synthesis commenced by treating 2,5-dihydrofuran 1.43 with n-BuLi to afford a rapid ring-
opening. Silylation of the ensuing lithium alkoxide using di-tert-butylchlorosilyl triflate followed by 
chloride displacement with potassium nitroacetaldehyde gave nitroalkene 1.44. This species was 
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found to be intrinsically unstable losing the nitroalkene fragment when stored at room temperature 
or purified using conventional methods i.e. chromatography and distillation. Hence, Denmark and 
Martinborough decided to purify 1.44 using filtration through Celite. Extensive investigations 
revealed that the crucial [4 + 2]/[3 + 2] cycloaddition could be attained when 1.44 was treated with 
methylaluminum bis(2,6-diphenyloxide) (MAPh) and a chiral vinyl ether followed by heating. The 
desired product 1.45 arose from an exo [4 + 2] cycloaddition with excellent diastereofacial 
selectivity (44:1) and a [3 + 2] cycloaddition proceeding with exclusive exo selectivity and complete 
facial selectivity. The silaketal tether was believed to enforce the exo approach of the dipolarofile to 
the 1,3-dipole from the face to which the tether was attached. 
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Scheme 1.8 Denmark’s [4+2]/[3+2] cycloaddition approach to 1.1. 
 
The final hydroxylated stereogenic center at C(6) was introduced using Sharpless asymmetric 
dihydroxylation in the presence of an anthraquinone ligand (DHQD)2-AQN. This ligand provided 
excellent diastereofacial selectivity, and 1.46 was obtained in 86% yield. With all stereogenic 
centers in place all that remained was formation of the bicyclic indolizidine structure. This was 
attained by activating the primary alcohol of 1.46 using selective tosylation and Raney-Ni catalyzed 
hydrogenolytic unmasking of the nitroso acetal. Ultimately, 1.1 was prepared by exposing the di-
tert-butylsilylene 1.47 to HF in MeOH and subjecting the ensuing fluoride salt to cation-exchange 
chromatography. In summary, Denmark has synthesized 1.1 in 8 steps commencing from 2,5-
dihydrofuran and 18% overall yield. This synthetic approach constitutes the shortest synthesis of 1.1 
reported to date. Despite its initial lability, the silaketal functionality served to afford both excellent 
levels of diastereocontrol and to protect the C(8) and C(1) hydroxy groups.  
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1.4.2 Somfai’s Approach 
In 1998 Somfai81 launched an approach toward polyhydroxylated alkaloids, i.e. aza-sugars, founded 
on enantioselective asymmetric catalysis. Later this strategy was successfully implemented in the 
total synthesis of 1.1 (Scheme 1.9). The six-membered ring of 1.1 was constructed through an 
intramolecular epoxide opening, whereas the five-membered ring was produced through 
intramolecular reductive amination. The stereogenic centers at C(6), C(7), C(8), and C(8a) were 
formed via the successive us of the Sharpless asymmetric dihydroxylation and epoxidation 
protocols, and the final stereocenter at C(1) was set using a Sakurai allylation.  
PMBO
OEt
O
1. AD-mix-α, CH3SO2NH2
2. 2-methoxypropene, p-TsOH (cat.)
3. DIBAL
1. (+)-DIPT, Ti(Oi-Pr)4, TBHP
2. TBDPSCl, Et3N, DMAP
O
O
OH
O
O
OTBDPS
O
OPMB
OPMB
O
O
OTBDPS
O
NH2
O
O
OTBDPS
NH
OH
O
O
CHO
NBn
BnO
O
O NBn
BnO OH
H
O
O NBn
BnO
CHO
OH
H
N
HO
OHH
HO
HO
(72% yield, 97% ee)
(78% yield)
1. DDQ
2. MsCl, DIPEA
3. NaN3
4. Ph3P, H2O
(69% yield)
EtOH, Δ
(100% yield)
1. KHMDS, BnBr
2. K2CO3, BnBr
3. TBAF
4. (COCl)2, Et3N, DMSO
(74% yield)
TiCl4
(71% yield)
SiMe3
1. OsO4, NMO
2. NaIO4, NaHCO3
(84% yield)
H2, Pd/C
then TFA
(81% yield)
8a
1.48
1.49
1.50 1.51
1.52 1.53
1.54 1.55 (+)-Castanospermine (1.1)
1
7
6
8
 
Scheme 1.9 Somfai’s total synthesis of 1.1. 
 
Diene 1.48 was dihydroxylated with AD-mix-α and the resulting diol was protected as the 
corresponding acetonide and subsequently reduced using DIBAL to afford allylic alcohol 1.49 in 
72% yield and 97% ee. Sharpless epoxidation of the protected 1.49 in the presence of stoichiometric 
amounts of (+)-diisopropyl tartrate followed by silylation furnished 1.50 in good yield and with high 
diastereoselectivity (de > 95%). Epoxide 1.50 was transformed into the primary amine 1.51 through 
a four step sequence involving protection-deprotection routines on the primary alcohol groups and a 
Staudinger reduction. The primary amine 1.51 smoothly underwent cyclization when heated in 
EtOH to afford 1.52. This piperidine derivative is the product of a 6-endo-tet cyclization in which 
SN2-opening of the epoxide by nitrogen installs the correct stereochemistry of the future bridgehead 
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site (C8a). The corresponding 5-exo-tet process is disfavored since it would lead to a trans-fused 
bicyclo[3.3.0]-nonane system.82 Benzylation followed by desilylation and Swern oxidation 
furnished aldehyde 1.53. A Sakurai reaction of aldehyde 1.53 with allyltrimethylsilane in the 
presence of titanium tetrachloride afforded the stereocenter at C(1). This gave alkene 1.54 in 71% 
yield with great diastereoselectivity (de > 95). The completion of the synthesis was attained through 
oxidative cleavage of 1.54 to provide aldehyde 1.55, which upon reductive amination and global 
deprotection furnished (+)-castanospermine (1.1). In summary, Somfai and co-workers have attained 
1.1 in an overall yield of 13% over 18 steps.  
1.4.3 Mariano’s Approach 
In 1996 Mariano and co-workers83 reported their first explorations of a pyridinium salt 
photoelectrocylization-aziridine ring-opening sequence. Later this methodology was combined with 
enzymatic hydrolysis using electric eel acetylcholinesterase (EEACE), thus affording efficient 
access to enantiopure cyclopentene building blocks like 1.56 (Scheme 1.10).84-86  In 2005 Mariano21 
used this cyclopentene as starting point for a total synthesis of 1.1. A central design feature in this 
approach was the ring rearrangement metathesis to form the piperidine ring of 1.1 followed by 
installation of the stereogenic centers at C(6) and C(7) by way of a regio- and diastereoselective 
hydroxylation process. 
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Scheme 1.10 Mariano’s total synthesis of 1.1. 
 
Starting from 1.56, a metathesis cascade using Grubbs 2nd generation catalyst 1.32 provided the 
tetrahydropyridine 1.57. X-ray crystallographic analysis of tetrahydropyridine 1.57 revealed that it 
existed in a diaxial conformation. This preference probably stems from relief of A1,3-strain between 
the N-acetyl and the allyl side chain in the alternative diequatorial conformation. Consequently, the 
hydroxy group at C(8) can be used to guide regio- and diastereoselective epoxidation of the 
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endocyclic alkene moiety. Vanadyl-mediated epoxidation of 1.57 produced epoxide 1.58, a crucial 
intermediate in this concise synthesis of (+)-castanospermine (1.1). trans-Diaxial ring-opening 
under mild basic conditions followed by Brown hydroboration/oxidation provided the primary 
alcohol 1.59 in relatively poor yield for this four step sequence. Cyclization under Mitsunobu 
conditions followed by hydrogenolysis of the benzyl protection groups completed the synthesis of 
(+)-castanospermine (1.1). To summarize, Mariano have completed the total synthesis of 1.1 in 9 
steps and 6.3% overall yield commencing from 1.56.  
1.4.4 Poisson’s Approach 
In 2006 Poisson and co-workers87 revealed their first interest in a unified route to polyhydroxylated 
indolizidines completing the total synthesis of (−)-swainsonine and (+)-6-epicastanospermine. Later 
this strategy was implemented in the total synthesis of (+)-castanospermine (Scheme 1.11).22 A 
central design feature was to deploy a diastereoselective [2 + 2] cycloaddition with dichloroketene 
in combination with a Beckmann ring expansion to forge the pyrrolidene moiety.  
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Scheme 1.11 Poisson’s diastereoselective [2 + 2] cycloaddition approach to 1.1. 
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The synthesis was initiated when the potassium alkoxide of (R)-stericol 1.60 was reacted with 
trichloroethylene. Subsequent treatment of this material with excess n-BuLi and allyl iodide 
afforded cis-β-elimination, chlorine-lithium exchange, and allylation of the ensuing lithio-ynol 
ether. This material was exposed to DIBAL providing cis-enolether 1.61. Exposing 1.61 to in situ 
generated dichloroketene gave cyclobutanone 1.62 with excellent diastereoselectivity and 
subsequent Beckmann ring-expansion with Tamura’s reagent (O-mesitylenesulfonyl-
hydroxylamine, MSH) furnished the five-membered lactam 1.63. Unfortunately, attempts to install 
the hydroxy group at C(8) in a diastereoselective manner using SeO2 afforded a 1:1 diastereomeric 
mixture. This could, however, be remedied by subjecting this mixture to an oxidation/reduction 
sequence with DMP and LiAlH4, which predominantly afforded the desired isomer 1.64 (dr  = 
92:8). Diene 1.65 was easily attained through bisilylation, selective hydrolysis of the silyl imidate, 
and N-allylation under phase-transfer conditions. Upon removal of the TIPS protecting group, the 
key RCM gave the bicyclic lactam 1.66 in good yield.  
 
When 1.66 was exposed to hydroboration and oxidation, a 1.5:1 mixture of the bicyclic lactam 1.67 
and the octahydroindolizidine 1.68 was obtained (both as single diastereomers dr > 95:5). All efforts 
to increase the amount of 1.68 relative to 1.67 were unrewarding, hence Poisson and co-workers 
decided to convert the bicyclic lactam 1.67 into the corresponding acetonide, which was readily 
reduced to a protected indolizidine and subsequently deprotected to furnish 1.1. Moreover, 
octahydroindolizidine 1.68 was smoothly converted into 1.1 when treated with hydrochloric acid in 
ethanol. In summary, Poisson has realized the total synthesis of 1.1 in 16 steps and 1.8% overall 
yield starting from 1.60. The highlights of this synthesis were a diastereoselective [2 + 2] 
cycloaddition followed by a Beckmann ring expansion to afford the five-membered moiety of (+)-
castanospermine 1.60 and a metathesis-hydroboration/oxidation sequence to install the piperidine 
ring.  
 
1.5 Summary 
The natural product (+)-castanospermine (1.1) was first isolated and characterized in 1981. Recent 
biological studies have demonstrated that (+)-castanospermine may find use in the treatment of 
dengue virus and hepatitis C virus. Moreover, the highly condensed nature of (+)-castanospermine 
(1.1) continues to inspire synthetic chemists, and this has resulted in 11 syntheses since 1996. 
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Unsurprisingly, the preferred chiral starting material is readily available D-glucose. The construction 
of the octahydroindolizidine skeleton has been achieved in several efficient ways, some of the most 
popular solutions involve RCM or reductive amination cascades. In 1999 Denmark disclosed the 
shortest synthesis of (+)-castanospermine reported to date. This synthesis clearly stands out, since it 
not only provides access to 1.1 in 8 steps from 2,5-dihydrofuran, but also serves as a general entry 
point to bicyclic azasugars. 
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2 The Total Synthesis of (+)-Castanospermine 
2.1 Retrosynthetic Analysis and Synthetic Design 
Our interest in (+)-castanospermine (2.1) arose from the acknowledgement of the important 
biological properties displayed by this natural compound and closely related congeners. Moreover, 
we sought to demonstrate the advantage of implementing two key metal-mediated protocols in a 
concise synthesis of (+)-castanospermine, which would provide the shortest synthesis of 2.1 starting 
from chiral pool material (cf. Chapter 1). 
 
In designing our synthetic strategy toward (+)-castanospermine (2.1) the central feature was to 
construct the [5-6] indolizidine system of (+)-castanospermine through a strain-releasing 
transannular cyclization of expoxide 2.2 (Scheme 2.1). This epoxide could arise from 
diastereoselective epoxidation of the nine-membered cycloalkene 2.3, which would in turn be 
accessed through a medium-ring metathesis reaction of an N-alkylated homoallyl amine of type 2.4. 
Homoallyl amine 2.4 could originate from the unsaturated aldehyde 2.5 by suitable reductive 
amination conditions. The aldehyde 2.5 would be easily available from a protected derivative of 
methyl 6-iodoglucopyranoside 2.6 by a zinc-mediated reductive fragmentation. 
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Scheme 2.1 Retrosynthesis of (+)-castanospermine. 
 
Ultimately, the requisite iodopyranoside 2.6 would be attained from methyl α-D-glucopyranoside 
(2.7) through selective iodination of the 6-position followed by protection of the remaining hydroxy 
groups. 
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2.2 Background on the Zinc-Mediated Reductive Fragmentation 
Carbohydrates are densely functionalized chiral molecules and thus serve as valuable starting 
materials for chemical synthesis. Since carbohydrates contain no C-C double bonds the primary 
obstacle in order to use these chiral building blocks in ring closing metathesis (RCM) is the efficient 
introduction of two olefins. This can be achieved in two separate steps using the zinc-mediated 
reductive fragmentation of ω-haloglycosides originally developed by Bernet and Vasella88 to 
simultaneously provide a terminal alkene and liberate an aldehyde functionality at the anomeric 
center. The ensuing aldehyde can be transformed into an olefin utilizing a range of different 
organometallic reagents furnishing carbohydrate derived α,ω-dienes. In 1999 Madsen and co-
workers89,90 disclosed an elegant zinc-mediated tandem reaction converting ω-iodoglycosides into 
α,ω-dienes in one pot (Scheme 2.2). The zinc-mediated reductive fragmentation generated an 
aldehyde 2.8 that could be chain-elongated using in situ generated organozinc nucleophiles. Takai-
methylenation91,92 furnished the corresponding one carbon elongated product poised to undergo 
ring-closing metathesis. The methylenation reagent was formed in situ from diiodomethane and zinc 
in the presence of Lewis acid, typically TMSCl or TiCl4, and a catalytic amount of PbCl2.  
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Scheme 2.2 The zinc-mediated reductive fragmentation.  
 
Moreover, the reductive fragmentation could be coupled with vinylation, which simultaneously 
afforded a two-carbon elongation and generated a novel stereocenter. The vinylation, however could 
not be performed under Barbier-type conditions, since zinc does not readily undergo oxidative 
addition to vinyl bromide. In the event, it was decided to preform divinyl zinc by magnesium-zinc 
transmetallation of vinylmagnesium bromide prior to the reaction. Arguable, the most powerful 
extension of this methodology was achieved when the reductive fragmentation was combined with 
zinc mediated Barbier-type allylation. This allowed for concomitant 3-carbon chain elongation and 
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generation of up to two stereocenters in one pot. Later developments revealed that the aldehyde 
moiety could be trapped with an amine providing an imine in situ, which in turn underwent zinc-
mediated alkylation. Subsequent ring-closing metathesis efficiently provided access to amino sugar 
derivatives.93  
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Figure 2.1 A selection of natural products prepared using the reductive fragmentation RCM methodology. 
 
The methodology has played a critical role in the synthesis of several polyhydroxylated natural 
products by the Madsen laboratory including: conduritols,90,94,95 (+)-cyclophellitol,96 pancratistatin97 
and 7-deoxy pancratistatin,98 gabosines, inositols,99 and calystegines B2, B3, B4, and A3.100-103 A 
selection of these molecules is depicted in Figure 2.1. 
 
2.3 Synthesis of the Key Diene Intermediatea 
The construction of the prerequisite diene 2.9 became the first problem at hand. The synthesis 
commenced from cheap and commercially available methyl α-D-glucopyranoside (2.7). Initially this 
pyranoside was treated with iodine and triphenylphosphine in refluxing THF to give the desired 
selective iodination. The ensuing ω-iodopyranoside 2.10 was easily separated from 
triphenylphosphine oxide by use of reverse-phase column chromatography and isolated in 87% yield 
(Scheme 2.3). This product was conveniently recrystallized from ethanol in high yield.104  Protection 
of the 2-, 3-, and 4-hydroxy groups as benzyl ethers was smoothly achieved by treating ω-
iodopyranoside 2.10 with an excess of benzyl trichloroacetimidate under acidic conditions. This 
gave the desired benzyl-protected crystalline ω-iodopyranoside 2.11 in 90% yield.    
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Scheme 2.3 Preparation of ω-iodopyranoside 2.11. 
                                                 
a Initial work on this project was conducted by Master student Mette Mikkelsen. 
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The attained tribenzyl ether 2.11 was sonicated in the presence of activated, powdered zinc to 
furnish unsaturated aldehyde 2.12.104  The aldehyde could easily be purified by use of silica-gel 
chromatography without epimerization of the α-stereocenter. However, upon standing this 
stereocenter epimerized readily, even when the compound was stored in the freezer, hence in 
practice the crude aldehyde was used directly in the subsequent step (Scheme 2.4).  
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Scheme 2.4 Synthesis of the RCM precursor. 
 
We attempted to perform the reductive amination as a one-pot sequence where 2.13 was formed in 
the presence of NaCNBH3105 or NaBH(OAc)3,106 homoallyl amine, and acetic acid. Unfortunately, 
these experiments provided the desired amine 2.13 in only a moderate yield along with reduced 
aldehyde and epimerized amine. Therefore it was decided to perform the zinc-mediated 
fragmentation and the reductive amination in two separate steps. After some experiments it was 
found that employing NaCNBH3 as the reducing agent in the presence of an excess of homoallyl 
amine and powdered 4Å molecular sieves in THF furnished the desired amine in 89% yield. Careful 
adjustment to pH 7-8 using acetic acid and allowing for complete formation of the imine before 
adding NaCNBH3 proved to be crucial in order to avoid epimerization and direct reduction of the 
aldehyde. The ensuing amine 2.13 was smoothly converted into the corresponding 
trifluoroacetamide 2.9 by treatment with trifluoroacetic anhydride in the presence of triethylamine, 
thus providing access to the requisite RCM precursor in only five steps from methyl α-D-
glucopyranoside. 
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2.4 Background on the Ring-Closing Metathesis 
The cyclization of diene precursors in the presence of transition metals with the simultaneous 
release of ethylene has advanced into one of the most useful reaction in modern organic synthesis. 
This process is known as the ring-closing olefin metathesis (RCM). The broadly accepted 
mechanism for the olefin metathesis known as the “carbene” mechanism was proposed by Hérisson 
and Chauvin in 1971107 with key experimental evidence supporting this proposal being disclosed by 
the Grubbs,108,109 Katz,110-112 and Casey113,114 groups. The mechanistic picture invokes metal carbene 
intermediates as propagating species in the catalytic cycle. These investigations prompted the 
development of well-defined catalysts from the Schrock group115 at MIT and the Grubbs group116 at 
Caltech. Following these pioneering investigations alkene metathesis has emerged into one of the 
most important C-C bond forming processesa in organic synthesis.117-122 This was highly 
emphasized in 2005, the year the Nobel Prize was shared by R. H. Grubbs, R. R Schrock, and Y. 
Chauvin for their contributions to the development of highly efficient catalyst and advancement of 
the fundamental understanding of the mechanistic scenario of the olefin metathesis reaction.123-125 
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Scheme 2.5 A selection of metathesis reactions in organic synthesis. 
 
Molybdenum and ruthenium catalysts have been applied to a broad repertoire of metathesis reaction 
(Scheme 2.5). Ring-opening metathesis polymerization (ROMP) has been put to great use in the 
preparation of macromolecules.126,127 Recent advances in catalyst design, especially by Grubbs and 
                                                 
a The palladium catalyzed cross-coupling reactions are probably the only processes rivalling metathesis when 
considering the influence these reactions continue to have on the planning and execution of organic synthesis. 
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co-workers, have rendered cross-metathesis (CM) an important synthetic tool.128,129 The youngest 
member of this family the ring-closing alkyne metathesis has primarily been utilized by the Fürstner 
group for macrocyclization.130-133 In combination with partial hydrogenation under Lindlar 
conditions this methodology exclusively provides access to Z-isomers, thus providing an elegant 
solution to the lack of control over the configuration of the newly formed double bond in the 
traditional RCM when applied to macrocyclization.134 
 
The most widely used metathesis catalyst are based on either molybdenum or ruthenium (Figure 2.2) 
Although complexes of metals such as tungsten,135 rhenium,136 and osmium137 have found use in 
olefin metathesis, these exhibit lower stability and/or reactivity and have not attracted extensive 
investigations. The molybdenum catalyst 2.14 developed by Schrock115 is one of the most active 
metathesis catalysts. This catalyst, however, is highly sensitive toward air and moisture, thus 
requiring a glove box for proper handling. Furthermore, only a limited range of polar functional 
groups are tolerated. In 1992 Grubbs and co-workers57 disclosed the first well-defined ruthenium 
based metathesis catalyst 2.15 and three years later in 1995 complex 2.16 now known as Grubbs’ 1st 
generation catalyst was published.138 While the ruthenium based catalysts displayed lower reactivity 
than the molybdenum catalyst 2.14 this was outweighed by a higher stability toward air and 
moisture and greater functional group tolerance, assets making 2.16 one of the most widely used 
metathesis catalysts.  
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Figure 2.2 A selection of commonly used metathesis catalysts. 
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Following Arduengo’s seminal report139,140 on N-heterocyclic carbenes (NHC’s) significantly more 
active catalysts 2.17 and 2.18 containing both phosphine and NHC ligands were disclosed almost 
simultaneously by Herrmann,141 Nolan,142 and Grubbs (2nd generation Grubbs’ catalyst).143 Along 
this line Hoveyda developed 2.19 and 2.20 bearing a chelating carbene ligand.144,145 The family of 
Hoveyda catalysts, whose activity compares to the second generation Grubbs catalyst, is particularly 
useful for difficult metathesis cases of polysubstituted olefins. Two of the latest additions to this 
family of metathesis catalysts are 2.21 and 2.22, which have been shown to offer great increases in 
activity for the formation of tetrasubstituted olefins via RCM and for the construction of 
disubstituted olefins containing allylic substituents.129,146 This increased activity has been attributed 
to less steric hindrance around the ruthenium center.147,148 
  
Ring-closing olefin metathesis has found widespread use in addressing the synthetic challenge of 
forming medium sized carbo- and heterocycles.149-151 Medium sized rings are generally understood 
to contain 8 to 11 atoms within the ring.152 The preparation of medium sized rings from acyclic 
precursors represents a significant challenge because of unfavorable enthalpic and entropic factors. 
The stereochemical features disfavoring medium sized ring formation are primarily bond angle 
deformations (Baeyer strain), forced adoption of eclipsed conformations (Pitzer strain), and most 
importantly transannular strain resulting from unfavorable interactions between groups that lie 
across the ring from one another. Moreover, there is a substantial entropic cost associated with the 
transition state leading to the cyclized product.152 Therefore the formation of medium sized rings by 
RCM generally requires a diene that is conformationally predisposed to undergo cyclization or an 
appropriately placed functional group that can possible act as an internal ligand for the catalyst.150 
An example illustrating the use of appropriately placed substituents to facilitate ring closure was 
disclosed by Crimmins in 1999.153,154 A crucial step in Crimmins and co-workers154 total synthesis 
of (+)-laurencin was the RCM forming the eight-membered ether 2.23 (Scheme 2.6a). 
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Scheme 2.6 RCM for the formation of eight-membered rings. 
 
In comparison Hoveyda155 reported a successful RCM on sulfonamide linked diene 2.26 while the 
diene ether 2.27 exclusively produced dimers and oligomers when exposed to 2.15 (Scheme 2.6b). 
This significant difference was attributed to the vicinal stereocenters in 2.24, which were suggested 
to induce a conformation positioning the olefinic chains close to each other by virtue of the gauche 
effect (cf. Newmann projection 2.25). The contrast in efficiency of the depicted approaches to eight-
membered rings clearly demonstrates that subtle structural differences can drastically influence, 
which reaction manifold is favored i.e. cyclization vs. dimerization and/or oligorimerization when 
RCM is applied to the formation of medium sized rings.      
 
2.5 Completion of (+)-Castanospermine 
2.5.1 Ring-Closing Metathesis Approach to the Azacyclononene 
With access to gram quantities of diene 2.9 our focus shifted toward identifying suitable reaction 
conditions for the crucial ring-closing metathesis (Table 2.1). At the onset diene 2.9 was subjected 
to an array of metathesis catalysts 2.16, 2.18, 2.20, 2.22, 2.28, and 2.29 under highly dilute 
conditions i.e. 0.2 mM in CH2Cl2 at 40 oC (entries 1-6). These reaction conditions afforded almost 
no conversion of the starting material, which could be recovered in nearly quantitative yield. 
Although discouraged by these initial results we found it reassuring that homodimeric cross-
metathesis products were not observed under these conditions. Previously Percy and co-workers156 
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as well as Creighton and co-workers157 have reported isolation of open-chain homodimers from 
RCM reaction run under high dilution. The low reactivity for the RCM can possibly be ascribed to 
the electron deficient nature of the olefin at C(8a) and the build-up of transannullar strain during 
cyclization vide supra. Moreover, it is conceivable that the sp2-nature of the amide nitrogen enforces 
the pendant olefins to adopt an unproductive orientation, thus providing a significant barrier to 
cyclization.  
Table 2.1 Optimization of the RCM. 
entry catalyst(20 mol%)
additive
(30 mol%) solvent T(°C)
[M] 
(mM)
% yield 
(2.30)
% yield 
(2.31)
1 2.16 - CH2Cl2 40 0.2 0 0
2 2.18 - CH2Cl2 40 0.2 0 0
3 2.20 - CH2Cl2 40 0.2 0 0
4 2.22 - CH2Cl2 40 0.2 0 0
5 2.28 - CH2Cl2 40 0.2 0 0
6 2.29 - CH2Cl2 40 0.2 0 0
7 2.16 - PhH 80 0.2 0 0
8 2.18 - PhH 80 0.2 63 11
9 2.20 - PhH 80 0.2 52 16
10 2.22 - PhH 80 0.2 71 9
11 2.28 - PhH 80 0.2 0 0
12 2.29 - PhH 80 0.2 59 10
13 2.22 - PhH 80 1.0 51 12
14 2.22b - PhH 80 0.5 78 7
15 2.22 Ti(Oi-Pr)4 PhH 80 0.5 73 8
16 2.22 BHT PhH 80 0.5 69 13
17 2.22c - PhH 80 0.5 52 5
18 2.22 - PhMe 110 0.5 41 18
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In order to circumvent these activation barriers we decided to perform the reaction in refluxing 
benzene. Significantly, neither Grubbs’ 1st generation catalyst138 2.16 nor the Neolyst catalyst158,159 
2.28 afforded conversion at these elevated temperatures (entries 7 and 11). We were especially 
surprised that the Neolyst catalyst failed to provide any of the desired cyclized product since this 
ruthenium indenylidene complex on several occasions has been reported to be particularly suitable 
for the formation of medium sized rings through RCM.160,161 This effectiveness toward slow RCM 
reactions has been ascribed to higher stability in solution, however it remains unclear whether this 
originates from slow initiation, slow recapture of the catalytically active species or slow 
decomposition of the latter.162 Gratifyingly, when the more reactive 2nd generation ruthenium 
carbene complexes where employed the desired nine-membered heterocycle 2.30 was attained in 
moderate to good yields (entries 8-9, and 12) A byproduct observed in all these reactions was the 
eight-membered N-heterocycle 2.31 which most likely stems from ruthenium-catalyzed 
isomerization of the electron rich terminal double bond prior to ring closure.163-165 Several reports 
indicate that decomposition products of ruthenium-metathesis catalysts may be responsible for this 
type of side reaction.166,167  
 
From the above experiments it was evident that the N-tolyl catalyst 2.22 recently developed by 
Grubbs, Schrodi and co-workers146 was the catalyst of choice for this difficult metathesis reaction 
furnishing the desired heterocycle 2.30 in 71% yield along with only 9% of the undesired eight-
membered heterocycle 2.31. The superior performance of 2.22 in comparison to earlier versions of 
the NHC-type catalysts has previously been proposed to stem from the more open steric 
environment around the ruthenium center allowing the catalyst to accommodate more sterically 
demanding organic fragments.129,148 Attempting to render this protocol amenable to scale-up we 
decided to perform the reaction at 1.0 mM concentration of diene 2.9 (entry 13). This unfortunately 
also provided considerable amounts of the homodimer. To our delight it was possible to obtain the 
prerequisite product 2.30 in 78% yield when the reaction was conducted at a 0.5 mM concentration 
adding the catalyst 2.22 slowly over 20 h (entry 14). Efforts to increase this yield even further by 
adding Ti(Oi-Pr)4 or BHT168 did not prove fruitful (entries 15 and 16). The addition of Ti(Oi-Pr)4 is 
believed to break-up chelates formed between the ruthenium catalyst and substrate, which could 
potentially act unfavorably as catalyst sinks.169-172 Moreover, decreasing the catalyst loading while 
maintaining the slow addition or increasing reaction temperature caused a decrease in yield (entries 
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17 and 18). Although a relatively high loading of 2.22 as well as highly dilute conditions were 
required to provide the desired nine-membered heterocycle 2.30 in good yield (entry 14) these 
optimized conditions did allow us to continue our synthetic explorations toward (+)-
castanospermine (2.1).  
2.5.2 The Transannular Cyclization 
With the nine-membered heterocycle 2.30 in hand we sat out to investigate ways to perform the 
crucial diastereoselective epoxidation and transannular ring closure5,160,173,174 that would ultimately 
provide the fused [5-6] indolizidine system of (+)-castanospermine. At the onset it was attempted to 
subject alkene 2.30 to standard Prilezhaev epoxidation conditions (Table 2.2).175,176  
Table 2.2 Screening of epoxidation conditions. 
entry oxidant catalyst additive solvent T(°C) notesa
1 mCPBA - - CH2Cl2 0 <10% conversion after 48 h
2 mCPBA - - CH2Cl2 23
~80% conversion after 24 h one 
major product (~90%) and one minor 
product
3 mCPBA - KF CH2Cl2 23
<25% conversion after 48 h
sluggish
4 mCPBA - Na2HPO4 CH2Cl2 23
<50% conversion after 48 h
sluggish
5 mCPBA - NaHCO3 CH2Cl2 23
<50% conversion after 48 h
sluggish
6 oxone - CF3COCH3NaHCO3
CH3CN 0
full conversion after 4 h one major 
product (~90%) and one minor product
7 DMDO - - acetone -15 full conversion after 6 hseveral products
8 UHP -
TFAA
Na2CO3
CH2Cl2 0
full conversion after 7 h
several products
9 UHP MeReO3 - 23
full conversion after 48 h one major 
product (~90%) and one minor product
aConversion and progress judged by TLC.
N
O
BnO
BnO
BnO
NBnO
BnO
BnO various epoxidation
conditions
F3C
O
F3C
O
2.30 2.32
 
 
Treating 2.30 with mCPBA at 0 oC afforded less than 10% conversion after 48 h stirring while 
performing the same experiment at 23 oC led to almost full conversion into the requisite epoxide 
(entries 1 and 2). TLC analysis as well as 1H NMR of the crude reaction mixture indicated the 
presence of two epoxides in >9:1 ratio.a Unfortunately all efforts to purify the desired epoxide 2.32 
                                                 
a The absolute configuration of the major epoxide was deduced from the transannular cyclization product. 
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from this reaction mixture led to decomposition. Attempts to add KF to complex any m-
chlorobenzoic acid present177,178 or buffer179 the reaction afforded slow conversion into the epoxide 
(entries 3 to 5). Luckily, it was found that the in situ generated dioxirane of 1,1,1-trifluoroacetone180 
cleanly converted 2.30 into the desired epoxide (1H NMR revealed a >9:1 ratio of two epoxides, 
entry 6). A range of other epoxidation conditions181,182 were also tested and only the MeReO3-
catalyzed epoxidation afforded considerable conversion into the desired epoxide (entries 7 to 9). 
 
F3COCN
OBn
H
H
OBnH
BnO H
H
H
H NCOCF3
BnO
OBn
H
H
HH
H
BnO H
barrier height: 16.3 kJl/mol
i.e. conformation locked
F3COCN
OBnOBn
H
BnO H
H
H
H
N
O
BnO
BnO
BnO
F3C
O
N
O
BnO
BnO
BnO
F3C
O
O
O
CF3
CH3
O
O
CF3
CH3
β-attack
α-attack
a)
b)
A B
2.32
 
Scheme 2.7 Proposed transition state for the diastereoselective epoxidation. 
 
A conformational search183-186,a on azacyclononene 2.30 revealed that this nine-membered ring is 
strongly biased toward conformation A which is 16.3 kJ/mol lower in energy than B (Scheme 2.7a). 
This conformational preference most likely stems from a minimization of transannular strain. 
Conformation A suggests that the β-face of the alkene is more open and therefore should be 
                                                 
a A conformational search using mixed torsional/low-mode sampling was carried out using Macromodel v. 9.6 release 
110 as incorporated in the Maestro suite from Schrödinger Inc (for current versions, see http://www.schrodinger.com). 
The OPLS-2005 force field was used including the GB/SA salvation model with parameters suitable for water. Only 
structures within 21 kJ/mol of the global minimum were retained and the search was carried out for 50,000 steps to 
ensure completeness.  The author acknowledges assistant Professor Peter Fristrup for valuable assistance in conducting 
the conformational search.  
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preferentially attacked by an external oxidant, thus providing a reasonable explanation for the 
observed diastereoselectvity (Scheme 2.7b).187-189 
 
Having identified suitable reaction conditions for the diastereoselective epoxidation our focus 
shifted toward the key transannular cyclization. The crude epoxide was used directly for this step to 
avoid decomposition of the labile epoxide during work-up. Inspired by conditions developed by 
White and Hrnciar190 we treated the crude epoxide 2.32 with an excess of LiOH in a mixture of 
EtOH/H2O at 100 oC. TLC revealed multiple products, however, the desired and known 
octahydroindolizidine 2.33 was isolated in 24% yield (Scheme 2.8).5 Structural analysis of the 
byproducts revealed the strained bicyclic compound 2.34 as a major component isolated in 35% 
yield. While the formation of 2.34 was unexpected due to its highly strained nature the generation of 
2.34 may most likely be ascribed to the close proximity of the amine moiety to C(1).a 
N
O
BnO
BnO
BnO
F3C
O
NBnO
BnO
BnO
F3C
O
N
H OH
BnO
BnO
BnO
oxone
1,1,1-trifluoroacetone
NaHCO3, Na2EDTA
MeCN/H2O, -10 to 0 oC
LiOH
EtOH/H2O, 100 oC N
OHBnO
BnO
BnO
H
+
(24% yield) (35% yield)
~1 : 1.5
2.32
2.33 2.34
1
2.30
 
Scheme 2.8 Initial attempt to perform the transannular cyclization. 
 
In efforts to maximize the formation of the desired octahydroindolizidine 2.33 a range of different 
deprotection/cyclization conditions were surveyed and the ratio between 2.33 and 2.34 was judged 
by 1H NMR of the crude reaction mixture (Table 2.3). Using LiOH to facilitate the deprotection and 
subsequent cyclization in different solvent mixtures at 50 oC did improve this ratio slightly (entries 
1-3). When the reaction was conducted at lower temperatures using KO(t-Bu) in combination with 
one equivalent of water to mediate the deprotection, 2.33 was attained as the major product in a 4:1 
ratio (entries 4, 7 and 8).191 The counterion proved to be of importance since neither NaO(t-Bu) nor 
LiO(t-Bu) afforded full conversion of the starting material. 
 
                                                 
a The structure of this byproduct has been assigned by extensive 2D NMR-studies. 
2 The Total Synthesis of (+)-Castanospermine 
 31
Table 2.3 Optimization of the transannular cyclization. 
entry base additive solvent T(°C) 2.33 : 2.34a
1 LiOH - EtOH/H2O=1:1 100 1:1.5
2 LiOH - EtOH/H2O=1:1 50 1:1.2
3 LiOH - THF/MeOH/H2O=2:2:1 50 1:1
4 KO(t-Bu) H2O Et2O 23 2.3:1
5 NaO(t-Bu)b H2O Et2O 23 1.9:1
6 LiO(t-Bu)b H2O Et2O 23 1.4:1
7 KO(t-Bu) H2O Et2O 0 4:1
8 KO(t-Bu) H2O Et2O -78 3.7:1
a Ratio determined by 1H NMR. b Less than 50% conversion as judged by 1H NMR.
1) oxone, 1,1,1-trifluoroacetone
    NaHCO3, Na2EDTA, 
    MeCN/H2O = 1/1, -10 to 0 oC
2) base, solvent, temp.NBnO
BnO
BnO
F3C
O
N
H OH
BnO
BnO
BnO
N
OHBnO
BnO
BnO
H
+
2.33 2.34
2.30
 
 
Gratifyingly, when azacyclononene 2.30 was subjected to our optimized epoxidation/cyclization 
sequence the desired octahydroindolizidine 2.33 was obtained in 44% overall yield for these three 
chemical transformations i.e. diastereoselective epoxidation, deprotection, and concomitant 
transannular closure (Scheme 2.9).  
1) oxone, 1,1,1-trifluoroacetone
    NaHCO3, Na2EDTA, 
    MeCN/H2O = 1/1, -10 to 0 oC
2) KOt-Bu, H2O, Et2O
    0 to 22 oC
NBnO
BnO
BnO
F3C
O
N
H OH
BnO
BnO
BnO
(44% yield)
N
H OH
HO
HO
HO
H2, Pd/C
HCl (aq)
MeOH, 22 oC
(94% yield) (+)-Castanospermine (2.1)2.33
2.30  
Scheme 2.9 Completion of (+)-castanospermine (2.1). 
 
When 2.33 was exposed to deprotection conditions reported by Miller and Chamberlin5 we obtained 
(+)-castanospermine (2.1) in 94% yield with all spectral data in accordance with literature data.   
 
2.6 Summary 
We have successfully prepared (+)-castanospermine (2.1) in a highly concise manner. The synthesis 
comprises no more than nine steps from methyl α-D-glucopyranoside and provides the natural 
product in 22% overall yield (Scheme 2.10). Only the asymmetric synthesis reported by Denmark in 
1999 provides a more concise route to (+)-castanospermine (2.1).  
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O
OMe
OHHO
HO
HO
Methyl α-D-gluco-
pyranoside
O
OMe
OBnBnO
BnO
I
N
OHHO
HO
HO
(+)-Castanospermine (2.1)
H
NBnO
BnO
BnO
F3C
O
2 steps 4 steps 3 steps
(22% yield, 9 steps)
2.11
2.30  
Scheme 2.10 Key intermediates in the total synthesis of (+)-castanospermine (2.1). 
 
The key steps in our synthetic approach are a zinc-mediated reductive fragmentation of 2.11, a 
challenging ruthenium-catalyzed ring-closing metathesis affording 2.30, and a strain-driven N-
deprotection/transannular cyclization cascade. Moreover, this synthesis underscores the 
effectiveness of employing a zinc-fragmentation ring-closing metathesis sequence in the 
development of highly efficient synthetic routes from carbohydrates. 
 
2.7 Experimental 
2.7.1 Materials and Methods 
1H NMR and 13C NMR spectra were recorded using a Bruker AC-200 MHz or a Varian Mercury 
300 MHz. Chemical shifts were measured in ppm and coupling constants in Hertz (Hz). The shifts 
were measured relative to the signals for residual CHCl3 (7.26 ppm), CDCl3 (77.0 ppm), CD3OD 
(4.84 ppm), and CD3OD (49.05 ppm). Multiplicities are reported as follows; s = singlet, d = doublet, 
t = triplet, q = quartet, m = multiplet, br s = broad singlet. All 13C NMR spectra were proton 
decoupled. IR spectra were obtained by use of a Bruker-α-P FT-IR spectrophotometer or a Perkin-
Elmer 1600 FTIR spetrophotometer using either thin films or a KBr matrix (for solids) and are 
reported in wavenumbers (cm-1). Melting points were obtained from a H. Heidolph and Schwabach, 
type 10 apparatus and are uncorrected. Thin layer chromatography was performed on aluminium 
plates precoated with silica gel (Merck; 60 F254) using the solvent systems indicated. Compounds 
were visualized by illumination using a UV lamp (254 nm) or by charring after dipping in a solution 
of anisaldehyde (15 g) in ethanol (250 mL) and concentrated sulfuric acid (2.5 mL). 
Chromatographic purifications were performed by silica-gel chromatography192,193 using Amicron 
Matrex 60 Å; 35-70 μm. Optical rotations were measured on a Perkin Elmer 241 polarimeter 
operating on the sodium D line with a path length of 100 mm and are reported as: 
[α]Τ (concentration in g/100mL, solvent). All compounds on which HRMS were performed 
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exhibited pure 1H NMR spectra and showed one spot by TLC analysis. HRMS analyses were 
conducted by Dr. Kenneth B. Jensen, the Mass Spectrometry Laboratory, Department of Chemistry, 
University of Southern Denmark, Odense or by Dr. Gustav Bojesen the Mass Spectrometric 
Research Unit, Department of Chemistry, University of Copenhagen. Commercially available 
reagents were used as received unless otherwise indicated. Air- and moisture sensitive reactions 
were carried out in oven-dried glassware sealed with rubber septa under a positive pressure of argon 
from a manifold or balloon.  All solvents were of HPLC grade. Tetrahydrofuran, diethyl ether, and 
toluene were distilled under nitrogen from Na-benzophenone prior to use. Dichloromethane was 
dried over 4 Å molecular sieves. Dimethylsulfoxide was distilled under a positive pressure of argon 
and stored over 4 Å molecular sieves. 
2.7.2 Synthesis of (+)-Castanospermine 
Methyl 6-deoxy-6-iodo-D-glucopyranoside (2.10) 
O
OMe
OHHO
HO
I
O
OMe
OHHO
HO
HO
PPh3, I2, imidazole
THF, 62 oC
(87% yield) 2.10Methylα-D-glucopyranoside  
A solution of methyl α-D-glucopyranoside (4.5 g, 23.2 mmol), Ph3P (9.13 g, 34.8 mmol), and 
imidazole (3.16 g, 46.4 mmol) in THF (180 mL) was heated to reflux. I2 (8.83 g, 34.8 mmol) was 
dissolved in THF (50 mL) and added to the reaction mixture in a dropwise manner. The resulting 
yellow/orange solution was refluxed until TLC revealed full conversion of the starting material 
(typically 2 h). The mixture was allowed to cool to room temperature, filtered, and concentrated in 
vacuo to afford a yellow/orange syrup. The syrup was purified by reverse phase column 
chromatography (H2O:MeOH = 9:1) to afford 2.10 (6.14 g, 87% yield) as a white solid: mp = 146-
148 oC (EtOH), lit.104 mp = 147-148 oC (EtOH); Rf  = 0.22 (CHCl3:MeOH = 9:1); 1H NMR (300 
MHz, D2O) δ 4.86 (d, J = 3.6 Hz, 1H), 3.80-3.68 (m, 2H), 3.66 (dd, J = 10.0, 4.1 Hz, 1H), 3.53 (s, 
3H), 3.52-3.46 (m, 2H), 3.4 (q, J = 8.8 Hz, 1H); 13C NMR (75.4 MHz, D2O) δ  100.0, 74.1, 73.1, 
71.8, 70.8, 56.0, 7.2; IR (Neat) 3434, 3289, 2978, 2912, 2867, 2843, 1456, 1409, 1373, 1240, 1142, 
1062, 1032, 1011, 991, 884, 749 cm-1. Spectral data are in accordance with literature values.104 
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Methyl 2,3,4-tris-O-benzyl-6-deoxy-6-iodo-D-glucopyranoside (2.11) 
O
OMe
OBnBnO
BnO
I
O
OMe
OHHO
HO
I
2.10 2.11
O CCl3
NH
TfOH
p-dioxane, 0 to 23 oC
(90% yield)  
Iodosugar 2.10 (1.0 g, 3.30 mmol) was placed in a 100 mL round bottom flask, dissolved in 1,4-
dioxane (22.0 mL), and benzyltrichloroacetimidate (3.74 g, 14.8 mmol) was added. The pale yellow 
solution was cooled to 0 oC by use of an ice/water bath. Triflic acid (500 μL) was added in a 
dropwise manner until pH < 1, the cooling was removed and the resulting dark orange solution was 
stirred at 23 oC for 50 min. The reaction mixture was diluted with diethyl ether (50 mL) and 
quenched with saturated aqueous NaHCO3 (10 mL). The phases were separated and the organic 
phase was washed with H2O (10 mL), brine (10 mL), dried over MgSO4, filtered, and concentrated 
in vacuo to afford a viscous oil. The crude oil was purified by flash chromatography (98:2 → 95:5 
→ 90:10, Heptane-EtOAc, dry-loaded using SiO2) to afford 2.11 (1.57 g, 90% yield) as a viscous 
colorless oil that crystallized upon standing; mp = 60-61 °C, lit.104 mp = 61-62 oC (heptane-EtOAc); 
Rf = 0.18 (heptane:EtOAc = 7:3); [α]D21 = +33.2 (c 2.0, CHCl3); 1H NMR (300 MHz, CDCl3) δ 
7.39-7.27 (m, 15H), 5.00 (d, J = 10.8 Hz, 1H), 4.95 (d, J = 10.9 Hz, 1H), 4.81 (d, J = 11.4 Hz, 2H), 
4.69 (d, J = 10.9 Hz, 1H), 4.66 (d, J = 12.1 Hz, 1H), 4.61 (d, J = 3.58 Hz, 1H), 4.02 (dd, J = 9.5, 8.8 
Hz, 1H), 3.54 (dd, J = 9.7, 3.6 Hz, 1H), 3.50-3.43 (m, 2H), 3.42 (s, 3H), 3.37-3.27 (m, 2H); 13C 
NMR (75.4 MHz, CDCl3) δ 138.5, 138.0, 137.9, 128.5, 128.5 (two peaks), 128.4, 128.1, 128.0, 
128.0, 127.9, 127.7, 98.1, 81.5, 81.4, 80.0, 75.8, 73.4, 69.2, 55.5, 7.7; IR (Neat) 3089, 3065, 3030, 
3003, 3986, 2897, 2865, 1497, 1454, 1359, 1194, 1138, 1088, 1029, 736 cm-1. Spectral data are in 
accordance with literature values.104 
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But-3-enyl-((2S,3S,4R)-2,3,4-Tris(benzyloxy)-hex-5-enyl)-amine (2.13)  
1. Zn 
   THF:H2O = 9:1, 40 oC, )))
2. homoallyl amine (10 equiv)
    AcOH, NaCNBH3, 4Å MS
    THF, 0 to 23 oC
O
OMe
OBnBnO
BnO
I
(89% yield)
NBnO
BnO
BnO
H
2.11 2.13
 
2.11 (2.0 g, 3.75 mmol) was placed in a 100 mL conical flask and dissolved in a mixture of THF 
(16.9 mL) and water (1.88 mL). Zn (2.46 g, 37.6 mmol) was added and the flask was immersed into 
a sonication apparatus preheated to 40 oC. The solution was sonicated for 1 h upon which TLC 
revealed full conversion of the starting material. The suspension was filtered through a plug of celite 
using Et2O (50 mL). Saturated aqueous NaHCO3 (25 mL) was added to the filtrate, the phases were 
separated, and the aqueous phase was extracted with Et2O (3 x 25 mL). The combined organics were 
washed with brine, dried over MgSO4, filtered, and concentrated in vacuo to afford a pale yellow 
viscous oil. The crude oil was purified by flash chromatography (9:1 → 4:1; heptane:EtOAc) to 
afford aldehyde 2.12 as a colorless oil (1.55 g, 99%). The oil was used directly in the next step since 
the aldehyde epimerizes when stored in the freezer. 4Å powdered molecular sieves (7.43 g, 2.0 
g/mmol) was placed in 100 mL round bottom flask and activated by use of heat gun (5 min heating 
under high vacuum 1-2 mbar). The aldehyde (1.55 g, 3.71 mmol) and homoallyl amine (2.64 g, 37.1 
mmol) were dissolved in THF (65.6 mL) and added to the round bottom flask. AcOH (2.75 mL) was 
added in a dropwise manner until pH = 7-8. The suspension was cooled to 0 oC by use of an 
ice/water bath. After 30 min stirring was NaCNBH3 (1.17 g, 18.6 mmol) added in one portion and 
the mixture was allowed to warm to 21 oC. The reaction mixture was stirred for 14 h and then 
quenched by addition of saturated aqueous NaHCO3 (25 mL). The mixture was filtered and the filter 
cake was washed with EtOAc (3 x 50 mL). The phases were separated and the aqueous phase 
extracted with EtOAc (3 x 25 mL). The combined organics were washed with brine (25 mL), dried 
over Na2SO4, filtered and concentrated under reduced pressure to afford a pale yellow oil. The crude 
product was purified using flash chromatography (CH2Cl2:MeOH = 9:1) to afford 2.13 (1.56 g 89% 
over two steps) as a colorless oil; Rf = 0.23 (CH2Cl2:MeOH = 9:1); [α]D21 =  -39.4° (c 1.6, CHCl3); 
1H NMR (300 MHz, CDCl3) δ  7.30-7.22 (m, 15H), 5.86 (ddd, J = 14.0, 9.9, 7.6 Hz, 1H), 5.62 (ddt, 
J = 13.8, 10.3, 7.0 Hz, 1H), 5.31-5.19 (m, 2H), 4.98 (ddd, J = 13.8, 3.0, 1.5 Hz, 1H), 4.95-4.91 (m, 
1H), 4.72 (d, J = 11.4 Hz, 1H), 4.67 (d, J = 11.4 Hz, 1H), 4.61 (d, J = 11.5 Hz, 1H), 4.59 (d, J = 11.7 
Hz, 1H), 4.54 (d, J = 11.5 Hz, 1H), 4.31 (d, J = 11.7 Hz, 1H), 4.00 (dd, J = 7.5, 4.7 Hz, 1H), 3.79 
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(dd, J = 11.4, 5.7 Hz, 1H), 3.55 (t, J = 5.0 Hz, 1H), 2.69 (dd, J = 12.4, 5.0 Hz, 1H), 2.59 (dd, J =  
12.4, 6.8 Hz, 1H), 2.43 (t, J = 6.9 Hz, 2H), 2.06 (q, J = 6.9 Hz, 2H); 13C NMR (50.3 MHz, CDCl3) δ 
138.4, 138.1, 136.0, 135.5, 128.2, 128.1, 127.8, 127.5, 118.5, 116.2, 82.0, 80.3, 78.6, 74.7, 73.1, 
70.4, 49.4, 48.7, 33.8; IR (Neat) 3088, 3065, 3029, 2976, 2863, 1496, 1454, 1392, 1351, 1330, 1306, 
1207, 1088, 1067, 996, 917, 734, 697 cm-1; HRMS (ESI+) calc’d for C31H37NO3Na ([M+Na]+) 
494.2666, found 492.2647. 
 
But-3-enyl-((2S,3S,4R)-2,3,4-tris-benzyloxy-hex-5-enyl)-trifluoroacetamide (2.9)  
NBnO
BnO
BnO
H
TFAA, Et3N
CH2Cl2, 0 oC
(93% yield)
NBnO
BnO
BnO
F3C
O2.13
2.9  
Amine 2.13 (1.13 g, 2.30 mmol) was dissolved in dichloromethane (24.0 mL), Et3N (1.0 mL, 727 
mg, 7.2 mmol) was added and the solution was cooled to 0 oC by use of an ice/water bath. 
Trifluoroaceticanhydride (680 μL, 1.0 g, 4.8 mmol) was added in a dropwise manner and the 
reaction mixture was stirred for 30 min at 0 oC. The mixture was diluted with dichloromethane (50 
mL) and quenched with saturated aqueous NaHCO3 (25 mL) at 0 oC. The phases were separated and 
the aqueous phase was extracted with dichloromethane (2 x 25 mL). The combined organic phases 
were dried over MgSO4, filtered, and concentrated under reduced pressure. The crude oil was 
purified by flash chromatography (98:2 → 95:5, heptane-EtOAc) to afford 2.9 (1.26 g, 93% yield) 
as a viscous colorless oil; Rf = 0.41 (heptane:EtOAc = 70:30); [α]D21 = -52.8 (c 2.0, CHCl3) 1H 
NMR (300 MHz, CDCl3) major rotamer: δ 7.34-7.14 (m, 15H), 5.90 (ddd, J = 17.3, 10.4, 7.9 Hz, 
1H), 5.72-5.46 (m, 1H), 5.32 (dd, J = 10.2, 1.2 Hz, 1H), 5.29-5.21 (m, 1H), 5.06-4.91 (m, 2H), 4.76 
(d, J = 11.8 Hz, 1H), 4.70 (d, J = 11.8 Hz, 1H), 4.64 (d, J = 11.8 Hz, 1H), 4.55 (d, J = 11.4 Hz, 
1H), 4.47 (d, J = 11.4 Hz, 1H), 4.38 (d, J = 11.8 Hz, 1H), 4.15 (dd, J = 7.8, 5.0 Hz, 1H), 4.06 (ddd, 
J = 8.6, 5.0, 3.4 Hz, 1H), 3.77 (dd, J = 13.9, 3.4 Hz, 1H), 3.52-3.29 (m, 4H), 2.19 (q, J = 7.3 Hz, 
2H); 13C NMR (75.4 MHz, CDCl3) δ major rotamer: 157.1 (q, JCF = 35.6 Hz), 138.1, 138.1, 138.0, 
135.1, 133.3, 128.4, 128.4, 128.4, 128.3, 128.0, 127.9, 127.9, 127.8, 127.6, 119.3, 117.8, 116.4 (q, 
JCF = 288 Hz), 80.7, 80.2, 76.0, 73.9. 73.8, 70.6, 48.8, 48.6, 32.9; 19F NMR (282 MHz, CDCl3) 
δ major rotamer: -69.43 (s, 3F); minor rotamer: -68.34 (s, 3F); IR (Neat) 3089, 3067, 3032, 2910, 
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2871, 1687, 1454, 1252, 1206, 1144, 1122, 1089, 1072, 735, 698 cm-1; HRMS (ESI+) calc’d for 
C33H36F3NO4Na ([M+Na]+) 590.2489, found 590.2472. 
 
(3S,4S,5R)-3,4,5-tribenzyloxy-1-trifluoroacetyl-1-aza-cyclonon-6-en (2.30) and (3S,4S,5R)-
3,4,5-tribenzyloxy-1-trifluoroacetyl-1-aza-cyclooct-6-en (2.31)  
NBnO
BnO
BnO
F3C
O
2.22 (20 mol%)
PhH, 80 oC
(2.30: 78% yield)
(2.31: 7% yield)
NBnO
BnO
BnO
F3C
O
2.302.9
NBnO
BnO
BnO
O
CF3
2.31
+
 
Diene 2.9 (100 mg, 0.185 mmol) was dissolved in benzene (370 ml, 0.5 mM). The solution was 
degassed using sonication (5 min under a positive flow of Ar). The solution was heated to 80 oC. 
The catalyst 2.22 (21 mg, 0.037 mmol) was dissolved in benzene (20 mL) and added to the reaction 
mixture in a dropwise manner over 20 h by use of a syringe pump. After 24 h stirring the reaction 
mixture was allowed to cool to room temperature and concentrated under reduced pressure to afford 
a dark green oil. The crude oil was purified using flash chromatography (98:2 → 95:5, heptane-
EtOAc) to afford 2.30 (78 mg, 78%) as a colorless oil that crystallized upon standing and 2.31 (6.8 
mg, 7%) as a colorless oil. 
 
2.30: mp = 76-77 °C (heptane-EtOAc); Rf  = 0.18 (heptane:EtOAc 9:1); [α]D21 = +33.8 (c 1.6, 
CHCl3); 1H NMR (300 MHz, CDCl3) δ major rotamer: 7.46-7.13 (m, 15H), 5.93-5.84 (m, 1H), 
5.72 (t, J = 10.0 Hz, 1H), 4.87 (d, J = 11.1 Hz, 1H), 4.83 (d, J = 10.7 Hz, 1H), 4.70 (t, J = 11.3 Hz, 
2H), 4.62 (d, J = 11.7 Hz, 1H), 4.45 (d, J = 11.7 Hz, 1H), 4.38-4.27 (m, 1H), 4.05 (ddd, J = 9.3, 6.7, 
2.9 Hz, 1H), 3.93 (dd, J = 14.0, 2.7 Hz, 1H), 3.90-3.81 (m, 1H), 3.66 (dd, J = 8.4, 6.7 Hz, 1H), 3.41 
(dd, J = 13.9, 9.1 Hz, 1H), 3.07-2.76 (m, 1H), 2.55-2.11 (m, 2H); 13C NMR (75.4 MHz, CDCl3) δ 
major rotamer:158.7 (q, JCF = 35.4 Hz), 138.6, 138.5, 138.1, 133.7, 129.0, 128.3, 128.3, 128.2, 
128.1, 127.9, 127.8, 127.5, 127.4, 118.1, 116.2 (q, JCF = 288 Hz), 114.3, 84.5, 78.1, 75.0, 74.6, 73.3, 
70.6, 51.9, 48.5, 27.8; 19F NMR (282 MHz, CDCl3) δ  major rotamer: -69.6 (s, 3F); minor 
rotamer: -67.9 (s, 3F); IR (Neat) 3090, 3062, 3031, 2929, 2900, 2871, 1692, 1454, 1205, 1144, 
1093, 1068, 736, 698 cm-1; HRMS (ESI+) calc’d for C31H32F3NO4Na ([M+Na]+) 562.2176, found 
562.2152. 
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2.31: Rf  =  0.20 (heptane:EtOAc 9:1); 1H NMR (300 MHz, CDCl3) δ major rotamer: 7.39-7.19 
(m, 15H), 5.89-5.58 (m, 2H), 4.77 (d, J = 11.2 Hz, 1H), 4.70 (d, J = 11.5 Hz, 1H), 4.62 (d, J = 11.3 
Hz, 2H), 4.59 (d, J = 11.5 Hz, 1H), 4.50 (d, J = 11.6 Hz, 1H), 4.37 (dd, J = 8.8, 5.4 Hz, 1H), 4.13 
(dd, J = 8.5, 5.6 Hz, 1H), 4.02 (d, J = 13.8 Hz, 1H), 3.82-3.65 (m, 4H); 13C NMR (50.3 MHz, 
CDCl3) δ major rotamer: 157.0 (q, JCF = 37.0 Hz), 138.3, 138.2, 137.8, 134.2, 128.3, 127.9, 127.7, 
126.0, 116.4 (q, JCF = 287 Hz), 83.5, 78.5, 77.3, 74.6, 72.8, 71.8, 47.2, 46.4; 19F NMR (282 MHz, 
CDCl3) δ  major rotamer: -69.5 (s, 3F); minor rotamer: -68.2 (s, 3F); IR (Neat) 3088, 3063, 3031, 
2924, 2870, 1692, 1497, 1454, 1206, 1184, 1143, 1100, 1028, 736, 697 cm-1; [α]D22 = +23.9 (c 0.85, 
CHCl3); HRMS (ESI+) calc’d for C30H30NO4Na ([M+Na]+) 548.2020 , found 548.2036.  
 
(1S,6S,7R,8R,8aR)-1-Hydroxy-6,7,8-tribenzyloxy-indolizidine (2.33).  
NBnO
BnO
BnO
F3C
O
N
H OH
BnO
BnO
BnO
1. oxone, NaHCO3
     1,1,1-trifluoroacetone
    Na2EDTA, MeCN/H2O
    -10 to 0 oC
2. KO(t-Bu), H2O
    Et2O, 0 to 23 oC
(44% yield)
2.30
2.33
 
Oxone (114 mg, 0.185 mmol) and NaHCO3 (24 mg, 0.286 mmol) were added to a solution of 
Na2EDTA (186 µL, 0.4 mM in H2O), 1,1,1-trifluoroacetone (100 µL), and CH3CN (500 µL) 
precooled to -10 oC by use of a MeOH/ice bath.  Within 5 min stirring the suspension became pale 
yellow.  2.30 (20 mg, 0.037 mmol) was dissolved in CH3CN (500 µL) and added in a dropwise 
manner. The mixture was allowed to warm to 0 oC and stirred for 4 h upon which TLC revealed full 
consumption of 2.30. The reaction mixture was diluted with CH2Cl2 (5 mL) and washed with 
saturated aqueous NaHCO3. The aqueous phase was extracted with CH2Cl2 (3 x 2.5 mL) and the 
combined organics were dried over Na2SO4, filtered and concentrated under reduced pressure. The 
crude oil was dissolved in Et2O (7.4 mL) and the solution was cooled to 0 oC. H2O (1.2 µL, 0.064 
mmol) and KO(t-Bu) (71 mg, 0.634 mmol) were added. After 30 min stirring the mixture was 
allowed to warm to room temperature and stirred for an additional 10 h. H2O (2.5 mL) was added, 
the phases were separated, and the aqueous phase was extracted with CH2Cl2 (3 x 2.5 mL). The 
combined organics were dried over K2CO3, filtered, and concentrated under reduced pressure. The 
crude oil was purified by preparative TLC (heptane:CH2Cl2:MeOH 7:7:2) to afford 2.33 (7.6 mg, 
44% over two steps) as a pale yellow oil: Rf  = 0.42 (7:7:2, heptane:CH2Cl2:MeOH); [α]D21 = +35.5 
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(c 0.96, CH2Cl2); 1H NMR (300 MHz, CDCl3) δ 7.72-7.22 (m, 15H), 4.99 (d, J = 10.9 Hz, 1H), 4.87 
(d, J = 11.6 Hz, 2H), 4.80 (d, J = 11.5 Hz, 1H), 4.71 (d, J = 11.6 Hz, 1H), 4.66 (d, J = 11.6 Hz, 
1H), 4.31-4.14 (m, 1H), 3.74-3.62 (m, 2H), 3.61-3.51 (m, 1H), 3.26 (dd, J = 10.6, 4.9 Hz, 1H), 3.16-
3.00 (m, 1H), 2.26-2.06 (m, 1H), 2.00 (t, J = 10.4, 1H), 1.94 (dd, J = 9.4, 3.6 Hz, 1H), 1.79-1.71 (m, 
1H), 1.40 (d, J = 8.1 Hz, 1H); 13C NMR (75.4 MHz, CDCl3) δ 138.8 (2C), 138.4, 128.5 (3C), 128.3, 
128.1, 127.9, 127.8, 127.6, 127.5, 87.3, 79.2, 76.9, 75.6, 74.3, 72.9, 71.8, 70.7, 54.3, 51.6, 33.6; IR 
(Neat) 3450, 3088, 3063, 3030, 2925, 2855, 2812, 1713, 1678, 1606, 1497, 1454, 1400, 1167, 1135, 
1097, 1068, 1028, 734, 697 cm-1; HRMS (ESI+) calc’d for C29H33NO4Na ([M+Na]+) 482.2303, 
found 482.2293. Spectral data are in accordance with literature values.5  
 
(3S,4R,5R,6S,7R)-3,4,5-Tris-benzyloxy-1-aza-bicyclo[5.2.0]nonan-6-ol (2.34) 
 
N
OHBnO
BnO
BnO
H
2.34  
2.34 was isolated as a byproduct from the strain-releasing cyclization of 2.32 as a pale yellow oil: Rf 
= 0.23 (heptane:CH2Cl2:MeOH = 7:7:2); 1H NMR (300 MHz, CDCl3) δ 7.36-7.25 (m, 15H); 4.82 
(d, J = 10.9 Hz, 1H), 4.55 (d, J = 11.6 Hz, 1H), 4.65 (d, J = 11.3 Hz, 1H), 4.75 (d, J = 7.1 Hz, 1H), 
4.73 (d, J = 11.2 Hz, 1H), 4.71 (d, J = 6.3 Hz, 1H), 3.76 (dd, J = 7.0, 2.7 Hz, 1H), 3.70-3.57 (m, 
3H), 3.44 (t, J = 7.6 Hz, 1H), 3.30-3.19 (m, 1H), 3.09 (dd, J = 11.1, 3.9 Hz, 1H), 3.04-2.93 (m, 3H), 
2.46 (dd, J = 10.7, 8.9 Hz, 1H), 2.33-2.18 (m, 1H), 1.90-1.81 (m, 1H); IR (Neat) 3420, 3030, 2923, 
2852, 1497, 1363, 1261, 1211, 1139, 1095, 734, 697 cm-1; HRMS (ESI+) calc’d for C29H33NO4Na 
([M+Na]+) 482.2303, found 482.2281.  
 
(1S,6S,7R,8R,8aR)-1,6,7,8-Tetrahydroxy-indolizidine, (+)-Castanospermine (2.1)  
N
H OH
BnO
BnO
BnO N
H OH
HO
HO
HO
H2, Pd/C, HCl (aq)
MeOH
(94% yield)2.33 2.1  
2.33 (23.7 mg, 0.0516 mmol) was dissolved in MeOH (7.1 mL). Pd/C (23 mg, 10% Pd) and 
concentrated HCl (78 μL) were added. The mixture was stirred under an H2-atmosphere at room 
temperature for 48 h upon which TLC revealed full conversion of 2.33. Amberlite (1.0 g, Amberlite 
IRA-400(OH)) was added. After 2 h stirring the solution was filtered through a plug of celite 
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utilizing MeOH. The filtrate was concentrated under reduced pressure to provide (+)-
castanospermine (2.1) (9.2 mg, 94%) as colorless oil that crystallized slowly. An analytical sample 
was prepared by recrystallization from EtOH: mp 209-213 oC dec (lit. mp 212-215 oC); 1H NMR 
(300 MHz, D2O) δ 4.43-4.25 (m, 1H), 3.65-3.59 (m, 1H), 3.60 (t, J = 9.3 Hz, 1H), 3.32 (t, J = 9.1 
Hz, 1H), 3.18 (dd, J = 10.8, 5.2 Hz, 1H), 3.08 (dt, J = 9.2, 2.1 Hz, 1H), 2.39-2.29 (m, 1H), 2.21 (q, J 
= 9.2 Hz, 1H), 2.06 (t, J = 10.7 Hz, 1H), 2.02 (dd, J = 9.8, 4.5 Hz, 1H), 1.71 (dddd, J = 13.8, 8.7, 
8.5, 1.3 Hz, 1H); 13C NMR (50.3 MHz, D2O) δ 78.0, 70.4, 69.1, 68.6, 68.0, 54.4, 50.6, 31.7; IR 
(Neat); [α]D21 = +72.4° (c 0.22, H2O); HRMS (ESI+) calc’d for C8H15NO4Na ([M+Na]+) 212.0894, 
found 212.0888. In accordance with literature data.1 
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3 Synthesis of the Macrocyclic Core of (–)-Pladienolide B 
3.1 Natural Product Inspired Drug Discovery 
Natural products have played a major role in the development of organic chemistry on both a 
theoretical and experimental level. The diverse natural product landscape has proven itself to be an 
invaluable resource in the search for lead agents of medicinal importance.194 The impact of 
biologically active natural products on drug development manifests itself in virtually every major 
therapeutic area. Nearly 50% of the drugs approved since 1994 are based on natural products.195 
Currently over a 100 natural-product-derived compounds are undergoing clinical trials and more 
than 100 similar projects are in preclinical trials.196   
 
One concern associated with natural products in relation to drug development is that these 
compounds were not designed for human therapeutics. Hence, while many of these molecules 
exhibit excellent in vitro and in vivo activities they may not be suitable as drugs due to undesirable 
pharmacokinetic properties and undesired side effects.197 Analogs can be pursued by post 
manipulation of the natural product, however, this practice is often complicated by the functional 
groups already in place. Another bottleneck in the development of interesting leads from natural 
products is their often limited availability from natural sources.198 This supply issue can in some 
cases e.g. the anticancer agent (+)-discodermolide199-203 be resolved through total synthesis. 
Nonetheless some natural products are too complex to manufacture a practical fashion, which will 
impact supply. Diverted total synthesis (DTS) or function oriented synthesis (FOS) are two similar 
concepts recently coined by Danishefsky204 and Wender,198 respectively. The central principle of 
these two concepts is that the function of a biologically active natural product can be imitated, fine-
tuned or improved by replacement with simpler molecular scaffolds designed to incorporate the 
pharmacophoric elements of the lead natural product. The identification of simpler scaffolds will 
allow for shorter synthesis thereby circumventing the supply issue and for facile lead 
optimization.198,204  
 
An interesting example illustrating this concept are Wender’s studies and syntheses of bryostatin 
analogs.205 The bryostatins are highly complex natural products isolated from marine bryozoa in 
only 0.00014% yield (Figure 3.1).206 This family of natural products has attracted much attention as 
3 Synthesis of the Macrocyclic Core of (–)-Pladienolide B 
 42
anticancer agents due to their ability to induce apoptosis in cancer cells.207 Furthermore, studies 
have revealed that bryostatins enhance learning and memory in animal models, which suggests a 
potential use in the treatment of cognitive impairments.208 
O O
O O
OH
O
O
OH
OHH
CO2MeO
MeO2C
HO
OAc
AB
C
O O O
O O
OH
O
O
OH
OHH
CO2MeC7H15 O
Bryostatin 1 (3.1), PKC, Ki = 1.4 nM
>70 steps total
Lead analog (3.2), PKC, Ki = 0.3 nM
29 total steps
 
Figure 3.1 Bryostatin 1 (3.1) and lead analog 3.2. 
 
Until Trost’209 recent and very concise synthesis of bryostatin 16 (39 total steps, 26-step longest 
linear sequence) chemical syntheses210-212 of bryostatins required > 70 total steps. Based on 
pharmocophoric modeling and extensive synthetic studies Wender and co-workers205,213 realized the 
preparation of the bryostatin analog 3.2 with protein kinase C (PKC) affinities comparable to 
naturally occurring bryostatin 1 (3.1). Importantly, 3.2 was available in 29 total steps, a savings of 
10 steps over the shortest synthesis of bryostatin. This illustrates how the design of new simplified 
analogs can lead to molecules superior in function to the natural product and which are accessible in 
fewer steps.  
 
3.2 The FD-895 and Pladienolide Polyketides 
3.2.1 Isolation and Structural Determination  
FD-895 (3.3, Figure 3.2) and the pladienolides (Figure 3.3) belong to a structurally unique family of 
12-membered macrocyclic polyketides. FD-895 (3.3) was isolated in 1994 by Mizoue and co-
workers214 from the fermentation broth of Streptomyces hygrosopicus. In 2004 the pladienolides 
were isolated from Streptomyces platensis Mer-11107 by way of an assay targeting compounds that 
inhibit cell signaling pathways in a tumor-specific microenvironment (Figure 3.3).215-217 These novel 
polyketides contain a 12-membered macrocyclic core, a 12-carbon diene side-chain, up to 11 
stereocenters and an E-olefin embedded in the macrocyclic ring.  
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OH
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OHOMe
FD-895 (3.3)
O
 
Figure 3.2 Planar structure of macrolide FD-895 (3.3). 
 
While the absolute configuration of FD-895 (3.3) still remain elusive the absolute configurations of 
pladienolide B (3.5) and pladienolide D (3.7) were recently determined by NMR and synthetic 
studies.168,218 The stereochemistry of the other congeners are hitherto unknown, but are expected to 
follow from 3.5 and 3.7. 
compound R1 R2 R3 R4 R5
pladienolide A (3.4) H H H H OH
pladienolide B (3.5) Ac H H H OH
pladienolide C (3.6) Ac H H
pladienolide D (3.7) Ac OH H H OH
pladienolide E (3.8) Ac H OH H OH
pladienolide F (3.9) H OH H H OH
pladienolide G (3.10) H H OH H OH
O
OH
O
OH
O
OR1
R3 R2
R5 R4
The stereochemical assignment of pladienolide B (3.5) and pladienolide D 
(3.7) were recently determined by NMR and synthetic methods.
Stereochemistry of the congerners are expected to follow from 3.5 and
3.7, but have yet to be confirmed.
O
7
 
Figure 3.3 Structure of pladienolides (A-G). 
3.2.2 Biological Activity 
FD-895 (3.3) exhibited potent in vitro anticancer activity against numerous cultured tumor cells with 
IC50-values ranging from 2-8.0 ng/mL. Moreover, FD-895 (3.3) showed strong cytocidal activity 
against HL-60/ADR cells, which are resistant to the DNA intercalating anticancer drug 
adriamycin.214 Six of the seven pladienolides were reported to inhibit hypoxia-induced gene 
expression of vascular endothelial growth factor (VEGF) in U251 human glioma cells (Table 3.1).215 
The most active pladienolides i.e. B, C and D had IC50-values in the low nanomolar range (entries 2-
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4). Furthermore the pladienolides inhibited cancer cell growth.215 Interestingly, pladienolides B, C, 
and D all have the C(7) acetyl group (pladienolide numbering) in place (cf. Figure 3.3). Lack of this 
acetate decreased the biological activity by more than two orders of magnitude as witnessed by 
pladienolides A, F, and G (entries 1 and 6,7).215  
Table 3.1 Inhibition of hypoxia-induced VEGF-PLAP secretion and anti-proliferative activity of pladienolides. 
entry compound anti-VEGF-PLAP activityIC50 (nM)
anti-proliferative activity
IC50 (nM)
1 pladienolide A (3.4) 451.5 967.5
2 pladienolide B (3.5) 1.8 3.5
3 pladienolide C (3.6) 7.4 14.7
4 pladienolide D (3.7) 5.1 6.0
5 pladienolide E (3.8) 65.2 146.8
6 pladienolide F (3.9) 2894.2 2595.2
7 pladienolide G (3.10) > 10,000 > 10,000
 
 
In addition pladienolide B (3.5) was tested in a 39-cell cancer panel experiment, which indicated 
that the compound has a unique mode of antitumor action unlike those of anticancer drugs currently 
in clinical use.217 Notably, pladienolides B (3.5) and D (3.7) also caused in vivo tumor regression in 
several human cancer xenograft models. In the most sensitive model, using BSY-1 human breast 
tumor xenografts in nude mice, tumors were completely regressed at day 15 after the first 
administration of pladienolide B(3.5).217 It has recently been reported that a derivative of 
pladienolide B has entered human clinical trials for cancer.219  
 
In 2007 Kotake and co-workers220 from Eisai, Co., Ltd. in Japan utilized differently tagged 
pladienolide B (3.5) and D (3.7) derivatives as chemical probes to identify their target protein and 
elucidate their mode of action. These studies led to a proposed mechanism involving binding to the 
splicing factor SF3b an essential component of the spliceosome.220 The spliceosome is an 
intracellular complex consisting of multiple proteins and ribonucleoproteins. This molecular 
assembly is the main cellular machinery guiding RNA-splicing, that is, the removal of non-coding 
introns from precursor messenger RNA (pre-mRNA).221,222 It has been suggested that splicing 
events may play an essential role in cancer development, thus inhibition of the spliceosome could 
serve as a novel target for anticancer drugs.223-227  
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3.3 Previous Synthetic Efforts Toward the Pladienolide Family of Natural Products 
The unique biological profile of pladienolide B has spurred considerable interest from the scientific 
community. Kotake and co-workers168 disclosed the first total synthesis of pladienolide B in 2007, 
whereas Burkart and co-workers228 have conducted synthetic studies on the pladienolide B side-
chain. The subsequent discussion will be limited to Kotake’s total synthesis.  
3.3.1 Kotake’s Total Synthesis of Pladienolide B 
The central design feature in Kotake’s approach to pladienolide B (3.5) was to install the stereogenic 
centers in a reagent-controlled manner (Scheme 3.1). Additionally, it was planned to build 3.5 
through the coupling of the side-chain moiety 3.11 and the macrolide core 3.12. The macrolide core 
3.12 was build from 3.13 and 3.14 employing an esterification and RCM sequence.168 
 
O
OH
O
OH
O
HO
O
O
O
PgO +
O
OPg
O
OPg
OPg
R2
R1
OH
R2
HO
OPg
O
OPg
OPg
+
Pladienolide B (3.5)
 C(9)-C(14) fragment
9
14
 C(1)-C(8) fragment
8
1
C(15)-C(23) fragment
23
15
7 6
3.11 3.12
3.13 3.14
 
Scheme 3.1 Kotake’s convergent approach to pladienolide B (3.5). 
 
Kotake’s synthesis of the C(1)-C(8) fragment 3.14 commenced from aldehyde 3.15 which is 
available in two steps from nerol (Scheme 3.2).229 When 3.15 was subjected to the Sm(II)-mediated 
asymmetric Reformatsky reaction disclosed by Fukuzawa and co-workers230 β-hydroxy amide 3.16 
was attained in 90% yield and 82% de. β-hydroxyamide 3.16 was smoothly converted into methyl 
ester 3.17 through a three step sequence. In order to install the hydroxy groups at C(6) and C(7) 
Kotake168 employed the Sharpless asymmetric dihydroxylation. Unfortunately, the asymmetric 
dihydroxylation only proceeded in 76% de and the resulting diastereomers were inseparable. 
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Benzylidene acetal protection of this mixture followed by removal of the PMB-group and 
recrystallization furnished the primary alcohol 3.18 as a single diastereomer. Sequential oxidation, 
Wittig olefination, and methyl ester hydrolysis gave the requisite C(1)-C(8) fragment 3.19. 
PMBO
OH
N
O
O
O
Br
Sm, CH2I2
(90% yield)
(82% de)
PMBO
OHN
O
O
O
PMBO
OTBS
O
MeO
1. LiOH, H2O2
2. TMSCH2N2
3. TBSCl, imidazole
(85% yield)
1. AD-mix-α
    MeSO4NH2
2. PhC(OMe)2, PPTS
3. DDQ
HO
OTBS
O
MeO
O
O
Ph
OTBS
O
HO
O
O
Ph
1. DMP
2. n-BuLi, Ph3PCH3Br
3. LiOH (aq)
(64% yield)
(45% yield)3.15 3.16 3.17
3.18 3.19
7 6 8
1
 
Scheme 3.2 Kotake’s synthesis of the C(1)-C(8) fragment 3.19. 
 
Construction of the C(9)-C(14) fragment 3.22 began with installation of the C(10) and C(11) 
stereogenic centers employing an anti-aldol reaction developed by Paterson and co-workers 
(Scheme 3.3).231 Aldehyde 3.20 was exposed to the boron-enolate generated from a chiral ketone 
and Cy2BCl, affording 3.21 upon silylation. An additional four steps including oxidative cleavage 
and Wittig methylenation furnished the prerequisite C(9)-C(14) unit 3.22.168   
PMBO CHO PMBO
OTBS
O
OBz
PMBO
OH
1. LiBH4
2. NaIO4
3. n-BuLi, Ph3PCH3Br
4. HCl (aq)
(72% yield)
O
OBz
1. 
   Cy2BCl, Me2NEt
2. TBSOTf, 2,6-lutidine
(81% yield)3.20 3.21 3.22
10
11
9
14
 
Scheme 3.3 Kotake’s synthesis of the C(9)-C(14) fragment 3.22. 
 
The C(1)-C(8) fragment 3.19 and the C(9)-C(14) fragment 3.22 were unified by means of a 
Yamaguchi-type232 esterification reaction (Scheme 3.4). Acid 3.19 was treated with 2,4,6-
trichlorobenzoyl chloride and the ensuing mixed acid anhydride was subjected to alcohol 3.22 and 
DMAP furnishing triene 3.23 in excellent yield. The central 12-membered lactone 3.25 was formed 
in moderate yield through a demanding RCM.168 Subsequent deprotection and oxidation gave 3.26, 
poised to undergo coupling with a side-chain fragment. 
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Ru
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Mes Mes
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O
HO
O
O
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2,4,6-trichlorobenzoyl chloride
Et3N, THF then
3.22, DMAP, PhMe
(93% yield)
OTBS
O
O
O
O
Ph
PMBO
3.24, BHT
PhMe, 110 oC
(49% yield)
O
O
O
Ph
O
OTBS
O
H
O
O
O
Ph
O
OTBS
PMBO
1. DDQ
2. DMP
(80% yield)
3.19 3.23
3.25 3.26 3.24  
Scheme 3.4 RCM approach to macrolide moiety 3.26. 
 
Preparation of the side-chain C(15)-C(23) fragment 3.33 started from the known β-hydroxy amide 
3.27 (Scheme 3.5).168 Treating 3.27 with N,O-dimethylhydroxylamine hydrochloride and trimethyl 
aluminium furnished the corresponding Weinreb amide, which upon silylation and DIBAL-
reduction gave aldehyde 3.28 in excellent yield for this three step sequence. Next, the Julia-
Kocienski-olefination233 was employed to couple 3.29 and aldehyde 3.28, which provided the 
requisite trans-olefin 3.30 exclusively.  
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Scheme 3.5 Synthesis of the C(15)-C(23) side-chain fragment 3.33. 
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After removal of the benzyl-group, the ensuing alcohol was transformed into sulfone 3.31 with 
concomitant desilylation during the oxidation. The side-chain fragment was completed utilizing the 
asymmetric Shi-epoxidation234,235 followed by silylation to afford the desired epoxide 3.33 as a 
single diastereomer after recrystallization. 
 
With access to the side-chain fragment 3.33 and macrolide 3.26 Kosake and co-workers168 sought to 
couple these employing the Julia-Kocienski-olefination (Scheme 3.6). In the event, exposing 
macrolide 3.26 to sulfone 3.33 and KHMDS afforded the desired E,E-diene 3.34 in good yield. 
Initial attempts to effect global deprotection of 3.34 under acidic conditions were hampered by the 
hydrolytic stability of the benzylidene group as well as opening of the epoxide by the C(21) hydroxy 
group forming a tetrahydrofuran ring.  Therefore, the two silyl-groups were converted into acid-
stable dichloroacetyl groups and the benzylidene group was removed with PPTS and MeOH 
furnishing diol 3.35. Ultimately, methanolysis of 3.35 followed by regioselective acetylation of the 
more nucleophilic hydroxy group at C(7) gave pladienolide B 3.5. 
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O
OH
O
O
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Scheme 3.6 Kotake’s end-game. 
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In summary, Kotake and co-workers168 have completed the first total synthesis of pladienolide B. 
The longest linear sequence contains 22 steps from nerol providing 3.5 in 2.1% overall yield. This 
synthesis confirmed the absolute stereochemistry of pladienolide B (3.5). Key to the completion of 
3.5 was the implementation of a RCM reaction to forge the 12-membered macrolide. Additionally, 
the exploitation of the Julia-Kocienski-olefination to install the side-chain allows for late-stage 
modifications and provides a practical route to novel pladienolide B analogs.  
 
3.4 Idea, Stereochemical Rationale, and Retrosynthesis 
Our interest in pladienolide B and closely related congeners was prompted by the highly interesting 
biological profile displayed by this family of natural products. The highly potent in vitro and in vivo 
antitumor activity as well as the unique mechanism of action presented by this class of compounds 
makes pladienolide B (3.5) a promising lead structure in the identification of novel anti-cancer 
agents. At the onset of our synthetic endeavors in April 2005 only the planar structure of 
pladienolide B had been reported.216 Structurally, the macrocyclic core of pladienolide bares a 
strong resemblance to 10-deoxymethynolide (3.36) the aglycon of the known antibiotic 
neomethymycin that is produced by Streptomyces venzuelae (Figure 3.4).236 Moreover the side-
chain of pladienolide B is closely related to the side-chain of herboxidiene (3.37), which was 
isolated from Streptomyces A7947.237,238  From an evolutionary point of view it is feasible that 
pladienolide B (3.5) and other secondary metabolites such as 10-deoxymethynolide (3.36) and 
herboxidiene (3.37) could be synthesized by polyketide synthases encoded by related gene 
clusters.239-242 Consistent with a common biogenesis for these polyketides we hypothesized that the 
absolute stereochemistry of the macrocyclic core 3.38 would correlate with that of 3.36 and 3.37. 
Thus we focused our synthetic studies on the projected core structure 3.38, the enantiomer of the 
(+)-pladienolide B (3.5) core. A successful synthesis of this macrocyclic core could potentially 
clarify whether it is the core structure that is responsible for the biological activity. Additionally, a 
successful synthetic strategy to the macrocyclic core would provide an excellent platform for further 
analog synthesis and structure activity relationship plotting.  
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Figure 3.4 Streptomyces metabolites and projected core structure 3.38. 
 
In targeting the core structure 3.38 we sought to install the stereogenic centers in a purely reagent 
controlled fashion allowing for maximum flexibility and access to all sixteen stereoisomers (Scheme 
3.7). We envisioned cleavage of the 12-membered macrolide by scission of the C(1)-O ester bond 
and the C(8)-C(9) bond affording a C(9)-C(11) fragment 3.39 and a C(1)-C(8) fragment 3.40. We 
expected that these fragments could be coupled employing Julia-Kocienski-olefination233,243 and 
macrolactonization. 
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Scheme 3.7 Retrosynthesis of (−)-pladienolide B core (3.38). 
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The C(9)-C(11) fragment 3.39 could arise from the commercially available bromide 3.41. 
Importantly, both enantiomers of this bromide are available. We anticipated that the vicinal oxygen-
substituted stereocenters could be installed employing the Sharpless asymmetric dihydroxylation.244 
Key intermediate 3.42 would result from a chiral auxiliary-mediated acetate aldol condensation of 
an acetylthiazolidinethione245 3.43 and aldehyde 3.44, ultimately available from nerol.  
 
3.5 Preparation of the C(1)-C(8) Aldehyde Fragment  
3.5.1 The Asymmetric Acetate Aldol Reactiona 
Construction of the prerequisite aldehyde 3.44 became the first problem at hand (Scheme 3.8). The 
synthesis commenced from cheap and commercially available nerol (3.45). Initially nerol (3.45) was 
treated with acetic anhydride and triethylamine to give 3.46. Acetate 3.46 was converted into 
epoxide 3.47 by exposure to mCPBA, which was subsequently opened and cleaved using aqueous 
periodic acid to furnish the desired aldehyde 3.44.246 This product was conveniently distilled in high 
yield. 
mCPBA, CH2Cl2
    -20 to 0 oC
(81% yield)
AcO
AcOH5IO6 (aq)
THF, 0 oC 
(86% yield)
HO
Ac2O, Et3N, DMAP
22 oC
(80% yield)
AcO
O
OH
nerol (3.45) 3.46 3.47
3.44  
Scheme 3.8 Preparation of aldehyde 3.44. 
 
In efforts to install the hydroxy-substituted stereocenter at C(3) we recruited an auxiliary-mediated 
asymmetric acetate aldol reaction. The development of auxiliary-based asymmetric acetate aldol 
reactions have proven to be difficult247 in comparison to the auxiliary-based diastereoselective 
propionate aldol reactions pioneered by Evans and co-workers.248 The auxiliaries, such as Evan’s N-
oxazolidinones, which have provided excellent diastereoselectivities in various aldol additions, only 
afforded poor selectivities in the acetate aldol addition.249 The diminished diastereoselectivity of the 
                                                 
a The research described in this chapter was conducted in collaboration with Dr. Philip R. Skaanderup. 
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acetate aldol reaction in comparison to the high level of diastereoselectivity attainable in propionate 
aldol reactions, has been attributed to the lack of α-substitution of the enolate, which is believed to 
be an important stereocontrol element.250 Following pioneering work by Nagao and Fujita,245 the 
research groups of Vilarrasa,251,252 Crimmins,250 and Sammakia253,254 have shown that 
thiazolidinethione-based auxiliaries can overcome this impediment and furnish high level of 
diastereoselectivities in the acetate aldol addition. 
 
A small library of thiazolidinethione auxiliaries were prepared in order to uncover suitable reaction 
conditions for the asymmetric acetate aldol reaction. Synthesis of the thiazolidinethione auxiliaries 
was readily accomplished from the corresponding amino acids (Scheme 3.9). Subjecting an amino 
acid to in situ generated borane furnished the corresponding amino alcohol,255 which was smoothly 
converted to the corresponding thiazolidinethione (3.48, 3.49, and 3.50) upon exposure to a 
refluxing mixture of carbon disulfide and 2.0 M KOH.256 Compounds 3.48 and 3.49 were easily 
recrystallized from ethanol and diethyl ether, respectively, while 3.50 had to be purified using silica-
gel chromatography. These auxiliaries were subsequently acylated with acetyl chloride in the 
presence of triethylamine furnishing 3.51, 3.52, and 3.53 in excellent yields. Notably, both 3.52 and 
3.53 were viscous oils while 3.51 was readily recrystallized from ethanol on > 20 gram scale.  
AcCl, DMAP (10 mol%)
Et3N
CH2Cl2, 22 oC
NS
S
R
O
NHS
S
R
HO
NH2
R
O 1. NaBH4, I2
    THF, 0 to 65 oC
2. CS2, KOH (aq)
    110 oC
R = Bn: 3.48 (83% yield)
R = i-Pr: 3.49 (64% yield)
R = t-Bu: 3.50 (68% yield)
R = Bn: 3.51 (90% yield)
R = i-Pr: 3.52 (92% yield)
R = t-Bu: 3.53 (94% yield)  
Scheme 3.9 Synthesis of thiazolidinethione auxiliaries. 
 
After screening a range of different tertiary amine bases including triethylamine, (−)-sparteine and 
TMEDA in combination with titanium tetrachloride for enolization of the thiazolidinethione 
auxiliaries, we found that diisopropylethylamine (Hünig’s base) provided superior yields and 
selectivities.251 Treating the auxiliaries with titanium tetrachloride and Hünigs base at -40 oC 
followed by addition of aldehyde 3.44 gave the desired aldol condensation products 3.54-3.56 in 
good yields and with moderate diastereoselectivity (Table 3.2). Notably, the reaction had to be 
stirred at -78 oC for 22 h to reach full conversion. Previously Vilarrasa251 reported that this type of 
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transformation had reached full conversion within ten minutes. A possible explanation for this 
significant rate difference could be competing coordination of the acetate group to the Lewis acid. 
Table 3.2 Screening of thiazolidinethione auxiliaries. 
entry R %yield (a)a %yield (b) %yield (a + b) dr (a:b)
1 Bn 70 19 89 4:1
2 i-Pr 68 14 82 5:1
3 t-Bu 74 13 87 6:1
OHN
O
AcO
OHN
O
AcOAcO
NS
S
R
O
OH
+
TiCl4, DIPEA
-40 to -78 oC
22 h SS
SS
R R
+
R = Bn:                              
R = i-Pr:                                
R = t-Bu:
a Isolated yields.
1.7 equiv 1.0 equiv
3.54b
3.55b
3.56b
3.54a
3.55a
3.56a
 
 
Although both the valine 3.52 and the tert-leucine-derived 3.53 auxiliaries afforded slightly 
improved product ratios (entries 2 and 3), we settled for the phenylalanine-derived auxiliary, since 
all intermediates leading to 3.51 were highly crystalline allowing for easy purification during scale-
up. Interestingly, if the enolate of 3.51 was generated from dichlorophenylborane and (−)-sparteine 
as disclosed by Sammakia.253 3.54b was attained as the major product (Scheme 3.10). Hence, 
employing the same acetylthiazolidinethione 3.51 for diastereomeric control we were able to access 
either diastereomer 3.54a or 3.54b as the major product by fine-tuning the reaction conditions.a  
OHN
O
AcO
OHN
O
AcOAcO
NS
S
Bn
O
OH
+
PhBCl2, (−)-sparteine
CH2Cl2,-78 oC
SS
SS
Bn Bn1.3 equiv 1.0 equiv
(63% yield)(11% yield) 1:6 d.r.
+
3.54a 3.54b
 
Scheme 3.10 Accessing 3.54b as the major product. 
 
The observed selectivity in the titanium tetrachloride-mediated acetate aldol reaction can be 
explained by at least two different transition state models (Figure 3.5). Crimmins and co-workers250 
                                                 
a The absolute stereochemistry of 3.54b was assigned using Mosher’s ester analysis (Dale, A. J.; Mosher, H. S. J. Am. 
Chem. Soc. 1973, 95, 512-519). This experiment was carried out by Dr. Philip R. Skaanderup. 
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have invoked a highly ordered chelated transition state 3.57. In this case the diastereoselectivity 
would arise from the preference of the R-group to adopt a pseudoequatorial position to avoid any 
1,3-diaxial interactions with the auxiliary. In contrast, Evans257 has suggested a boat-like transition 
state 3.58, which is supported by semiempirical calculations reported by Houk and co-workers.258  
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Figure 3.5 Possible models to account for the observed stereoselectivity. 
 
Sammakia253 have proposed the open transition state 3.59 to account for the stereochemistry in the 
dichlorphenylborane-mediate acetate aldol condensation. The closed chair transition state 3.60 may 
also be operative. The conformation of the closed transition state 3.60 can possibly be explained by 
a tendency to minimize the dipole interactions between the thiocarbonyl group of the auxiliary and 
the developing carbonyl of the aldolate.253 However, this interpretation is possibly an 
oversimplification, since Evans249 has shown that dipole effects are not a decisive stereochemical 
control element in the case of oxazolidinone auxiliary-mediated aldol reactions.  
3.5.2 Installation of the C(7) and C(6) Stereocenters 
The successful execution of the acetate aldol reaction allowed us to focus on the diastereoselective 
installation of the C(6) and (7) hydroxy groups. To this end we decided to employ the Sharpless 
asymmetric dihydroxylation (Scheme 3.11).244,259 After TBS-protection of the C(3) hydroxy group, 
compound 3.61 was exposed to standard Sharpless asymmetric dihydroxylation conditions using 
(DHQD)2PHAL (3.62) to induce stereoselectivity.260 The desired diol 3.63a was attained in 80% 
yield and greater than 20:1 diastereoselectivity at the newly formed stereocenters. Unfortunately, the 
secondary acetate 3.63b was also formed in 15% yield and all attempts to convert this byproduct 
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into 3.63a were unsuccessful. Nonetheless, we settled for these reaction conditions, since 3.63a was 
produced with excellent diastereoselectivity and furthermore 3.63a and 3.63b were easily separated 
by silica-gel chromatography. The depicted stereochemistry was assigned employing Sharpless’ 
empirical model (mnemonic device),260 which has recently been updated by Norrby and co-
workers.261,a 
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Scheme 3.11 Installation of the C(7) and C(6) hydroxy groups. 
 
The key aldehyde fragment 3.66 was smoothly prepared from diol 3.63a (Scheme 3.12). Treating 
3.63a with 2,2’-dimethoxypropane under acid conditions furnished acetonide 3.64 in excellent yield. 
Subsequent exposure to K2CO3 in methanol afforded acetate cleavage and concomitant methyl ester 
formation to provide the requisite primary alcohol 3.65.  
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Scheme 3.12 Synthesis of the key C(1)-C(8) fragment 3.66. 
                                                 
a This assignment was later confirmed by X-ray crystallography (cf. Chapter 3.8). 
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Subjecting the primary alcohol 3.65 to Parikh-Döring oxidation conditions gave aldehyde 3.66 in 
good yield. Aldehyde 3.66 could be purified using silica-gel chromatography without epimerization, 
however, in general it was used in its crude form. 
 
3.6 The Julia-Kocienski-Olefination Approach to Fragment Coupling 
Based on the seminal publications by Julia243 and Kocienski233 a one-pot alternative to the classical 
Julia-olefination,262 namely the Julia-Kocienski olefination, has emerged as a powerful tool for 
advanced fragment linkage and olefin formation in total synthesis.263,264 Our studies on the Julia-
Kocienski-olefination began with the synthesis of C(9)-C(11) sulfone fragments 3.70 and 3.71 
(Scheme 3.13). These sulfones were easily prepared from commercially available bromide 3.41. 
Treating 3.41 with DMAP and TBSCl furnished 3.67 in excellent yield. The heterocyclic sulfones 
3.70 and 3.71 were prepared from 3.67 by a two step S-alkylation/S-oxidation sequence. Alkyl 
bromide 3.67 was condensed with 1-phenyl-1H-tetrazole-5-thiol or 2-mercaptobenzothiazole in the 
presence of cesium carbonate affording the required sulfides 3.68 and 3.69 in high yield. These 
heteroarylthioethers 3.68 and 3.69 were easily oxidized to corresponding sulfone fragments 3.70 and 
3.71 when exposed to mCPBA. 
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Scheme 3.13 Synthesis of the C(9)-C(11) sulfones 3.70 and 3.71. 
 
With 3.70 and 3.71 in hand, a careful survey of conditions for the fragment coupling was conducted 
(Table 3.3). It was found that deprotonating sulfone 3.70 with KHMDS followed by addition of 
aldehyde 3.66 under conditions reported by Kocienski265 to furnish high E-selectivity gave an 
inseparable mixture of 3.72a and 3.72b (E:Z = 1:1) in low yield (entry 1). Ishigami266 has recently 
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shown that adding 18-crown-6 led to improved levels of E-selectivity and yield. Unfortunately, in 
our case the yield and selectivity remained low under these reaction conditions (entry 2). 
Implementing very polar and strongly coordinating solvents for this transformation as described by 
Jacobsen267 furnished the desired E-alkene exclusively, but in unsatisfactory yield (entry 3). Finally, 
it was attempted to implement sulfone 3.71 under reaction conditions disclosed by 
Ramachandran,268 which provided good selectivity but low yield (entry 4). 
Table 3.3 Attempted Julia-Kocienski olefination. 
entry sulfone base/additive solvent T(oC)a 3.72a (E):3.72b(Z)b % yield (a+b)c
1 3.70 KHMDS DME -78 to 22 oC 1:1 11
2 3.70 KHMDS/18-crown-6 THF -78 to 22 oC 1:1 13
3 3.70 LiHMDS DMF:DMPU = 1:1 -35 to 22 oC "E only" 18
4 3.71 NaHMDS DMF -60 to 22 oC 8:1 23
O
OTBSMeO
O
O
O  various olefination
    conditions
OTBSMeO
O
TBSO
OTBSMeO
O
TBSO
+
3.72a 3.72b3.66
a Base (1.05 equiv) and sulfone (1.1 equiv) was stirred at the indicated start temperature for 10 min. 3.66 (1.0 equiv) was added and then 
the mixture was allowed to warm to 22 oC (room temperature). b Determined by 1H NMR analysis of the crude product mixtures. c Isolated 
yield, 3.72a and 3.72b were inseparable by silica-gel chromatography.
H
O
O
O
O
 
 
In all cases unreacted aldehyde 3.66 could be recovered from the reaction mixture, thus the low 
yield for this transformation may most likely be attributed to the highly congested sterical 
environment of aldehyde 3.66 as well as competing self-condensation of the sulfones. Further 
attempts to perform this transformation under Barbier-type conditions in order to limit potential self-
condensation of the sulfones were fruitless.264 The low yields of these reactions were detrimental to 
our synthetic endeavors toward the macrocyclic core of (−)-pladienolide B, hence we settled for 
alternative ways to install the C(8)-C(9) (E)-alkene. 
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3.7 The Metathesis-Esterification Approach 
Two alternative strategies to the Julia-Kocienski-olefination approach were considered. We 
envisioned that the macrocyclic core 3.38 could arise from an esterification ring-closing metathesis 
sequence or through cross-metathesis followed by macrolactonization (Scheme 3.14). The requisite 
C(9)-C(11) coupling partner 3.73 would be available from commercial (S)-Roche ester, while the 
C(1)-C(8) fragment 3.74 could be attained from aldehyde 3.66 (cf. Scheme 3.11).  
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Scheme 3.14 Metathesis esterification approach to the macrocyclic core 3.38. 
 
3.7.1 The Esterification-Ring-Closing Metathesis Approach 
Preparation of the requisite acid 3.77 was achieved from alcohol 3.65 employing a three-step 
oxidation, Wittig methylenation, and ester hydrolysis sequence (Scheme 3.15).  
OTBSMeO
O
HO
OTBSMeO
O
OTBS
O
HO
1. SO3 pyr, DMSO, DIPEA
    CH2Cl2 -30 to -15 oC
2. n-BuLi, Ph3PCH3Br
    THF, -78 oC
(72% yield)
LiOH (aq)
THF, 22 oC
(91% yield)
MeO O
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3.773.65
O
O
O
O
O
O
O
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Scheme 3.15 Preparation of acid 3.77. 
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Significantly, aldehyde 3.66 had to be stirred with the phosphonium ylide at -78 oC for at least 12 h 
to reach full conversion. Premature warming to ambient temperature furnished low yields of the 
desired product 3.75, likely due to competing deprotonation reactions. In some cases 5-10% of 3.76, 
resulting from elimination of the OTBS-group, were isolated. Hydrolysis of methyl ester 3.75 gave 
3.77 in excellent yield. 
 
The alkene building block 3.82 was prepared from (S)-Roche ester (3.78) through a five-step 
sequence (Scheme 3.16). Initial tritylation followed by lithium aluminum hydride reduction, Swern 
oxidation, and Wittig methylenation afforded the tritylated alcohol 3.73 smoothly. Implementing 
BCl3 followed by methanol269 for deprotection of 3.73 cleanly generated the primary alcohol 3.82 by 
TLC, however, facile isolation of this compound was precluded due to the volatility of this 
compound. Hence, it was decided to use 3.82 as a solution in CH2Cl2 for the subsequent 
esterification reaction. 
O
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OTr
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O
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TrCl
DMAP, Et3N
CH2Cl2, 23 oC
(96% yield)
LiAlH4
THF, 0 oC
(98% yield)
(COCl)2
DMSO, Et3N
CH2Cl2, -78 oC
(96% yield)
n-BuLi, Ph3PCH3Br
THF, -78 to 22 oC
(89% yield)
BCl3
CH2Cl2, -30 oC
then MeOH OH
clean reaction by TLC
attained as a solution in CH2Cl2
3.73
(S)-Roche ester (3.78) 3.79 3.80 3.81
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Scheme 3.16 Preparation of alkene building blocks 3.73 and 3.82. 
 
An esterification reaction between acid 3.77 and alcohol 3.82 utilizing the protocol of Yamaguchi 
and co-workers232 afforded the bis terminal olefin 3.83 in good yield (Scheme 3.17). Next, the key 
RCM reaction was investigated. After surveying a range of different RCM-conditions we found that 
the macrocycle 3.84 could be obtained in 23% yield when exposed to Hoveyda-Grubbs’ 2nd 
generation catalyst145 3.24 in refluxing dichloromethane under highly dilute conditions. Several 
unidentified products, likely resulting from dimerization and isomerization163,164 of the double bonds 
were observed by TLC. The sterically demanding nature of the C(8) alkene, the presence of an 
allylic methyl group270 as well as the potential chelation of the catalyst to the ester moiety169-172 can 
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explain the difficulties associated with this RCM. Additionally, several other groups have reported 
limited success in forming 12-membered rings utilizing RCM.271,272 
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Scheme 3.17 RCM approach to macrocycle 3.84. 
 
Concurrent with our efforts toward implementing the esterification-RCM approach we had initiated 
investigations on a cross-metathesis macrolactonization sequence to couple the C(9)-C(11)-fragment 
3.73 and forge the 12-membered macrocycle. Recognizing that the RCM would require extensive 
optimization to provide meaningful yields of the desired macrocycle, combined with the 
achievement of positive results in our cross-metathesis approach (cf. Chapter 3.7.2) led us to pursue 
the latter strategy.  
3.7.2 The Cross Metathesis-Macrolactonization Approach 
With 3.73 and 3.75 in hand we set out to investigate the cross-metathesis macrolactonization 
sequence to form the C(8)-C(9) E-olefin and forge the 12-membered macrocycle (Scheme 3.18). At 
the outset of our coupling studies, a number of conditions were tested with limited success. Treating 
3.75 with 10 mol% of Grubbs’ 2nd generation-catalyst143 or Hoveyda-Grubbs’ 2nd generation-
catalyst145 and two equivalents of 3.73 in refluxing dichloromethane furnished less than 30% of the 
desired alkene.  However, two important observations from these experiments were encouraging; 
3.75 was not undergoing homodimerization, and only the (E)-alkene 3.85 was being formed from 
3.75. In addition we found that 3.73 underwent homodimerization to furnish 3.86 on prolonged 
stirring. In an attempt to avoid competing dmierization of 3.73, we decided to use 3.86 for the cross-
metathesis reaction in combination with the more stable Hoveyda-Grubbs’ 2nd generation catalyst. 
This approach was met with little success, since 3.86 was only slowly participating in the desired 
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CM-process. Finally, it was attempted to add four equivalents of 3.86 in two portions over the 
course of the reaction. Moreover, the catalyst loading was increased to 20 mol% of Hoveyda-Grubbs 
2nd generation catalyst (added in three portions). Satisfyingly, this afforded the desired (E)-alkene 
3.85 in 76% yield. With this result at hand we decided to venture forward eager to explore the key 
macrolactonization. 
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Scheme 3.18 Synthesis of seco-acid 3.88. 
 
As a prelude to the macrolactonization we had to selectively unmask the trityl protected hydroxy 
group and hydrolyse the methyl ester functionality. Conventional protocols for selective removal of 
the trityl blocking group using formic acid in ether273 or diethyl aluminium chloride in 
dichloromethane274 were unsatisfactory and led to multiple byproducts possibly resulting from 
competing desilyation and/or acetonide cleavage. Therefore we employed BCl3 in combination with 
methanol, which has been reported by Jones269 to selectively cleave trityl-ethers in the presence of 
silyl-protecting groups. Gratifyingly, when 3.85 was treated with BCl3 at -30 oC followed by 
quenching with methanol 3.87 was obtained cleanly in 84% yield. Subsequent methyl ester 
hydrolysis using lithium hydroxide furnished the prerequisite seco-acid 3.88 in quantitative yield.  
 
In order to close the macrocycle we settled for the Yamaguchi-protocol, which has proved itself to 
be an excellent methodology for performing macrolactonizations in numerous total syntheses.275 In 
the classical procedure a mixed anhydride is preformed between 2,4,6-trichlorobenzoyl chloride and 
a seco-acid in tetrahydrofuran in the presence of triethylamine. After filtration of the NEt3-HCl salt, 
the mixed anhydride is added slowly to a highly diluted solution of DMAP in toluene or benzene at 
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reflux.232 A popular modification of this protocol was developed by Yonemitsu.276 Yonemitsu 
observed that the direct addition of a large excess of DMAP to a highly dilute solution of the 
preformed mixed anhydride, generally at ambient temperature, afforded macrolactonization in high 
yield. Two advantages of this “modified” Yamaguchi protocol are that slow addition of the mixed 
anhydride is unnecessary and the milder reaction conditions (room temperature vs. reflux in benzene 
or toluene). Initially we attempted to close the macrocycle using the “modified” Yamaguchi 
procedure, which presented the mildest reaction conditions. Although a rapid reaction was taking 
place affording rapid conversion of the mixed anhydride, the desired macrolactone 3.84 was only 
isolated in a moderate 34% yield (Scheme 3.19).a Therefore we decided to implement the classical 
Yamaguchi-protocol. We found that adding the preformed mixed anhydride slowly over one hour to 
a refluxing solution of DMAP in benzene furnished the desired macrolactone in 63% yield (final 
cyclization concentration 0.0004 M). Neither an increase in the reaction temperature by switching to 
toluene nor a decrease in reaction temperature improved this yield.  
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Scheme 3.19 Macrolactonization. 
 
3.8 Completion of the Macrocyclic Core of (−)-Pladienolide B 
With the prerequisite macrolactone 3.84 at hand we investigated ways to concomitantly remove the 
acetonide and TBS groups (Scheme 3.20). Initially we attempted to subject 3.84 to different 
mixtures of THF, AcOH, H2O at room temperature or 50 oC. Even after prolonged heating i.e. 48 h 
at 50 oC only low conversion was observed. Therefore we decided to implement deblocking 
conditions previously deployed by Nicolaou and co-workers277 in their total synthesis of the 
kinamycins. In the event, macrolactone 3.84 was dissolved in acetonitrile at room temperature and 
treated with aqueous HF furnishing the desired triol 3.89 in excellent yield. 
                                                 
a The major byproducts from this reaction are likely oligomers/dimers. 
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Scheme 3.20 Completion of the macrocyclic core of (−)-pladienolide B (3.38). 
 
Having finally arrived at triol 3.89 the completion of the macrocyclic core structure of (−)-
pladienolide B required differentiation between the C(3), C(6), and C(7) hydroxy groups.  This was 
easily achieved by treating triol 3.89 with trimethyl orthoacetate and CSA followed by cleavage of 
the putative cyclic orthoester 3.90 with aqueous acetic acid. The exquisite regioselectivity of this 
acetylation is most likely caused by a propensity to place the acetyl-group on the sterically less 
congested secondary hydroxy group at C(7). Satisfyingly, we were able to attain X-ray quality 
crystals of 3.38 by recrystallization from diisopropylether (DIPE) and methanol. Thus based on the 
known stereochemistry of coupling fragment 3.73, which relates back to the (S)-Roche ester, the 
structure and absolute stereochemistry of the (−)-pladienolide B core 3.38 was unambiguously 
assigned by single-crystal X-ray crystallography (Figure 3.6). Gratifyingly, this result verifies the 
absolute stereochemistry that was previously assigned by Mosher ester analysis (the acetate aldol) 
and by analogy (the Sharpless asymmetric dihydroxylation).  
OH
O
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macrocyclic core of
(−)-pladienolide B (3.38)
 
Figure 3.6 X-ray crystal structure of the macrocyclic core of (−)-pladienolide B (3.38). 
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The triol 3.89 and the (−)-pladienolide B core 3.38 were tested against a cancer cell line proliferation 
assay. To our disappointment these compound exhibited no activity. This can possibly be ascribed to 
the fact that we have targeted the enantiomeric core of (+)-pladienolide B (3.5). However, recent 
studies by Webb278 on (+)-pladienolide B (3.5) inspired compounds have shown that both the epoxy 
group and carbonyloxy are key pharmocophoric elements. Moreover, an appropriately constrained 
linker to impart a proper conformational presentation of the functional groups was crucial to obtain 
biological activity. In combination with our observations this seems to suggest that the side-chain 
moiety is essential for potent anticancer activity. 
 
3.9 Summary 
Hitherto the project has culminated in an efficient synthesis of the macrocyclic core of (−)-
pladienolide B (3.38) i.e. the enantiomer of the (+)-pladienolide B core (Scheme 3.21). The 
macrocyclic core 3.38 was achieved in 16 steps and 6.5% overall yield starting from nerol. The 
synthesis relied on a chiral auxiliary-mediated asymmetric aldol addition and the Sharpless 
asymmetric dihydroxylation to install the three oxygen substituted stereocenters at C(3), C(6), and 
C(7). The macrocyclic core was forged using an (E)-selective cross-metathesis followed by 
Yamaguchi-macrolactonization. The C(7) acetyl group was efficiently installed utilizing orthoester 
ring-opening. Unfortunately, this structure 3.38 exhibited no anti-cancer activity. 
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Scheme 3.21 Synthesis of the macrocyclic core of (−)-pladienolide B. 
 
While this synthesis has targeted the enantiomeric core of (+)-pladienolide B it still retains its 
validity, since the strategy is purely reagent controlled. Thus the knowledge gathered throughout 
these studies can easily be applied in the synthesis of both the macrocyclic core of (+)-pladienolide 
B as well as more advanced analogs. Unfortunately, time constraints precluded the author from 
pursuing these intriguing aspects of the project. 
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3.10 Experimental 
3.10.1 Materials and Methods 
See chapter 2.7.1 for general experimental information. 
3.10.2 Synthesis of the Macrocyclic Core of (−)-Pladienolide B 
Neryl Acetate (3.46) 
AcOHO
Ac2O, Et3N, DMAP
22 oC
(80% yield) 3.46  
To a stirred solution of nerol (57 mL, 0.32 mol) in CH2Cl2 (150 mL) was added Et3N (89 mL, 0.64 
mol) and DMAP (1.0 g, 8.2 mmol) followed by dropwise addition of Ac2O (45 mL, 0.48 mol). The 
reaction mixture was stirred at 22 oC for 1 h then diluted with Et2O (800 mL). The mixture was 
washed with saturated aqueous CuSO4 (3 x 200 mL), H2O (150 mL), and brine (150 mL), dried over 
MgSO4, and concentrated in vacuo to afford a pale yellow oil. The crude oil was distilled (bp 89-90 
°C, 1 mbar lit. bp.279 136-140  °C, 60 mbar) to afford 3.46 (50.1 g, 80% yield) as a colorless oil: Rf = 
0.56 (heptane:EtOAc = 4:1); 1H NMR (300 MHz, CDCl3) δ 5.35 (dq, J = 7.3, 1.4 Hz, 1H), 5.11-5.05 
(m, 1H), 4.55 (dq, J = 7.3, 0.9 Hz, 2H), 2.16-2.04 (m, 4H), 2.04 (s, 3H), 1.77-1.75 (m, 3H), 1.67 (d, 
J = 0.9 Hz, 3H), 1.59 (d, J = 0.7 Hz, 3H); 13C NMR (75.4 MHz, CDCl3) δ 171.0, 142.6, 132.1, 
123.4, 119.0, 61.0, 32.1, 26.5, 25.6, 23.4, 21.0, 17.6; IR (film) 2968, 2932, 1742, 1733, 1447, 1377, 
1234, 1023, 956, 826. Spectral data are in accordance with literature values.280  
 
Acetic acid (Z)-5-(3,3-dimethyl-oxiranyl)-3-methyl-pent-2-enyl ester (3.47) 
mCPBA, CH2Cl2
    -20 to 0 oC
(81% yield)
AcO AcO
O
3.473.46  
Acetate 3.46 (20.0 g, 0.102 mol) was dissolved in CH2Cl2 (100 mL) and cooled to -20 °C using a 
MeOH/ice bath. mCPBA (27.6 g, 0.112 mol, ~70% pure) as a suspension in CH2Cl2 (400 mL) was 
added over 2 h keeping the internal temperature below -5 °C. The cooling bath was removed and the 
mixture was stirred for an additional 2 h at 22 oC. The mixture was cooled to 0 °C using an ice/water 
bath, Ca(OH)2 (31 g, 0.42 mol) was added, and the suspension was stirred for an additional 30 min. 
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The resulting suspension was filtered and the filter cake was washed with CH2Cl2 (250 mL). The 
combined organic phases were washed with brine (100 mL), dried over MgSO4, and concentrated in 
vacuo to afford an oil. The crude oil was distilled (bp 108-110 °C, 3 mbar, lit. bp.279 108-110° C, 2.7 
mbar) to afford 3.47 (17.6 g, 81% yield) as a colorless oil: Rf = 0.27 (heptane:EtOAc = 4:1); 1H 
NMR (300 MHz, CDCl3) δ 5.39 (t, J = 7.3 Hz, 1H), 4.57 (d, J = 7.3 Hz, 2H), 2.69 (t, J = 6.3 Hz, 
1H), 2.24 (t, J = 7.8 Hz, 2H), 2.0 (s, 3H), 1.78-1.77 (m, 3H), 1.73-1.54 (m, 2H), 1.29 (s, 3H), 1.25 
(s, 3H);  13C NMR (75.4 MHz, CDCl3) δ 171.0, 141.7, 119.7, 63.7, 60.8, 58.3, 28.8, 27.5, 24.8, 23.4, 
21.0, 18.7; IR (film) 2964, 1740, 1458, 1379, 1236, 1119, 1024, 956, 866, 68. Spectral data are in 
accordance with literature values.246 
 
Acetic acid (Z)-3-methyl-6-oxo-hex-2-enyl ester (3.44) 
AcO
H5IO6 (aq)
THF, 0 oC 
(86% yield)
AcO
O OH
3.47 3.44  
Epoxide 3.47 (10.3 g, 0.048 mol) was dissolved in THF (100 mL), cooled to 0 °C using an ice/water 
bath, and a solution of H5IO6 (13.2 g, 0.058 mol) in water (100 mL) was added in a dropwise 
manner over 30 min. The mixture was stirred at 0 °C for an additional 4 h. The mixture was diluted 
with Et2O (300 mL), washed with brine (2 x 50 mL), dried over MgSO4, and concentrated in vacuo 
to afford a colorless oil. The crude oil was distilled (bp 89-90 °C, 1 mbar, lit. bp.5 102-105 °C, 2.7 
mbar) to afford 3.44 (7.0 g, 86% yield) as a colorless oil: Rf = 0.18 (heptane:EtOAc = 4:1); 1H NMR 
(300 MHz, CDCl3) δ 9.77 (t, J = 1.4 Hz, 1H), 5.42-5.36 (m, 1H), 4.58-4.56 (m, 2H), 2.58-2.52 (m, 
2H), 2.45-2.39 (m, 2H), 2.04 (s, 3H), 1.75 (dt, J = 1.0, 2.3 Hz, 3H); 13C NMR (75.4 MHz, CDCl3) δ 
201.4, 171.0, 140.4, 120.5, 60.7, 42.1, 24.3, 23.1, 21.0; IR (film) 2969, 2729, 1734, 1448, 1380, 
1236, 1025, 959. Spectral data are in accordance with literature values.246 
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(S)-4-Benzylthiazolidine-2-thione (3.48) 
NHS
S
Bn
HO
NH2
Bn
O 1. NaBH4, I2
    THF, 0 to 65 oC
2. CS2, KOH (aq)
    110 oC
83% (yield)
3.48
 
NaBH4 (16.4 g, 0.43 mol) was suspended in THF (500 mL) and the mixture was cooled to 0 oC 
while stirring. L-Phenylalanine (30.0 g, 0.18 mol) was added in one portion. I2 (45.5 g, 0.18 mol) 
was dissolved in THF (150 mL) and added dropwise over 1 h by use of addition funnel resulting in 
vigorous evolution of hydrogen. After addition of the iodine solution was complete and the gas 
evolution had ceased the ice/water bath was removed, the mixture heated to reflux for 20 h, and then 
allowed to cool to ambient temperature. MeOH (~300 mL) was added until the mixture became 
clear. After 1 h stirring the mixture was concentrated under reduced pressure and the resulting white 
paste was dissolved by addition of 2.0 M NaOH (300 mL). The solution was stirred for 8 h and 
extracted with CH2Cl2 (3 x 500 mL). The combined organic extracts were dried over Na2SO4, 
filtered, and concentrated in vacuo to afford the desired product as a white powder (27.2 g, 
quantitative). The crude product was used without further purification.  
 
(S)-2-Amino-3-phenylpropan-1-ol (30.0 g, 0.198 mol) was suspended in aqueous KOH (2.0 M, 500 
mL). Carbon disulfide (76.1g, 60.6 mL, 1.0 mol) was added to the suspension, and the mixture was 
heated to reflux for 14 h. The resulting bright orange suspension was allowed to cool to ambient 
temperature. The reaction mixture was extracted with CH2Cl2 (3 x 500 mL), dried over Na2SO4, and 
concentrated in vacuo to afford the crude product as a white solid. Recrystallization from EtOH 
afforded 3.48 (34.6 g, 83% yield) as white needles: mp 88-89 °C (EtOH), lit. mp281 79-80 °C 
(hexanes, ethyl acetate); Rf  = 0.5 (CH2Cl2); [α]23D = -118 (c 1.7, CHCl3); 1H NMR (300 MHz, 
CDCl3) δ 7.77 (br s, 1H), 7.38-7.19 (m, 5H), 4.51-4.41 (m, 1H), 3.58 (dd, J = 11.2, 7.7 Hz, 1H), 
3.31 (dd, J = 11.2, 6.8 Hz, 1H), 3.04 (dd, J = 13.5, 7.6 Hz, 1H), 2.97 (dd, J =13.5, 6.6 Hz, 1H); 13C 
NMR (75.4 MHz, CDCl3) δ 200.8, 135.7, 129.0, 128.9, 127.4, 65.0, 39.9, 38.1; IR (KBr) 3145, 
2939, 1494, 1457, 1440, 1342, 1294, 1267, 1192, 1160, 1075, 1046, 1030, 971, 951, 747, 735, 695, 
658, 647. Spectral data are in accordance with literature values.281 
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1-((S)-4-Benzyl-2-thiooxothiazolidin-3-yl)ethanone (3.51) 
NHS
S
Ph
NS
S
Ph
OAcCl, DMAP (10 mol%)
Et3N
CH2Cl2, 22 oC
(90% yield)
3.48 3.51  
Thiazolidinethione 3.48 (19.0 g, 90.8 mmol), DMAP (1.12 g, 9.08 mmol), and Et3N were dissolved 
in CH2Cl2 (250 mL) and cooled to 0 °C while stirring on an ice/water bath. AcCl (9.7 mL, 136 
mmol) was added dropwise to the stirred solution and the resulting yellow solution was allowed to 
warm to 22 oC.  The reaction mixture was stirred at 22 oC for 14 h, quenched with saturated aqueous 
NH4Cl (50 mL) and diluted with Et2O (750 mL). The organic phase was washed with saturated 
aqueous CuSO4 (3 x 200 mL), H2O (200 mL), and brine (200 mL), dried over MgSO4, and 
concentrated in vacuo to afford the crude product as a yellow solid. The crude product was 
recrystallized from EtOH to afford 3.51 (20.6 g, 90% yield) as yellow needles: mp 88-90 °C 
(EtOH); Rf  = 0.12 (heptane:EtOAc = 4:1); [α]23D = +243 (c 1.1, CHCl3); 1H NMR (300 MHz, 
CDCl3) δ 7.39-7.25 (m, 5H), 5.38 (dddd, J = 10.6, 6.7, 3.9, 0.4 Hz, 1H), 3.38 (ddd, J = 11.5, 7.2, 1.1 
Hz, 1H), 3.22 (dd, J = 13.2, 3.8 Hz, 1H), 3.04 (dd, J = 13.3, 10.6 Hz, 1H), 2.89 (dd, J = 11.6, 0.4 Hz, 
1H), 2.80 (s, 3H); 13C NMR (75.4 MHz, CDCl3) δ 201.5, 170.6, 136.4, 129.4, 128.8, 127.1, 68.1, 
36.6, 31.7, 27.0; IR (KBr) 3027, 2962, 2919, 1705, 1493, 1455, 1443, 1432, 1410, 1364, 1338, 
1317, 1277, 1213, 1177, 1135, 1086, 1059, 1021, 1002, 955, 925, 898, 847, 750, 706, 672. Spectral 
data are in accordance with literature values.282 
 
(S)-4-Isopropyl-thiazolidine-2-thione (3.49) 
NHS
S
3.49  
Prepared by the typical method employing L-valine (2.27 g, 0.019 mol). The crude product was 
recrystallized from Et2O to afford 3.49 (2.01 g, 64% yield) as a white solid: mp 71-73 °C (Et2O), lit. 
mp256 66-67 °C; Rf  = 0.73 (EtOAc); [α]21D = -38.14 (c 0.95, CHCl3); 1H NMR (300 MHz, CDCl3) δ 
7.77 (br s, 1H), 4.09-3.96 (m, 1H), 3.51 (dd, J = 11.1, 8.2 Hz, 1H), 3.32 (dd, J = 11.1, 8.5 Hz, 1H), 
2.03-1.91 (m, 1H), 1.03 (d, J = 6.8 Hz, 3H), 1.00 (d, J = 6.80 Hz, 3H); 13C NMR (75.4 MHz, 
3 Synthesis of the Macrocyclic Core of (–)-Pladienolide B 
 69
CDCl3) δ  200.7, 70.0, 35.6, 31.8, 18.7, 18.1;  IR (film) 3146, 2961, 2872, 1492, 1391, 1372, 1314, 
1272, 1191, 1163, 1094, 1040, 978, 661. Spectral data are in accordance with literature values.256 
 
1-((S)-4-Isopropyl-2-thioxo-thiazolidin-3-yl)-ethanone (3.52) 
NS
S O
3.52  
Prepared by the typical method employing 3.49 (500 mg, 3.1 mmol). The crude product was purified 
using silica-gel chromatography (9:1 → 4:1, heptane-EtOAc) to afford 3.52 (579 mg, 92% yield) as 
a clear yellow oil: Rf  = 0.53 (heptane:EtOAc = 4:1); [α]22D = +471.1 (c 0.93, CHCl3); 1H NMR (300 
MHz, CDCl3) δ 5.15 (ddd, J = 7.6, 6.2, 1.1 Hz, 1H), 3.51 (dd, J = 11.5, 8.0 Hz, 1H), 3.02 (dd, J = 
11.5, 1.2 Hz, 1H), 2.77 (s, 3H), 2.50-2.19 (m, 1H), 1.06 (d, J = 6.82 Hz, 3H), 0.98 (d, J = 6.95 Hz, 
3H); 13C NMR (75.4 MHz, CDCl3) δ 203.2, 170.6, 71.2, 30.7, 30.3, 26.9, 19.0, 17.7; IR (film) 2963, 
2933, 2875, 1696, 1468, 1411, 1366, 1307, 1245, 1207, 1099, 1074, 1033, 1009, 975, 858. Spectral 
data are in accordance with literature values.283 
 
(S)-4-tert-Butyl-thiazolidine-2-thione (3.50) 
NHS
S
3.50  
Prepared by the typical method employing L-tert-leucinol (2.0 g, 0.0152 mol). The crude product 
was purified using silica-gel chromatography (CH2Cl2) to afford 3.50 (1.82 g, 68% yield) as a white 
solid: mp 133-135 °C (CH2Cl2), lit.253 mp 140-141 oC; Rf  = 0.46 (CH2Cl2); [α]22D = -43.5 (c 1.0, 
CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.44 (br s, 1H), 4.02 (t, J = 8.8, 1H), 3.54-3.27 (m, 2H), 1.01 
(s, 9H); 13C NMR (75.4 MHz, CDCl3) δ 201.1, 73.5, 34.5, 34.2, 25.8; IR (film) 3151, 2959, 2903, 
2870, 1504, 1474, 1293, 1236, 1202, 1074, 1042, 937. Spectral data are in accordance with literature 
values.253 
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1-((S)-4-tert-Butyl-2-thioxo-thiazolidin-3-yl)-ethanone (3.53) 
NS
S O
3.53  
Prepared by the typical method employing 3.50 (500 mg, 2.85 mmol). The crude product was 
purified using silica-gel chromatography (4:1 → 1:1, heptane-EtOAc) to afford 3.53 (583.8 mg, 
94% yield) as a clear yellow oil: Rf  = 0.49  (heptane:EtOAc = 7:3); [α]23D = +566 (c 0.98, CHCl3); 
1H NMR (300 MHz, CDCl3) δ 5.31 (dd, J = 8.4, 0.8 Hz, 1H), 3.53 (dd, J = 11.8, 8.4 Hz, 1H), 3.10 
(dd, J = 11.8, 0.8 Hz, 1H), 2.77 (s, 3H), 1.03 (s, 9H); 13C NMR (75.4 MHz, CDCl3) δ 205.2, 170.3, 
71.9, 37.9, 30.4, 26.8, 26.7; IR (film) 2963, 2908, 2873, 1694, 1474, 1367, 1357, 1267, 1216, 1186, 
1083, 1031, 1016. Spectral data are in accordance with literature values.253 
 
Acetic acid (Z)-(S)-8-((S)-4-benzyl-2-thioxo-thiazolidin-3-yl)-6-hydroxy-3-methyl-8-oxo-oct-2-
enyl ester (3.54a) and acetic acid (Z)-(R)-8-((S)-4-benzyl-2-thioxo-thiazolidin-3-yl)-6-hydroxy-
3-methyl-8-oxo-oct-2-enyl ester (3.54b) 
OHN
O
AcO
OHN
O
AcO
NS
S
Bn
O 1. TiCl4, DIPEA
    -40 to -78 oC
2. 3.44, 22 h
SS
SS
Bn Bn
+
3.51 (3.54a: 70% yield)
(3.54b: 19% yield)
3.54a 3.54b  
3.48 (10.0 g, 39.8 mmol) was dissolved in CH2Cl2 (250 mL) and cooled to -40 °C. TiCl4 (4.5 mL, 
41.0 mmol) was added dropwise to the resulting yellow solution followed by dropwise addition of 
diisopropylethylamine (7.13 mL, 41.0 mmol). The resulting dark red mixture was cooled to -78 °C 
and stirred for an additional 2 h. 3.44 (3.98 g, 23.4 mmol) was dissolved in CH2Cl2 (50 mL) and 
added dropwise to the reaction mixture. The mixture was stirred at -78 °C for an additional 20 h, 
quenched with a solution of saturated aqueous NH4Cl (50 mL) and H2O (50 mL), and diluted with 
Et2O (500 mL). The organic phase was separated, washed with water (100 mL), brine (100 mL), 
dried over MgSO4, and concentrated in vacuo to afford the crude product as a viscous yellow oil. 
The crude oil was purified using silica-gel chromatography (4:1 → 2:1, heptane-EtOAc) to afford 
3.54a (6.92 g, 70% yield) and 3.54b (1.85 g, 19% yield), both as clear yellow oils.  
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3.54a: Rf = 0.20 (heptane:EtOAc= 2:1); [α]23D = +159 (c 2.2, CHCl3); 1H NMR (300 MHz, CDCl3) 
δ 7.37-7.23 (m, 5H), 5.41-5.34 (m, 2H), 4.69-4.50 (m, 2H), 4.17-4.01 (m, 1H), 3.59 (dd, J = 17.8, 
2.5 Hz, 1H), 3.38 (dd, J = 11.5, 7.2 Hz, 1H), 3.19 (dd, J = 13.2, 4.0 Hz, 1H), 3.15 (dd, J = 17.8, 9.4, 
1H), 3.02 (dd, J = 13.2, 10.4 Hz, 1H), 2.99 (d, J = 4.0 Hz, 1H), 2.87 (d, J = 11.5, 1H), 2.41-2.25 (m, 
1H), 2.25-2.12 (m, 1H), 2.04 (s, 3H), 1.75 (d, J = 0.8 Hz, 3H), 1.68-1.54 (m, 2H); 13C NMR (75.4 
MHz, CDCl3) δ 201.2, 172.7, 171.0, 141.8, 136.2, 129.3, 128.8, 127.1, 119.7, 68.2, 66.7, 60.9, 45.9, 
36.6, 34.2, 31.9, 27.8, 23.2, 21.0; IR (film) 3505, 2934, 1735, 1691, 1443, 1364, 1259, 1241, 1162, 
1039, 749, 703; HRMS (ESP+) calc’d for C21H27NO4Na ([M+Na]+) 444.1275, found 444.1278. 
 
3.54b: Rf = 0.24 (heptane:EtOAc= 2:1); [α]23D = +90 (c 2.0, CHCl3); 1H NMR (300 MHz, CDCl3) 
δ 7.38-7.22 (m, 5H), 5.42-5.34 (m, 2H), 4.66-4.52 (m, 2H), 4.98-3.94 (m, 1H), 3.47 (dd, J =17.6, 9.1 
Hz, 1H), 3.40-3.28 (m, 2H), 3.20 (dd, J = 13.2, 4.0 Hz, 1H), 3.02 (dd, J = 13.2, 10.4 Hz, 1H), 2.89 
(d, J = 11.6 Hz, 1H), 2.38-2.13 (m, 2H), 2.04 (s, 3H), 1.75 (d, J = 0.7 Hz, 3H), 1.68-1.50 (m, 2H); 
13C NMR (75.4 MHz, CDCl3) δ 201.3, 173.3, 170.9, 141.8, 136.2, 129.3, 128.8, 127.1, 119.6, 68.1, 
67.3, 60.9, 45.5, 36.6, 34.4, 31.9, 27.7, 23.2, 21.0; IR (film) 3504, 3026, 2837, 1735, 1690, 1442, 
1363, 1345, 1257, 1239, 1168, 1037; HRMS (ESP+) calc’d for C21H27NO4NaS2 ([M+Na]+) 
444.1275, found 444.1270. 
 
Acetic acid (Z)-(S)-6-hydroxy-8-((S)-4-isopropyl-2-thioxo-thiazolidin-3-yl)-3-methyl-8-oxo-oct-
2-enyl ester (3.55a) and acetic acid (Z)-(R)-6-hydroxy-8-((S)-4-isopropyl-2-thioxo-thiazolidin-3-
yl)-3-methyl-8-oxo-oct-2-enyl ester (3.55b) 
OHN
O
O
O
S
S
OHN
O
O
O
S
S
3.55a 3.55b  
Prepared by the typical method employing 3.52 (187 mg, 0.920 mmol) and 3.44 (92 mg, 0.54 
mmol). The crude product was purified using silica-gel chromatography (4:1 → 2:1, heptane-
EtOAc) to afford 3.55a (137.2 mg, 68% yield) and 3.55b (28.2 mg, 14% yield), both as clear yellow 
oils. 
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3.55a: Rf = 0.28 (heptane:EtOAc = 2:1); [α]23D = +286  (c 2.6, CHCl3); 1H NMR (300 MHz, CDCl3) 
δ 5.37 (t, J = 7.3, 7.3 Hz, 1H), 5.16 (ddd, J = 7.8, 6.3, 1.0 Hz, 1H), 4.71-4.45 (m, 2H), 4.18-3.96 (m, 
1H), 3.61 (dd, J = 17.7, 2.5 Hz, 1H), 3.52 (dd, J = 11.5, 8.0 Hz, 1H), 3.15 (dd, J = 17.7, 9.3 Hz, 
1H), 3.03 (dd, J = 11.5, 1.1 Hz, 1H), 2.98 (br s, 1H), 2.44-2.11 (m, 3H), 2.05 (s, 3H), 1.76 (d, J = 
1.3 Hz, 3H), 1.73-1.52 (m, 2H), 1.06 (d, J = 6.9 Hz, 3H), 0.97 (d, J = 6.9 Hz, 3H); 13C NMR (75.4 
MHz, CDCl3) δ 203.0, 172.8, 171.1, 142.0, 119.7, 71.3, 66.99, 61.0, 45.6, 34.3, 30.8, 30.5, 27.9, 
23.3, 21.1, 19.0, 17.8; IR (film) 3529, 2964, 1735, 1700, 1443, 1364, 1240, 1169, 1091, 1038; 
HRMS (ESP+) calc’d for C17H27NO4NaS2 ([M+Na]+) 396.1279, found 396.1257. 
 
3.55b: Rf  = 0.38 (heptane:EtOAc = 2:1); [α]23D = +193 (c 0.74, CHCl3); 1H NMR (300 MHz, 
CDCl3) δ 5.37 (t, J = 7.1 Hz, 1H), 5.18 (ddd, J = 7.7, 6.4, 1.0 Hz, 1H), 4.73-4.42 (m, 2H), 4.08-3.90 
(m, 1H), 3.52 (dd, J = 11.5, 7.9 Hz, 1H), 3.48 (dd, J = 17.4, 9.3 Hz, 1H), 3.32 (dd, J = 17.4, 2.9 Hz, 
1H), 3.04 (dd, J = 11.5, 1.1 Hz, 1H), 2.46-2.12 (m, 3H), 2.05 (s, 3H), 1.76 (d, J = 1.1 Hz, 3H), 1.73-
1.48 (m, 2H), 1.06 (d, J = 6.9 Hz, 3H), 0.98 (d, J = 6.9 Hz, 3H); 13C NMR (75.4 MHz, CDCl3) 
δ 203.1, 173.5, 171.1, 142.1, 119.7, 71.3, 67.6, 61.0, 45.3, 34.6, 30.7, 30.6, 27.9, 23.4, 21.1, 19.1, 
17.8; IR (film) 3519, 2963, 2874, 1733, 1699, 1468, 1442, 1363, 1248, 1169, 1037; HRMS (ESP+) 
calc’d for C17H27NO4NaS2 ([M+Na]+) 396.1279, found 396.1257. 
 
Acetic acid (Z)-(S)-8-((S)-4-tert-butyl-2-thioxo-thiazolidin-3-yl)-6-hydroxy-3-methyl-8-oxo-oct-
2-enyl ester (3.56a) and acetic acid (Z)-(R)-8-((S)-4-tert-butyl-2-thioxo-thiazolidin-3-yl)-6-
hydroxy-3-methyl-8-oxo-oct-2-enyl ester (3.56b) 
OHN
O
O
O
S
S
OHN
O
O
O
S
S
3.56a 3.56b  
Prepared by the typical method employing 3.53 (200 mg, 0.920 mmol) and 3.44 (92 mg, 0.54 
mmol). The crude product was purified using silica-gel chromatography (4:1 → 2:1, heptane-
EtOAc) to afford 3.56a (154.9 mg, 74% yield) and 3.56b (27.2 mg, 13% yield), both as clear yellow 
oils. 
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3.56a: Rf  = 0.17 (heptane:EtOAc = 7:3); [α]23D = +325 (c 0.72, CHCl3); 1H NMR (300 MHz, 
CDCl3) δ 5.37 (t, J = 7.3 Hz, 1H), 5.31 (d, J = 8.6 Hz, 1H), 4.81-4.45 (m, 2H), 4.18-3.92 (m, 1H), 
3.58 (dd, J = 17.7, 2.5 Hz, 1H), 3.54 (dd, J = 11.8, 8.3 Hz, 1H), 3.15 (dd, J = 17.7, 9.2 Hz, 1H), 
3.11 (d, J = 11.8 Hz, 1H), 3.04 (br s, 1H), 2.44-2.11 (m, 2H), 2.05 (s, 3H), 1.76 (s, 3H), 1.68-1.51 
(m, 2H), 1.03 (s, 9H); 13C NMR (75.4 MHz, CDCl3) δ 220.4, 172.3, 171.0, 142.0, 119.7, 72.0, 67.3, 
61.0, 45.1, 37.8, 34.3, 30.5, 27.9, 26.8, 23.3, 21.0; IR (film) 3518, 2964, 2873, 1732, 1692, 1471, 
1442, 1367, 1316, 1234, 1150, 1137, 10485, 976; HRMS (ESP+) calc’d for C18H29NO4NaS2 
([M+Na]+) 410.1431, found 410.1446. 
 
3.56b: Rf  = 0.21 (heptane:EtOAc = 7:3); [α]23D = +305 (c 0.33, CHCl3); 1H NMR (300 MHz, 
CDCl3) δ 5.37 (t, J = 7.2 Hz, 1H), 5.34 (d, J = 8.4 Hz, 1H), 4.72-4.47 (m, 2H), 3.99 (dq, J = 7.8, 3.7 
Hz, 1H), 3.54 (dd, J = 11.8, 8.3 Hz, 1H), 3.48 (dd, J = 17.4, 9.4 Hz, 1H), 3.32 (dd, J = 17.4, 2.8 Hz, 
1H), 3.30 (d, J = 2.8 Hz, 1H), 3.11 (d, J = 11.8 Hz, 1H), 2.45-2.10 (m, 2H), 2.05 (s, 3H), 1.76 (s, 
3H), 1.73-1.47 (m, 2H), 1.03 (s, 9H); 13C NMR (50.3 MHz, CDCl3) δ 205.2, 172.8, 171.0, 142.0, 
119.7, 72.1, 67.5, 61.0, 45.1, 37.9, 34.6, 30.5, 28.0, 26.8, 23.3, 21.0; IR (film) 3523, 2964, 1732, 
1692, 1471, 1443, 1367, 1317, 1235, 1197, 1149, 1136, 1086, 1045, 1021; HRMS (ESP+) calc’d for 
C18H29NO4NaS2 ([M+Na]+) 410.1431, found 410.1445. 
. 
Acetic acid (Z)-(S)-8-((S)-4-benzyl-2-thioxo-thiazolidin-3-yl)-6-(tert-butyl-dimethyl-silanyl-
oxy)-3-methyl-8-oxo-oct-2-enyl ester (3.61) 
OHN
O
AcO
S
S
Bn
TBSOTf, DIPEA
CH2Cl2
(92% yield)
OTBSN
O
AcO
S
S
Bn
3.613.54a  
3.54a (3.42 g, 8.11 mmol) was dissolved in CH2Cl2 (50 mL) and the resulting clear yellow solution 
was cooled to -78 °C while stirring. A solution of diisopropylethylamine (2.1 mL, 12.2 mmol) and 
tert-butyldimethylsilyl trifluoromethanesulfonate (2.6 mL, 11.4 mmol) in CH2Cl2 (10 mL) was 
added dropwise to the reaction mixture. The mixture was stirred at -78 °C for 3 h, quenched with 
MeOH (10 mL), and allowed to warm to ambient temperature. The reaction mixture was diluted 
with Et2O (300 mL), washed with H2O (4 x 50 mL), brine (50 mL), dried over MgSO4, and 
concentrated in vacuo to afford a yellow viscous oil. The crude product was purified using silica-gel 
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chromatography (19:1 → 4:1, heptane-EtOAc) to afford 3.61 (4.02 g, 92% yield) as a yellow oil: Rf 
= 0.33 (heptane:EtOAc = 6:1); [α]23D = +146 (c 2.3, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.41-
7.13 (m, 5H), 5.32 (dt, J = 7.3, 0.9 Hz, 1H), 5.24 (ddd, J = 10.7, 6.9, 3.8 Hz, 1H), 4.52 (d, J = 7.3 
Hz, 2H), 4.35-4.21 (m, 1H), 3.55 (dd, J = 16.7, 7.8 Hz, 1H), 3.31 (dd, J =11.5, 7.1 Hz, 1H), 3.23-
3,14 (m, 2H), 3.00 (dd, J = 13.1, 10.6 Hz, 1H), 2.84 (d, J = 11.6 Hz, 1H), 2.43-2.00 (m, 2H), 2.00 (s, 
3H), 1.73 (d, J = 0.9 Hz, 3H), 1.69-1.48 (m, 2H), 0.82 (s, 9H), 0.06 (s, 3H), 0.02 (s, 3H); 13C NMR 
(75.4 MHz, CDCl3) δ 201.1, 171.9, 170.9, 142.6, 136.5, 129.4, 128.8, 127.1, 119.1, 68.8, 68.6, 60.8, 
45.6, 36.4, 36.1, 32.1, 27.5, 25.7, 23.5, 21.0, 17.9, -4.4, -4.6; IR (film) 3026, 2954, 2931, 2855, 
1735, 1701, 1472, 1364, 1234, 1164, 1041, 837, 777, 702; HRMS (ESP+) calc’d for 
C27H41NO4NaSiS2 ([M+Na]+) 558.2144, found 558.2162. 
 
Acetic acid (2R,3S,6S)-8-((S)-4-benzyl-2-thioxo-thiazolidin-3-yl)-6-(tert-butyl-dimethyl-silanyl-
oxy)-2,3-dihydroxy-3-methyl-8-oxo-octyl ester (3.63a) and acetic acid (1R,2S,5S)-7-((S)-4-
benzyl-2-thioxo-thiazolidin-3-yl)-5-(tert-butyl-dimethyl-silanyloxy)-2-hydroxy-1-hydroxyme-
thyl-2-methyl-7-oxo-heptyl ester (3.63b) 
OTBSN
O
AcO
S
S
Bn
K2OsO2(OH)4 (2.0 mol%)
(DHQD)2PHAL (4.0 mol%)
K3Fe(CN)6, K2CO3, MeSO4NH2
t-BuOH:H2O = 1:1, 0 oC
3.61
OTBSN
O
AcO
S
S
Bn
OH
OH
OTBSN
O
HO
S
S
Bn
AcO
OH
+
(3.63a: 80% yield, dr > 20:1)
(3.63b: 15% yield, dr > 20:1) 3.63a 3.63b  
A mixture of potassium carbonate (1.52 g, 11.0 mmol), potassium hexacyanoferrate(III) (3.63 g, 
11.0 mmol), methanesulfonamide (700 mg, 7.35 mmol),  K2OsO2(OH)4 (26.9 mg, 0.073 mmol), and 
(DHQD)2PHAL (115 mg, 0.147 mmol) in H2O (15.0 mL) and t-BuOH (15.0 mL), was stirred at 22 
oC for 15 min. The mixture was cooled to 0 °C and stirred for 15 min. 3.61 (1.98 g, 3.67 mmol) was 
dissolved in CH2Cl2 (5.0 mL) and added to the reaction mixture in one portion. The mixture was 
stirred at 0 °C for 24 h, subsequently allowed to warm to ambient temperature, and quenched with 
Na2SO3 (500 mg). The reaction mixture was diluted with EtOAc (200 mL), washed with H2O (50 
mL), brine (50 mL), dried over Na2SO4, and concentrated in vacuo to afford a dark yellow viscous 
oil. The crude oil was purified using silica-gel chromatography (2:1, heptane-EtOAc) to afford 
3.63a (1.67 g, 80% yield) and 3.63b (309 mg, 15% yield), both as bright yellow oils. 
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3.63a: Rf  = 0.16 (heptane:EtOAc = 2:1); [α]23D = +103 (c 2.0, CHCl3); 1H NMR (300 MHz, CDCl3) 
δ 7.65-7.05 (m, 5H), 5.28 (ddd, J = 10.7, 7.0, 4.0 Hz, 1H), 4.41-4.49 (m, 2H), 4.08 (dd, J = 11.6, 8.4 
Hz, 1H), 3.69 (ddd, J = 8.3, 3.9, 2.4 Hz, 1H), 3.57 (dd, J = 16.9, 7.3 Hz, 1H), 3.35 (dd, J = 11.5, 7.0 
Hz, 1H), 3.31-3.18 (m, 2H), 3.03 (dd, J = 13.0, 10.7 Hz, 1H), 2.88 (d, J = 11.5 Hz, 1H), 2.11 (s, 
3H), 1.81-1.55 (m, 3H), 1.50-1.37 (m, 1H); 1.21 (s, 3H), 0.86 (s, 9H), 0.10 (s, 3H), 0.06 (s, 3H); 13C 
NMR (75.4 MHz, CDCl3) δ 201.1, 171.9, 171.4, 136.5, 129.4, 128.9, 127.1, 75.7, 73.0, 69.1, 68.5, 
65.9, 45.5, 36.5, 32.1, 32.0, 30.8, 25.7, 23.2, 20.9, 17.9, -4.3, -4.6; IR (film) 3504, 2955, 2929, 2856, 
1743, 1690, 1452, 1363, 1257, 1169, 1046, 836, 775; HRMS (ESP+) calc’d for C27H43NO6NaSiS2 
([M+Na]+) 592.2199, found 592.2196. 
 
3.63b: Rf  = 0.10 (Heptane:EtOAc = 2:1); [α ]23D = +30.9 (c 0.31, CHCl3);1H NMR (300 MHz, 
CDCl3) δ 7.36-7.14 (m, 5H), 5.22 (ddd, J = 10.8, 7.0, 4.0 Hz, 1H), 4,75 (t, J = 4.5 Hz, 1H), 4.34-
4.23 (m, 1H), 3.91-3.73 (m, 2H), 3.50 (dd, J = 17.0, 7.3 Hz, 1H), 3.29 dd (11.5, 7.0 Hz, 1H), 3.24-
3.09 (m, 2H), 2.96 (dd, J = 13.1, 10.6 Hz, 1H), 2.82 (d, J = 11.5 Hz, 1H), 2.08 (s, 3H), 1.74-1.39 (m, 
4H), 1.13 (s, 3H), 0.79 (s, 9H), 0.04 (s, 3H), 0.00 (s, 3H); 13C NMR (75.4 MHz, CDCl3) δ 201.2, 
171.8, 171.0, 136.4, 129.4, 128.9, 127.2, 77.6, 73.9, 68.8, 68.5, 62.1, 45.4, 36.5, 33.7, 32.1, 30.7, 
25.7, 23.3, 21.1, 18.0, -4.4, -4.6; IR (film) 3450, 2954, 2928, 2892, 2857, 1734, 1707, 1690, 1451, 
1433, 1380, 1292, 1257, 1230, 1168, 1045, 835; HRMS (ESP+) calc’d for C27H43NO6NaSiS2 
([M+Na]+) 592.2199, found 592.2196. 
 
Acetic acid (4R,5S)-5-[(S)-5-((S)-4-benzyl-2-thioxo-thiazolidin-3-yl)-3-(tert-butyl-dimethyl-
silanyloxy)-5-oxo-pentyl]-2,2,5-trimethyl-[1,3]dioxolan-4-ylmethyl ester (3.64) 
OTBSN
O
AcO
S
S
Bn
OH
OH
OTBSN
O
AcO
S
S
Bn
2,2'-dimethoxypropane
p-TsOH (cat)
CH2Cl2, 22 oC
(97% yield)
3.643.63a
O
O
 
3.63a (1.67 g, 2.9 mmol) was dissolved in CH2Cl2 (50 mL), 2,2-dimethoxypropane (7.2 mL, 59 
mmol), and one grain of para-toluenesulfonic acid monohydrate were added while stirring. The 
resulting bright yellow solution was stirred at 22 oC for 30 min, diluted with Et2O (250 mL), washed 
with saturated aqueous NaHCO3 (100 mL), H2O (100 mL), brine (100 mL), dried over MgSO4, and 
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concentrated in vacuo to afford a yellow viscous oil. The crude product was purified using silica-gel 
chromatography (2:1, heptane-EtOAc) to afford 3.64 (1.72 g, 97% yield) as a yellow oil: Rf  = 0.68 
(eluent: heptane:EtOAc = 1:1); [α]23D = +129 (c 1.9, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.42-
7.22 (m, 5H), 5.26 (ddd, J = 10.5, 6.8, 3.8 Hz, 1H), 4.44-4.30 (m, 1H),  4.25 (dd, J = 11.6, 3.9 Hz, 
1H), 4.12 (dd, J = 11.6, 7.9 Hz, 1H), 3.97 (dd, J =7.9, 3.9 Hz, 1H), 3.56 (dd, J = 16.9, 7.9 Hz, 1H), 
3.34 (dd, J = 11.6, 7.1 Hz, 1H), 3.29-3.20 (m, 1H), 3.18 (dd, J = 16.9, 4.0 Hz, 1H), 3.04 (dd, J = 
13.1, 7.9 Hz, 1H), 2.88 (d, J = 11.6 Hz, 1H), 2.11 (s, 3H), 1.92-1.58 (m, 3H), 1.45 (s, 3H), 1.38 (s, 
3H), 1.28 (s, 3H), 1.26-1.16 (m, 1H), 0.85 (s, 9H), 0.09 (s. 3H), 0.05 (s, 3H); 13C NMR (75.4 MHz, 
CDCl3) δ 201.1, 172.1, 170.8, 136.6, 129.4, 128.9, 127.2, 108.2, 81.7, 81.2, 69.1, 68.7, 62.5, 45.7, 
36.5, 32.1, 31.0, 29.7, 28.3, 27.0, 25.8, 23.0, 20.9, 18.0, -4.4, -4.7; IR (film) 2932, 2856, 1744, 1701, 
1457, 1370, 1231, 1167, 1044, 836, 776; HRMS (ESP+) calc’d for C30H47NO6NaSiS2 ([M+Na]+) 
632.2512, found 632.2490. 
 
(S)-3-(tert-Butyl-dimethyl-silanyloxy)-5-((4S,5R)-5-hydroxymethyl-2,2,4-trimethyl-[1,3]dioxo-
lan-4-yl)-pentanoic acid methyl ester (3.65) 
OTBSN
O
AcO
S
S
Bn
OTBS
O
HO
MeO
K2CO3
MeOH, 22 oC
(99% yield)
3.64 3.65
O
O
O
O
 
3.64 (1.51 g, 2.48 mmol) was dissolved in MeOH (100 mL) and K2CO3 (1.71 g, 12.4 mmol) was 
added while stirring at 22 oC. The bright yellow mixture became colorless within 5 minutes, and the 
mixture was stirred for an additional 1 h at 22 oC. The reaction mixture was diluted with Et2O (200 
mL), washed with H2O (50 mL), brine (50 mL), dried over MgSO4, and concentrated in vacuo to 
afford an oil. The crude product was purified using silica-gel chromatography (4:1, heptane-EtOAc) 
to afford 3.65 (956 mg, 99% yield) as a colorless oil: Rf  = 0.69 (EtOAc); [α]23D = +1.49 (c 1.6, 
CHCl3); 1H NMR (300 MHz, CDCl3) δ 4.15-4.05 (m, 1H), 3.93 (dd, J = 7.9, 3.6 Hz, 1H), 3.80 (ddd, 
J = 11.9, 7.9, 4.1 Hz, 1H), 3.69 (dd, J = 7.6, 3.6 Hz, 1H), 3.66 (s, 3H), 2.51-2.36(m, 2H), 1.65-1.65 
(m, 2H), 1.63-1.49 (m, 2H), 1.42 (s, 3H), 1.37 (s, 3H), 1.25 (s, 3H), 1.20-1.05 (m, 1H), 0.86 (s, 9H), 
0.05 (s, 3H), 0.03 (s, 3H); 13C NMR (75.4 MHz, CDCl3) δ 172.1, 107.8, 84.7, 80.9, 69.5, 61.2, 51.5, 
42.4, 30.9, 30.1, 28.3, 27.0, 25.7, 23.3, 17.9, -4.5, -4.9; IR (film) 3473, 2954, 2858, 1739, 1472, 
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1463, 1436, 1378, 1315, 1217, 1054, 1005, 927, 897, 837, 812, 777, 710, 664; HRMS (ESP+) calc’d 
for C19H38O6NaSi ([M+Na]+) 413.2331, found 413.2320. 
 
(S)-3-(tert-Butyl-dimethyl-silanyloxy)-5-((4S,5S)-5-formyl-2,2,4-trimethyl-[1,3]dioxolan-4-yl)-
pentanoic acid methyl ester (3.66) 
OTBS
O
HO
MeO OTBS
O
O
MeO
SO3 pyr
DMSO, DIPEA
CH2Cl2 -30 to -15 oC
(86% yield)3.65 3.66
O
O
O
O
 
3.65 (708 mg, 1.81 mmol) was dissolved in CH2Cl2 (50 mL) and cooled to -40 °C while stirring. 
Diisopropylethyl amine (1.2 mL, 7.25 mmol) and DMSO (1.5 mL) were added. SO3.Pyr (866 mg, 
5.44 mmol) was dissolved in DMSO (3.5 mL) and added dropwise to the reaction mixture. The 
mixture was allowed to warm to -15 °C, quenched with saturated aqueous NaHCO3 (25 mL) and 
allowed to warm to ambient temperature. The reaction mixture was diluted with Et2O (200 mL), 
washed with H2O (50 mL), saturated aqueous CuSO4 (3 x 50 mL), H2O (50 mL), brine (50 mL), 
dried over MgSO4 and concentrated in vacuo to afford a colorless oil. The crude product could be 
purified using silica-gel chromatography (4:1, heptane-EtOAc) to afford 3.66 (605 mg, 86% yield) 
as a colorless oil, in practice, however, the crude product was used without further purification: Rf = 
0.73 (heptane:EtOAc = 1:1); [α]23D = -30.0 (c 1.3, CHCl3); 1H NMR (300 MHz, CDCl3) δ 9.74 (d, J 
= 1.9 Hz, 1H), 4.15-4.03 (m, 1H), 4.11 (d, J = 1.9 Hz, 1H),  3.65 (s, 3H), 2.51-2.29 (m, 2H), 1.78-
1.53 (m, 3H), 1.52 (s, 3H), 1.39 (s, 6H), 1.34-1.13 (m, 1H), 0.84 (s, 9H), 0.03 (s, 3H), 0.01 (s, 3H); 
13C NMR (75.4 MHz, CDCl3) δ 200.2, 171.9, 110.0, 87.8, 83.5, 69.2, 51.5, 42.4, 31.6, 30.9, 27.9, 
27.0, 25.7, 24.5, 17.9, -4.59, -4.95; IR (film) 2954, 2858, 1738, 1473, 1463, 1437, 1380, 1313, 1252, 
1218, 1074, 1007, 837, 777; HRMS (ESP+) calc’d for [M+Na]+) C19H36O6SiNa 411.2173, found 
411.2173. 
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((S)-3-Bromo-2-methyl-propoxy)-tert-butyl-dimethyl-silane (3.67) 
Br
OH
Br
OTBS
TBSCl, DMAP
CH2Cl2, 22 oC
(94% yield)3.41 3.67  
DMAP (969 mg, 8.1 mmol) was dissolved in CH2Cl2 (50 mL) and (S)-(−)-3-bromo-2-methyl-1-
propanol (1.0 g, 6.5 mmol) was added followed by tert-butyl-chlorodimethylsilane (1.18 g, 7.8 
mmol) while stirring at 22 oC. The mixture was stirred at 22 oC for an additional 12 h, diluted with 
Et2O (100 mL), washed with H2O (50 mL), saturated aqueous CuSO4 (3 x 50 mL), H2O (50 mL), 
brine (50 mL), dried over MgSO4, and concentrated in vacuo to afford a colorless low-viscous oil. 
The crude product was purified using silica-gel chromatography (heptane) to afford 3.67 (1.64 g, 
94% yield) as a colorless oil: Rf = 0.87 (heptane:EtOAc = 4:1); [α]23D = +11.8 (2.0, CHCl3); 1H 
NMR (300 MHz, CDCl3) δ 3.62-3.40 (m, 4H), 2.05-1.89 (m, 1H), 0.98 (d, J = 6.77 Hz, 3H), 0.89 (s, 
9H), 0.06 (s, 6H); 13C NMR (75.4 MHz, CDCl3) δ 65.3, 38.1, 37.7, 25.9, 18.3, 15.5, -5.5; IR (film) 
3050, 2955, 2930, 2858, 1472, 1387, 1361, 1337, 1258, 1231, 1143, 1101, 1021, 1006, 939, 837, 
776, 668.  
 
5-[(S)-3-(tert-Butyl-dimethyl-silanyloxy)-2-methyl-propane-1-sulfanyl]-1-phenyl-1H-tetrazole 
(3.68) 
Br
OTBS
S
OTBS
N
N
NN
Ph
HS N
N
NN
Ph
Cs2CO3
DMF, 22 oC
(95% yield)3.67 3.68  
3.67 (500 mg, 1.87 mmol) was dissolved in DMF (10 mL). Cs2CO3 (1.22 g, 3.74 mmol) and 1-
phenyl-1H-tetrazole-5-thiol (500 mg, 2.81 mmol) were added while stirring at 22 oC. The mixture 
was stirred at 22 oC for an additional 20 h, quenched with an aqueous solution of NaOH (10 mL, 
5%), and extracted with heptane (3 x 50 mL). The combined organic phases were dried over 
MgSO4, and concentrated in vacuo to afford a colorless oil. The crude product was purified using 
silica-gel chromatography (9:1, heptane-EtOAc) to afford 3.68 (647 mg, 95% yield) as a colorless 
oil: Rf = 0.31 (heptane:EtOAc = 4:1); [α]23D = -2.14 (2.0, CHCl3); 1H NMR (300 MHz, CDCl3) δ 
7.62-7.52 (m, 5H), 3.64 (dd, J = 10.0, 4.8 Hz, 1H), 3.37 (dd, J = 12.8, 6.6 Hz, 1H); 3.52 (dd, J = 
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10.0, 5.7 Hz, 1H), 3.50 (dd, J = 12.8, 6.7 Hz, 1H), 2.22-2.05 (m, 1H), 1.04 (d, J = 6.8, 3H), 0.88 (s, 
9H), 0.03 (s, 6H); 13C NMR (75.4 MHz, CDCl3) δ 154.9, 133.7, 130.0, 129.7, 123.9, 66.3, 36.9, 
35.5, 25.8, 18.2, 16.2, -5.5, -5.5; IR (film) 3070, 2956, 2857, 1598, 1501, 1471, 1386, 1316, 1250, 
1146, 1088, 1015, 979, 939, 800, 760, 694, 667; HRMS (ESP+) calc’d for C17H28N4ONaSSi 
([M+Na]+) 387.1646, found 387.1659. 
 
5-[(S)-3-(tert-Butyl-dimethyl-silanyloxy)-2-methyl-propane-1-sulfonyl]-1-phenyl-1H-tetrazole 
(3.70) 
S
OTBS
N
N
NN
Ph
S
OTBS
N
N
NN
PhmCPBA, NaHCO3
CH2Cl2, 22 oC
(93% yield)
O
O
3.68 3.70
 
3.68 (640 mg, 1.76 mmol) was dissolved in CH2Cl2 (50 mL) and NaHCO3 (740 mg, 8.8 mmol) was 
added while stirring at rt. mCPBA (760 mg, 4.4 mmol, ~70% pure) was dissolved in CH2Cl2 (50 
mL) and added to the reaction mixture in one portion. The reaction mixture was stirred for an 
additional 10h, poured into a solution of saturated aqueous NaHCO3 (25 mL) and saturated aqueous 
Na2S2O3 (25 mL). The organic layer was separated and the aqueous phase was extracted with 
CH2Cl2 (2 x 50 mL). The combined organic phases were dried over MgSO4 and concentrated in 
vacuo to afford a colorless oil. The crude product was purified using silica-gel chromatography (9:1, 
heptane-EtOAc) to afford 3.70 (649 mg, 93% yield) as a colorless oil that crystallizes upon standing: 
mp 29-31 °C; Rf = 0.44 (heptane:EtOAc = 4:1); [α]23D = +3.59 (2.3, CHCl3); 1H NMR (300 MHz, 
CDCl3) δ 7.76-7.55 (m, 5H), 4.05 (dd, J = 14.6, 4.9 Hz, 1H), 3.72 (dd, J = 10.0, 4.6 Hz, 1H), 3.55 
(dd, J = 14.6, 7.7 Hz, 1H), 3.50 (dd, J = 10.0, 5.6 Hz, 1H), 2.57-2.37 (m, 1H), 1.16 (d, J = 6.9 Hz. 
3H), 0.89 (s, 9H), 0.05 (s, 6H); 13C NMR (75.4 MHz, CDCl3) δ 154.0, 133.1, 131.4, 129.7, 125.1, 
66.1, 58.5, 31.2, 25.8, 18.2, 16.8, -5.5, -5.5; IR (KBr) 3078, 2929, 2858, 1499, 1473, 1328, 1260, 
1153, 1100, 1027, 827, 777, 761, 687, 669, 631; HRMS (ESP+) calc’d for C17H28N4O3NaSSi 
([M+Na]+) 419.1544, found 419.1552. 
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2-[(S)-3-(tert-Butyl-dimethyl-silanyloxy)-2-methyl-propylsulfanyl]-benzothiazole (3.69) 
Br
OTBS
S
OTBS
S
N
HS
S
N
Cs2CO3
DMF, 22 oC
(91% yield)3.67 3.69  
3.67 (444 mg, 1.66 mmol) was dissolved in DMF (10 mL). Cs2CO3 (1.08 g, 3.31 mmol) and 2-
mercaptobenzothiazole (333 mg, 1.99 mmol) were added while stirring at 22 oC. The suspension 
was stirred at 22 oC for an additional 14 h, quenched with an aqueous solution of NaOH (10 mL, 
5%), and extracted with heptane (3 x 50 mL). The combined organic phases were dried over 
MgSO4, and concentrated in vacuo to afford a colorless oil. The crude product was purified using 
silica-gel chromatography (9:1, heptane-EtOAc) to afford 3.69 (535 mg, 91% yield) as a colorless 
oil: Rf = 0.66 (heptane:EtOAc = 4:1); [α]23D = +5.05 (1.5, CHCl3); 1H NMR (300 MHz, CDCl3) 
δ 7.85 (ddd, J = 8.2, 1.2, 0.6 Hz, 1H), 7.75 (ddd, J = 7.9, 1.3, 0.6 Hz, 1H), 7.44-7.36 (m, 1H), 7.28 
(ddd, J = 7.9, 7.3, 1.4 Hz, 1H), 3.66 (dd, J = 10.0, 5.2 Hz, 1H), 3.55 (dd, J = 10.0, 5.9 Hz, 1H), 3.51 
(dd, J = 12.9, 6.2, 1H), 3.23 (dd, J = 12.9, 7.1 Hz, 1H), 2.24-2.03 (m, 1H), 1.07 (d, 6.8 Hz, 3H), 0.91 
(s, 9H), 0.06 (s, 3H), 0.05 (s, 3H); 13C NMR (75.4 MHz, CDCl3) δ 167.7, 153.3, 135.1, 125.9, 124.0, 
121.4, 120.9, 66.4, 37.0, 36.0, 25.9, 18.3, 16.3, -5.4, -5.5;  IR (film) 3050, 2956, 2928, 2857, 1463, 
1429, 1387, 1361, 1309, 1251, 1096, 1018, 995, 939, 837, 776, 754, 726, 668; HRMS (ESP+) calc’d 
for C17H27NONaS2Si ([M+Na]+) 376.1196, found 376.1183. 
 
2-[(S)-3-(tert-Butyl-dimethyl-silanyloxy)-2-methyl-propane-1-sulfonyl]-benzothiazole (3.71) 
S
OTBS
S
N
S
OTBS
S
N
mCPBA, NaHCO3
CH2Cl2, 22 oC
(89% yield)
O
O
3.69 3.71
 
3.69 (300 mg, 0.85 mmol) was dissolved in CH2Cl2 (15 mL) and NaHCO3 (357 mg, 4.25 mmol) was 
added while stirring at 22 oC. mCPBA (524 mg, 2.13 mmol, ~70% pure) was dissolved in CH2Cl2 
(15 mL) and added to the reaction mixture in one portion. The reaction mixture was stirred for an 
additional 10h, poured into a solution of saturated aqueous NaHCO3 (10 mL) and saturated aqueous 
Na2S2O3 (10 mL). The organic layer was separated and the aqueous phase was extracted with 
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CH2Cl2 (50 mL). The combined organic phases were dried over MgSO4, and concentrated in vacuo 
to afford a colorless oil. The crude product was purified using silica-gel chromatography (9:1, 
heptane-EtOAc) to afford 3.71 (291 mg, 89% yield) as a colorless oil: Rf = 0.40 (heptane:EtOAc = 
4:1); [α]23D = +7.93 (1.3, CHCl3);1H NMR (300 MHz, CDCl3) δ 8.26-8.18 (m, 1H), 8.05-7.98 (m, 
1H), 7.73-7.55 (m, 2H), 3.83 (dd, J = 14.5, 4.5 Hz, 1H), 3.64 (dd, J = 10.0, 4.8 Hz, 1H), 3.43 (dd, J 
= 10.0, 6.2 Hz, 1H), 3.29 (dd, J = 14.5, 8.0 Hz, 1H), 2.51-2.30 (m, 1H), 1.13 (d, J = 6.8 Hz, 3H), 
0.82 (s, 9H), 0.00 (s, 3H), -0.02 (s, 3H); 13C NMR (75.4 MHz, CDCl3) δ 166.4, 152.7, 136.8, 127.9, 
127.6, 125.5, 122.3, 66.2, 57.5, 31.5, 25.7, 18.1, 16.7, -5.5, -5.6; IR (film) 3050, 2959, 2930, 1557, 
1471, 1394, 1326, 1252, 1149, 1025, 940, 836, 689, 667, 632; HRMS (ESP+) calc’d for 
C17H27NO3NaS2Si ([M+Na]+) 408.1095, found 408.1088. 
 
(3S,6S,7R)-7-tert-Butoxy-3-(tert-butyl-dimethyl-silanyloxy)-6-hydroxy-6-methyl-non-8-enoic 
acid methyl ester (3.75) 
OTBSMeO
O
O
OTBSMeO
O
n-BuLi, Ph3CH3Br
    
THF, -78 oC
(72% yield) 3.753.65
H
O
O
O
O
 
Triphenylphosphonium bromide (1.23 g, 2.04 mmol) was azeotroped with toluene (3 x 10 mL) and 
suspended in THF (50 mL). The suspension was cooled to -78 °C while stirring and n-BuLi (1.09 
mL, 1.85 mmol, 1.7 M in cyclohexane) was added. The resulting bright yellow suspension was 
stirred at -78 °C for an additional 1 h. Crude 3.65 (~1.85 mmol) was azeotroped with benzene (3 x 
10 mL), dissolved in THF (10 mL), and added dropwise to the reaction mixture while stirring. The 
reaction mixture was stirred at -78 °C for an additional 12 h. The mixture was allowed to warm to 
22 oC and stirred for an additional 1 h, quenched with saturated aqueous NH4Cl (25 mL), diluted 
with Et2O (250 mL), washed with H2O (50 mL), brine (50 mL), dried over MgSO4, and 
concentrated in vacuo. The crude product was purified using silica-gel chromatography (9:1, 
heptane-EtOAc) to afford 3.75 (518 mg, 72% yield, from 3.65) as a colorless oil: Rf = 0.18 
(heptane:EtOAc = 4:1); [α]23D = -6.36 (c 1.5, CHCl3); 1H NMR (300 MHz, CDCl3) δ  5.70 (ddd, J = 
17.3, 10.5, 6.9 Hz, 1H), 5.28 (ddd, J = 17.3, 1.7, 1.2 Hz, 1H), 5.16 (ddd, J = 10.5, 1.7, 1.2 Hz, 1H), 
4.09 (dt, J = 6.9, 1.0, 1.0 Hz, 1H), 4.07-3.93 (m, 1H), 3.54 (s, 3H), 2.41-2.24 (m, 3H), 1.69-1.35 (m, 
3H), 1.32 (s, 3H), 1.10 (s, 3H), 1.08-0.93 (m, 1H), 0.74 (s, 9H), -0.06 (s, 3H), -0.09 (s, 3H); 13C 
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NMR (75.4 MHz, CDCl3) δ 172.1, 132.50, 118.7, 107.6, 85.8, 82.2, 69.7, 51.4, 42.5, 31.1, 30.8, 
28.2, 27.0, 25.7, 22.7, 17.9, -4.5, -5.0; IR (film) 3025, 2928, 2856, 1739, 1559, 1472, 1436, 1377, 
1257, 1059, 924, 870, 838, 778; HRMS (ESP+) calc’d for C20H38NO5NaSi ([M+Na]+) 409.2381, 
found 409.2392. 
 
(E)-5-((4S,5R)-2,2,4-Trimethyl-5-vinyl-[1,3]dioxolan-4-yl)-pent-2-enoic acid methyl ester (3.76) 
MeO O
3.76
O
O
 
3.76 was isolated as a byproduct from the Wittig olefination of 3.65 as a colorless oil: Rf = 0.42 
(heptane:EtOAc = 7:3); [α]23D = -28.9 (c 1.4, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.00 (dt, J = 
15.7, 6.9 Hz, 1H), 5.90-5.73 (m, 1H), 5.83 (dt, J = 15.7, 1.6, 1H), 5.40 (ddd, J = 17.2, 1.6, 1.2 Hz, 
1H), 5.29 (ddd, J = 10.5, 1.7, 1.0 Hz, 1H), 4.22 (dt, J = 6.9, 1.1 Hz, 1H), 3.72 (s, 3H), 2.48-2.32 (m, 
1H), 2.32-2.14 (m, 1H), 1.78-1.62 (m, 1H), 1.43 (s, 3H), 1.38 (s, 3H), 1.36-1.26 (m, 1H), 1.25 (s, 
3H); 13C NMR (75.4 MHz, CDCl3) δ 67.1, 149.6, 132.3, 120.7, 119.0, 107.8, 85.8, 82.0, 51.4, 34.0, 
28.3, 27.0, 26.2, 22.7; IR (film) 2985, 2936, 1726, 1658, 1436, 1378, 1327, 1265, 1218, 1194, 1105, 
1056, 1024, 991, 911, 870, 799; HRMS (ESP+) calc’d for C14H2O4Na ([M+Na]+) 277.1411, found 
277.1409. 
 
(S)-3-(tert-Butyl-dimethyl-silanyloxy)-5-((4S,5R)-2,2,4-trimethyl-5-vinyl-[1,3]dioxolan-4-yl)-
pentanoic acid (3.77) 
O
OTBSMeO
O
O
O
OTBS
O
O
HO
LiOH (aq)
THF, 22 oC
(91% yield)3.75 3.77  
3.75 (100 mg, 0.259 mmol) was dissolved in THF (50 mL) and LiOH (25 mL, 0.3 M) was added. 
The solution was stirred at 22 oC for 20 h, diluted with EtOAc (100 mL), washed with NaH2PO4 (60 
mL, 1.0 M in H2O), brine (60 mL), dried over Na2SO4, and concentrated in vacuo to afford  a 
viscous oil. The crude product was purified using silica-gel chromatography (3:7 → 2:1, heptane-
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EtOAc) to afford 3.77 (88 mg, 91%) as a colorless oil: Rf = 0.31 (heptane:EtOAc = 2:1); [α]23D = -
25.9 (c 0.29, CHCl3); 1H NMR (300 MHz, CDCl3) δ 5.80 (ddd, J = 17.2, 10.5, 6.8 Hz, 1H), 5.46-
5.32 (m, 1H), 5.28 (ddd, J = 10.5, 1.6, 1.1 Hz, 1H), 4.21 (dt, J = 6.9, 1.1, 1.1 Hz, 1H), 4.14-4.01 (m, 
1H), 2.57-2.44 (m, 2H), 1.84-1.69 (m, 1H), 1.65-1.49 (m, 2H), 1.43 (s, 3H), 1.37 (s, 3H), 1.22 (s, 
3H), 1.12 (dt, J = 14.6, 4.6, 4.6 Hz, 1H), 0.88 (s, 9H), 0.09 (s, 3H), 0.07 (s, 3H); 13C NMR (75.4 
MHz, CDCl3) δ 175.9, 132.4, 118.8, 107.6, 85.8, 82.1, 69.7, 31.1, 30.8, 28.2, 27.0, 25.7, 22.7, 17.9, 
-4.6, -4.9; IR (film) 3092, 2932, 2857, 1711, 1473, 1377, 1251, 1219, 1251, 1219, 1058, 992, 927, 
837, 776; HRMS (ESP+) calc’d for C19H36O5SiNa ([M+Na]+) 395.2225, found 395.2235. 
 
(2S)-Methyl-3-trityloxy-propionic acid methyl ester (3.79) 
O
OH
OMe
O
OTr
OMe
TrCl
DMAP, Et3N
CH2Cl2, 23 oC
(96% yield)
(S)-Roche ester (3.78) 3.79
 
To a solution of trityl chloride (42.5 g, 152 mmol) in CH2Cl2 (250 mL) was added Et3N (23.6 mL, 
169 mmol), DMAP (2.06 g, 6.9 mmol), and (S)-Roche ester (3.78) (10.0 g 84.7 mmol). After stirring 
at 23 oC for 12 h the reaction was quenched with saturated aqueous NH4Cl (100 mL), and diluted 
with CH2Cl2 (200 mL). The organic phase was washed with H2O (3 x 200 mL), brine (200 mL), 
dried over MgSO4 and concentrated in vacuo to afford a pale yellow solid. The crude product was 
recrystallized from EtOH to afford 3.79 (29.3 g, 96% yield) as white needles: mp 90-91°C (EtOH), 
lit.284 mp 84-85 °C (EtOH); Rf = 0.24 (heptane:EtOAc = 4:1); [α]23D = +17.7 (c 1.9, CHCl3); 1H 
NMR (300 MHz, CDCl3) δ 7.44-7.40 (m, 6H), 7.35-7.19 (m, 9H), 3.71 (s, 3H), 3.31 (dd, J = 8.6, 7.1 
Hz, 1H), 3.18 (dd, J = 8.7, 5.8 Hz, 1H), 2.86-2.66 (m, 1H), 1.16 (d, J = 7.1 Hz, 3H); 13C NMR (75.4 
MHz, CDCl3) δ 175.4, 143.9, 128.9, 127.8, 127.0, 86.3, 65.2, 51.6, 40.3, 13.9; IR (KBr) 3057, 3000, 
2970, 2908, 2861, 1727, 1490, 1379, 1223, 1197, 1143, 1090, 990, 964, 902, 840, 771, 710, 697, 
632. Spectral data are in accordance with literature values.284 
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(2R)-Methyl-3-trityloxypropan-1-ol (3.80) 
O
OTr
OMe
OTr
OH
LiAlH4
THF, 0 oC
(98% yield)
3.79 3.80
 
3.79 (25.0 g, 69.3 mmol) was dissolved in THF (500 mL) and cooled to 0 °C while stirring. LiAlH4 
(104 mL, 1.0 M solution in THF) was added dropwise over 30 min. The reaction mixture was stirred 
at 0 °C for an additional 2 h and allowed to warm to 22 oC. After 2 h, the reaction was quenched 
carefully with H2O (25 mL) followed by saturated aqueous Rochelle’s salt (150 mL) The mixture 
was stirred for 12 h at 22 oC and diluted with Et2O (500 mL). The aqueous layer was separated and 
extracted with Et2O (2 x 200 mL). The combined organic extracts were dried over MgSO4 and 
concentrated in vacuo to afford a colorless oil that crystallized upon standing. The crude solid was 
recrystallized from Et2O and hexane to afford 3.80 (22.5 g, 98% yield) as a white solid: mp 69-71 
°C (Et2O, hexane), lit.285 mp 74-76 °C (EtOAc, hexanes); Rf = 0.11 (heptane:EtOAc = 9:1); [α]23D = 
+29.1 (c 1.7, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.48-7.40 (m, 6H), 7.37-7.18 (m, 9H), 3.70-
3.51 (m, 2H), 3.24 (dd, J = 9.1, 4.5 Hz, 1H), 3.03 (dd, J = 9.1, 5.1 Hz, 1H), 2.33 (dd, J = 6.5, 5.1 Hz, 
1H), 0.87 (d, J = 7.0 Hz, 3H); 13C NMR (75.4 MHz, CDCl3) δ 143.8, 128.5, 127.8, 127.0, 87.0, 
67.6, 67.6, 35.9, 13.7; IR (KBr) 3313, 3057, 2959, 2909, 2868, 1596, 1488, 1448, 1215, 1160, 1073, 
1033, 990, 775, 146, 706, 633. Spectral data are in accordance with literature values.285  
 
(S)-2-Methyl-3-trityloxy-propionaldehyde (3.81) 
OTr
OH
OTr
O
H
(COCl)2
DMSO, Et3N
CH2Cl2, -78 oC
(96% yield)
3.80 3.81
 
Oxalyl chloride (11.3 mL, 133 mmol) was dissolved in CH2Cl2 (250 mL) cooled to -78 °C. DMSO 
(23.6 mL, 333 mmol) was added dropwise keeping the internal temperature below -60 °C. The 
mixture was stirred at -78 °C for an additional 20 minutes. 3.80 (22.1 g, 66.5 mmol) was dissolved 
in CH2Cl2 (50 mL) and added dropwise to the reaction mixture keeping the internal temperature 
below -70 °C. The mixture was stirred for an additional 45 minutes followed by addition of Et3N (37 
mL, 266 mmol). The reaction mixture was allowed to warm to 0 °C then quenched with saturated 
aqueous NaHCO3 (100 mL). The organic phase was separated, washed with H2O (100 mL), 
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saturated aqueous CuSO4 (3 x 100 mL), H2O (100 mL), brine (100 mL), dried over MgSO4, and 
concentrated in vacuo to afford a pale yellow solid. The crude product was recrystallized from 
hexane to afford 3.81 (21.1 g, 96% yield) as colorless needles with spectral: mp 91-93°C (hexanes); 
Rf = 0.60 (heptane:EtOAc = 1:1); [α]23D = +25.7  (c 1.7, CHCl3); 1H NMR (300 MHz, CDCl3) 
δ 9.71 (d, J = 1.7 Hz, 1H), 7.49-7.40 (m, 6 H), 7.36-7.21 (m, 9H), 3.43-3.31 (m, 2H), 2.72-2.55 (m, 
1H), 1.14 (d, J = 7.1 Hz, 3H); 13C NMR (75.4 MHz, CDCl3) δ 204.1, 143.6, 128.6, 127.8, 127.1, 
86.6, 63.6, 47.0, 10.8; IR(KBr) 3085, 3059, 2979, 2867, 2830, 2740, 1720, 1596, 1488, 1449, 1400, 
1219, 1154, 1122, 1092, 1076, 1047, 778, 768, 711, 698, 632. Spectral data are in accordance with 
literature values.286 
 
(3S)-Methyl-4-trityloxybut-1-en (3.73) 
OTr
O
H
OTr
n-BuLi, Ph3PCH3Br
THF, -78 to 22 oC
(89% yield)
3.733.81  
Triphenylphosphonium bromide (32.5 g, 90.9 mmol) was azeotroped with toluene (3 x 50 mL) and 
suspended in THF (500 mL). The suspension was cooled to -78 °C while stirring and n-BuLi (47.2 
mL, 86.3 mmol, 1.83 M in cyclohexane) was added dropwise. The resulting bright yellow 
suspension was stirred at -78 °C for an additional 1 h.  3.81 (15.0 g, 45 mmol) was dissolved in THF 
(50 mL) and added dropwise to the reaction mixture. The reaction mixture was stirred for 1 h at -78 
°C, allowed to warm to room 22 oC. After an additional 12 h stirring at 22 oC the reaction was 
quenched with MeI (6.2 mL, 100 mmol), stirred for 2 h at 22 oC, diluted with Et2O (500 mL), 
washed with H2O (3 x 200 mL), brine (200 mL), dried over MgSO4, and concentrated in vacuo to 
afford a pale yellow oil. The crude product was purified using silica-gel chromatography (19:1, 
heptane-EtOAc) to afford 3.71 (13.2 g, 89%) as a colorless viscous oil: Rf = 0.63 (heptane:EtOAc = 
4:1); [α]23D = -1.53  (c 1.7, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.62-7.10 (m, 15H), 5.82 (ddd, J 
= 17.3, 10.4, 7.0 1H), 5.12-4.96 (m, 2H), 3.01 (dd, J = 8.6, 6.6 Hz, 1H), 2.93 (dd, J = 8.6, 6.6 Hz, 
1H), 2.58-2.40 (m, 1H), 1.04 (d, J = 6.8 Hz, 3H);13C NMR (75.4 MHz, CDCl3) δ 144.3, 141.7, 
128.7, 127.7, 126.8, 113.8, 86.1, 68.0, 38.3, 16.8; IR (film) 3061, 3034, 2963, 2911, 2867, 1639, 
1595, 1489, 1447, 1418, 1382, 1365, 1215, 1153, 1030, 994, 924, 898, 775, 741, 697; HRMS 
(ESP+) calc’d for C24H24ONa ([M+Na+]) 351.1720, found 353.1721.  
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(R)-2-Methyl-but-3-en-1-ol (3.82) 
OTr
BCl3
CH2Cl2, -30 oC
then MeOH OH
clean reaction by TLC
attained as a solution in CH2Cl2
3.73 3.82
 
3.73 (2.0 g, 6.1 mmol) was dissolved in CH2Cl2 (10 mL) and the resulting clear solution was cooled 
to -30 °C while stirring. BCl3 (3.67 mL, 3.67 mmol, 1.0 M in CH2Cl2) was added dropwise. The 
mixture became bright yellow instantaneously. The mixture was stirred for an additional 30 min at -
30 °C and was subsequently quenched with MeOH (1.0 mL) and poured into saturated aqueous 
NaHCO3 (15 mL). The organic layer was separated and the aqueous phase was extracted with 
CH2Cl2 (1 x 10 mL). The combined organic phases were washed with brine (25 mL), and dried over 
MgSO4 to afford a solution of 3.82 in CH2Cl2 (~0.3M) along with TrOMe (~0.3 M). This solution 
was used for the subsequent esterification reaction.  
 
(S)-3-(tert-Butyl-dimethyl-silanyloxy)-5-((4S,5R)-2,2,4-trimethyl-5-vinyl-[1,3]dioxolan-4-yl)-
pentanoic acid (R)-2-methyl-but-3-enyl ester (3.83) 
O
OTBS
O
O
O
O
OTBS
O
O
HO
1. 2,4,6-trichlorobenzoyl chloride
    Et3N, CH2Cl2, 22 oC
2. 3.82, DMAP, PhH, 22 oC
(87% yield) 3.833.77  
3.77 (50 mg, 0.134 mmol) was azeotroped with benzene (3 x 5 mL) and dissolved in CH2Cl2 (2.5 
mL). Triethylamine (296 μL, 2.13 mmol) was added in one portion followed by 2,4,6-
trichlorobenzoyl chloride (167 μL, 1.07 mmol). The resulting solution was allowed to stir for an 
additional 30 minutes at 22 oC, then the reaction mixture was taken up into a syringe, and added to a 
solution of DMAP (211 mg, 1.73 mmol) and 3.82 (~0.67 mmol, as ~0.3 M solution in CH2Cl2) in 
benzene (25 mL). The resulting cloudy yellow suspension was stirred for 20 h at 22 oC. Saturated 
aqueous NaHCO3 (25 mL) was added to the reaction mixture and the resulting biphasic mixture was 
stirred for 1 h. The organic layer was separated and the aqueous layer was extracted with EtOAc (3 
x 50 mL). The combined organic phases were dried over Na2SO4, and concentrated in vacuo to 
afford a pale yellow residue. The crude product was purified using silica-gel chromatography (9:1 
→ 4:1, heptane-EtOAc) to afford 3.83 (52 mg, 87% yield): Rf = 0.59 (heptane:EtOAc = 4:1); [α]23D 
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= - 3.4 (c 0.26, CHCl3); 1H NMR (300 MHz, CDCl3) δ 5.81 (ddd, J = 17.3, 10.4, 6.9 Hz, 1H), 5.74 
(ddd, J = 17.3, 10.4, 7.0 Hz, 1H), 5.48-5.33 (m, 1H), 5.28 (ddd, J = 10.4, 1.6, 1.0 Hz, 1H), 5.07 (dt, 
J = 17.3, 1.5 Hz, 1H), 5.06-5.00 (m, 1H), 4.20 (dt, J = 6.9, 1.0 Hz, 1H), 4.16-4.05 (m, 1H), 3.99 
(dd, J = 10.7, 6.8 Hz, 1H), 3.89 (dd, J = 10.7, 6.7 Hz, 1H), 2.72-2.17 (m, 3H), 1.77-1.47 (m, 3H), 
1.43 (s, 3H), 1.37 (s, 3H), 1.21 (s, 3H), 1.17-1.06 (m, 1H), 1.04 (d, J = 6.83 Hz, 3H), 0.86 (s, 9H), 
0.05 (s, 3H), 0.03 (s, 3H); 13C NMR (75.4 MHz, CDCl3) δ 171.7, 140.0, 132.5, 118.8, 114.9, 107.6, 
85.9, 82.2, 69.6, 68.3, 42.7, 36.8, 31.1, 30.9, 28.2, 27.1, 25.8, 22.7, 17.9, 16.4, -4.5, -4.9; IR (film) 
3058, 2932, 2877, 2847, 1735, 1473, 1377, 1351, 1217, 1058, 1000, 919, 887, 776; HRMS (ESP+) 
calc’d for C24H44O5SiNa ([M+Na]+) 463.2851, found 463.2861. 
 
(E)-(3aR,6R,11S,13aS)-11-(tert-Butyl-dimethyl-silanyloxy)-2,2,6,13a-tetramethyl-3a,6,7,10,11 
,12,13,13a-octahydro-1,3,8-trioxa-cyclopentacyclododecen-9-one (3.84) 
OTBS
O
O OTBS
O
O
3.24 (10 mol%)
CH2Cl2, 0.5 mM, 40 oC
(23% yield)3.83 3.84
O
O
O
O
 
3.83 (50 mg, 0.11 mmol) was dissolved in CH2Cl2 (227 mL) and deoxygenated via argon purge and 
sonication. Hoveyda-Grubbs’ 2nd generation catalyst (3.24) (6.9 mg, 0.011 mmol) was added and the 
resulting clear green solution was heated to reflux while stirring. After 20 h stirring TLC revealed 
full conversion of the starting material and the mixture was allowed to cool to ambient temperature 
and concentrated under reduced pressure. The crude product was purified using silica-gel 
chromatography (19:1, heptane-EtOAc) to afford 3.84 (10.4 mg, 23% yield) as a colorless oil. For 
characterization data cf. the macrolactonization approach.  
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(S)-3-(tert-Butyl-dimethyl-silanyloxy)-5-[(4S,5R)-2,2,4-trimethyl-5-((E)-(R)-3-methyl-4-trityl-
oxy-but-1-enyl)-[1,3]dioxolan-4-yl]-pentanoic acid methyl ester (3.85) 
OTBS
O
MeO
TrO
OTBS
O
MeO
3.24 (20 mol%)
3.73 (4 equiv)
CH2Cl2, 40 oC
(76% yield)3.75 3.85
O
O
O
O
 
3.75 (313 mg, 0.81 mmol) and 3.73 (533 mg, 1.62 mmol) were dissolved in CH2Cl2 (25 mL) and 
deoxygenated via argon purge and sonication (5 min). Hoveyda-Grubbs’ 2nd generation catalyst 
(3.24) (38 mg, 0.081 mmol) was added and the mixture was deoxygenated via argon purge and 
sonication (5 min). The mixture was heated to reflux and stirred for 20 h, then additional 3.73 (533 
mg, 1.62 mmol) and 3.24 (19 mg, 0.041 mmol) were added. After an additional 18 h of stirring at 
reflux, a final portion of 3.24 (19 mg, 0.041 mg) was added. The resulting green solution was stirred 
18 h at reflux. The solvent was then removed in vacuo, and the residue was purified using silica-gel 
chromatography (19:1 → 9:1, heptane-EtOAc) to afford 3.85 (422 mg, 76% yield) as a colorless oil: 
Rf = 0.42 (heptane:EtOAc = 1:1); [α]23D = -15.9 (c 0.21, CHCl3); 1H NMR (300 MHz, CDCl3) 
δ 7.46-7.20 (m, 15 H), 5.81 (dd, J = 15.4, 7.4 Hz, 1H), 5.45 (ddd, J = 15.4, 7.9, 1.1 Hz, 1H), 4.14 
(dd, J = 7.9, 1.1 Hz, 1H), 4.15-4.06 (m, 1H), 3.66 (s, 3H), 3.03 (dd, J = 8.7, 6.5 Hz, 1H), 2.94 (dd, J 
= 8.7, 6.6 Hz, 1H), 2.51-2.34 (m, 3H), 1.75-1.53 (m, 3H) 1.42 (s, 3H), 1.36 (s, 3H), 1.17 (s, 3H), 
1.07-0.91 (m, 1H),1.06 (d, J = 6.8 Hz, 3H), 0.85 (s, 9H), 0.04 (s, 3H), 0.02 (s, 3H); 13C NMR (75.4 
MHz, CDCl3) δ 172.1, 144.2, 139.5, 128.7, 127.7, 126.9, 123.6, 107.3, 86.2, 86.0, 82.2, 69.8, 67.9, 
51.5, 42.7, 37.4, 31.1, 31.0, 28.3, 27.1, 25.7, 22.5, 17.9, 17.0, -4.4, -4.9; IR (film)3050, 3030, 2954, 
2929, 2851, 1741, 1449, 1376, 1251, 1217, 1075, 1085, 974, 836, 775, 707; HRMS (ESP+) calc’d 
for C42H58O6NaSi ([M+Na]+) 709.3895, found 709.3921. 
 
((E,2R,5R)-2-Methyl-5-((trityloxy)methyl)hex-3-enyloxy)triphenylmethane (3.86) 
TrO
OTr
3.86  
3.86 was isolated as a byproduct from the CM of 3.75 as a white powder: Rf  = 0.43 (heptane:EtOAc 
= 9:1); [α]22D = -8.4 (c 2.7, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.49-7.42 (m, 12H), 7.36-7.17 
(m, 18H), 5.43 (dd, J = 4.1, 1.9 Hz, 2H), 3.03 (dd, J = 8.6, 6.4 Hz, 2H), 2.91 (dd, J = 8.6, 7.0 Hz, 
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2H), 2.55-2.36 (m, 2H), 1.07 (d, J = 6.9 Hz, 6H); 13C NMR (75.4 MHz, CDCl3) δ 144.4, 132.7, 
128.7, 127.6, 126.7, 86.0, 68.2, 37.3, 17.4; IR (film) 3058, 3022, 2962, 2908, 2882, 2867, 1491, 
1448, 1215, 1181, 1151, 1074, 1030, 1074, 1030, 1003, 983, 897, 763, 702, 633; HRMS (ESP+) 
calc’d for C46H44O3Na ([M+Na]+) 651.3234, found 651.3216. 
 
(S)-3-(tert-Butyl-dimethyl-silanyloxy)-5-[(4S,5R)-5-((E)-(R)-4-hydroxy-3-methyl-but-1-enyl)-
2,2,4-trimethyl-[1,3]dioxolan-4-yl]-pentanoic acid methyl ester (3.87) 
OTBS
O
MeO
TrO
OTBS
O
MeO
HO
BCl3
CH2Cl2, -30 oC
then MeOH
(84% yield)3.85 3.87
O
O
O
O
 
3.85 (146 mg, 0.213 mmol) was dissolved in CH2Cl2 (10 mL) and the resulting clear solution was 
cooled to -30 °C while stirring. BCl3 (128 μL, 0.128 mmol, 1.0 M in CH2Cl2) was added dropwise. 
The mixture became bright yellow instantaneously. The mixture was stirred for an additional 30 min 
at -30 °C and was subsequently quenched with MeOH (3.0 mL) and poured into saturated aqueous 
NaHCO3 (15 mL). The organic layer was separated and the aqueous phase was extracted with 
CH2Cl2 (5 x 10 mL). The combined organic phases were washed with brine (25 mL), dried over 
MgSO4, and concentrated in vacuo to afford a colorless sticky oil. The crude product was purified 
using silica-gel chromatography (4:1 → 2:1, heptane-EtOAc) to afford 3.87 (80.4 mg 84% yield) as 
a colorless oil: Rf = 0.44 (heptane:EtOAc = 3:7); [α]23D = +2.7 (c 0.29, CHCl3); 1H NMR (300 MHz, 
CDCl3) δ 5.76 (ddd, J = 15.6, 7.3, 0.8 Hz, 1H), 5.53 (ddd, J = 15.6, 7.4, 1.1 Hz, 1H), 4.19 (dd, J = 
7.4, 0.8 Hz, 1H), 4.18-4.04 (m, 1H), 3.65 (s, 3H), 3.60-3.38 (m, 2H), 2.50-2.30 (m, 1H), 2.48 (dd, J 
= 14.6, 7.1 Hz, 1H), 2.39 (dd, J = 14.6, 5.7 Hz, 1H), 1.78-1.49 (m, 3H), 1.43 (s, 3H), 1.36 (s, 3H), 
1.28-1.10 (m, 1H), 1.19 (s, 3H), 1.05 (d, J = 6.8 Hz, 3H), 0.86 (s, 9H), 0.06 (s, 3H), 0.03 (s, 3H); 13C 
NMR (75.4 MHz, CDCl3) δ 172.2, 137.6, 125.2, 107.4, 85.5, 82.2, 69.6, 67.2, 51.5, 42.6, 39.4, 31.0, 
30.7, 28.2, 27.1, 25.7, 22.7, 17.9, 16.1, -4.5, -4.9; IR (film) 3450, 2930, 1732, 1443, 1405, 1220, 
1105, 830, 777, 705; HRMS (ESP+) calc’d for C23H44O6SiNa ([M+Na]+) 469.2799, found 469.2785. 
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(S)-3-(tert-Butyl-dimethyl-silanyloxy)-5-[(4S,5R)-5-((E)-(R)-4-hydroxy-3-methyl-but-1-enyl)-
2,2,4-trimethyl-[1,3]dioxolan-4-yl]-pentanoic acid (3.88) 
OTBS
O
O
O
MeO
HO
OTBS
O
O
O
HO
HOLiOH (aq)
THF, 23 oC
(100% yield)3.87 3.88  
3.87 (59 mg, 0.132 mmol) was dissolved in THF (50 mL) and LiOH (25 mL, 0.3 M) was added. The 
solution was stirred at 23 oC for 13 h, diluted with EtOAc (100 mL), washed with NaH2PO4 (60 mL, 
1.0 M in H2O), brine (60 mL), dried over Na2SO4, and concentrated in vacuo to afford  a viscous oil. 
The crude product was purified using silica-gel chromatography (3:7 → 0:1, heptane-EtOAc) to 
EtOAc) to afford 3.88 57 mg (100%) as a colorless oil: Rf = 0.32 (heptane:EtOAc = 3:7); [α]23D = -
12.8 (c 0.35, CHCl3); 1H NMR (300 MHz, CDCl3) δ 5.74 (ddd, J = 15.6, 7.30, 0.6 Hz, 1H), 5.51 
(ddd, J = 15.6, 7.4, 1.0 Hz, 1H), 5.40 (br s, 2H), 4.18 (dd, J = 7.3, 1.0 Hz, 1H), 4.13-4.01 (m, 1H), 
3.58-3.41 (m, 2H), 2.57-2.33 (m, 3H), 1.78-1.49 (m, 3H), 1.42 (s, 3H), 1.36 (s, 3H), 1.28-1.11 (m, 
1H), 1.19 (s, 3H), 1.03 (d, J = 6.8 Hz, 3H), 0.87 (s, 9H), 0.07 (s, 3H), 0.06 (s, 3H); 13C NMR (75.4 
MHz, CDCl3) δ 175.3, 137.7, 125.0, 107.4, 85.4, 82.2, 69.7, 67.0, 42.2, 39.2, 31.3, 31.1, 28.3, 27.0, 
25.7, 22.7, 17.9, 16.1, -4.6, -5.0; IR (film)  3395, 2954, 2930, 2857, 1713, 1472, 1463, 1377, 1256, 
1218, 1192, 1094, 1035, 974, 922, 837, 812, 776, 735; HRMS (ESP+) calc’d for C22H42O6SiNa 
([M+Na]+) 453.2643, found 453.2622. 
 
(E)-(3aR,6R,11S,13aS)-11-(tert-Butyl-dimethyl-silanyloxy)-2,2,6,13a-tetramethyl-3a,6,7,10,11,-
12,13,13a-octahydro-1,3,8-trioxa-cyclopentacyclododecen-9-one (3.84) 
OTBS
O
O
O
HO
HO
OTBS
O
O
O
O
1. 2,4,6-trichlorobenzoyl chloride
   Et3N, CH2Cl2, 0 oC to 22 oC
2. DMAP, PhH, 80 oC
(63% yield)3.88 3.84  
3.88 (36.4 mg, 0.085 mmol) was azeotroped with benzene (3 x 5 mL) and dissolved in CH2Cl2 (3.0 
mL). Triethylamine (188μL, 1.35 mmol) was added in one portion followed by 2,4,6-
trichlorobenzoyl chloride (106 μL, 0.68 mmol). The resulting solution was allowed to stir for an 
additional 30 minutes at room 22 oC and then the reaction mixture was diluted with benzene (10 
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mL), taken up into a syringe, and added dropwise over 1h by use of a syringe pump to a refluxing 
solution of DMAP (134 mg, 1.10 mmol) in benzene (225 mL). The resulting cloudy yellow 
suspension was stirred for an additional 30 minutes at reflux and allowed to cool to ambient 
temperature. Saturated aqueous NaHCO3 (100 mL) was added to the reaction mixture and the 
resulting biphasic mixture was stirred for 2 h. The organic layer was separated and the aqueous layer 
was extracted with EtOAc (3 x 50 mL). The combined organic phases were dried over Na2SO4, and 
concentrated in vacuo to afford a pale yellow residue. The crude product was purified using silica-
gel chromatography (19:1, heptane-EtOAc) to afford 3.84 (21.1 mg, 63% yield) as a colorless oil: Rf 
= 0.38 (heptane:EtOAc = 9:1); [α]23D = -5.7 (c 0.27, CHCl3); 1H NMR (300 MHz, CDCl3) δ 5.57 
(dd, J = 15.5, 7.7 Hz, 1H), 5.46 (dd, J = 15.5, 8.0 Hz, 1H), 4.20 (d, J = 7.7 Hz, 1H), 4.05-3.88 (m, 
3H), 2.80-2.60 (m, 1H), 2.55 (dd, J = 14.2, 4.3 Hz, 1H), 2.32 (dd, J = 14.2, 10.7 Hz, 1H), 1.75 (ddd, 
13.3, 11.6, 7.7 Hz, 1H), 1.64-1.48 (m, 2H), 1.44 (s, 3H), 1.38 (s, 3H), 1.33 (ddd, J = 10.9, 5.4, 2.6 
Hz, 1H), 1.29 (s, 3H), 1.04 (d, J = 6.9 Hz, 3H), 0.87 (s, 9H), 0.09 (s, 3H), 0.08 (s, 3H);  13C NMR 
(75.4 MHz, CDCl3) δ 170.5, 136.1, 129.2, 107.8, 84.6, 83.3, 71.2, 67.3, 43.7, 36.9, 34.7, 31.9, 28.9, 
27.2, 25.7, 25.3, 18.0, 16.0, -4.5, -4.6; IR (film) 3026, 2964, 2932, 2862, 1733, 1472, 1451, 1374, 
1267, 1190, 1103, 1082, 1046, 1005, 974, 923, 887, 837, 774; HRMS (ESP+) calc’d for ([M+Na]+) 
435.2537, found 435.2524. 
 
(E)-(4S,7S,8R,11R)-4,7,8-Trihydroxy-7,11-dimethyl-oxacyclododec-9-en-2-one (3.89) 
OTBS
O
O
HF (aq), CH3CN
22 oC
(92% yield)
OH
O
OH
OH
O
3.84 3.89
O
O
 
3.84 (19.6 mg, 48 μmol) was dissolved in MeCN (10 mL) and HF (0.5 mL, 40%) was added while 
stirring at 22 oC. The solution was stirred at 22 oC for 3 h and poured into saturated aqueous 
NaHCO3 (10 mL). The mixture was diluted with EtOAc (25 mL). The organic phase was separated 
and the aqueous phase was extracted with EtOAc (5 x 25 mL). The combined organic phases were 
dried over Na2SO4 and concentrated in vacuo to afford a white solid. The crude product was purified 
using silica-gel chromatography (EtOAc) to afford 3.89 (11.3 mg, 92% yield) as a white powder: Rf 
= 0.20 (EtOAc); [α]23D =  -9.12 (c 0.19, CH3OH); 1H NMR (300 MHz, CD3OD) δ 5.69 (dd, J = 
15.2, 9.5 Hz, 1H), 5.34 (dd, J = 15.2, 9.7 Hz, 1H), 4.40 (t, J = 10.8 Hz, 1H), 3.85-3.47 (m, 1H), 3.73 
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(dd, J = 10.8, 4.9 Hz, 1H), 3.71 (d, J = 9.6 Hz, 1H), 2.69-2.55 (m, 1H), 2.54-2.52 (m, 2H), 1.64-1.43 
(m, 2H), 1.50-1.13 (m, 2H), 1.26 (s, 3H), 1.02 (d, J = 6.8 Hz, 3H); 13C NMR (75.4 MHz, CD3OD) 
δ 172.7, 137.6, 131.8 78.2, 74.5, 70.5, 67.8, 40.0, 39.7, 37.2, 30.2, 24.7, 16.2; IR (film)  3344, 293, 
2841, 1720, 1651, 1564, 1501, 1462, 1400, 1350, 1092, 917, 880, 775; HRMS (ESP+) calc’d for 
C13H22O5Na ([M+Na]+) 281.1359, found 281.1351. 
 
Acetic acid (E)-(3R,6R,7S,10S)-7,10-dihydroxy-3,7-dimethyl-12-oxo-oxacyclododec-4-en-6-yl 
ester (3.38) 
OH
O
OH
OH
O OH
O
OAc
OH
O
macrocyclic core of
(−)-pladienolide B (3.38)
3.89
1. CH3C(OCH3)3, CSA
    CH2Cl2, 0 oC
2. AcOH (aq), 22 oC
(86% yield)
 
3.89 (9.4 mg, 36 μmol) was dissolved in CH2Cl2 (5 mL) and the solution was cooled to 0 °C while 
stirring. Trimethyl orthoacetate (46 μL, 364 μmol) was added in one portion followed by CSA (one 
grain). The mixture was stirred at 0 °C for an additional 1.5 h and AcOH (5 mL, 80% in water) was 
added in one portion. The reaction mixture was allowed to warm to 22 oC and stirred for an 
additional 1.5 h. The solvent was removed in vacuo and the crude mixture was azeotroped with 
toluene (3 x 5 mL) to afford a white powder. The crude product was purified using silica-gel 
chromatography (3:7, heptane-EtOAc) to afford 3.38 (9.4 mg, 86%) as a white powder. X-ray 
quality crystals were obtained by recrystallization from diisopropylether and methanol: Rf = 0.16 
(heptane:EtOAc = 3:7); [α]23D =  -45.1 (c 0.059 , CHCl3);  1H NMR (300 MHz, CDCl3) δ 5.65 (dd, J 
= 15.2, 9.30 Hz, 1H), 5.53 (dd, J = 15.2, 9.6 Hz, 1H), 5.07 (d, J = 9.3 Hz, 1H), 4.69 (dd, J =11.8, 
10.9 Hz, 1H), 3.83-3.68 (m, 1H), 3.58 (dd, J = 10.9, 4.9 Hz, 1H), 2.66 (dd, J = 15.4, 3.7, 1H), 2.61-
2.46 (m, 1H), 2.55 (dd, J = 15.4, 3.1 Hz, 1H), 2.09 (s, 3H), 1.77-1.56 (m, 1H), 1.56-1.44 (m, 1H), 
1.45-1.23 (m, 2H), 1.20 (s, 3H), 1.00 (d, J = 6.6 Hz, 3H); 13C NMR (50.3 MHz, CDCl3) δ 172.6, 
169.6, 140.4, 125.9, 78.7, 73.3, 69.1, 66.1, 39.1, 38.0, 35.1, 29.6, 24.7, 21.3, 15.6; IR (film) 3453, 
3000, 2947, 2885, 1733, 1707, 1463, 1427, 1375, 1256, 1173, 1137, 1101, 1080, 1054, 1023, 992, 
920, 899, 800, 743, 668, 666; HRMS (ESP+) calc’d for C15H24O6Na ([M+Na]+) 323.1465, found 
323.1450. 
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4 Ruthenium- and Iridium-Catalyzed C-C Bond Formation 
A pivotal challenge in synthetic organic chemistry is the efficient construction of C-C bonds 
allowing for the rapid build-up of molecular complexity. The last three to four decades have seen the 
appearance of several highly efficient transition metal catalyzed C-C bond forming protocols 
offering great control in terms of chemo-, diastereo-, and enantioselectivity. Prominent among these 
processes are the olefin metathesis reaction121 (cf. chapter 2.4) and the palladium-catalyzed coupling 
reactions.287,288 When evaluating these processes from an atom economical perspective the olefin 
metathesis clearly stands out as a superior transformation, since ethylene is the only formed 
byproduct,a whereas palladium-catalyzed cross-coupling reactions produce large amounts of 
inorganic salts often with relatively high molecular weight. The term atom economy was introduced 
in 1991 by Professor Barry M. Trost from Stanford University (Figure 4.1).289-292 This term was 
meant to serve as a guiding principle for evaluating the efficiency of specific chemical processes and 
moreover highlight the limitations associated with the conventional yield and selectivity founded 
assessment of synthetic efficiency.  
reaction yield =
atom economy =
quantity of product
theoretical quantity of product
Mw of desired product
Mw of all products
x 100%
x 100%
 
Figure 4.1 Traditional reaction yield vs. atom economy. 
 
The reaction yield is only concerned with the quantity of the desired product that is isolated relative 
to the theoretical quantity of the product. In contrast atom economy takes all used reagents and 
unwanted products into account along with the desired product. A corollary of the atom economy 
concept is that if maximum incorporation of reagents into the product cannot be achieved, then 
ideally the amount of side product (waste) should be minute and environmentally innocuous. As is 
evident from the cross coupling reactions, which are some of the true work horses in organic 
synthesis, there is still vast room for improvement in striving toward environmentally benign 
chemical transformations. Recently, Noyori stated the following goal for future synthetic chemists: 
“Ideally, we should aim at synthesizing target compounds with 100% yield and 100% selectivity and 
                                                 
a In the case of ring-opening metathesis polymerization no byproduct is formed i.e. the atom economy is 100%. 
4 Ruthenium- and Iridium-Catalyzed C-C Bond Formation 
 94
avoid the production of waste. This process must be economical, safe, resource-efficient, energy-
efficient and environmentally benign.”293 
 
A recent approach to construct C-C bonds in a catalytic manner relies on a transition metal catalyzed 
hydrogen autotransfer process to couple alcohols and various carbon nucleophiles producing water 
as the only byproduct. Hereby providing a “greener” alternative to the traditional coupling of enolate 
derivatives and alkyl halides/pseudohalides.294-296 
 
4.1 The Transition Metal-Catalyzed Hydrogen Autotransfer Process  
4.1.1 Background 
A traditional means to construct C-C bonds in organic synthesis is based on the coupling of enolate 
derivatives with alkyl halides. From an atom economical and environmental perspective this 
approach suffers from several disadvantages, such as the required use of stoichiometric amounts of 
strong base and generation of large amounts of waste resulting from the halide leaving group. An 
emerging alternative is the hydrogen autotransfer process. This process, allowing for alkylation of 
diverse nucleophiles e.g. ketones, nitriles and activated methylene compounds using alcohols, was 
demonstrated by Guerbert297 already in 1908. However, this process had received sparse attention 
until recent developments by particularly Grigg,298 Cho,299,300 Yus,301,302 and Williams.303,304  
OH
R2
MLn
base
MLn(H)2
R1EWG
R2
R1EWG + + H2O
MLn
O
R2
R1EWG +
base R1EWG
R2
+ H2O
 
Scheme 4.1 Hydrogen autotransfer process. 
 
Common features for these hydrogen autotransfer processes are the involvement of three 
fundamental steps: transition metal catalyzed alcohol dehydrogenation affording an 
aldehyde/ketone, which undergoes condensation or olefination to furnish an unsaturated product, 
which is ultimately hydrogenated delivering the saturated product (Scheme 4.1). Overall this process 
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changes the usual nucleophilic reactivity of alcohols by in situ generation of a highly electrophilic 
aldehyde poised to undergo reaction with an appropriate nucleophile furnishing the desired alkylated 
product with water as the only byproduct. 
 
Recently, several iridium and ruthenium based protocols for the alkylation of e.g. ketones,300,301,305-
307 barbiturates,308 and certain nitriles309-312 have been disclosed (representative examples are 
depicted in Scheme 4.2). Yus302 disclosed the facile α-alkylation of ketones utilizing 
[Ru(DMSO)4]Cl2 as catalyst and achieved the formation of 4.1 in 72% yield. The iridium based 
catalyst system consisting of [Ir(cod)Cl]2 and PPh3 was also found to be an efficient catalyst for the 
alkylation of ketones with primary alcohols.305 Notably, this methodology proceeded with excellent 
regioselectivity affording 4.2 in high yield. Grigg and co-workers310,313 have reported the iridium-
catalyzed alkylation of arylacetonitriles furnishing 4.3 and additionally utilized indoles as 
nucleophiles in alkylation reactions with alcohols to provide 4.4.  
Ph
O
[Ru(DMSO)4]Cl2 (2 mol%)
BnOH, KOH 
p-dioxane, 80 oC
(72% yield)
Ph
O
Ph
Ph
O
[Ir(cod)Cl]2 (2 mol%)
PPh3 (8 mol%),KOH (20 mol%)
n-BuOH
neat, 100 oC
(71% yield)
Ph
O
Ph CN
[Cp*IrCl2]2 (2.5 mol%)
KOH (15 mol%)
BnOH
neat, 100 oC
(88% yield)
Ph CN
Ph
N
H
N
H
Ph
[Cp*IrCl2]2 (2.5 mol%)
KOH (20 mol%)
BnOH
neat, 100 oC
(80% yield)
4.1
4.2
4.3
4.4
 
Scheme 4.2 Representative alkylation protocols with alcohols. 
 
In recent years a range of heterogeneous catalyst have also been shown to facilitate related 
alkylation processes, including polymer supported palladium,314 palladium nanoparticles in 
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aluminium hydroxide,306 ruthenium-grafted hydrotalcite,309 alumina-supported silver particles,315 
and nickel nanoparticles.307 Additionally, this methodology has found widespread application in the 
construction of various heterocycles,316-321 alkylation of amines,322-326 carbamates/amides327, and 
sulfonamides.328 Considering the aforementioned examples, the hydrogen autotransfer process have 
obviously emerged as an atom efficient and “green” protocol for the alkylation of various 
nucleophiles utilizing primary alcohols. However, future progress to provide more active catalysts to 
make this process operational at ambient temperatures, encompass secondary alcohols, and allow for 
asymmetric alkylations is necessary to provide a powerful synthetic tool. 
4.1.2 Mechanistic Considerations 
The mechanistic scenario of the transfer hydrogenation of carbonyl compounds with alcohols and of 
the transition metal catalyzed reduction of α,β-unsaturated carbonyl species have been subject to 
intense investigations.329 In contrast a combined mechanistic understanding of the hydrogen 
autotransfer process utilizing alcohols to alkylate e.g. ketones has hitherto not attracted much 
attention and mechanisms proposed by Cho,300 Yus,302 and Williams330 are mostly based on 
speculation providing cycles similar to the one depicted in scheme 4.1.     
 
For transition metals it is widely accepted that hydrogen transfer reactions can occur via two main 
pathways involving either a monohydride or a dihydride metal intermediate (Scheme 4.3).329 
LnM
LnMH2
OH
H
O
R1 R2
OH
H
R1 R2
O
LnMX
OH
H
O
R1 R2
OH
H
R1 R2
O
LnMH
+
HX
dihydride pathway monohydride pathway
 
Scheme 4.3 Dihydride and monohydride pathways. 
 
The dihydride route involves a formal oxidative addition with regard to the metal center followed by 
a reductive elimination. Conversely, the monohydride pathway contains no formal change in the 
oxidation state of the metal center. A general feature for catalysts operating through the dihydride 
mechanism is that the C-H and O-H loose their “identity” when they are transferred to the acceptor. 
This can be ascribed to the fact that the two hydrogens become equivalent after being transferred to 
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the metal center. In the monohydride case the C-H hydrogen from the donor ends up as C-H in the 
product. The reason for this observation is that only the C-H hydrogen forms the hydride on the 
metal, thus being transferred to the carbonyl carbon of the acceptor.331 Bäckvall has designed a 
clever experiment to determine whether the dihydride or the monohydride pathway is operational. 
That is racemization of α-deuterated (S)-phenylethanol ((S)-4.5) (Scheme 4.4). If the dihydride 
mechanism is occurring the deuterium will be scrambled between carbon and oxygen, whereas the 
monohydride pathway will exclusively incorporate deuterium at carbon.332  
OH
Ph D
Me
LnM
Ph Me
O
Ln-xMDH+
-LnM
OH
Ph D
Me
OD
Ph H
Me+
OH
Ph D
Me
LnM
Ph Me
O
Ln-xMD  +  H+
-LnM
OH
Ph D
Me
dihydride pathway
monohydride pathway
1    :    1
(S)-4.5
(S)-4.5 (±)-4.5
(±)-4.5  
Scheme 4.4 Mono vs. dihydride mechanism. 
 
In general the rhodium- and iridium-catalyzed hydrogen transfer reactions proceeded via the 
monohydride mechanism, exhibiting little dependence on the ancillary ligand. The outcome on the 
ruthenium-catalyzed racemizations varied depending on the catalyst precursor employed. For 
instance The reaction utilizing [RuCl2PPh3] was shown to proceed via the dihydride pathway (37% 
(±)-4.5), whereas Shvo’s catalyst (cf. Table 4.1)333 operated through the monohydride mechanism 
(95% (±)-4.5).332 
 
4.2 Alkylation of Oxindoles 
4.2.1 Background and Significance 
The oxindoles, specifically those containing C(3) functionalization represent a common and 
important motif in numerous natural products334-339 and biologically active molecules.340-344 An 
important example is the tyrosine kinase inhibitor sunitinib (4.6), which is marketed by Pfizer Inc. 
as an antitumor agent (Figure 4.2a). Recently He and co-workers340 disclosed the synthesis and 
biological evaluation of spirocyclopropane 4.7 exhibiting significant inhibition of HIV-1 non-
nucleoside reverse transcriptase (EC50 = 15 nM, for comparison nervirapine, which is in clinical use 
has EC50 = 50 nM). In 2008 researchers from EGIS pharmaceuticals identified 4.8 as a 5-HT7 
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receptor antagonist. Hitherto the functional significance of the 5-HT7 receptor is largely unknown, 
however, this receptor has been associated with a variety of CNS functions and disorders e.g. 
schizophrenia345 and depression.346,347    
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Figure 4.2 Representative biologically active 3-substituted oxindoles. 
 
The 3,3’-pyrrolidinyl-spirooxindole motif holds a prominent position among oxindole based natural 
products (Figure 4.2b).336 (−)-Horsfiline (4.9) was disclosed in 1991348, spirotryptostatin (4.10) was 
isolated from the fermentation broth of Aspergillus fumigatus,349 and strychnofoline (4.11) from the 
leaves of Strychnos usambarensis.350 Both spirotryptostatin (4.10) and strychnofoline (4.11) have 
shown potential as anticancer agents by virtue of their ability to inhibit mitosis in a number of cell 
lines.336 
 
In recent years several excellent methods to arylate and allylate the C(3) position of oxindole have 
appeared. Willis351 and later Buchwald352 have efficiently arylated the C(3) position of oxindoles 
employing palladium in combination with the bulky electron rich phosphine 4.12 (Scheme 4.5a). In 
2006 Trost and Zhang found that molybdenum and 4.13353,354 in comparison to palladium355 
provided superior enantioselectivities in the allylation of oxindoles (Scheme 4.5b).   
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Scheme 4.5 Representative protocols for catalytic C(3) functionalization of oxindoles. 
 
In contrast to these efficient catalytic procedures, the C(3) position is usually alkylated using 
stoichiometric amounts of base and alkyl halides. These processes are often hampered by poor 
regioselectivity and bisalkylation. Realizing this impediment we envisioned that the hydrogen 
autotransfer methodology would provide an efficient means to alkylate the C(3) position of oxindole 
in a catalytic and environmentally friendly manner. As detailed above oxindoles, specifically those 
containing C(3) functionalization represent an important motif in numerous natural products and 
pharmaceutical agents. Moreover, to the best of the author’s knowledge this would constitute the 
first catalytic procedure for alkylating oxindoles.a 
 
                                                 
a Simultaneously with the publication of our work, Grigg and co-workers disclosed an iridium catalyzed C(3) alkylation 
of oxindole with alcohols. (Grigg, R.; Whitney, S.; Sridharan, V.; Keep, A.; Derrick, A. Tetrahedron, 2009, 63, 4375-
4383). 
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4.2.2 Catalyst Optimization  
Optimal reaction conditions were identified through a systematic study of various reaction 
parameters such as solvent, transition metal and ligand. The initial experiments focused on 
developing an efficient protocol for the direct alkylation of oxindole (4.14) with pentan-1-ol (Table 
4.1). This system would provide a simple testing ground for a range of different catalysts.  
Table 4.1 Screening of alkylation catalysts. 
entry catalyst
catalyst
loading 
[mol%]
ligand 4.15 (%)b
1 [Cp*IrCl2]2 1.0 - >95
2 [IrCl(cod)]2 1.0 PPh3 32c
3 [RuCl3  xH2O] 2.0 PPh3 >95c
4 [RuCl3  xH2O] 2.0 - 0
5 [RuCl2(PPh3)3] 2.0 - >95
6 [Ru(p-cymene)Cl2]2 1.0 - 47
7 [Ru(p-cymene)Cl2]2 1.0 4.16 >95d
8 [Ru(PPh3)3(CO)H2] 2.0 - 53
9 [Ru(PPh3)3(CO)H2] 2.0 4.16 81d
10 4.17 1.0 - >95
11 [Ru(acac)3] 1.0 - 0
pentan-1-ol (1.1 equiv)
catalyst, ligand 
NaOH (10 mol%)
110 oCNH
O
N
H
O
4.14 4.15
Ru
H
RuPh
PhPh
Ph
O
H
O
Ph
Ph
Ph
Ph
4.17
Shvo's catalyst
O
PPh2PPh2
4.16
Xantphos
a Oxindole (2.0 mmol) was reacted with pentan-1-ol (2.2 mmol) under the influence of 
catalyst (1.0-2.0 mol%) and NaOH (10 mol%) at 110 oC for 20 h.  b Conversion was
estimated by 1H NMR spectroscopy based oxindole. c PPh3 (4.0 mol%). d Xantphos
(2.0 mol%).
 
 
The characteristic C(3) protons of oxindole and the alkylated product offered a convenient method 
to monitor the reaction by 1H NMR. Since the commercially available chloro-bridged iridium 
complex [Cp*IrCl2]2 has recently found widespread use in hydrogen transfer processes we decided 
to employ it for this test reaction. The synthesis and catalytic activity of [Cp*IrCl2]2 were originally 
disclosed by Maitlis and co-workers.356-358 Fujita and co-workers have successfully deployed 
[Cp*IrCl2]2 for the direct alkylation of secondary alcohols with primary alcohols,359 whereas Grigg 
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and co-workers have selectively monoalkylated arylacetonitriles,310 tert-butyl cyanoacetate,311 and 
barbiturates308 implementing [Cp*IrCl2]2. 
 
Initial experiments surveying a range of different bases, reaction temperatures, and solvents 
established that performing the reaction under neat conditions at 110 oC, in the presence of 1.0 
mol% [Cp*IrCl2]2 and 10 mol% NaOH in a sealed heavy-walled vial cleanly provided the 3-
alkylation product 4.15 in almost quantitative yield (entry 1). Somewhat surprisingly, when 
[IrCl(cod)]2 was deployed in combination with PPh3 the desired product was only observed in 32% 
yield (entry 2). Ishii and co-workers305 have previously utilized [IrCl(cod)]2 and PPh3 in 
combination with KOH or NaOH for the direct α-alkylation of ketones. Although [Cp*IrCl2]2 
presented itself as an effective catalyst for the selective C(3) alkylation of oxindole we decided to 
pursue a cheaper ruthenium based catalyst system.a When pentane-1-ol and oxindole 4.14 were 
heated in the presence of [RuCl3·xH2O] and PPh3 the desired product 4.15 was obtained cleanly 
within 20 h of stirring (entry 3).b The preformed complex [RuCl2(PPh3)3] performed equally well, 
whereas omitting PPh3 led to complete recovery of the starting material (entries 4 and 5). The test 
reaction was subjected to a selection of other ruthenium based catalysts, which revealed that [Ru(p-
cymene)Cl2]2 and [Ru(PPh3)3(CO)H2] in combination with xantphos (4.16) 312 as well as Shvo’s 
catalyst333 4.17 furnished the desired product in high yield (entries 7, 9, and 10). Deploying 
[Ru(acac)3], [Ru(PPh3)3(CO)H2], and [Ru(p-cymene)Cl2]2 with no additional phosphine ligand 
afforded either relatively low conversion into the desired product or no reaction. Interestingly, 
competing N- or O-alkylation was not observed for any of the investigated catalyst systems. While 
several ruthenium based catalysts proved very effective in facilitating the desired alkylation of 
oxindole, we decided to settle for a mixture of [RuCl3·xH2O] and PPh3, which offered the simplest 
and cheapest alternative.c 
 
With this catalyst system at hand we decided to conduct a number of experiments designed to 
investigate the influence of base and solvent in the alkylation reaction (Table 4.2). Sodium 
                                                 
a For comparison: The price for [RuCl3·xH2O] is 5.79 $/mmol while the price for [IrCl3·xH2O] is 29.6 $/mmol (both 
based on anhydrous Mw). These prices were adopted from Aldrich on the 19th of June 2009.  
b Monitoring the reaction by use of 1H NMR revealed almost complete conversion within 12 h. Isolation of the alkylated 
product after 12 h and 20 h afforded 4.15 in 87% and 89%, respectively i.e. the product appeared to be stable under the 
reaction conditions. 
c Changing the ratio between [RuCl3·xH2O] and PPh3 to 1:1 furnished a decrease in reaction rate, whereas a change to 
1:3 had no significant influence on the rate. 
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hydroxide and potassium hydroxide seemed to perform equally well in the alkylation reaction 
(entries 1 and 2). Substituting NaOH with carbonates revealed a significant influence of the 
counterion. Both sodium and potassium carbonate failed to afford full conversion into 4.15, whereas 
cesium carbonate cleanly furnished 4.15 (entries 3-5). Employing triethylamine also led to 
diminished yields of the desired product due to slow conversion of the starting material. In the 
absence of base the starting material was isolated in quantitatively, which is not surprising since the 
putative Knoevenagel-type condensation between the in situ generated aldehyde and oxindole is 
facilitated by base. Moreover, Bäckvall and Chowdhury360 reported on the effect of base on the 
[RuCl2(PPh3)3]-catalyzed transfer hydrogenation. It was observed that the addition of a catalytic 
amount of base afforded a rate enhancement of about 103-104 times.  
Table 4.2 Screening of solvent and base. 
entry base solvent
1 NaOH - >95
2 KOH - >95
3 Na2CO3 - 58
4 K2CO3 - 80
5 Cs2CO3 - >95
6 Et3N - 39
7 - - 0
8 NaOH toluene >95c
9 NaOH p-dioxane 92c
10 NaOH water 58c
pentan-1-ol (1.1 equiv)
[RuCl3  xH2O] (2.0 mol%) 
PPh3 (4.0 mol%)
base (10 mol%)
solvent, 110 oC, 20 h
a Oxindole (2.0 mmol) was reacted with pentan-1-ol (2.2 mmol)
under the influence of RuCl3  xH2O (2.0 mol%), PPh3 (4.0 mol%),
and base (10 mol%) at 110 oC  for 20 h. b Conversion was estimated 
by 1H NMR spectroscopy based oxindole. c Solvent (1.0 mL) added.
N
H
O
N
H
O
4.14 4.15
4.15 (%)b
 
 
With a fully developed system in hand, our focused shifted toward developing a practical isolation 
procedure. We found that simple dilution of the crude reaction mixture utilizing CH2Cl2 followed by 
treatment with silica-gel and removal of residual solvent under high vacuum furnished a powder that 
was easily purified over silica gel providing the products in high yield. 
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4.2.3 Scope and Limitations 
At this stage we commenced an exploration of the substrate scope of the reaction (Table 4.3 and 
4.4). The C(3) alkylation of oxindole was general for a wide range of o-, m- and p-substituted benzyl 
alcohols. Most notable is the tolerance of one o-substituent, which would provide significant steric 
hindrance to the catalyst during the hydrogen transfer process. Alkyl substituted benzyl alcohols and 
benzyl alcohol were excellent coupling partners (entries 2, 6 and 13). Also the pharmaceutically 
relevant fluorine substituents were tolerated (entries 3, 4, and 11).  
Table 4.3 C(3) alkylation of oxindoles. 
entry alcohol product yieldb
1 HO
N
H
O 89
2
3
4
5
6
7
8
HO
R
N
H
O
R R = H
       F
       CF3
        Cl
       Me
       OMe
       NHPiv
89
83
86
89
92
83
74c
 9
10 HO
N
R
O
       Bn
       PMB
91
92
11
12
13
14 HO
R
N
H
O
R
       F
       Cl
       Me
       OMe
81
88
90
85
15
HO
OMe
N
H
O
OMe
84
a The oxindole (2.0 mmol) was reacted with the alcohol (2.2 mmol) under the influence of
RuCl3xH2O (2.0 mol%), PPh3 (4.0 mol%), and base (10 mol%) at 110 oC  for 20 h. b Isolated 
yield. c Toluene (1.0 mL) used as cosolvent.
N
O
N
O
R1
[RuCl3  xH2O] (2.0 mol%) 
R1OH (1.1 equiv)
PPh3 (4.0 mol%)
NaOH (10 mol%)
110 oC, 20 h
R2 R2
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Importantly, aryl chlorides were compatible with the alkylation protocol providing a useful chemical 
handle for further manipulations. Biologically important methoxy substituents o, m or p were also 
well tolerated. Moreover, a selection of protecting groups such as amide, benzyl and p-
methoxybenzyl were compatible with the reaction conditions. It should be noted that Boc-protection 
of the oxindole nitrogen afforded low conversion due to competing decarboxylation. 
 
A naphthalene alcohol also proved compatible with the alkylation protocol affording the desired 
product in excellent isolated yield (entry 1, Table 4.4). A variety of pharmacophoric functionalities 
including catechol, furan, thiophene, and unprotected indole allowed for efficient alkylation of 
oxindole (entries 2-5).  
Table 4.4 C(3) alkylation of oxindoles employing heteroaromatic and secondary alcohols. 
entry alcohol product yieldb
1
HO N
H
O
87
2
O
O
HO
N
H
O
O
O
79
3
4
X
HO
N
H
O
X
X = O
       S
71c
81
5
N
H
OH
N
H
O
NH
72c
6
OH
N
H
O 73
d
N
H
O
N
H
O
R
[RuCl3  xH2O] (2.0 mol%) 
ROH (1.1 equiv)
PPh3 (4.0 mol%)
NaOH (10 mol%)
110 oC, 20 h
a Oxindole (2.0 mmol) was reacted with the alcohol (2.2 mmol) under the influence of
RuCl3xH2O (2.0 mol%), PPh3 (4.0 mol%), and base (10 mol%) at 110 oC  for 20 h. b Isolated 
yield. c Toluene (1.0 mL) used as cosolvent. d Stirred for 48 h with 5 equiv (10 mmol) of the
alcohol.  
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Interestingly, attempts to alkylate oxindole with 2-hydroxymethylfuran under the standard neat 
reaction conditions primarily afforded decomposition, whereas addition of toluene furnished smooth 
conversion into the desired product. Initial experiments employing propan-2-ol in the alkylation 
procedure were met with limited success affording mixtures of the desired product and the α,β-
unsaturated condensation product as well as unreacted oxindole. However, stirring oxindole with an 
excess of propan-2-ol (5 equiv) at 110 oC for 48h afforded full conversion and the desired product 
was isolated in 73% yield (entry 6). 
 
Several substrates either failed completely to provide the corresponding alkylated product or only 
led to trace amounts of the desired product (Figure 4.3). The highly congested 2,6-dimethoxybenzyl 
alcohol 4.18 and 2,4,6-trimethylbenzyl alcohol 4.19 afforded the desired product in less than 25% 
yield as judged by 1H NMR even after prolonged heating at elevated temperatures i.e. 20 h stirring 
at 180 oC instead of 110 oC. Subjecting the pentafluorobenzyl alcohol 4.20 to the standard alkylation 
conditions gave the desired alkylation product in less than 5%. Using 4-bromobenzyl alcohol 4.21 as 
well as 4-(hydroxymethyl)benzonitrile 4.22 furnished complex reaction mixtures. This can most 
likely be ascribed to hydrodehalogenation and hydrolysis, respectively. In order to circumvent 
problems caused by in situ hydrolysis of the nitrile functionality it was attempted to employ Cs2CO3 
for the alkylation, however, this did not resolve the problem. 
HO HO
F
F
F
F
F
HO OH HOn
n = 0-2 OH
n
n = 1-2
MeO
OMe
HO
N
H
HO
Ot-Bu
O
R
HO
R = Br 4.21
       CN 4.224.18 4.19 4.20
4.23 4.24
 
Figure 4.3 Substrates failing to furnish efficient C(3) alkylation of oxindole. 
 
Furthermore a range of α,ω-diols were tested for the alkylation procedure, since these alcohols 
would afford a chemical handle for further manipulations. Unfortunately, α,ω-diols furnished only 
trace amount of the desired product and generally 1H NMR as well as GC/MS of the crude reaction 
mixture were messy. When 4-penten-1-ol (4.23) was employed, a 2:1 mixture of 4.15 and the 
corresponding α,β-unsaturated oxindole was attained in a modest 27% yield. All attempts to deploy 
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cyclohexanol and cyclopentanol in the alkylation protocol gave inseparable mixtures of the α,β-
unsaturated condensation product and the desired product. Thus for secondary alcohols the reduction 
of the putative intermediate α,β-unsaturated carbonyl species appears to be the rate-limiting step. 
Recognizing the biological importance of the 3,3’-pyrrolidinyl-spirooxindole motif we decided to 
explore the utility of carbamate 4.24 in the alkylation procedure. To our dismay all efforts to 
facilitate alkylation and subsequent cyclization deploying 4.24 were unfruitful furnishing less than 
10% conversion of the starting material. This may most likely be ascribed to 4.24 chelating to 
ruthenium thus acting as a catalyst sink shutting down the catalytic cycle. 
 
Bäckvall and co-workers360 have previously shown that the active catalyst when utilizing 
RuCl2(PPh)3 for transferhydrogenation is most likely RuH2PPh3. Starting from [RuCl3·xH2O] and 
PPh3 it is reasonable to assume that this active catalyst is formed in situ.360 Based on this assumption 
and the observations that base is a necessary additive, and the intermediate α,β-unsaturated carbonyl 
could be isolated in certain cases a mechanism is tentatively proposed (Scheme 4.6). A 
coordinatively unsaturated complex 4.25 is formed in situ and upon coordination of alcohol and β-
hydride elimination a dihydride species 4.26 is formed along with the aldehyde 4.27. This aldehyde 
possibly leaves the coordination sphere of ruthenium before undergoing a base mediated 
condensation with oxindole. Ultimately, the α,β-unsaturated oxindole 4.28 is reduced by the 
ruthenium dihydride complex 4.26 affording the saturated product 4.29 and regenerating the active 
catalyst 4.25. 
RuH2(PPh3)3
R
N
H
O
N
H
O
R
Ru(PPh3)3
R
O
H
OH
RuH(PPh3)3
N
H
O
R
N
H
O
R
+ OH
H2O +  OH
4.25
4.26
4.27
4.28
4.29
 
Scheme 4.6 Tentative mechanism for the ruthenium catalyzed alkylation. 
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4.3 Summary 
We have developed an efficient protocol based on a hydrogen autotransfer process to directly 
alkylate the C(3) position of oxindole (Scheme 4.7). While several iridium and ruthenium catalyst 
proved to efficiently mediate this transformation we settled for the very cheap ruthenium source 
[RuCl3·xH2O] in combination with PPh3 and sodium hydroxide. The reaction required in general 2.0 
mol% of [RuCl3·xH2O], 4.0 mol% of PPh3 and 10 mol% of sodium hydroxide to afford full 
conversion at 110 oC under neat reaction conditions. This procedure provides a relatively simple and 
highly atom-economical alternative to traditional alkylation procedures involving stoichiometric 
amount of base and alkyl halides. 
R1OH (1.1 equiv)
[RuCl3  xH2O] (2.0 mol%) 
PPh3 (4.0 mol%)
NaOH (10 mol%)
110 oC, 20 h
21 examples, 71-92% yield
N
O
R2
R2 = H, Bn, PMB
N
O
R2
R1
 
Scheme 4.7 Ruthenium-catalyzed C(3) alkylation of oxindoles. 
 
The reaction was highly selective for the formation of C(3) substituted oxindole. Moreover, this 
transformation was tolerant towards a relatively wide range of functional groups and could be 
applied to o-, m-, and p-substituted benzyl alcohols, several aromatic heterocycles, primary and 
secondary alcohols. This straightforward procedure allows for the synthesis of biologically 
important oxindoles starting from readily available oxindoles and alcohols. 
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4.4  Experimental Procedures 
4.4.1 Materials and Methods 
See chapter 2.7.1 for general experimental information. 
4.4.2 Synthesis of 3-Alkylated Oxindoles 
General Method for 3-Alkylation of Oxindole 
[RuCl3·xH2O] (8.3 mg, 0.04 mmol), PPh3 (21.0 mg, 0.08 mmol), NaOH (8.0 mg, 0.2 mmol), 
oxindole (266 mg, 2.0 mmol), and the alcohol (2.2 mmol) were placed in a 7-mL thick-walled 
screw-cap vial. The vial was purged with Ar and sealed with a screw-cap. The mixture was placed in 
an aluminum block preheated to 110 °C and stirred for 20 h or until 1H NMR of the crude reaction 
mixture showed complete consumption of the oxindole. The reaction mixture was allowed to cool to 
room temperature followed by dilution with CH2Cl2 (10 mL). SiO2 was added and the suspension 
was concentrated under reduced pressure to afford a powder that was purified by use of silica-gel 
chromatography (3 x 15cm SiO2, 9:1→4:1→3:7 n-Hexane:EtOAc). 
 
3-Pentyl-1,3-dihydro-indol-2-one (4.15) [Table 4.3, Entry 1] 
N
H
O
 
Isolated yield: 89% 
Colorless oil; Rf = 0.18 (heptane:EtOAc = 7:3); 1H NMR (300 MHz, CDCl3) δ 8.99 (br s, 1H), 7.26-
7.17 (m, 2H), 7.08-6.98 (m, 1H), 6.92 (d, J = 7.6 Hz, 1H), 3.48 (t, J = 5.9 Hz, 1H), 2.28-1.86 (m, 
2H), 1.55-1.16 (m, 6H), 0.88 (t, J = 6.94 Hz, 3H); 13C NMR (75.4 MHz, CDCl3) δ 180.8, 141.6, 
129.9, 127.7, 124.1, 122.2, 109.7, 46.1, 31.8, 30.5, 25.4, 22.4, 14.0; IR (Neat) 3211, 3094, 3060, 
3031, 2955, 2928, 2858, 1701, 1620, 1470, 1338, 1219, 1100, 749 cm-1; HRMS (ESI+) calc’d for 
C15H21N2O ([M+H+MeCN]+) 245.1654, found 245.1649.  
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3-Benzyl-1,3-dihydro-indol-2-one [Table 4.3, Entry 2] 
N
H
O
 
Isolated yield: 89% 
Pale yellow needles; mp. 129-130 °C (heptane:EtOAc), Lit.361 129-131 °C; Rf = 0.12 
(heptane:EtOAc = 7:3); 1H NMR (300 MHz, CDCl3) δ 8.41 (br s, 1H), 7.30-7.11 (m, 6H), 6.90 (dt, J 
= 7.6, 1.0 Hz, 1H), 6.83 (d, J = 7.8 Hz, 1H), 6.75 (d, J = 7.4 Hz, 1H), 3.76 (dd, J = 9.2, 4.5 Hz, 
1H), 3.50 (dd, J = 13.7, 4.6 Hz, 1H), 2.95 (dd, J = 13.7, 9.2 Hz, 1H); 13C NMR (75.4 MHz, 
CDCl3) δ 179.9, 141.4, 137.8, 129.4, 128.9, 128.3, 127.9, 126.6, 124.8, 122.0, 109.7, 47.5, 36.6; IR 
(Neat) 3207, 3086, 3028, 2921, 2893, 1701, 1619, 1469, 1402, 1304, 1228, 1154, 749, 697 cm-1, 
MS: m/z 223 [M]. Spectral data in accordance with literature values.362 
 
3-(4-Fluoro-benzyl)-1,3-dihydro-indol-2-one [Table 4.3, Entry 3] 
N
H
O
F
 
Isolated yield: 83% 
Colorless needles; mp. 151-152 °C (heptane:EtOAc); Rf = 0.11 (heptane:EtOAc = 7:3); 1H NMR 
(300 MHz, CDCl3) δ 8.13 (br s, 1H), 7.17 (ddt, J = 7.6, 1.4, 0.8 Hz, 1H), 7.14-7.05 (m, 2H), 6.97-
6.86 (m, 3H), 6.86-6.78 (m, 2H), 3.72 (dd, J = 8.5, 4.6 Hz, 1H), 3.41 (dd, J = 13.8, 4.6 Hz, 1H), 
3.01 (dd, J = 13.8, 8.5 Hz, 1H); 13C NMR (75.4 MHz, CDCl3) δ 179.6, 161.7 (d, J = 245 Hz), 141.8, 
133.2 (d, J = 3.2 Hz), 130.8 (d, J = 7.9 Hz), 128.6, 128.1, 124.6, 122.1, 115.1 (d, J = 21.2 Hz), 
109.8, 47.6, 35.6; 19F NMR (282 MHz, CDCl3) δ -116.69 (dd, J = 9.0, 4.9 Hz, 1F); IR (Neat) 3210, 
3092, 3071, 2927, 2892, 1707, 1620, 1601, 1509, 1471, 1300, 1224, 831, 751 cm-1; HRMS (ESI+) 
calc’d for C15H13FNO ([M+H]+) 242.0981, found 242.0987. 
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3-(4-Trifluoromethyl-benzyl)-1,3-dihydro-indol-2-one [Table 4.3, Entry 4] 
N
H
O
CF3
 
Isolated yield: 86% 
Colorless needles; mp. 112-113 °C (heptane:EtOAc); Rf = 0.092 (heptane:EtOAc = 7:3); 1H NMR 
(300 MHz, CDCl3) δ 8.80 (br s, 1H), 7.49 (d, J = 8.0 Hz, 2H), 7.27 (d, J = 8.0 Hz, 2H), 7.24-7.14 
(m, 1H), 6.95 (dt, J = 7.6, 1.0 Hz, 1H), 6.88-6.81 (m, 2H), 3.78 (dd, J = 8.5, 4.7 Hz, 1H), 3.49 (dd, J 
= 13.8, 4.7 Hz, 1H), 3.09 (dd, J = 13.8, 8.5 Hz, 1H); 13C NMR (75.4 MHz, CDCl3) δ 179.2, 141.7, 
141.4, 129.7, 129.0 (q, J = 32.4 Hz), 128.3, 128.3, 125.2 (q, J = 3.8 Hz), 124.6, 124.1 (q, J = 271.9 
Hz), 122.2, 109.9, 47.1, 36.2; 19F NMR (282 MHz, CDCl3) δ -62.82 (s, 3F); IR (Neat) 3207, 3093, 
3062, 3031, 2929, 2894, 2839, 1706, 1620, 1471, 1418, 1323, 1230, 1164, 1120, 1109, 1067, 1019, 
836, 751 cm-1; HRMS (ESI+) calc’d for C18H16F3N2O ([M+H+MeCN]+) 333.1215, found 333.1207. 
 
3-(4-Chloro-benzyl)-1,3-dihydro-indol-2-one [Table 4.3, Entry 5] 
N
H
O
Cl
 
Isolated yield: 89% 
Pale yellow crystals; mp. 138-140 °C (heptane:EtOAc); Rf = 0.11 (heptane:EtOAc = 7:3); 1H NMR 
(300 MHz, CDCl3) δ 8.86 (br s, 1H), 7.20-7.15 (m, 3H), 7.08 (d, J = 8.4 Hz, 2H), 6.94 (t, J = 7.5 
Hz, 1H), 6.84 (d, J = 8.0 Hz, 2H), 3.73 (dd, J = 8.5, 4.6 Hz, 1H), 3.41 (dd, J = 13.8, 4.6 Hz, 1H), 
2.99 (dd, J = 13.8, 8.5 Hz, 1H); 13C NMR (75.4 MHz, CDCl3) δ 179.4, 141.4, 136.0, 132.5, 130.7, 
128.5, 128.4, 128.1, 124.6, 122.1, 109.8, 47.3, 35.8;  IR (Neat) 3211, 3090, 3062, 3030, 2924, 2859, 
1704, 1620, 1491, 1470, 1408, 1337, 1302, 1228, 1196, 1155, 1093, 1016, 825 cm-1; HRMS (ESI+) 
calc’d for C15H13ClNO ([M+H]+) 258.0686, found 258.0681. 
 
4 Ruthenium- and Iridium-Catalyzed C-C Bond Formation 
 111
3-(4-Methyl-benzyl)-1,3-dihydro-indol-2-one [Table 4.3, Entry 6] 
N
H
O
Me
 
Isolated yield: 92% 
White powder; mp. 149-150 °C (heptane:EtOAc); Rf = 0.11 (heptane:EtOAc = 7:3); 1H NMR (300 
MHz, CDCl3) δ 8.28 (br s, 1H), 7.16 (ddt, J = 7.7, 1.2, 0.8 Hz, 1H), 7.06 (br s, 4H), 6.90 (dt, J = 7.6, 
1.0 Hz, 1H), 6.84-6.76 (m, 2H), 3.73 (dd, J = 9.1, 4.5 Hz, 1H), 3.45 (dd, J = 13.7, 4.4 Hz, 1H), 2.91 
(dd, J = 13.7, 9.1 Hz, 1H), 2.31 (s, 3H); 13C NMR (75.4 MHz, CDCl3) δ 180.0, 141.5, 136.1, 134.6, 
129.2, 129.1, 129.0, 127.8, 124.8, 121.9, 109.8, 47.6, 36.2, 21.0; IR (Neat) 3204, 3091, 3056, 3024, 
2921, 2858, 1702, 1619, 1515, 1485, 1470, 1408, 1228, 1101, 814, 749 cm-1; HRMS (ESI+) calc’d 
for C16H16NO ([M+H]+) 238.1231, found 238.1232. 
 
3-(4-Methoxy-benzyl)-1,3-dihydro-indol-2-one [Table 4.3, Entry 7] 
N
H
O
OMe
 
Isolated yield: 83% 
Colorless needles; mp. 110-111 °C, Lit.363 114 °C; Rf = 0.07 (heptane:EtOAc = 7:3); 1H NMR (300 
MHz, CDCl3) δ 8.34 (br s, 1H), 7.21-7.13 (m, 1H), 7.13-7.02 (m, 2H), 6.91 (dt, J = 7.5, 1.1 Hz, 1H), 
6.82 (d, J = 7.9 Hz, 2H), 6.80-6.72 (m, 2H), 3.77 (s, 3H), 3.71 (dd, J = 8.9, 4.5 Hz, 1H), 3.42 (dd, J 
= 13.8, 4.5 Hz, 1H), 2.92 (dd, J = 13.8, 8.9 Hz, 1H); 13C NMR (75.4 MHz, CDCl3) δ 180.3, 158.5, 
141.8, 130.6, 129.9, 129.3, 128.2, 125.0, 122.2, 113.9, 110.1, 55.4, 48.1, 36.0; IR (Neat) 3194, 3091, 
3059, 3032, 3011, 2953, 2932, 2915, 2835, 1703, 1615, 1511, 1470, 1441, 1337, 1301, 1246, 1101, 
1034, 828, 750 cm-1, MS: m/z 253 [M].  
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2,2-Dimethyl-N-[4-(2-oxo-2,3-dihydro-1H-indol-3-ylmethyl)-phenyl]-propionamide [Table 4.3, 
Entry 8] 
N
H
O
NH
O
 
Isolated yield: 74% 
White powder; mp. 212-214 °C (CH3CN); Rf = 0.48 (CH2Cl2:CH3OH = 9:1); 1H NMR (300 MHz, 
DMSO-d6) δ 10.28 (br s, 1H), 9.08 (br s, 1H), 7.44 (d, J = 8.5 Hz, 2H), 7.08 (t, J = 7.5 Hz, 1H), 
7.02 (d, J = 8.5 Hz, 2H), 6.90 (d, J = 7.2 Hz, 1H), 6.83 (t, J = 7.4 Hz, 1H), 6.70 (d, J = 7.7 Hz, 1H), 
3.75 (dd, J = 7.5, 5.0 Hz, 1H), 3.25 (dd, J = 13.7, 5.0 Hz, 1H), 2.91 (dd, J = 13.7, 7.5 Hz, 1H), 1.19 
(s, 9H); 13C NMR (50.3 MHz, DMSO-d6) δ 178.1, 176.2, 142.6, 137.5, 132.6, 129.2, 128.9, 127.5, 
124.3, 120.9, 119.9, 109.1, 46.5, 34.6, 27.2; IR (Neat) 3321, 3201, 3108, 3029, 2962, 2923, 2874, 
2816, 1698, 1659, 1601, 1514, 1470, 1411, 1322, 1241, 925, 828, 749; HRMS (ESI+) calc’d for 
C20H23N2O2 ([M+H]+) 323.1752, found 323.1756.  
  
1-Benzyl isatin364 
N
H
O
O
N
Bn
O
O
NaH, BnBr
DMF, 0 oC
(74% yield)  
Isatin (2.94 g, 20 mmol) was placed in a 250 mL round bottom flask and dissolved in DMF (37 mL). 
The resulting bright orange solution was cooled to 0 °C by the use an ice/water bath. NaH (55% 
dispersion in mineral oil, 916 mg, 21 mmol) was added portionwise resulting in a deep purple 
solution. The solution was stirred until any effervescence had ceased (~15 min). Benzyl bromide 
(4.10 g, 2.85 mL, 24 mmol) was added in a dropwise manner and the resulting red-brown mixture 
was stirred for an additional 30 min at 0 °C. H2O (176 mL) was added to precipitate the product. 
The product was filtered and recrystallized from EtOH. Yield 3.52 g (74%) of the title product as 
orange needles: mp. 129-130 °C (EtOH), Lit.365 133-135 °C (EtOH:H2O); Rf = 0.66 (EtOAc); 1H 
NMR (300 MHz, CDCl3) 7.62 (ddd, J = 7.6, 1.4, 0.6 Hz, 1H), 7.48 (dt, J = 7.6, 1.4 Hz, 1H), 7.41-
7.27 (m, 5H), 7.09 (dt, J = 7.6, 0.8 Hz, 1H), 6.79-6.75 (m, 1H), 4.94 (s, 2H); 13C NMR (75.4 MHz), 
CDCl3 δ 183.2, 158.2, 150.6, 138.3, 134.4, 129.0, 128.1, 127.4, 125.3, 123.8, 117.6, 111.0, 44.0; IR 
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(Neat) 3062, 3031, 2954, 2929, 1736, 1612, 1496, 1470, 1437, 1350, 1177, 1096 cm-1, MS: m/z 237 
[M]. Spectral data in accordance with literature values.364 
 
1-Benzyl-1,2-dihydro-indol-2-one364 
N
Bn
O
N
Bn
O
O
H2NNH2 H2O
(71% yield)
 
1-Benzyl isatin (2.37 g, 10 mmol) was suspended in hydrazine hydrate (11 mL) and the mixture was 
heated to reflux until the gas evolution had stopped (4 h). The reaction mixture went from orange 
via green to yellow within this time. The reaction mixture was allowed to cool to ambient 
temperature and extracted with EtOAc (3 x 25 mL). The combined organic phases were dried over 
Na2SO4, filtered, and concentrated under reduced pressure. The crude yellow product was 
recrystallized from Et2O. Yield 1.59 g (71%) of the title compound as off-white needles: mp. 67-68 
°C (Et2O), Lit.366 68 °C (Et2O); Rf = 0.29 (heptane:EtOAc = 7:3); 1H NMR (300 MHz, 
CDCl3) δ 7.33-7.24 (m, 6H), 7.22-7.11 (m, 1H), 7.01 (dt, J = 7.6, 1.0 Hz, 1H), 6.72 (d, J = 7.8 Hz, 
1H), 4.92 (s, 2H), 3.63 (s, 2H); 13C NMR (75.4 MHz, CDCl3) δ 175.1, 144.2, 135.8, 128.7, 127.7, 
127.5, 127.3, 124.4, 124.3, 122.3, 109.0, 43.7, 35.7; IR (Neat) 3087, 3057, 3032, 2945, 2918, 1700, 
1613, 1487, 1466, 1378, 1225, 1196, 1165, 748, 725 cm-1, MS: m/z 223 [M]. Spectral data in 
accordance with literature values.364 
 
1,3-Dibenzyl-1,3-dihydro-indol-2-one [Table 4.3, Entry 9] 
N
Bn
O
 
Isolated yield: 91% 
White powder; mp. 97-98 °C (n-hexane:EtOAc); Rf = 0.36 (heptane:EtOAc = 7:3); 1H NMR (300 
MHz, CDCl3) δ 7.24-7.07 (m, 9H), 7.01-6.88 (m, 4H), 6.55 (d, J = 7.7 Hz, 1H), 5.04 (d, J = 15.8 
Hz, 1H), 4.64 (d, J = 15.8 Hz, 1H), 3.86 (dd, J = 8.1, 4.3 Hz, 1H), 3.51 (dd, J = 13.5, 4.3 Hz, 1H), 
3.14 (dd, J = 13.5, 8.1 Hz, 1H); 13C NMR (75.4 MHz, CDCl3) δ 176.8, 143.3, 137.3, 135.5, 129.6, 
128.6, 128.2, 128.1, 127.9, 127.3, 126.8, 126.6, 124.4, 122.1, 109.0, 47.0, 43.5, 36.4; IR (Neat) 
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3106, 3086, 3060, 3029, 2919, 1711, 1613, 1489, 1466, 1361, 1187, 751, 698 cm-1; HRMS (ESI+) 
calc’d for C22H20NO ([M+H]+) 314.1545, found 314.1541. 
 
1-(4-Methoxy-benzyl)-1H-indole-2,3-dione  
N
H
O
O
N
PMB
O
ONaH
p-methoxy benzyl bromide
DMF, 0 oC
(85% yield)  
Isatin (2.94 g, 20 mmol) was placed in a 250 mL round bottom flask and dissolved in DMF (37 mL). 
The resulting bright orange solution was cooled to 0 °C by the use an ice/water bath. NaH (55% 
dispersion in mineral oil, 916 mg, 21 mmol) was added portionwise resulting in a deep purple 
solution. The solution was stirred until any effervescence had ceased (~15 min). para-Methoxy 
benzyl bromide (4.83 g, 3.46 mL, 24 mmol) was added in a dropwise manner and the resulting red-
brown mixture was stirred for an additional 30 min at 0 °C. H2O (176 mL) was added to precipitate 
the product. The product was filtered and recrystallized from EtOH. Yield 4.55 g (85%) of the title 
compound as orange needles: mp. 161-162 °C (EtOH), Lit.367 171-172 °C; Rf = 0.65 (EtOAc); 1H 
NMR (300 MHz, CDCl3) δ 7.60 (ddd, J = 7.5, 1.3, 0.6 Hz, 1H), 7.48 (dt, J = 7.8, 1.4 Hz, 1H), 7.29-
7.26 (m, 2H), 7.08 (dt, J = 7.6, 0.8 Hz, 1H), 6.90-6.84 (m, 2H), 6.80 (br d, J = 8.0 Hz, 1H), 4.87 (s, 
2H), 3.78 (s, 3H); 13C NMR (75.4 MHz, CDCl3) δ 183.3, 159.3, 158.1, 150.7, 138.2, 128.8, 126.4, 
125.3, 123.7, 117.6, 114.3, 111.0, 55.2, 43.4; IR (Neat) 3087, 3057, 3032, 2945, 2918, 1700, 1613, 
1487, 1466, 1344, 1225, 1196, 1165, 748, 725, 697 cm-1, MS: m/z 267 [M]. Spectral data in 
accordance with literature values.368  
 
1-(4-Methoxy-benzyl)-1,3-dihydro-indol-2-one  
N
PMB
O
N
PMB
O
O
H2NNH2 H2O
(81% yield)
 
1-(4-Methoxy-benzyl)-1H-indole-2,3-dione (2.67 g, 10 mmol) was suspended in hydrazine hydrate 
(11 mL) and the mixture was heated to reflux until the gas evolution had stopped (4 h). The reaction 
mixture went from orange via green to yellow within this time. The reaction mixture was allowed to 
cool to ambient temperature and extracted with EtOAc (3 x 25 mL). The combined organic phases 
were dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude yellow 
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product was recrystallized from EtOH. Yield 2.07 g (81%) of the title compound as pale yellow 
needles: mp. 105-106 °C (EtOH), Lit.367 103-104 °C; Rf = 0.21 (heptane:EtOAc = 7:3); 1H NMR 
(300 MHz, CDCl3) δ 7.27-7.22 (m, 4H), 7.21-7.13 (m, 1H), 7.00 (dt, J = 7.6, 1.0 Hz, 1H), 6.87-6.80 
(m, 1H), 6.75 (d, J = 7.8 Hz, 1H), 4.85 (s, 2H), 3.77 (s, 3H), 3.60 (s, 2H); 13C NMR (75.4 MHz, 
CDCl3) δ 175.0, 159.0, 144.3, 128.7, 127.9, 127.7, 124.4, 124.3, 122.2, 114.0, 109.0, 55.2, 43.1, 
35.7; IR (Neat) 3055, 3036, 2999, 2954, 2932, 2915, 2836, 1698, 1612, 1511, 1487, 1438, 1378, 
1276, 1175, 1165, 1031, 748 cm-1, MS: m/z 253 [M]. Spectral data in accordance with literature 
values.369  
 
3-Benzyl-1-(4-methoxy-benzyl)-1,3-dihydro-indol-2-one [Table 4.3, Entry 10] 
N
PMB
O
 
Isolated yield: 92% 
Pale yellow oil; Rf = 0.18 (heptane:EtOAc = 7:3); 1H NMR (300 MHz, CDCl3) δ 7.24-7.19 (m, 3H), 
7.17-7.04 (m, 3H), 6.98-6.85 (m, 4H), 6.79-6.69 (m, 2H), 6.58 (d, J = 7.8 Hz, 1H), 4.97 (d, J = 15.5 
Hz, 1H), 4.59 (d, J = 15.5 Hz, 1H), 3.83 (dd, J = 8.2, 4.3 Hz, 1H), 3.76 (s, 3H), 3.50 (dd, J = 13.6, 
4.4 Hz, 1H), 3.11 (dd, J = 13.6, 8.2 Hz, 1H); 13C NMR (75.4 MHz, CDCl3) δ 176.8, 158.8, 143.4, 
137.4, 129.6, 128.3, 128.2, 128.2, 127.8, 127.6, 126.5, 124.4, 122.0, 114.0, 109.0, 55.2, 47.0, 42.9, 
36.4; IR (Neat) 3058, 3030, 3001, 2929, 2835, 1708, 1612, 1512, 1488, 1466, 1359, 1247, 1177, 
1033, 750, 700 cm-1; HRMS (ESI+) calc’d for C23H22NO2 ([M+H]+) 344.1651, found 344.1647.  
 
3-(2-Fluoro-benzyl)-1,3-dihydro-indol-2-one [Table 4.3, Entry 11] 
N
H
O
F
 
Isolated yield: 81% 
Off-white needles; mp. 123-124 °C (heptane:EtOAc); Rf = 0.17 (heptane:EtOAc = 7:3); 1H NMR 
(300 MHz, CDCl3) δ 8.55 (br s, 1H), 7.36-7.10 (m, 3H), 7.10-7.02 (m, 1H), 7.01 (d, J = 8.2 Hz, 
1H), 6.89 (dt, J = 7.6, 1.1 Hz, 1H), 6.86 (d, J = 7.6 Hz, 1H), 6.72 (d, J = 7.3 Hz, 1H), 3.80 (dd, J = 
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9.1, 5.2 Hz, 1H), 3.55 (dd, J = 13.9, 5.2 Hz, 1H), 2.96 (dd, J = 13.9, 9.1 Hz, 1H); 13C NMR (75.4 
MHz, CDCl3) δ 180.0, 161.2 (d, J = 245.9 Hz), 141.5, 131.5 (d, J = 4.5 Hz), 128.7, 128.5 (d, J = 
8.1 Hz), 128.0, 125.1 (d, J = 15.3 Hz), 124.7, 123.9 (d, J = 3.6 Hz), 122.0, 115.3 (d, J = 22.1 Hz), 
109.8, 46.1 (d, J = 1.4 Hz), 30.0 (d, J = 1.8 Hz); IR (Neat) 3208, 3087, 3061, 3032, 1700, 1619, 
1599, 1490, 1469, 1456, 1337, 1304, 1229, 1185, 1100, 746 cm-1; HRMS (ESI+) calc’d for 
C15H13FNO ([M+H]+) 242.0981, found 242.0987. 
 
3-(2-Chloro-benzyl)-1,3-dihydro-indol-2-one [Table 4.3, Entry 12] 
N
H
O
Cl
 
Isolated yield: 88% 
Pale yellow powder; mp. 89-91 °C (n-hexane:EtOAc); Rf = 0.17 (heptane:EtOAc = 7:3); 1H NMR 
(300 MHz, CDCl3) δ 9.14 (br s, 1H), 7.33-7.17 (m, 1H), 7.15-6.94 (m, 4H), 6.76 (d, J = 7.8 Hz, 
1H), 6.70 (dt, J = 7.6, 1.0 Hz, 1H), 6.44 (d, J = 5.5 Hz, 1H), 3.75 (dd, J = 9.9, 5.5 Hz, 1H), 3.47 
(dd, J = 13.8, 5.5 Hz, 1H), 2.80 (dd, J = 13.8, 9.9 Hz, 1H); 13C NMR (75.4 MHz, CDCl3) δ 179.7, 
141.4, 135.9, 134.4, 131.9, 129.7, 128.8, 128.3, 128.0, 126.6, 124.9, 122.0, 109.8, 45.2, 34.8; IR 
(Neat) 3209, 3060, 2928, 1701, 1619, 1470, 1337, 1229, 1053, 908, 748, 676 cm-1; HRMS (ESI+) 
calc’d for C15H13ClNO ([M+H]+) 258.0686, found 258.0693. 
 
3-(2-Methyl-benzyl)-1,3-dihydro-indol-2-one [Table 4.3, Entry 13] 
N
H
O
Me
 
Isolated yield: 90% 
Pale yellow needles; mp. 106-108 °C (heptane:EtOAc); Rf = 0.21 (heptane:EtOAc = 7:3); 1H NMR 
(300 MHz, CDCl3) δ 7.67 (br s, 1H), 7.23-7.12 (m, 5H), 6.91-6.77 (m, 2H), 6.54 (d, J = 7.3 Hz, 
1H), 3.71 (dd, J = 10.9, 4.6 Hz, 1H), 3.52 (dd, J = 14.0, 4.6 Hz, 1H), 2.82 (dd, J = 14.0, 10.9 Hz, 
1H), 2.30 (s, 3H); 13C NMR (75.4 MHz, CDCl3) δ 180.2, 141.4, 136.7, 136.5, 130.5, 130.0, 129.1, 
127.9, 126.8, 125.9, 125.0, 121.9, 109.8, 46.3, 34.3, 19.6; IR (Neat) 3192, 3077, 3061, 3021 2955, 
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2929, 1705, 1620, 1485, 1470, 1402, 1338, 1307, 1230, 749 cm-1; HRMS (ESI+) calc’d for 
C16H16NO ([M+H]+) 238.1232, found 238.1227. 
 
3-(2-Methoxy-benzyl)-1,3-dihydro-indol-2-one [Table 4.3, Entry 14] 
N
H
O
MeO
 
Isolated yield: 85% 
Colorless needles; mp. 120-121 °C (heptane:EtOAc); Rf = 0.16 (heptane:EtOAc = 7:3); 1H NMR 
(300 MHz, CDCl3) δ 8.21 (br s, 1H), 7.27 (dt, J = 7.8, 1.7 Hz, 1H), 7.14 (tt, J = 7.7, 1.1 Hz, 1H), 
7.11 (dd, J = 7.5, 1.7 Hz, 1H), 6.92-6.80 (m, 4H),  6.54 (d, J = 7.4 Hz, 1H), 3.92 (dd, J = 10.0, 5.1 
Hz, 1H), 3.82 (s, 3H), 3.60 (dd, J = 13.4, 5.1 Hz, 1H), 2.75 (dd, J = 13.4, 10.0 Hz, 1H); 13C NMR 
(75.4 MHz, CDCl3) δ 180.7, 157.7, 141.5, 131.4, 129.6, 128.1, 127.6, 126.5, 125.0, 121.6, 120.1, 
110.2, 109.6, 55.1, 45.4, 32.2; IR (Neat) 3212, 3081, 3063, 3030, 2938, 2835, 1704, 1620, 1494, 
1470, 1438, 1338, 1308, 1245, 1179, 1111, 1052, 1031 749 cm-1; HRMS (ESI+) calc’d for 
C16H16NO2 ([M+H]+) 254.1181, found 254.1176. 
 
3-(3-Methoxy-benzyl)-1,3-dihydro-indol-2-one [Table 4.3, Entry 15] 
N
H
O
OMe
 
Isolated yield: 84% 
White powder; mp. 87-88 °C (hexane:EtOAc), Lit.370 87-88 °C (hexane:EtOAc); Rf = 0.19 
(heptane:EtOAc = 7:3); 1H NMR (300 MHz, CDCl3) δ 8.52 (br s, 1H), 7.17 (t, J = 7.9 Hz, 2H), 6.91 
(dt, J = 7.6, 1.0 Hz, 1H), 6.86-6.70 (m, 5H), 3.75 (dd, J = 9.3, 4.4 Hz, 1H), 3.73 (s, 3H) 3.48 (dd, J 
= 13.7, 4.4 Hz, 1H), 2.91 (dd, J = 13.7, 9.3 Hz, 1H); 13C NMR (75.4 MHz, CDCl3) δ 179.9, 159.4, 
141.5, 139.3, 129.3, 128.9. 127.9, 124.8, 122.0, 121.7, 114.6, 112.3, 109.8. 55.1, 47.5, 36.6; IR 
(Neat) 3202, 3090, 3059, 3029, 2943, 2834, 1700, 1618, 1600, 1486, 1469, 1438, 1336, 1293, 1260, 
1228, 1153, 751 cm-1, MS: m/z 253 [M]. Spectral data in accordance with literature values.370 
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3-Naphthalen-1-ylmethyl-1,3-dihydro-indol-2-one [Table 4.4, Entry 1] 
N
H
O
 
Isolated yield: 87% 
Yellow needless; mp. 109-110 °C (hexane:EtOAc); Rf = 0.27 (heptane:EtOAc = 7:3); 1H NMR (300 
MHz, CDCl3) δ 8.89 (br s, 1H), 8.27 (d, J = 8.3 Hz, 1H), 7.98-7.91 (m, 1H), 7.85 (d, J = 8.2 Hz, 
1H), 7.64-7.50 (m, 2H), 7.45 (dd, J = 8.2, 7.1 Hz, 1H), 7.32 (d, J = 6.9 Hz, 1H), 7.18 (t, J = 7.7 Hz, 
1H), 6.94 (d, J = 7.7 Hz, 1H), 6.81 (dt, J = 7.6, 1.0 Hz, 1H), 6.42 (d, J = 7.5 Hz, 1H), 4.16 (dd, J = 
13.9, 3.9 Hz, 1H), 3.92 (dd, J = 11.0, 3.9 Hz, 1H), 3.07 (dd, J = 13.9, 11.0 Hz, 1H); 13C NMR (75.4 
MHz, CDCl3) δ 180.1, 141.4, 134.2, 134.0, 131.6, 129.4, 129.0, 127.9, 127.9, 127.8, 126.3, 125.8, 
125.3, 125.1, 123.6, 121.9, 109.8, 46.3, 34.9; IR (Neat) 3204, 3060, 2945, 2892, 2836, 1700, 1620, 
1598, 1469, 1306, 1018, 784, 751 cm-1; HRMS (ESI+) calc’d for C19H16NO ([M+H]+) 274.1232, 
found 274.1232. 
 
3-Benzo[1,3]dioxol-5-ylmethyl-1,3-dihydro-indol-2-one [Table 4.4, Entry 2] 
N
H
O
O
O
 
Isolated yield: 79% 
Pale yellow needles; mp. 135-136 °C (heptane:EtOAc); Rf = 0.10 (heptane:EtOAc = 7:3); 1H NMR 
(300 MHz, CDCl3) δ 9.04 (br s, 1H), 7.18 (ddt, J = 7.7, 1.3, 0.8 Hz, 1H), 6.93 (dt, J = 7.6, 1.0 Hz, 
1H), 6.87 (d, J = 7.8 Hz, 1H), 6.82 (d, J = 7.3 Hz, 1H), 6.69 (d, J = 2.7 Hz, 1H), 6.67 (d, J = 3.5 
Hz, 1H), 6.61 (dd, J = 8.0, 1.6 Hz, 1H), 5.91 (s, 2H), 3.69 (dd, J = 9.0, 4.6 Hz, 1H), 3.40 (dd, J = 
13.8, 4.6 Hz, 1H),  2.88 (dd, J = 13.8, 9.1 Hz, 1H); 13C NMR (75.4 MHz, CDCl3) δ 179.7, 147.5, 
146.2, 141.4, 131.4, 128.8, 127.9, 124.7, 122.5, 122.0, 109.8, 109.6, 108.0, 100.8, 47.7, 36.4; IR 
(Neat) 3215, 3092, 3062, 3029, 2895, 1705, 1620, 1502, 1489, 1470, 1443, 1337, 1191, 1039, 933, 
813, 751 cm-1; HRMS (ESI+) calc’d for C16H14NO3 ([M+H]+) 268.0974, found 268.0967. 
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3-Furan-2-ylmethyl-1,3-dihydro-indol-2-one [Table 4.4, Entry 3] 
N
H
O
O
 
Isolated yield: 71% 
Toluene (1.0 mL) was used as co-solvent. 
White powder; mp. 146-147 °C (n-Hexane:EtOAc);  Rf = 0.16 (heptane:EtOAc = 7:3); 1H NMR 
(300 MHz, CDCl3) δ 8.65 (br s, 1H), 7.34 (dd, J = 1.9, 0.8 Hz, 1H), 7.24-7.15 (m, 1H), 6.94 (dt, J = 
7.6, 1.0 Hz, 1H), 6.88 (d, J = 7.8 Hz, 1H), 6.79 (d, J = 7.4 Hz, 1H), 6.29 (dd, J = 3.2, 1.9 Hz, 1H), 
6.03 (dd, J = 3.2, 0.8 Hz, 1H), 3.81 (dd, J = 9.5, 4.6 Hz, 1H), 3.48 (dd, J = 15.0, 4.6 Hz, 1H), 2.99 
(dd, J = 15.0, 9.5 Hz, 1H); 13C NMR (75.4 MHz, CDCl3) δ 179.7, 151.9, 141.5, 141.4, 128.7, 128.0, 
124.6, 122.2, 110.3, 109.8, 107.3, 45.2, 29.0; IR (Neat) 3182, 3150, 2964, 2902, 2839, 1699, 1619, 
1470, 1341, 1263, 1230, 1008, 738 cm-1; HRMS (ESI+) calc’d for C13H12NO2 ([M+H]+) 214.0868, 
found 214.0867. 
 
3-Thiophen-2-ylmethyl-1,3-dihydro-indol-2-one [Table 4.4, Entry 4] 
N
H
O
S
 
Isolated yield: 81% 
Yellow needles; mp. 154-155 °C (heptane:EtOAc); Rf = 0.22 (heptane:EtOAc = 7:3); 1H NMR (300 
MHz, CDCl3) δ 8.23 (br s, 1H), 7.23-7.18 (m, 1H), 7.10 (dd, J = 5.1, 1.1 Hz, 1H), 7.04-6.93 (m, 
2H), 6.89-6.74 (m, 3H), 3.76 (dd, J = 8.1, 4.4 Hz, 1H), 3.61 (ddd, J = 14.8, 4.4, 0.8 Hz, 1H), 3.34 
(dd, J = 14.8, 8.1 Hz, 1H); 13C NMR (75.4 MHz, CDCl3) δ 179.8, 142.1, 140.0, 128.9, 128.6, 127.0, 
126.8, 125.0, 124.7, 122.6, 110.3, 48.1, 31.0; IR (Neat) 3206, 3092, 3030, 2916, 2841, 1701, 1620, 
1485, 1470, 1435, 1337, 1186, 750, 697 cm-1; HRMS (ESI+) calc’d for C13H12NOS ([M+H]+) 
230.0640, found 230.0638. 
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3-[2-(1H-Indol-3-yl)-ethyl]-1,3-dihydro-indol-2-one [Table 4.4, Entry 5] 
N
H
O
H
N
 
Isolated yield: 72 % 
Pale yellow oil; Rf = 0.47 (CH2Cl2:CH3OH = 9:1); 1H NMR (300 MHz, CDCl3) δ 8.78 (br s, 1H), 
8.02 (br s, 1H), 7.60 (d, J = 7.8 Hz, 1H), 7.35-7.32 (m, 1H), 7.29 (d, J = 7.4 Hz, 1H), 7.26-7.18 (m, 
2H), 7.1 (dt, J = 7.6, 1.3 Hz, 1H), 7.06 (dt, J = 7.6, 0.9 Hz, 1H), 6.98 (d, J = 2.3 Hz, 1H), 6.92 (d, J 
= 7.7 Hz, 1H), 3.59 (t, J = 6.0 Hz, 1H), 3.01-2.79 (m, 2H), 2.43-2.35 (m, 2H); 13C NMR (75.4 
MHz, CDCl3) δ 180.7, 141.6, 136.2, 129.7, 127.8, 127.3, 124.1, 122.3, 121.9, 121.5, 119.2, 118.8, 
115.3, 111.0, 109.8, 45.6, 31.0, 21.4; IR (Neat) 3410, 3299, 3058, 2926, 2855, 1697, 1620, 1470, 
1338, 1266, 1220, 1101, 909, 740 cm-1; HRMS (ESI+) calc’d for C18H17N2O ([M+H]+) 277.1341, 
found 277.1334. 
 
3-Isopropyl-1,3-dihydro-indol-2-one [Table 4.4, Entry 6] 
N
H
O
 
Isolated yield: 73% 
10 mmol (5 equiv) isopropyl alcohol was used and the reaction was run for 48 h at 110 oC. 
White powder; mp.108-109 °C (n-Hexane:EtOAc), Lit.371 105-106 °C; Rf = 0.23 (heptane:EtOAc = 
7:3); 1H NMR (300 MHz, CDCl3) δ 8.58 (br s, 1H), 7.29-7.17 (m, 2H), 7.01 (dt, J = 7.6, 1.0 Hz, 
1H), 6.89 (d, J = 7.7 Hz, 1H), 3.40 (d, J = 3.5 Hz, 1H), 2.59-2.42 (m, 1H), 1.13 (d, J = 7.0 Hz, 3H), 
0.92 (d, J = 6.8 Hz, 3H); 13C NMR (75.4 MHz, CDCl3) δ 180.5, 142.1, 128.3, 127.7, 124.5, 122.0, 
109.7, 52.2, 30.7, 19.9, 17.8; IR (Neat) 3172, 3139, 3063, 2959, 2872, 1692, 1616, 1470, 1414, 
1344, 1297, 1220, 1182, 749 cm-1; MS: m/z 175 [M]. Spectral data in accordance with literature 
values347  
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5 Studies Toward the Asymmetric Total Synthesis of Variecolin 
5.1 Introduction 
5.1.1 Isolation and Structural Determination 
The sesterterpenoid variecolin (5.1) was first isolated in 1991 from the fermentation broth of 
Aspergillus variecolor at Merck Research Laboratories (Figure 5.1, 5.1 and 5.2).372 Based on 2D 
NMR spectroscopy variecolin (5.1) was shown to possess a novel [5-8-6-5]-tetracyclic skeleton with 
an AB cis ring fusion, BC and CD trans ring fusions, eight stereocenters (two of which are 
quaternary carbon centers contained in the C ring), and a central eight-membered B ring. From 
biosynthetic considerations Hensens and co-workers proposed the absolute configuration depicted in 
Figure 5.1.  
O
H
H
OHC
HH
A
B C
D
Variecolin (5.1)
O
H
H
OHC
HH
originally proposed structure 5.2
 
Figure 5.1 The tetracyclic sesterterpenoid variecolin (5.1). 
The absolute configuration of variecolin (5.1), however, remained elusive until 2000, when 
Fujimoto and co-workers utilized HMBC NMR along with nuclear Overhauser effect (NOE) 
experiments to determine the absolute configuration of a (6R, 7R)-dimethyl-1,3,5-trioxacycloheptyl 
derivative of variecolin (5.3).373 Variecolin (5.1) was treated with a chiral diol, (2R, 3R)-(–)-butane-
2,3-diol under acidic conditions (Scheme 5.1). Analysis of the ensuing chiral bis-hemiketal 5.3 
revealed a significant NOE between H(6) and H(3’), indicating that the absolute configuration at 
C(6) is R. Therefore the absolute configuration of variecolin is as depicted in structure 5.1. 
5 Studies Toward the Asymmetric Total Synthesis of Variecolin 
 122
O
O
H
H
OHC
HH
(2R,3R)-(−)-butane-2,3-diol
p-TsOH, PhH
H
H
HH
O
O
O
O
O
HH3C
H
H3C
H
H
NOE
6 6
63'
5.3
3'
 
Scheme 5.1 Determination of the absolute configuration of variecolin (5.1). 
 
Since the original discovery of variecolin (5.1) a family of congeners has also been identified 
(Figure 5.2).373-375 In 1999 Kawai and co-workers374 reported the isolation of variecolactone (5.4) 
and variecolol (5.5) from the mycelium of Emericella purpurea. Both variecolactone (5.4) and 
variecolol (5.5) contain the [5-8-6-5]-tetracyclic skeleton of variecolin (5.1). However, in the case of 
5.4, a 5-membered lactone is present while in the case of 5.5, a 5-membered hemiketal ring exists. 
In addition, Kawai was able to obtain an X-ray crystal structure of variecolactone 5.4 confirming the 
relative structure. 
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Figure 5.2 Members of the variecolin family of sesterterpenoids. 
 
Later, Fujimoto and co-workers373 disclosed two novel members of the variecolin family, 
variecoacetals A (5.6) and B (5.7). Both compounds were isolated from the fungus Emericella 
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aurantiobrunnea. Four additional members, emericolins A–D (5.8, 5.9, 5.10, and 5.11, Figure 5.2) 
of the family were isolated from Emericella aurantiobrunnea in 2004 by Butler and co-workers.375 
Significantly, an X-ray crystal structure of variecolin (5.1) was attained for the first time, thus 
confirming the relative stereochemistry.  
5.1.2 Biological Activity 
The sesterterpenoid variecolin (5.1) has shown a broad range of biological activity since its isolation 
in 1991. In the original isolation paper Hensens and co-workers372 showed that variecolin (5.1) is an 
angiotension II receptor antagonist, which is a crucial receptor target in the treatment of 
hypertension (high blood pressure). Later, the immunosuppressive activities (IC50 values) of 
variecolin (5.1) and several of its congeners against Con A (T-cells) and LPS (B-cells) induced 
proliferation of mouse splenic lymphocytes were studied by Fujimoto.373,376  
 
Table 5.1 Immunosuppressive effects of variecolin (5.1) and congeners 5.4, 5.5, 5.6, and 5.7 compared to azathioprine, 
cyclosporine A, and FK506 on the Con A-induced and LPS-induced proliferation of mouse splenic lymphocytes 
IC50 (μg/mL)  
Compound Con A-induced LPS-induced 
Variecolin (5.1) 0.4 0.1 
Variecolol (5.5) 1.7 0.6 
Variecolactone (5.4) 8.0 2.5 
Variecoacetal A (5.6) 4.5 1.5 
Variecoacetal B (5.7) 6.5 2.2 
Azathioprine 2.7 2.7 
Cyclosporine A 0.04 0.07 
FK506 1.5 x 10-5 1.6 x 10-3 
 
Variecolin (5.1) displayed the highest immunosuppressive activity rivaling those of commercial 
drugs azathioprine and cyclosporine A. 5.1 is an order of magnitude more active than its congeners 
(5.4-5.7) indicating the significance of the conjugated aldehyde at C(20) and the ketone at C(5) for 
the biological activity. Immunosuppressants are of crucial importance as a countermeasure to acute 
rejection of new organ(s) after transplantation and in the treatment of autoimmune diseases such as 
multiple sclerosis. 
  
Most recently, Butler and co-workers375 have reported that variecolin (5.1) and variecolactone (5.4) 
are antagonists for the CCR5 chemokine receptor (IC50 = 9 and 32 μM, respectively) while the 
emericolins  A (5.8), B (5.9), C (5.10), and D (5.11) were inactive. Chemokines constitute a family 
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of intracellular messengers of importance for the development, homeostasis and immune response in 
the organism.377 The chemokine receptors CCR5 and CXCR4 belong to the cellular G-protein-
coupled system and mediate the physiological activities of the chemokines. Over the last decade, 
these receptors have presented themselves as novel targets for potential anti-HIV drugs.378-382 The 
glycoprotein gp120 which is situated on the viral envelope of HIV-1 mediates attachment to the 
target cell (macrophages and T-cells) through the engagement of two cellular receptor molecules: 
the CD4 glycoprotein and a coreceptor, most often CCR5.382 Since this coreceptor is a requisite for 
HIV-1 uptake, CCR5 presents itself as a prime target for new therapeutic agents. Perhaps more 
importantly genetic studies in EU subjects established that a 32 bp deletion within the coding region 
of the CCR5 gene (CCR5-Δ32) resulting in a non-functional receptor led to high resistance toward 
the R5-strain of HIV-1.383,384 Strikingly, it was established that functional CCR5 receptors are not 
essential for immune competence which provide an important proof-of-principle of the potential 
safety of CCR5-targeted therapeutics.385 
5.1.3 Proposed Biosynthesis 
In the isolation paper Hensens and co-workers372 proposed that the ABCD skeletal core of variecolin 
(5.1) can be traced back to the mevalonate biosynthetic pathway from geranylfarnesyl 
pyrophosphate (Scheme 5.2). Importantly, this proposal attempts to establish a biosynthetic linkage 
between variecolin (5.1) and prior knowledge about the structurally related classes of 
sesterterpenoids ceriferene (e.g. flocerol (5.12)) and ophiobolin (ophiobolin C (5.13)).386-388  The 
proposed biosynthetic pathway commences with the loss of the labile diphosphate (-OPP) to form an 
allylic carbocation. This initiates a concerted cyclization reaction that generates the core C-ring 
fused to a macrocycle and a secondary carbocation 5.14. Starting from this common intermediate 
two biosynthetic pathways diverge. The synthesis of the ophiobolins is triggered by a 1,5-hydride 
shift (pathway a) followed by oxidation to furnish ophiobolin C (5.13). The trans-fused CD-ring 
system of variecolin (5.1) and flocerol (5.12) is attained by a ring expansion via pathway b followed 
by a rapid cyclization. Subsequent β-hydride elimination installs the isopropenyl moiety of flocerol 
(5.12) and variecolin (5.1) (pathway c). Further oxidation provides flocerol as an [11-6-5] fused ring 
system. Alternatively, a concerted cyclization initiated by a 1,5-hydride shift generates the AB-ring-
system of variecolin (5.1) (pathway d).  
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Scheme 5.2 Hensens proposal for the biosynthesis of variecolin (5.1). 
 
5.2 Previous Synthetic Efforts 
Despite the interesting biological profile and complex unprecedented carbon skeleton variecolin 
(5.1) has only received scarce interest by the synthetic community. Hitherto no total synthesis has 
been reported and only two research groups have disclosed synthetic studies directed toward 
variecolin. 
5.2.1 Piers’ Sequential Annulation Approach 
In 1997, six years after the first isolation of variecolin (5.1), Piers and Boulet revealed their interest 
in the variecolin family disclosing a route to the CD-ring system.389 In his Ph.D. thesis from 2002,390 
Shawn Walker from the Piers research group reported the total synthesis of (±)-5-deoxyvariecolin 
(5.15), (±)-5-deoxyvariecolol (5.16), and (±)-5-deoxyvariecolactone (5.17) (cf. Scheme 5.5). The 
central design feature was to employ two sequential annulation protocols and a ring-expansion 
sequence to forge the carbon skeleton of variecolin (5.1). The synthesis commenced with the known 
ketone391 5.18 utilizing chemistry previously developed in the Piers laboratory (Scheme 5.3).389 
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TMSCl-accelerated conjugate addition of a higher order cuprate afforded the undesired cis-fused 
ketone 5.19 exclusively. This could, however, easily be rectified by treating cis-ketone 5.19 with 
NaOMe in MeOH providing a 14:1 ratio of the desired bicyclic trans-ketone 5.20 to cis-ketone 5.19 
in excellent yield.392,393 
O HO
TMSCl NaOMe HO
1. KDA, HMPA
2. LDA, MeI
3. I2
HO
Cu(CN)Li
(86% yield)
(95% yield)
Bu3Sn
I
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OI 1. n-BuLi2. PCC
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(61% yield)5.19 5.20
5.21 5.22
5.18
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Scheme 5.3 Preparation of the ring-expansion precursor. 
 
The quaternary stereocenter at C(11, variecolin numbering) was installed smoothly; initial kinetic 
deprotonation with KDA in the presence of the requisite additive HMPA and alkylation of the 
ensuing enolate with the bifunctional vinyl iodide394 followed by methylation provided after 
iododestannylation the necessary cyclization precursor 5.21. Treating vinyl iodide 5.21 with n-BuLi 
furnished rapid cyclization to afford a cycloheptene which upon oxidative rearrangement with 
PCC395,396 provided the desired cycloheptenone 5.22 in moderate yield. This cycloheptenone 5.22 
served as precursor to the central eight-membered B-ring, the hallmark of the variecolin 
sesterterpenoids.  
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Scheme 5.4 Ring expansion providing the central eight-membered B-ring. 
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Reduction of heptenone 5.22 under Birch-type conditions followed by PCC oxidation provided an 
inseparable 2.2:1.0 mixture of ketone products 5.23 and 5.24 (Scheme 5.4). Ketone 5.23 was 
transposed into 5.25 in 44% yield through a four step sequence. Cycloheptanone 5.25 was poised to 
undergo a four-step ring-expansion sequence to furnish the central B-ring. When cycloheptanone 
5.25 was treated with KHMDS and the resulting enolate trapped with TMSCl, a regioisomeric 
mixture of silyl enol ethers was obtained. This material was subjected to dioxygen-accelerated 
cyclopropanation conditions,397 and the ensuing silyl cyclopropyl ethers were treated with iron(III) 
chloride to give a mixture of β-chloro-ketones. Next, the mixture was reacted with NaOAc to afford 
two regioisomeric ketoenones in a combined 86% yield of which the desired cyclooctenone 5.26 
was attained as the major product in 64% yield over the four step sequence. 
 
With the BCD-ring system in place, cyclooctenone 5.26 was ready to undergo a 
methylenecyclopentane annulation forming the A ring (Scheme 5.5). In the event, Lewis-acid-
accelerated conjugate addition of a bifunctional homocuprate to cyclooctenone 5.26 followed by a 
Finkelstein reaction to afford a more reactive alkyl iodide and lithium tert-butoxide-mediated 
alkylation gave exclusively the desired cis-fused 5,8-ring system 5.27 in 53% yield for this three 
step sequence. Installation of C(20) was achieved by kinetic deprotonation of ketone 5.27 and 
subsequent trapping of the enolate with N-phenyltrifluoromethanesulfonimide to provide the 
corresponding triflate. This material was subjected to palladium-catalyzed carbonylation conditions 
affording ester 5.28 in good yield. After extensive experimentation, a crucial catalytic hydrogenation 
protocol for chemo- and diastereoselectively reducing the exocyclic methylene double bond in the 
presence of the isopropenyl moiety was discovered. Catalytic hydrogenation using 5% platinum on 
alumina followed by DIBAL reduction afforded allylic alcohol 5.29 as a single diastereomer in 
excellent yield. 
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Scheme 5.5 End-game for Walker’s and Piers’ approach.  
 
From the central allylic alcohol 5.29 several analogs of variecolin (5.1) could be synthesized with 
relative ease. Manganese dioxide oxidation of allylic alcohol 5.29 provided (±)-5-deoxyvariecolin 
(5.15) in good yield. (±)-5-deoxyvaricolol (5.16) could be attained from the same intermediate 5.29 
via a two step sequence. The addition of Pb(OAc)4 in the presence of CaCO3 afforded (±)-5-
deoxyvariecolol (5.16) and (±)-5-deoxyvariecolin (5.15) in a 2:3 ratio. Upon treatment with NaBH4 
(±)-5-deoxyvariecolin (5.15) was reduced to allylic alcohol 5.29 (58% yield) allowing for recycling, 
while (±)-5-deoxyvariecolol (5.16) could be isolated in 39% yield. The formation of the cyclic ether 
moiety in 5.16 probably proceeds via formation of an alkoxy radical formed through homolytic 
decomposition of an intermediate lead(IV) alkoxide, internal 1,5-hydrogen transfer to yield a C-5 
radical, and final ether ring closure.398 The cyclic ether was oxidized using Collins’ reagent 
providing (±)-5-deoxyvariecolactone (5.17) in excellent yield.    
 
In summary, Piers have provided access to the variecolin analogs (±)-5-deoxyvariecolin (5.15), (±)-
5-deoxyvariecolol (5.16), and (±)-5-deoxyvariecolactone (5.17) in a racemic manner employing a 
highly linear sequence. The longest linear sequence contains 28 steps providing (±)-5-
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deoxyvariecolactone (5.17) in an overall 1.0% yield. Unfortunately, the synthesis is marred by 
several inefficient steps which can be ascribed to selectivity issues and furthermore, the ring-
expansion to build the requisite eight-membered ring takes eleven steps from the seven-membered 
ring precursor. To complete the racemic synthesis and access the variecolin family all that remains 
is oxidation of C(5) to attain the correct oxidation state. 
5.2.2 Molander’s Samarium(II) Iodide-Mediated Annulation Approach 
The first enantioselective approach toward the total synthesis of variecolin (5.1) was reported by 
Molander and co-workers in 2001.399 This first generation approach was based on Hensens original 
assignment founded on biosynthetic consideration, hence the synthesis targeted ent-variecolin (5.2) 
while the second generation approach was based on the revised structure (cf. Figure 5.1).400 The 
central design feature in both approaches was to construct the eight-membered B-ring employing a 
samarium(II) iodide-mediated coupling-annulation sequence of an alkyl iodide 5.30 and bicyclic 
ketone 5.31 (Scheme 5.6). This strategy had previously been used by Molander to forge medium 
sized carbocycles.401,402 
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Scheme 5.6 Molander’s convergent approach to variecolin (5.1). 
 
The most important lesson from Molander’s first generation approach was provided by model 
studies on the sequenced samarium(II) iodide coupling-annulation (Scheme 5.7). These studies 
revealed that the sequenced coupling had to be performed in two separate steps. In the event, diol 
5.32 was converted into chloride 5.33 utilizing standard chemistry followed by a samarium(II) 
iodide-mediated coupling. Chloride 5.33 was obtained as a 1:1 diastereomeric mixture due to the 
employment of racemic material and the addition to the ketone occurring trans addition to the alkyl 
chloride side-chain. Employing a protocol developed by Sharpless,403 methyl ether 5.33 was 
oxidized using a catalytic amount of ruthenium tetraoxide generated in situ from ruthenium(III) 
chloride and sodium periodate which provided lactone 5.34 directly. When lactone 5.34 was 
exposed to samarium(II) iodide under photochemical conditions, the prerequisite hemiketal 5.35 was 
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attained in good yield providing important proof-of-principle for the potential utility of the this 
strategy in constructing the central ABC ring-system of variecolin (5.1). 
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Scheme 5.7 Model studies on the key samarium(II) iodide-mediate sequence. 
 
With this important knowledge in mind, Molander and co-workers embarked on the second 
generation approach toward variecolin (5.1). The initial focus was to devise efficient routes that 
would allow for asymmetric synthesis of the two coupling partners alkyl iodide 5.30 and ketone 
5.31. The preparation of alkyl iodide 5.30 commenced from prochiral meso-anhydride 5.36 which 
after subjection to desymmetrization conditions developed by Bolm and co-workers404 afforded 
monoester 5.37 in virtually quantitative yield and high ee (Scheme 5.8). A series of functional group 
manipulations furnished ester 5.38 which upon oxidative cleavage and decarboxylative cyclization 
provided cyclopentanone 5.39. Further standard transformations gave the requisite alkyl iodide 
coupling partner.     
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Scheme 5.8 Asymmetric synthesis of alkyl iodide 5.30. 
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The correct stereochemistry for the bicyclic ketone coupling partner 5.31 was attained from Hajos-
Parrish ketone 5.40 (Scheme 5.9).405,406 The overarching strategy was that the all-carbon quaternary 
stereocenter in the Hajos-Parrish ketone would allow for the diastereoselective formation of the 
remaining stereocenters in the coupling partner 5.31. Ketone 5.40 was reduced with DIBAL-HMPA 
in the presence of tert-butyl cuprate, and the ensuing aluminium enolate was trapped with allyl 
bromide. Ozonolysis of this material followed by selective Raney-Ni reduction and acetal formation 
afforded methyl ether ketal 5.41 in moderate yield for this four-step sequence. Unfortunately, a 
sequence consisting of a two-step Saegusa-oxidation407 and cuprate addition gave the wrong 
stereochemistry at C(16) providing the undesired diastereomer 5.42. However, this could relatively 
easily be resolved through Wolff-Kishner reduction, ozonolysis and epimerization in the presence of 
NaOMe. Finally, acetal 5.43 was transformed into the required fragment 5.31 through a series of 
standard manipulations.  
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Scheme 5.9 Synthesis of bicyclic ketone 5.31 commencing from Hajos-Parrish ketone 5.40. 
 
With access to enantiomerically pure coupling partners Molander and co-workers focused on the 
samarium(II) iodide-mediated Barbier-type coupling of fragment 5.31 and 5.30. Extensive 
experimentations revealed that HMPA was crucial in order to obtain moderate yields of the coupling 
product 5.44 (Scheme 5.10). It is well known that HMPA accelerates these Barbier-type couplings. 
This effect is ascribed to an increase in the reduction potential of samarium(II) iodide when 
coordinated to a Lewis basic co-solvent.408 The exact nature of the active species is still a subject of 
debate: in the presence of four equivalents of HMPA, Flowers and co-workers409,410 suggest an 
uncharged complex [SmI2(HMPA)4], while Skrydstrup and co-workers411,412 have provided 
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evidence for an ionic cluster [Sm(HMPA)4(THF)2]2+ 2 I-. From the tertiary alcohol 5.44 it took eight 
steps to arrive at the spirocyclic lactone 5.45. Gratifyingly, when the conditions developed for the 
model system were implemented, the hemiketal 5.46 containing the 5,8,6,5-tetracyclic system of 
variecolin (5.1) was obtained in 82% yield, however, due to several low-yielding steps en route to 
spirolactone 5.45 material constraints precluded further studies toward the total synthesis of 
variecolin (5.1). 
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Scheme 5.10 Molander’s construction of the ABCD ring system. 
 
In summary, Molander and co-workers have demonstrated the utility of samarium(II)-iodide-
mediated Barbier-type alkylation and annulation in the construction of the core skeleton of 
variecolin. Compared to Piers’ approach, Molander has achieved higher efficiency through a 
convergent synthetic strategy. Although the fragments 5.30 and 5.31 have been prepared in 
enantiomerically pure form, their synthesis still leaves room for improvement (11 steps to fragment 
5.30 16% overall yield, 13 steps to fragment 5.31 22% overall yield). Moreover, the synthesis of 
spirolactone 5.45 is hampered by several low-yielding steps, and perhaps most importantly, all 
attempts to install the C(11) quaternary stereocenter at a late stage in the synthesis have failed, 
which may call for a revised strategy confronting this problem at an earlier stage.  
 
5.3 Retrosynthetic Analysis and Synthetic Design 
Our efforts toward the synthesis of this intriguing family of sesterterpenoids was concentrated 
around variecolin (5.1), since it has a highly interesting biological profile, and furthermore, retains 
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the major structural challenges presented by this class of natural products. Therefore, it was 
anticipated that an efficient synthesis of variecolin would provide access to the remaining family 
members. With a novel tetracyclic ring system featuring a central eight-membered ring, eight 
stereogenic centers two of which are all-carbon quaternary, an AB cis ring fusion, BC and CD trans 
ring fusions, variecolin (5.1) is a topographically complex target molecule (Scheme 5.11). 
Additionally, the relatively low degree of oxidation of the central ring system poses a significant 
challenge in devising a synthetic strategy due to the scarcity of functional group handles.  
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Scheme 5.11 Retrosynthetic analysis of variecolin (5.1). 
 
The overarching strategy was to utilize the structural challenges presented by variecolin (5.1) to 
expand the boundaries of synthetic methodologies recently developed in the Stoltz laboratory.413-415 
A central design feature was to convergently unite an AB fragment 5.47 and a D-ring fragment 5.48 
through a two-carbon tether and subsequently forge the B-ring by way of reductive cyclization. We 
envisioned cleavage of the tetracyclic structure by scission of the C(10)-C(15) bond employing an 
intramolecular conjugate radical addition of the AB-ring into the D-ring enone. Disconnection of the 
C(11)-C(12) bond through reductive coupling would provide the AB-ring fragment 5.47 and the D-
ring precursor 5.48. We anticipated that the AB-ring fragment would be available from a Wolff-
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Cope rearrangement of the densely functionalized cyclobutane 5.49 which in turn could be derived 
from allylic alcohol 5.50 employing a tethered cycloaddition. Acyclcyclopentene 5.48 could arise 
from ring-contraction of vinylogous ester 5.51, ultimately accessible from β-ketoester 5.52 utilizing 
asymmetric decarboxylative allylation.   
 
5.4 A Tandem Wolff–Cope Based Approach Toward the AB-Ring System 
The unique structural features of eight-membered cycloalkanes have spurred much research to 
uncover conformational preferences, strain, and transannular interactions.416 Although eight-
membered rings are less common in nature than five- and six-membered rings, they still have a high 
prevalence among natural products.416 The synthesis of eight-membered carbocycles has been a 
long-standing problem since extrapolation of existing protocols for ring formation has proved 
difficult. Cyclization of acyclic precursors to construct eight-membered rings is disfavored by a high 
degree of ring strain and transannular interactions.417 Hence until the onset of the 1980s relatively 
few methods to synthesize eight-membered ring had been disclosed. However, the isolation of a 
variety of complex natural products containing this intriguing structural moiety have spurred great 
progress in synthetic methodology to assemble eight-membered rings since then.417,418 A prominent 
example that has impelled a tremendous amount of research is the anticancer agent paclitaxel 
(Taxol).419,420 Despite notable breakthroughs, the selective formation and functionalization of eight-
membered rings remain a significant challenge and an active research field.421-425 
5.4.1 Background for the Wolff-Cope Rearrangement 
A versatile and effective method for constructing functionalized seven- and eight-membered 
carbocycles is the ring-expansion of cis-1,2-divinylcyclobutanes and cis-1,2-divinyl-cyclopropanes 
via [3,3]-sigmatropic Cope rearrangements (Scheme 5.12). Starting around 1980, these 
rearrangements have proved a rapid and reliable route particularly to eight-membered carbocycles 
and have found widespread use in total synthesis.426 The thermal rearrangements of 
divinylcyclobutane 5.53 and divinylcyclopropane 5.54 were first reported by Vogel in 1958427 and 
1960,428 respectively.   
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Scheme 5.12 Strain-releasing Cope rearrangement. 
 
The mechanism of the Cope rearrangement has been subject to thorough investigations. Two 
concerted aromatic transition states are now broadly accepted for the parent 1,5-hexadiene namely: a 
chair-like transition state and a boat-like transition state. For the majority of 1,5-hexadienes the 
chair-like reaction path is dominant.429,430 In the cases of cis-divinylcyclobutane and cis-
divinylcyclopropane, however, it is widely believed that the rearrangement predominantly proceeds 
in a concerted fashion via boat-like transition states where the vinyl groups are situated above the 
cyclobutane and cylopropane ring in an endo fashion (Scheme 5.12).431-437  Based on kinetic 
measurements, DeBoer438 found that the activation energy Ea for the rearrangement of 5.53 into 5.55 
is 24.0 kcal/mol, which has recently been supported by theoretical studies by Ozkan and Zora.439 
Notably, Schneider and Rau discovered that the Ea for the rearrangement of 5.54 into 5.56 is 
approximately 4.0-5.0 kcal/mol lower i.e. 19.0-20.0 kcal/mol.440 This difference in Ea is further 
reflected in the difficulties encountered in trying to prepare 5.54 synthetically. It took thirteen years 
from Vogel’s original disclosure of this transformation until Brown and co-workers441 successfully 
prepared and isolated 5.54. Hence, the strain-releasing driven Cope rearrangement of 5.54 is 
proceeding at much lower reaction temperatures than the Cope rearrangement of 5.53. cis-
Divinylcyclopropane 5.54 has been shown to rearrange into 5.56 with a half-life of approximately 
90 s at 35 oC.441  
 
An early example exploring this type of transformation to prepare cyclooctaenones was disclosed by 
Danheiser.442 Creatively, Danheiser and co-workers used an electrocyclic ring-opening of a 
cyclobutenone to generate a vinylketene derivative that via a [2 + 2] cycloaddition provided a cis-
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divinyl cyclobutane (Scheme 5.13). At elevated reaction temperatures this intermediate underwent a 
Cope rearrangement furnishing 5.57 containing an eight-membered ring.a  
O O O
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5.57
 
Scheme 5.13 Danheiser’s formal [4 + 4] approach to cyclooctaenones.  
 
Recently, Snapper443 described an elegant cascade, which provide a concise entry into [5-8] fused 
ring systems. Ring-opening cross-metathesis afforded access to densely functionalized cis-
vinylcyclobutane derivatives readily undergoing a strain-releasing Cope rearrangement upon 
heating. Moreover, this methodology was implemented at key steps in the total synthesis of (+)-
asteriscanolide (5.59) by Limanto and Snapper in 2000 (Scheme 5.14).444 
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Scheme 5.14 Snapper’s approach to (+)-asteriscanolide (5.59). 
 
In 2003, Stoltz and co-workers413,445 realized the potential of combining the Wolff rearrangement 
and the strain-releasing Cope rearrangement of cis-vinylcyclopropane-type systems in tandem 
(Scheme 5.15). This interest was propelled by synthetic efforts toward guanacastepene A446-448 and 
ineleganolide.449 The requisite cycloheptadienone 5.60 was envisioned to arise from a ketene-Cope 
rearrangement with simultaneous opening of a cyclopropane ring. Ketene 5.61 could stem from 
diazoketone 5.62 through a Wolff rearrangement. 
                                                 
a Interestingly, the three major classes of pericyclic reactions (electrocyclic ring-opening, cycloaddition, and sigmatropic 
rearrangement) are combined in this protocol. 
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Scheme 5.15 The Wolff-Cope rearrangement approach to fused [5-7] systems. 
 
The Wolff rearrangement was first disclosed in 1902.450 Since the initial discovery the 
rearrangement has been studied in detail, and this has revealed numerous protocols facilitating the 
transformation both under photolytic and thermolytic conditions. Accordingly, α-diazoketone 5.63 
was prepared and subjected to a range of conditions including thermolysis in the presence of 
promoters such as Ag2O, AgOBz, CuI, and Cu(0).451-453 While the exploratory studies were met with 
limited success, a key finding from these investigations was that the homologated acid 5.64 was 
produced as one of the byproducts indicating that formation of the desired ketene was taking place 
while the ketene vinyl cyclopropane Cope rearrangement was not occurring (Scheme 5.16).   
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Scheme 5.16 Tandem Wolff-Cope rearrangement. 
 
After extensive experimentation, Stoltz and co-workers decided to employ sonochemical conditions 
originally disclosed by Montero454 for the Wolff rearrangement. These conditions afforded the 
desired Wolff-Cope rearrangement product 5.65 in 95% isolated yield. This silver-catalyzed process 
constitutes a mild protocol allowing for rapid access to highly functionalized fused [5-7] and [6-7] 
ring systems. 
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5.4.2 Retrosynthesis of the AB-Ring Fragment 
In order to probe the feasibility of the key Wolff-Cope rearrangement, we had to devise a 
stereoselective synthesis of a highly functionalized cyclobutene system. To this end we sought to 
implement an intramolecular cycloaddition between cyclobutadiene and an unactivated alkene 
(Scheme 5.17). Furthermore, it was envisioned that the alkene moiety of cyclobutene 5.66 could be 
regioselectively cleaved utilizing termini differentiating ozonolysis and ultimately provide access to 
Wolff-Cope substrate 5.49. We decided to devise a model system 5.67 to investigate the viability of 
the synthetic route leading to Wolff-Cope substrate 5.49 as well as to explore the possibility of 
telescoping the Wolff-Cope methodology to the synthesis of eight-membered rings. It was 
anticipated that this model system would retain most of the synthetic challenges presented by the 
real system, and that most of the intelligence gathered from these endeavors could be transferred to 
our total synthesis of variecolin. 
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Scheme 5.17 Retrosynthesis of the AB-fragment and the AB-fragment model.  
5.4.3 Model Studies on the Wolff-Cope Rearrangement Toward the AB-Ring Systema 
Our synthetic efforts necessitated the synthesis of an appropriate cyclobutadiene-iron species that 
would allow for efficient alcohol alkylation. To this end we decided to target trichloroacetimidate 
5.68 (Scheme 5.18).  We commenced from pyrone 5.69 which have previously been reported by 
Corey and Watt.455 Pyrone 5.69 was transformed into cyclobutadiene-iron complex 5.70 utilizing 
known methods.444 Reduction with DIBAL followed by treatment with sodium hydride and trapping 
with trichloroacetonitrile afforded trichloroacetimidate 5.68 in quantitative yield.  
                                                 
a The work described in chapter 5.4.3 was primarily performed by Ph.D. student Michael R. Krout, hence no 
experimental details will be provided. 
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Scheme 5.18 Synthesis of trichloroacetimidate 5.68. 
 
A copper(I)-catalyzed SN2 displacement of monoacetate (±)-5.71 with p-tolylmagnesium bromide 
smoothly afforded allylic alcohol (±)-5.72 (Scheme 5.19).456 The cycloaddition substrate 5.73 was 
attained in good yield through a lanthanum(III) triflate-catalyzed alkylation with 
trichloroacetimidate 5.68.457 Inspired by oxidative unmasking conditions previously employed by 
Snapper,458 we subjected (±)-5.73 to ceric ammonium nitrate which facilitated liberation of 
cyclobutadiene, that immediately underwent an intramolecular cycloaddition to provide the desired 
cyclobutene (±)-5.74 in good yield. Since the only observable product is the cycloadduct (±)-5.74, a 
concerted mechanism appears to be operative, which is in accordance with previous mechanistic 
investigations conducted by Houk and Snapper.459 This type of transformation was first reported by 
Grubbs460 employing tethered alkynes and has later been widely expanded by Snapper and co-
workers.443,444,458,461,462 
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Scheme 5.19 Intramolecular cycloaddition affording cyclobutene 5.74. 
 
Having established an efficient procedure for preparing cyclobutene 5.74 our focus shifted toward 
regioselective functionalization of the olefin moiety. Faced with this challenge, we decided to 
explore a termini differentiating ozonolysis first reported by Schreiber and co-workers.463 Subjecting 
cyclobutene 5.74 to typical conditions i.e. ozonolysis in NaHCO3-buffered CH2Cl2/MeOH followed 
by dehydration with acetic anhydride and triethylamine furnished a mixture of compounds 
consisting of acetal 5.75 and an inseparable mixture of acetal 5.76 and aldehyde 5.77 (Scheme 5.20). 
The mixture of 5.76 and 5.77 was employed directly in a Wittig methylenation, which provided 
acetal 5.76 as the major product along with minor amounts of the desired alkene 5.78. 
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Scheme 5.20 Termini differentiating ozonolysis. 
 
The formation of regioisomeric acetals 5.75 and 5.76 can be explained by two diverging 
fragmentation pathways (Scheme 5.21 pathway a and b) from the intermediate primary ozonide 
5.79. Breakdown of ozonide 5.79 via retro [2 + 3] cycloaddition along pathway a would locate the 
carbonyl oxide on the more hindered carbon C(8) (5.80), and subsequent nucleophilic attack by 
methanol followed by dehydration generates acetal 5.75. Fragmentation via pathway b would 
generate carbonyl oxide 5.81 which in turn can follow two different reaction pathways. Reaction 
with methanol through path c would after dehydration afford acetal 5.76, whereas initial attack on 
the carbonyl oxide moiety via path d ensued by dehydration generates the desired aldehyde 5.77. 
Despite the desired aldehyde 5.77 being the minor product of this reaction the, required reaction 
pathway b is favored in ~3:1 ratio which can possibly be explained by the sterics of cyclobutene 
5.74.  
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Scheme 5.21 Mechanistic rationale for the ozonolysis of cyclobutene 5.74. 
 
The fact that aldehyde 5.77 was formed as the minor component in the ozonolysis was detrimental 
to our progress toward a Wolff-Cope substrate. However, owing to the isomeric relationship of 
acetal 5.76 and aldehyde 5.77, we reasoned that these species could be equilibrated. It was found 
that treating acetal 5.76 and aldehyde 5.77 with 4 Å molecular sieves shifted the equilibrium in 
favor of the aldehyde (5.76:5.77 ~ 1:3) (Scheme 5.22). The predominant formation of acetal 5.76 
over aldehyde 5.77 during the ozonolysis is most likely a result of the close proximity of the 
carbonyl and the carbonyl oxide moieties on the cyclobutane ring. Moreover, from these results it is 
evident that acetal 5.76 constitutes the kinetic product while aldehyde 5.77 is the thermodynamically 
favored. The mixture of acetal 5.76 and aldehyde 5.77 was treated with 
methyltriphenylphosphonium bromide and potassium tert-butoxide in THF affording the desired 
alkene 5.78 in 40% yield over three steps along with 19% yield of acetal 5.76 which allowed for 
recycling of material through equilibration. Alkene 5.78 was treated with potassium 
trimethylsilanolate464 to afford the corresponding acid 5.82 which was transformed into α-
diazoketone 5.83 through the acid chloride and reaction with diazomethane under standard 
conditions. 
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Scheme 5.22 Synthesis of α-diazoketone 5.83. 
 
With α-diazoketone 5.83 in hand, we commenced studies on the crucial tandem Wolff-Cope 
rearrangement which ultimately would provide access to the eight-membered B-ring of variecolin 
(5.1, Scheme 5.23). Initial experiments revealed that the previously reported413 silver(I)-catalyzed 
sonochemical or photochemical reactions conditions were unsuitable for mediating the requisite 
Wolff-Cope rearrangement. A control experiment conducted in methanol clearly revealed that the 
photochemically induced Wolff rearrangement was rapidly taking place at room temperature since 
the intermediate ketene could be trapped as the corresponding Arndt-Eistert homologated ester in 
high yield. As discussed previously (cf. chapter 5.4.1), the Cope rearrangement of cis-
divinylcyclopropanes in general occurs at a much lower temperature than the corresponding 
rearrangement of cis-divinylcyclobutanes. This led us to investigate photochemical conditions for 
the initial Wolff rearrangement followed by thermolysis of the putative intermediate ketene. To our 
delight, cyclooctenone 5.84 was obtained in 59% yield when diazoketone 5.83 was subjected to 310 
nm light at room temperature followed by thermolysis at 80 oC. The stereochemical relationship in 
the product 5.84 can be accounted for by a boat-shaped transition state. The moderate yield could 
possibly be ascribed to the reactivity of the intermediate ketene and the time between photolysis and 
thermolysis. In order to address this problem we turned toward microwave conditions to promote the 
Wolff rearrangement465 with the hope that the heat developed during irradiation also would facilitate 
the Cope rearrangement. Gratifyingly, the requisite cyclooctene 5.84 was attained very cleanly in an 
excellent 95% yield.   
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Scheme 5.23 Wolff-Cope rearrangement affording cyclooctene 5.84. 
 
In conclusion, these model studies have firmly established that the Wolff-Cope rearrangement 
strategy should be applicable to the synthesis of the core B-ring of variecolin, and furthermore, these 
studies have unraveled a novel means to forge eight-membered rings in synthesis.  
5.4.4 Asymmetric Synthesis of the AB-Ring Fragmenta 
The asymmetric synthesis of the AB fragment required access to alcohol 5.50 in enantiopure form. 
We decided to commence from readily available meso-diacetate466 5.85 employing an enzyme-
catalyzed desymmetrization (Scheme 5.24).467 In the event, treating 5.85 with Novozym 435 under 
buffered conditions afforded the monoester 5.86 in excellent yield and 99% ee. A copper(I) cyanide-
catalyzed SN2 displacement of monoester 5.86 provided a mixture of alcohols 5.87 and 5.88 (95:5). 
This mixture was treated with benzoic acid, triphenylphosphine and DIAD to facilitate a Mitsunobu 
inversion furnishing the allylic benzoate 5.89 with the requisite syn relationship between C(3) and 
C(5).456 Methanolysis of ester 5.89 followed by lanthanum(III)-catalyzed coupling with the 
cyclobutadiene-iron derivative 5.68 furnished the prerequisite intramolecular cycloaddition substrate 
5.90. 
                                                 
a The work described in chapter 5.4.4 was primarily performed by Ph.D. student Michael R. Krout, hence no 
experimental details will be provided. 
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Scheme 5.24 Synthesis of cycloaddition precursor 5.90. 
 
In contrast to the model system (cf. Scheme 5.19), attempts to effect the intramolecular 
cycloaddition by treating 5.90 with ceric ammonium nitrate were met with limited success providing 
complex reaction mixtures. Presumably, this can be ascribed to increased steric hindrance in the 
transition state en route to the cycloadduct caused by the syn-relationship between the methyl group 
at C(3) and the tethered diene. The major competing reaction is likely to be intermolecular 
dimerization of cyclobutadiene, and therefore we decided to employ trimethylamine N-oxide which 
is known to provide a slower and more controlled release of cyclobutadiene compared to ceric 
ammonium nitrate.459 In the event, treating alkene 5.90 with trimethylamine N-oxide in refluxing 
acetone cleanly afforded the desired cycloadduct 5.66 as judged by TLC (Scheme 5.25). However, 
the volatility of this cyclobutene led to low isolated yields. Hence, cyclobutene 5.66 was only 
semipurifieda before being subjected to ozonolysis, acetal equilibration and Wittig methylenation 
providing olefins 5.91 and 5.92 along with acetals 5.93 and 5.94. This unoptimzed four step reaction 
sequence provided the desired alkene 5.91 in 19 % yield. 
                                                 
a The compound was purified by silica-gel chromatography, however, in general the fractions containing the desired 
product was not concentrated down to get a yield. 
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Scheme 5.25 Synthesis of alkene 5.91. 
 
Moreover, acetal 5.93 was of sufficient crystallinity to enable X-ray analysis, providing 
conformation of the relative stereochemistry of this polycyclic fragment (Figure 5.3). 
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Figure 5.3 X-ray structure of acetal 5.93. 
 
Alkene 5.91 was hydrolyzed using potassium trimethylsilanolate affording acid 5.95 in good yield 
(Scheme 5.26). Based on this intermediate, we decided to target two different AB-ring fragments 
5.96 and 5.47. The synthesis of α-diazoketone 5.97 was smoothly achieved by reacting acid 5.95 
with oxalyl chloride in the presence of a catalytic amount of DMF followed by treatment with 
diazomethane. When subjected to our optimized Wolff-Cope conditions this α-diazoketone 5.97 
afforded cyclooctene 5.96 cleanly in 79% yield. To access the AB fragment with a preinstalled 
methyl group at C(11, 5.47), we employed diazoethane. Unfortunately, this procedure provided the 
corresponding α-diazoketone 5.49 in reduced yield, and all attempts to improve on this were 
unfruitful. The first attempt to convert α-diazoketone 5.49 into the requisite cyclooctene 5.47 
implementing the microwave-mediated Wolff-Cope rearrangement gave 5.47 in a moderate 26% 
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yield along with multiple byproducts. In order to increase the yield, a range of different solvents 
were tested, and it was found that by switching to the less-polar solvent heptane, the desired 
cyclooctene 5.47 could be attained in 42% isolated yield.a 
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Scheme 5.26 Synthesis of the α-diazoketones and Wolff-Cope rearrangement. 
 
A key observation from these experiments is the significant drop in the yield of the Wolff-Cope 
product when introducing an α-alkyl substituent. This reduced yield combined with the detection of 
multiple byproducts suggests that competing reaction pathways are functioning under the reactions 
conditions. The Wolff-rearrangement has been subject to thorough mechanistic investigations, and it 
is widely accepted that two different pathways contribute to the formation of ketene 5.98 (Scheme 
5.27).452,468,469 The ketene can be formed either via a concerted mechanism expelling nitrogen as the 
substituent R1 migrates or through the intermediacy of an α-carbonyl carbene.  
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Scheme 5.27 Competing pathways of the Wolff-rearrangement. 
                                                 
a Ongoing efforts are directed toward improving the yield of this reaction as well as elucidating the structure of the major 
byproducts. One major byproduct seems to stem from intramolecular cyclopropanation i.e. carbene-like reactivity. 
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The factors governing whether the concerted path or the carbene path are operational are thus not 
completely understood. Nonetheless, it has been shown that the conformation of the O=C–C=N2 
group (i.e. s-Z versus s-E) has a significant influence on which pathway is dominating. Kaplan and 
co-workers470-472 have previously shown that the s-E conformation favors the carbene pathway, and 
in the case of α-diazoketone 5.49, the presence of an α-methyl group may enforce the adoption of 
an s-E conformation around the diazo-group, which could lead to carbene-like reactivity and in turn 
byproducts resulting from e.g. C-H insertion, 1,2-H shifts, and cyclopropanation. The mechanistic 
picture, however, is not clear-cut since some α-diazo ketones known to exist in the s-E 
conformation produce ketenes easily.473  
 
In summary, the successful synthesis of the AB-ring fragment has showcased the potential for 
utilizing the Wolff-Cope strategy in the construction of the central eight-membered ring of 
variecolin. Moreover this constitutes the first example of an α-substituted diazoketone undergoing 
the tandem Wolff-Cope rearrangement.  In addition, this route will provide material to support our 
ongoing studies focusing on fragment coupling studies toward completing the total synthesis of 
variecolin. 
 
5.5 Catalytic Asymmetric Synthesis of the D-ring Fragment 
5.5.1 Background for the Tsuji Allylation  
Quaternary stereocenters are ubiquitous in a wide variety of natural products with important 
structural and biological properties. As a result, the asymmetric catalytic construction of all-carbon 
quaternary stereocenters remains a significant challenge to synthetic chemists. Arguable the biggest 
impediment in devising such a method is to overcome the severe steric encumbrance faced in the 
bond-forming event. Therefore only a relatively limited range of both highly selective and mild 
methods are available.474-483 Palladium catalyzed asymmetric allylic alkylation also known as the 
Tsuji-Trost reaction has become one of the most efficient ways to construct C-C bonds with high 
levels of enantioselectivity. The stoichiometric allylic allylation was discovered more than 40 years 
ago by the Tsuji group and subsequently developed into a catalytic version by Trost and co-workers. 
Later developments by Hayashi,484 Ito,485-488 Trost,489-491 and Dai492 and their co-workers have led to 
asymmetric allylic alkylation of prochiral stabilized enolates providing an important method for 
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synthesizing all-carbon quaternary stereocenters (Scheme 5.28). In the realm of asymmetric allylic 
alkylation these reactions are rather unusual since the newly formed stereocenter is situated on the 
nucleophilic coupling partner.493,494 
O
EWG
EWG = CO2R, CN, Ph, etc.
+ OAc
Pd(0), L*
base
O
EWG
 
Scheme 5.28 Asymmetric allylic alkylation with stabilized enolates. 
 
One important limitation that has hampered this methodology is the requirement that the carbon 
nucleophile is a soft carbanion, typically derived from stabilized enolates 25. With the disclosure of 
protocols from Trost and co-workers495 and Dai and co-workers496 the first steps to overcome this 
impediment were taken (Scheme 5.29). Utilizing the C2-symmetric ligands 5.99 and 5.100 Trost495 
and Dai496, respectively, were able to demonstrate that the asymmetric allylation of tetralone 5.101 
was feasible through the lithium enolate (Scheme 5.29). 
O
+ OR
[η3-C3H5PdCl]2
5.99 or 5.100
LDA
O
R = COCH3, ligand 5.99:             (99% yield, 88% ee)
R = CO2CH2CH3, ligand 5.100:   (95% yield, 80% ee)
NH HN
O O
NH HN
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PPh2 Ph2P
Fe PPh2 Fe
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Scheme 5.29 Asymmetric allylic alkylation with unstabilized enolates. 
 
One inherent limitation for these later protocols is that there must be only one acidic site or a large 
pKa-difference between two acidic sites in the system to circumvent formation of mixtures of 
allylated products due to in situ enolate scrambling. Based on the pioneering work of Tsuji and co-
workers497-500 and Saegusa and co-workers,501 this caveat was finally overcome by elegant 
contributions from Stoltz’ and Trost’ laboratories starting in the mid 2000s. In 2004 Behenna and 
Stoltz explored chelating P/N ligands to develop an enantioselective Tsuji-allylation from allyl enol 
carbonate substrates relying on in situ generation of the unstabilized enolate, thus avoiding the use 
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of stoichiometric amounts of base and enolate scrambling (Scheme 5.30).415 Specifically, the tert-
butyl phosphinooxazoline (t-BuPHOX, 5.102) ligand framework developed in the 1990s by Pfaltz502 
and Williams503 led to the formation of 5.103 in excellent yield and with high ee. Interestingly, a 
range of solvents including ethereal (THF, p-dioxane, Et2O, tert-butyl methyl ether, i-Pr2O), 
aromatic (benzene, toluene), and carbonyl-containing (EtOAc) proved to be almost equally 
effective. Later developments by Stoltz and co-workers extended the asymmetric method 
methodology to encompass silyl enol ethers415,504 and β-ketoesters.414 Notably, the ketones produced 
from allyl β-ketoesters, allyl enol carbonates, and silyl enol ethers were formed in nearly identical 
yield and ee. The asymmetric alkylation employing racemic β-ketoesters involves a stereoablative 
enantioselective transformation.505 Initial deallylation of substrate of the β-ketoester followed by 
decarboxylation provides the prochiral enolate, which is enantioselectively alkylated. 
 
 
Scheme 5.30 Enantioenriched cyclic ketones from allyl enol carbonates, silyl enol ethers and β-ketoesters. 
 
In early 2005 Trost described a similar technology using the uniquely shaped bidentate phosphine 
ligand 5.104. This method was applied to a number of cyclic ketones two of which contained more 
than one acidic site (Scheme 5.31).506 Interestingly, p-dioxane proved to be the superior solvent for 
these reactions suppressing overalkylation for a range of substrates. Further studies by the Trost 
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laboratory revealed that this catalyst system was also applicable to acyclic enol carbonates and 
vinylogous thioester enolates generated from the corresponding allyl β-ketoester.  
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Scheme 5.31 Implementation of 5.104 for asymmetric allylation of unstabilized enolates. 
 
A notable feature of this chemistry is that the major enantiomer of the cycloalkanone product is the 
opposite when compared to previous work using similar ligands in the same enantiomeric series and 
preformed lithium enolates (cf. Scheme 5.29). This reversal in stereochemical outcome suggests that 
different mechanisms are operating.  
 
Hitherto, the asymmetric Tsuji allylation have seen relatively sparse use in total synthesis, thus most 
of the examples originate from the Stoltz507-512 and Trost513-516 laboratories. However, the prevalence 
of all-carbon quaternary stereocenters in natural products provides an excellent testing ground for 
the enantioselective Tsuji allylation. One class of compounds that pose this structural feature is a 
group of diterpernoids known as the cyanthins which include the tricyclic ketone (−)-cyanthiwigin F 
(5.105; Scheme 5.32). Recently, a double catalytic enantioselective Tsuji allylation took center stage 
in the enantioselective synthesis of (−)-cyanthiwigin F (5.105) by Enquist and Stoltz.510 
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Scheme 5.32. Double catalytic enantioselective Tsuji-allylation in the total synthesis of (–)-cyanthiwigin F (5.105). 
 
Treatment of a diastereomeric mixture (or either pure diastereomer) of bis(β-ketoester) 5.106 with 
Pd(dmdba)2 (5 mol%) and 5.102 (5.5 mol%) provided the bisalkylated products (R,R)-5.107 and 
meso-5.108 in a 4.4:1 diastereomeric ratio. The ee of the major diastereomer was found to be 99% 
ee. Two all-carbon quaternary stereocenters were formed in this single catalytic step, thus 
addressing what is arguable the most challenging structural features of (−)-cyanthiwigin (5.105) in 
an elegant and highly efficient manner. Notably, the ee of the desired diastereomer (R,R) was 99% 
and this increase occurs by virtue of the heterochiral diastereomer meso-5.108 acting as a “buffer” 
against formation of the undesired enantiomer i.e. the major diastereomer has experienced statistical 
amplification of its ee in line with the Horeau principle.517,518 Conversion of bisketone 5.107 into 
5.105 was achieved in six steps providing (−)-cyanthiwigin F in nine steps from diallyl succinate. 
 
The mechanistic scenario of the Tsuji-allylation has hitherto not been subject to thorough 
investigations. In 1980 Saegusa and co-workers reported cross-over with a non-enantioselective 
system and allyl β-ketoesters in DMF, however cross-over was suppressed when the reaction was 
conducted in benzene.501 To account for these results Saegusa proposed the catalytic cycle depicted 
in Scheme (5.33). The reaction is initiated by coordination of the allyl moiety to palladium followed 
by oxidative addition providing π-allylpalladium(II) compound A. This compound undergoes 
decarboxylation to afford a complex with the enolate coordinated to palladium B which upon 
reductive elimination could afford the allylated product via an inner-sphere process. Alternatively, 
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dissociation of the enolate forms a cationic π-allylpalladium(II) complex C which when attacked by 
the enolate anion generates the product by an outer-sphere process.           
 
R
O O
O
[PdoLn]
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R
R
O O
O
PdII
Ln
R
O
PdII
Ln
CO2
R
O O
O
LnPdII+
R
O
LnPdII+
cross-over
cross-over
outer-sphere
inner-sphere
ABC
 
Scheme 5.33 Possible catalytic cycle for the decarboxylative allylation. 
 
Later investigations by Stoltz and co-workers have shown scrambling of allyl termini and complete 
cross-over between differently deuteurated allyl enol carbonates in THF, p-dioxane and benzene 
suggesting the existence of a “discrete ketone enolate” (Scheme 5.34a). In contrast to these results 
Trost and co-workers observed only minor cross-over between allyl and crotyl carbonates (Scheme 
5.34b). The latter observation may be explained by the existence of a solvent caged contact ion-pair. 
This rationale is further substantiated by the fact that utilizing p-dioxane solvent was important in 
order to suppress overalkylation and enolate scrambling.a 
                                                 
a p-Dioxane has been shown to form solvent-caged contact ion-pairs more efficiently than THF. (Hogen-Esch, T. E.; 
Smid, J. J. Am. Chem. Soc. 1965, 87, 669-670). 
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Scheme 5.34 Cross-over experiments conducted by a) Stoltz and b) Trost. 
 
The cross-over experiments, however, are not instructive as to the mechanism of the C-C bond 
forming event or the origin of enantioselectivity. Recent computational modeling on the PHOX/Pd 
system supports the possible intermediacy of an inner-sphere palladium enolate B (cf. Scheme 5.33) 
rather than the outer-sphere nucleophile typical of traditional π-allyl alkylations.519 This would be 
consistent with the high regiochemical fidelity observed throughout these studies and could be an 
explanation as to why high ee’s can be obtained without prochiral allyl fragments.  
5.5.2 Retrosynthesis of the D-Ring Fragment 
In targeting the acylcyclopentene 5.48 we envisioned a scission of the C(15)-C(16) double bond 
employing an intramolecular aldol condensation of ketoaldehyde 5.109 (Scheme 5.35). 
Ketoaldehyde 5.109 could arise from cycloheptanone 5.110 which could result from vinylogous 
ester 5.51 utilizing a Stork-Danheiser-type transformation.520 This vinylogous ester would ultimately 
be available by enantioselective decarboxylative alkylation of β-ketoester 5.52.      
O
X
O
Oi-Bu
OO
O
O
Oi-Bu
O
O
5.48 5.109 5.110
5.51 5.52
15
16
 
Scheme 5.35 Retrosynthesis of the D-ring fragment. 
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Even though the γ-disubstituted acylcyclopentane moiety has a high prevalence among terpene 
natural products, the synthesis of this type of building blocks has attracted very little attention. To 
the best our knowledge there is only one prior example detailing studies on the synthesis of racemic 
acylcyclopentenes.521  
5.5.3 Asymmetric Synthesis of the D-Ring Fragmenta 
Implementation of the asymmetric decarboxylative Tsuji-allylation required efficient access to β-
ketoester 5.52. Although diketone 5.111 is commercially available, we decided to initiate the 
synthesis from cyclopentanone, since 5.111 decomposes upon storing and in addition its cost was 
prohibitive to our synthetic endeavors.b  There have been several synthetic approaches to diketone 
5.111.522-528 However, we settled for the synthetic sequence developed by Ragan and co-workers529 
since it avoids the use of heavy metal reagents and most importantly is amenable to large-scale 
preparation. Utilizing a sequence consisting of TMS-enolether preparation, [2+2] cycloaddition with 
in situ generated dichloroketene, and subsequent zinc-AcOH mediated reduction we were able to 
routinely prepare cycloheptadione 5.111 of suitable quality for further reactions on a 25 g scale in an 
overall yield of 79% starting from cyclopentanone (Scheme 5.36).  
O
Oi-Bu
O
O
O TMSO
O
ClCl
O
Oi-Bu
5.1115.112
1. TMSCl, Et3N, NaI
    CH3CN, 23 oC
2. Cl2CHCOCl, Et3N
    hexanes, 23 oC
Zn, AcOH, H2O
isopropyl alcohol
-10 to 23 oC
O
O
PPTS (cat.), i-BuOH
PhMe, 110 oC, Dean-Stark
(66% yield, four steps)
1. LDA, THF, -78 oC
    then
2. MeI, Cs2CO3
    CH3CN, 80 oC
NC O
O
(79% yield)
O
O
5.113
5.52
5.114
 
Scheme 5.36 Synthesis of β-ketoester 5.52. 
 
As previously noted by Ragan530 we observed that the success of the zinc-AcOH reduction relied 
heavily on temperature control during the addition of AcOH to the mixture of cyclobutanone 5.112, 
isopropyl alcohol and zinc. If the temperature rose above 0 oC we observed 5-20% formation of 
                                                 
a The research described in chapter 5.5.3 was carried out in collaboration with Ph.D. student Michael R. Krout. 
b 1,3-Cycloheptanedione is commercially available the approximate price per mole is $31,000. Adopted from Aldrich 
May 22th 2009.    
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acylcyclopentanone 5.113 which most likely occurs from C-C bond fragmentation (cleavage of 
silyl) prior to complete dechlorination. The formation of this byproduct could be almost completely 
suppressed when a mixture of MeOH and ice was deployed for efficient cooling. Reaction of 1,3-
cycloheptanedione 5.111 with iso-butanol under Dean-Stark conditions in the presence of PPTS 
smoothly produced vinylogous ester 5.114. Formation of β-ketoester 5.52 was achieved using 
acylation conditions inspired by work from Mander and co-workers.531 Vinylogous ester 5.114 was 
treated with LDA and allyl cyanoformate furnishing the C-acylated product cleanly as judged by 1H 
NMR of the crude reaction mixture. This material was exposed to MeI and Cs2CO3 in CH3CN 
affording β-ketoester 5.52 in 79% yield over the two steps. 
 
With β-ketoester 5.52 in hand the stage was set for installation of the quaternary stereocenter at 
C(14) implementing the asymmetric decarboxylative allylation. When β-ketoester 5.52  was treated 
with Pd2(pmdba)3 and (S)-t-BuPHOX 5.102 under standard allylation conditions414 it was readily 
converted into allyl ketone ester 5.51 in good yield and 84% ee (Table 5.2, entry 1). The absolute 
stereochemistry depicted for 5.51 is based on analogy to previously reported substrates. This initial 
result serves as a promising lead for further optimization and emphasizes the utility of vinylogous 
ester substrates in the asymmetric Tsuji-allylation. Although recent studies have revealed that the 
electronics of dba-type ligands can have a significant influence on the reaction rate of palladium 
couplings,532-535 the decision to implement Pd2(pmdba)3 as the source of palladium(0) was founded 
on practical considerations: dibenzylidene acetone (dba) was difficult to separate from the ketone 
product 5.51 while the more polar para-methoxy dibenzylidene acetone (pmdba) was easily 
removed.a In order to increase the ee we investigated a range of different solvents. Compared to 
previous results (cf. chapter 5.5.1) the employment of different solvents had a notable effect on the 
enantioselectivity. In the event we observed an inverse relationship between solvent dielectricity and 
enantioselectivity, i.e., a significant increase in ee from 84% to 88% manifested itself when going 
from THF to PhMe (Table 5.2, entries 1 to 5).  
 
                                                 
a Control experiments have revealed that Pd2(dba)3, Pd(dmdba)2, and Pd2(pmdba)3 provide yields and ee’s within 
experimental error. 
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Table 5.2 Ligand screen for the enantioselective Tsuji-allylation. 
entry ligand solventa yield (%)b ee (%)
1 5.102 THF 94 84
2 5.102 TBME 88 85
3 5.102 Et2O 93 86
4 5.102 PhH 84 86
5 5.102 PhMe 91 88
6 5.115 PhMe 57c 90
7 5.116 PhMe 77 72
O
Oi-Bu
O
O Pd2(pmdba)3 (2.5 mol%)
ligand (6.25 mol%)
solvent 0.1 M, 30 oC
O
Oi-Bu
5.52 (−)-5.51
a Identical results obtained at  0.2 M in 5.52. b Isolated 
yield. c 5 mol% of Pd2(pmdba)3 and 12.5 mol% 5.115
required to reach complete conversion.
Ph2P N
O
Ph2P N
O
(4-CF3-C6H4)2P N
O
CF3
5.102 5.115 5.116  
 
In an attempt to further increase ee we exposed β-ketoester 5.52 to the electron deficient phosphine 
5.115.536 This did in fact furnish an increase in ee to 90%, however the yield dropped significantly 
and it was necessary to use 10 mol% palladium to obtain reasonable conversion of the substrate 
(Table 5.2, entry 6). Furthermore the active complex generated from ligand 5.115 and Pd2(pmdba)3 
appeared to be highly sensitive to air. Employing the novel naphthyl-based phosphine 5.116 
unfortunately lead to a decrease in yield and ee. Consequently, we settled for a catalyst system 
consisting of Pd2(pmdba)3 and (S)-t-BuPHOX 5.102 in PhMe which provided the best compromise 
between yield, ee, and practicality.     
O
Oi-Bu
O
O Pd2(pmdba)3 (1.24 mol%)
5.102 (3.12  mol%)
PhMe (0.2 M), 30 oC
(98% yield, 88% ee)
O
Oi-Bu
36 mmol scale
(−)-5.51
 
Scheme 5.37 Large scale asymmetric Tsuji-allylation. 
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For scale-up purposes we found that the catalyst loading could be reduced to 1.2 mol% and the 
substrate concentration increased to 0.2 M thus keeping the catalyst concentration constant. The best 
yield was obtained when the reaction was conducted on 36 mmol scale affording the desired ketone 
5.51 in an excellent 98% yield and 88% ee (Scheme 5.37). 
 
With a route to the enantioenriched β-ketoester 5.51 firmly established, ways to perform the ring 
contraction to 5.117 was explored.  Treating β-ketoester 5.51 with lithium aluminium hydride 
followed by an acidic work-up smoothly provided a mixture of β-hydroxyketoester 5.118 and the 
desired cycloheptanone 5.119 in a 10:1 ratio (Scheme 5.38).   
O
Oi-Bu
LiAlH4
Et2O, 0 oC
then 10% HCl
(99% yield)
HO
O O OLiO(t-Bu)
t-BuOH
40 oC
(53% yield)
10   :   1
+
5.1175.118 5.119
 
Scheme 5.38 Initial investigations on the ring contraction.  
 
When a (10:1) mixture of β-hydroxyketoester 5.118 and cycloheptanone 5.119 was exposed to 
standard basic aldol conditions the requisite ring-contraction product 5.117 was obtained along with 
minor amounts of cycloheptanone 5.119. This preliminary result suggested that cycloheptanone 
5.119 was not readily being converted into acylcyclopentene 5.117.  Moreover, these compounds 
were very difficult to separate using silca-gel chromatography. Hence in order to improve the yield 
of this ring contraction, we decided to separate the mixture of β-hydroxyketoester 5.118 and 
cycloheptanone 5.119 and subject 5.118 to a range of different mild aldol conditions (Table 5.3). 
When the reaction was conducted in t-BuOH in the presence of a variety of tert-butoxide bases, 
LiO(t-Bu) presented itself as a good promoter for this retro-aldol aldol sequence (entries 1-4). 
Notably, switching to even milder reaction conditions using Cs2CO3 or LiOH as base and the non-
nucleophilic alcohol CF3CH2OH537 as additive the reaction cleanly provided the prerequisite product 
5.117 (entries 5 to 11).  
 
5 Studies Toward the Asymmetric Total Synthesis of Variecolin 
 158
Table 5.3 Optimization of the ring-contraction. 
entry base additive solvent(0.1 M) T(°C) % yield
a
1 LiO(t-Bu) - t-BuOH 40 68
2 NaO(t-Bu) - t-BuOH 40 52
3 KO(t-Bu) - t-BuOH 40 38
4 LiO(t-Bu) - THF 40 64
5 Cs2CO3 - THF 60 15
6 Cs2CO3 t-BuOH MeCN 40 32
7 Cs2CO3 i-PrOH MeCN 40 34
8 Cs2CO3 CF3CH2OH MeCN 40 71
9 Cs2CO3 CF3CH2OH THF 60 79
10 LiOH CF3CH2OH MeCN 40 27
11 LiOH CF3CH2OH THF 60 80
HO
O OO
base, additive
 solvent, temp
not observed
5.118 5.117 5.119
a Yield judged by 1H NMR.  
 
In scaling up this reaction we settled for the LiOH-mediated ring-contraction (Scheme 5.39). Using 
these optimized conditions β-hydroxyketoester 5.118 was isolated in 90% yield as a semicrystalline 
compound. Subsequent treatment with LiOH furnished acylcyclopentene 5.117 in 96% yield. 
Importantly, 5.117 was somewhat volatile so care had to be taken when concentrating this 
compound after silca-gel chromatography.  
O
Oi-Bu
LiAlH4
Et2O, 0 oC
then 10% HCl
(90% yield)
HO
O OLiOH
CF3CH2OH
THF, 60 oC
(96% yield)(-)-5.51
88% ee
5.118
1.5:1 dr
5.117
88% ee
 
Scheme 5.39 Optimized synthesis of acylcyclopentene 5.117. 
 
Even though the asymmetric Tsuji-allylation provided enone 5.117 with high ee it was desirable to 
improve the ee of this material. Until this point all synthetic intermediates had been oils, hence it 
was decided to explore ways to attain crystalline material from 5.117. Previous experience from the 
Stoltz laboratory415,507 had shown semicarbazone derivatives to be suitable for this purpose. To our 
delight semicarbazone 5.120 was obtained as a white solid when enone 5.117 was treated with 
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semicarbazide hydrochloride in the presence of methanol, H2O and pyridine at reflux providing 
5.120 in (84-86)% yield, the ee had increased slightly to 91% (determined by converting 5.120 back 
into enone 5.117) (Scheme 5.40). After some experimentation it was found that utilizing a biphasic 
system with NaOAc as the base consistently provided yields above 90% and the desired 
semicarbazone could easily be recovered by filtration when the reaction mixture had cooled to 
ambient temperature, again a slight increase in ee to 91% was observed.  
O N
H
NH2N
O
N
H
NH2N
O
O
(+)-5.120
(+)-5.117
(+)-5.120
semicarbazide HCl
NaOAc, H2O, 60 oC
(92% yield)
hexanes/PhMe (1:1)
recrystallize twice
(68% yield)
6 M HCl (aq)
THF/H2O, 23 oC
(93% yield)
91% ee 98% ee
98% ee
(+)-5.117
88% ee
 
Scheme 5.40 Enantioenrichment of enone 5.117. 
 
In order to improve the ee further, suitable recrystallization conditions had to be established. It took 
significant experimentation to discover that the semicarbazone 5.120 could be recovered in 68% 
yield providing a satisfying 98% ee after two recrystallizations from a mixture of hexanes and PhMe 
(1:1). Notably, stirring during the crystallization proved to be essential for the efficiency of the ee 
improvement. Without stirring product recovery was comparable, however an unstirred 
crystallization provided semicarbazone 5.120 of 94% ee, while the stirred crystallization provided 
semicarbazone of 98% ee (both after two crystallizations). The enantioenriched semicarbazone was 
easily reverted back into enone 5.117 by treatment with aqueous HCl at ambient temperature.a   
 
Thus far the absolute configuration of β-ketoester 5.51 and derivatives has been based on analogy. 
To verify this assignment it was decided to derivatize semicarbazone 5.120 and thereby attain the 
absolute configuration through X-ray crystallographic analysis. Initial attempts to derivatize 
                                                 
a These experiments served to illustrate that it was possible to increase the ee of 5.117 by derivatization/recrystal-
lization. In general, however, the 88% ee material was carried on.  
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semicarbazone 5.120 with (+)-isopinocampheylamine were met with limited success since the 
resulting derivative 5.121 was attained as a foam which even after extensive screening of 
crystallization conditions would not afford crystals of X-ray quality (Scheme 5.41). Consequently, 
we focused our attention on the semicarbazone derivative 5.122 which was easily obtained by 
heating 5.120 dissolved in m-xylene in the presence of 4-iodobenzyl amine. It was found that slow 
vapor diffusion of pentane into a chloroform solution of 5.122 furnished crystals suitable for X-ray. 
Satisfyingly, the X-ray structural analysis confirmed the absolute configuration of the Tsuji-
allylation.  
N
H
NH2N
O
(+)-5.120
91% ee
N
H
N
H
N
O
I
I
NH2
m-xylene, 150 oC
(89% yield)
 
N NH
O
HN
I
N
H
N
H
N
O m-xylene, 150 oC
(84% yield)
NH2
 foam crystalline solid
5.1225.121
 
Scheme 5.41. Determination of the absolute configuration of the D-ring fragment. 
 
With access to large quantities of enone 5.117, more than 15 g was prepared underscoring the 
efficiency of the synthetic route, we began searching for an appropriate blocking group for the 
carbonyl moiety of this enone. The blocking group should withstand conditions allowing for 
oxidative cleavage, reduction, and subsequent iodination. Initially we tested the dioxolane 5.123 
formed by treating acylcyclopentenone 5.117 with ethylene glycol and PPTS under Dean-Stark 
conditions (Scheme 5.42). a We were aware of the fact that this dioxolane might be easily 
                                                 
a These initial experiments with 5.123 were in fact carried out with racemic material, but to avoid confusion the correct 
stereochemistry is shown. This D-ring fragment has been synthesized using the route described to the enantioenriched 
fragment. The only difference was that the Tsuji-allylation was performed with an achiral version of the PHOX-ligand 
(cf. Chapter  5.8.4 for ligand syntheses). 
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hydrolyzed since it was situated in an allylic position. Therefore we decided to employ modified 
Johnson-Lemieux538 conditions for the oxidative cleavage i.e. OsO4-NaIO4 in various solvents 
mixtures e.g. organic solvent- phosphate buffer (pH = 7.0) (1:1 to 3:1), comprising organic solvents 
such as THF, acetone, and p-dioxane. This resulted in a very slow reaction exhibiting low selectivity 
for the terminal alkene. Moreover, the dioxolane was readily hydrolyzed under these conditions as 
revealed by TLC.  
O
OO
OO
PPTS, PhMe
110 oC, Dean-Stark
(82% yield)
HO OH
HO
OH
PPTS
PhMe, 110 oC
(77% yield) OH
OO
OH
OO
OsO4 (5 mol%)
NaIO4, 2,6-lutidine
p-dioxane/H2O (1:1), 0 oC
then NaBH4, 0 oC
(86% yield)
5.123
5.124 5.125
5.117
88% ee
 
Scheme 5.42 Regioselective oxidative cleavage. 
 
A recent report by Jin and co-workers539 stated how the addition of pyridine and 2,6-lutidine 
significantly increased the reaction rate of the OsO4-NaIO4-mediated oxidative cleavage. Hence we 
decided to test pyridine and 2,6-lutidine with OsO4-NaIO4 in a 3:1 mixture of p-dioxane-H2O. This 
did afford a fast conversion of 5.123 even at 0 oC (full conversion within 2 h), however we still 
observed hydrolysis of the dioxolane. Accordingly, it was determined to employ the acetal 5.124 
generated from neopentyl glycol and 5.117. Delightfully, dioxane 5.124 cleanly provided the 
oxidative cleavage when subjected to 2,6-lutidine with OsO4-NaIO4 in a 3:1 mixture of p-dioxane-
H2O at 0 oC as judged by 1H NMR of the crude mixture. Furthermore when this reaction mixture 
was quenched with NaBH4 the prerequisite alcohol 5.125 was attained in excellent yield. This one-
pot protocol constitutes a highly efficient way to transform a terminal alkene into the corresponding 
one-carbon shortened primary alcohol.  
 
Having identified an efficient route to the primary alcohol 5.125 we were eager to advance material 
toward the D-ring fragment. Acylcyclopentene 5.117 was protected implementing the optimized 
conditions which proceeded smoothly on gram scale, however it was found that the reductive work-
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up of the oxidative cleavage was impractical on more than 1 gram scale since the exothermic nature 
of the quench necessitated slow addition of NaBH4 (Scheme 5.43). In addition the presence of large 
amounts of dissolved borate salts eventually mediated hydrolysis of the acetal protecting group. 
Thus we decided to implement a two-step procedure involving a crude work up of the intermediate 
aldehyde followed by standard NaBH4 reduction at -21 oC. The ensuing primary alcohol 5.125 was 
easily converted into the D-ring fragment 5.126 by treatment with PPh3, imidazole and iodine. 
O
OO
OH
OO
PPTS, PhMe
110 oC, Dean-Stark
(82% yield)
HO OH
I
OO
1. OsO4 (2 mol%), 2,6-lutidine
    NaIO4, p-dioxane/H2O (1:1)
2. NaBH4, EtOH, -21 oC
(77% yield, two steps)
I2, Ph3P, imidazole
CH2Cl2, 0 to 23 oC
(92% yield)
5.124 5.125
5.126
14
5.117
88% ee
 
Scheme 5.43 Completion of the D-ring fragment. 
 
In summary, an efficient route affording the D-ring fragment 5.126 in high ee has been developed 
starting from easily available 1,3-cycloheptadione. Key to this achievement was the successful 
implementation of the enantioselective decarboxylative allylation of a seven-membered vinylogous 
ester setting the all-carbon quaternary stereocenter at C(14) and the realization of the retro-aldol-
aldol ring-contraction forming the five-membered D-ring. 
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5.6 Fragment Coupling and Radical Cyclization Studies 
As previously detailed we envisioned that variecolin could be simplified into two major fragments 
by disconnection of the C-ring, coupled by a reductive alkylation/cyclization sequence in the 
forward sense (Scheme 5.44).  In order to evaluate the potential of the coupling reaction for the 
union of our two major fragments 5.47 and 5.126 as well as the crucial conjugate intramolecular 
radical cyclization, model studies were undertaken. As our model we settled for the eight-membered 
enone 5.127. While this enone 5.127 is far from as rigid as the AB-ring fragment 5.47 we 
anticipated that the conformational constraints imposed on 5.127 by transannular strain would 
display the obstacles concerned with the conjugate reduction/alkylation sequence.  
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H
H
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O
H
H
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H
O
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O
O
O
coupling of AB and D fragment
model coupling of 5.127 and D fragment
5.47
5.126
5.127 5.126
 
Scheme 5.44 Variecolin end-game model. 
5.6.1 Model Studies on the Reductive Coupling 
Our model enone 5.127 was readily available following the procedure of Conia and co-workers.540 
Cycloheptanone was converted into the corresponding silyl enol ether utilizing standard conditions. 
The ensuing enol ether was reacted with chlormethylcarbene generated in situ from 1,1-
dichloroethane and n-BuLi to afford a diastereomeric mixture of chlorosiloxycyclopropanes 
(Scheme 5.45). Heating this material in methanol and triethyl amine provided the desired 
cyclooctenone 5.127 rearrangement and concomitant elimination of TMSCl.  
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Initially we sought to mediate the coupling of our model enone 5.127 and the D-ring fragment 5.126 
by conjugate reduction and trapping the enolate in situ. We deployed a range of different conditions 
known to facilitate 1,4-reduction including: Stryker´s reagent [(Ph3P)CuH]6,541,542 MeCu 
(cat.)/DIBAL,543 L-selectride,544 K-selectride,545 and CuI/n-Bu3SnH/LiCl546 and attempted to trap 
the generated enolate with the highly potent electrophile MeI. However, we either observed no 
reaction or 1,2-reduction.  
O
1. TMSCl, NaI, Et3N
    CH3CN, 23 oC
2. Cl2CHCH3, -43 to 0oC
3. Et3N, MeOH, 65 oC
(68% yield over three steps)
O
5.128 (0.5 mol%)
PhMe2SiH
PhH, 80 oC
(39% yield)
OSiMe2Ph
Si O Si
2
Pt
Karstedt's catalyst (5.128)
5.127 5.129
 
Scheme 5.45 Initial attempt to hydrosilylate enone 5.127. 
 
The fact that our attempts to achieve conjugate reduction utilizing metal hydrides provided mainly 
1,2-reduction seemed to indicate that the conjugation between the carbonyl and the α,β-alkene is 
less pronounced than for the corresponding five- and six-membered ring systems that readily 
undergoes 1,4-reduction.541-546 A plausible explanation is that the eight-membered ring, in order to 
allow for efficient overlap between the two π-orbital systems, would have to adopt a ring 
conformation disfavored by transannular strain.547 Recognizing this impediment we shifted our 
focus to implementing a two step procedure involving transition metal catalyzed hydrosilylation and 
subsequent alkyl lithium mediated alkylation. Our initial investigations were aimed at applying the 
hydrosilylation procedure developed by Johnson and Raheja548 to form triisopropsilyl enol ethers 
from cyclic enones using Karstedt’s catalyst 5.128 and (i-Pr)3SiH. After surveying a range of 
different silanes (i-Pr)3SiH, Et3SiH and PhMe2SiH we found that exposing enone 5.127 to 0.5 mol% 
5.128 and PhMe2SiH provided the desired silyl enol ether 5.129 in a moderate yield. Unfortunately 
all attempts to improve this yield further were futile. Therefore a selection of Rhodium(I) complexes 
including, Wilkinson’s catalyst Rh(PPh3)3Cl,549 Browns catalyst ([Rh(NBD)(DIPHOS-4)]BF4]),550 
and HRh(PPh3)4551,552 known to facilitate similar reactions were tested in order to find a catalyst that 
would mediate this transformation. Of the catalysts tested HRh(PPh3)4 proved superior providing the 
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desired silyl enol ether cleanly after 48 h stirring at room temperature under neat reaction conditions 
as judged by 1H NMR (Table 5.4). Despite the neat reaction conditions providing clean conversion 
of enone 5.127 into the desired silyl enol ether 5.129 these conditions were discarded for practical 
reasons.a   
                       Table 5.4 Solvent screening for the hydrosilylation. 
entry PhMe2SiH(equiv)a solvent
conversion
(%)b
reaction 
time (h)
1 1.5 neat 90 48
2 1.5 PhH 70 48
3 1.5 PhMe 25 48
4 1.5 CH2Cl2 50 48
5 1.5 THF 90 48
6 1.5 THF 75 20
7 5.0 THF >95 20
8 10.0 THF >95 20
O OSiMe2Ph
HRh(PPh3)4 (2.5 mol%)
PhMe2SiH
solvent, 0.5 M, 22 oC
aReactions were run on 0.18 mmol scale.  bConversion judged
 by 1HNMR (clean conversion i.e. less than 5-10% byproducts).
5.127 5.129
 
 
Screening a range of different solvents (Table 5.4) revealed that THF afforded a faster reaction than 
less polar solvents such as benzene, toluene and dichloromethane (entries, 2 to 4). It was desirable to 
reduce reaction time by adding several equivalents of PhMe2SiH (entries 5 to 8). The use of five 
equivalents of PhMe2SiH allowed for clean conversion of enone 5.127 into 5.129 within 20 h 
stirring at 22 oC. Applying these optimized conditions afforded the silyl enol ether 5.129 in a 
satisfying 76% isolated yield (Scheme 5.46). 
O OSiMe2Ph
HRh(PPh3)4 (2.5 mol%)
PhMe2SiH (5.0 equiv)
THF, 0.5 M, 22 oC
(76% yield)
MeLi, Me2Zn
THF, HMPA, -78 oC
then 5.126, -78oC to 23oC
(71% yield)
O
OO
5.1295.127 5.130
 
Scheme 5.46 Hydrosilylation and Noyori-type coupling. 
 
The identification of suitable hydrosilylation conditions allowed us to investigate ways to mediate 
the alkylation of 5.129. It was found that treating silyl enol ether with Noyori’s modified alkylation 
conditions553 provided the desired ketone 5.130 in a 71% yield as a 1:1.25 mixture of diastereomers 
                                                 
a It was expected that these reactions were to be conducted on a small scale rendering neat conditions impractical. 
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(Scheme 5.46).a Although the effect caused by adding dimethylzinc has not been investigated in 
detail 7Li NMR experiments have suggested that there is a dynamic interaction between the lithium 
enolate and dimethylzinc possibly generating a lithium alkoxydialkyl zincate.553 In any event 
conducting the alkylation in the absence of dimethyl zinc led to diminished yields due to lack of 
conversion.b  
 
It is widely accepted that transition metal catalyzed hydrosilylation proceeds via initial coordination 
of a silyl metal hydride complex to the carbonyl oxygen (Scheme 5.47).552,554  Zheng and Chan552 
have proposed simultaneous coordination to oxygen and alkene i.e. σ-coordination between oxygen 
and silicon and π-coordination between the metal and the double bond. This complex A rearranges 
with concomitant Si-Rh cleavage to afford intermediate B which upon reductive elimination 
furnishes silyl enol ether 5.129 and regenerates the catalyst.  
O
OSiMe2Ph RhLn PhMe2SiH
PhMe2Si-Rh(Ln)H
O
Me Si
Me2Ph
LnRh
H
OSiMe2Ph
RhLn
H
A
B
5.129
 
Scheme 5.47 Plausible mechanism for the hydrosilylation. 
 
If this mechanism is operative it may provide a plausible reason to the successful implementation of 
the transition metal catalyzed hydrosilylation in the eight-membered enone 5.127 case. It seems fair 
to assume that the simultaneous coordination of carbonyl and alkene could override the effect of any 
conformational preferences leading to a low degree of conjugation in the eight-membered ring-
system and thereby facilitate the desired 1,4-hydrosilylation.      
                                                 
a These model studies have been conducted with a racemic D-ring fragment.  
b Initial experiments were performed with the corresponding TMS enol ether readily available from cyclooctanone (cf. 
chapter 5.8.4). These experiments revealed that both HMPA and dimethylzinc were crucial additives. 
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5.6.2 Model Studies on the Radical Cyclization 
With our hands now on the alkylated product 5.130 we were eager to advance the material to 
imidazoyl thiocarbonate 5.131 in order to explore the pivotal radical cyclization (Scheme 5.48). The 
seemingly trivial task of reducing ketone 5.130 with NaBH4 under standard conditions was 
hampered by long reaction times and low yields. This inability to efficiently reduce ketone 5.130 
may most reasonably be assigned to the severe steric hindrance caused by the α all-carbon 
quaternary stereocenter. Gratifyingly, switching to LiAlH4 followed by aqueous acid work-up 
afforded the desired reduction and cleavage of the dioxane protecting group in a single operation. 
The alcohol 5.132 was isolated as a mixture of four diastereomers and no attempts were made to 
separate these. To effect radical formation we sought to implement a Barton-McCombie-type 
deoxygenation.555 Therefore the diastereomeric mixture of alcohols 5.132 was transformed into 
imidazoyl thiocarbonate 5.131 through the action of TCDI and a catalytic amount of DMAP.a 
During the initial investigations on the radical cyclization it was revealed that combination of AIBN 
and n-Bu3SnH afforded a cleaner and faster reaction than AIBN in combination with TTMS. 
Moreover it was found that slow addition of AIBN and n-Bu3SnH (over 5 h) to a refluxing solution 
of 5.131 in benzene was crucial to minimize formation of deoxygenation product 5.133. In the event 
radical cyclization of 5.131 furnished the requisite tricyclic system 5.134 as a mixture of 
diastereomers constituting the BCD ring system of the variecolin sesterterpenes in excellent yield 
along with minor amounts of the deoxygenated product 5.133.  
O
OO
OH
O
O
ON S
N
O
O
+
(83% yield) (9% yield)
AIBN (25 mol%)
n-Bu3SnH
PhH, reflux
LiAlH4, THF, 0 oC
then 10% HCl
0 to 21 oC
(81% yield)
DMAP (30 mol%)
TCDI
 CH2Cl2, 23 oC
(94% yield)
5.131 5.134 5.133
5.132
 
Scheme 5.48 End-game model studies. 
                                                 
a Attempts to install the thiocarbamate in the absence of DMAP resulted in sluggish reactions requiring reflux 
temperatures (1,2-dichloroethane or benzene as solvent) to reach full conversion. Moreover these conditions afforded up 
to 40% of an alkene product resulting from a Chugaev-type elimination.  
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In summary, these model studies have provided important information concerning the union of the 
AB-fragment and the D-fragment. A strategy to unite 5.126 and 5.127 through transition metal 
catalyzed hydrosilylation and alkylation has been developed. Moreover, conditions to facilitate the 
crucial conjugate radical cyclization have been discovered. While this model radical cyclization was 
unsuitable to afford information on the diastereoselectivity of this event it has provided important 
proof-of-principle for the tethered radical construction of the C(10)-C(15) bond in variecolin (5.1). 
Stereochemistry aside, these results have clearly shown that it should be feasible to couple the AB 
and D fragment and forge the C ring through a conjugate radical cylization thus affording a highly 
convergent approach to variecolin (5.1). Having reached this stage the authors external stay was 
coming to an end, however ongoing efforts by graduate student Michael R. Krout and Dr. Chris 
Henrya are directed toward assembling the AB-ring fragment and the D-ring fragment (cf. chapter 
5.7). 
 
5.7 Summary and Outlook 
Until this point the project has culminated in efficient synthetic routes to the two major building 
blocks for variecolin. We have developed synthetic routes to the enantiopure AB-fragments 5.96 and 
5.47 implementing the tandem Wolff-Cope to forge the central eight-membered ring. Hence we 
have successfully telescoped this methodology to the synthesis of highly functionalized eight-
membered rings (Scheme 5.49).  
OH
AcO
Hp-Tol
OH
H Hp-Tol
O
H
O
N2
p-Tol
O
H
H
O
H
O
H
O N2
O
H
H
O
R
OAc
AcO
H
OH
H
a)
b)
3 steps 5 steps
6 steps 5 steps
16% yield, 9 steps
R = H (5.96): 7.1% yield, 12 steps
R = Me(5.47): 2.9% yield, 12 steps
(±)-5.84(±)-5.71
(±)-5.85
  
Scheme 5.49 Synthesis of the AB-ring fragments. 
                                                 
a Dr. Chris Henry joined the project a few months after the author's departure from Caltech. 
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Additionally, we have devised an efficient route to the D-ring fragment 5.126 in high ee starting 
from easily available 1,3-cycloheptadione. Key to this achievement was the successful deployment 
of the enantioselective decarboxylative allylation toward a seven-membered vinylogous ester 
constructing the all-carbon quaternary stereocenter at C(14) and realization of the retro-aldol-aldol 
ring contraction forming the five-membered D-ring (Scheme 5.50). 
O
O
O
Oi-Bu
O
I
OO
4 steps 2 steps 3 steps
33% yield, 9 steps
5.111 5.126
14
 
Scheme 5.50 Synthesis of the D-Ring fragment. 
 
Finally, we have conducted model studies for the late stage coupling of the AB-ring fragment and 
the D-ring. These studies revealed the feasibility of performing a 1,4-hydrosilylation alkylation 
sequence followed by a conjugate radical cyclization to convergently combine the fragments and 
build the remaining C-ring (5.51). 
O
ON S
N O
O OSiMe2Ph 3 steps
34% yield, 5 steps
5.127 5.134
 
Scheme 5.51 End-game model studies. 
 
With asymmetric routes to the AB-fragment and the D-ring fragment established efforts are directed 
toward their efficient union through the two-step hydrosilylation Noyori-type alkylation pathway. 
We anticipate that the union of the AB-fragment 5.47 and D-fragment 5.126 will provide the 
depicted diastereomer (i.e. 5.135) based on the concave nature of the tricyclic system (Scheme 
5.52). The final C-C bond of the variecolin system will be formed using the radical cyclization 
conditions developed for the model system i.e. we expect that treating imidazoyl thiocarbonate 
5.136 with Bu3SnH and AIBN in refluxing benzene will generate the pentacyclic system 5.138. The 
stereochemical outcome of the radical cyclization can be rationalized based on minimization of 
developing steric interactions in the transition state i.e. 5.137. Most importantly, in the depicted 
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transition state model there are no severe 1,3-diaxial interactions developing while there is efficient 
orbital overlap between the sp3-centered radical and the alkene of the cyclopentene moiety. We 
expect that the final stereocenter at C(16) will be set under thermodynamic control either during the 
radical cyclization or in course of the work-up. The completion of the entire variecolin skeleton will 
lead us directly into the end-game. Wittig methylenation of 5.138 followed by oxidation with PCC 
will furnish lactone 5.140. Ultimately, DIBAL reduction of this and DMP oxidation will complete 
the total synthesis of variecolin (5.1). 
O
H
H
O O
I
O
H
H
O
O
O
1. LiAlH4
    then HCl (aq.)
2. TCDI, DMAP, CH2Cl2
O
H
H
O
Im S
AIBN
Bu3SnH
PhH, Δ
O
H
H
OHC
HH
O
H
H
O
HH
O
H
H
HH
O
H
H
HHO
O
H
H
HH
HO
PCC 1. DIBAL
2. DMP
NaBH4
CeCl3
Variecolin (5.1) Variecolol (5.5)
O
H
Me
Me
O
H
H
H H
Me
O
CH3PPh3+Br-
KOt-Bu
1. RhH(Ph3P)4
    PhMe2SiH
2. MeLi, Me2Zn
    then 5.126
5.47 5.126 5.135
5.136 5.137 5.138
5.139 5.140
 
Scheme 5.52 Proposed completion of variecolin (5.1) and congener variecolol (5.5). 
 
Selective Luche reduction of the enal moiety will afford variecolol (5.5). Upon completion the 
synthesis of variecolin (5.1) will have been accomplished in a longest linear sequence of 21 steps. 
Moreover the synthetic route has showcased the adaptability of the Wolff-Cope rearrangement 
toward construction of highly functionalized cyclooctanoid systems. Additionally, the asymmetric 
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decarboxylative allylation have been implemented in an efficient synthesis of the potentially widely 
applicable acylcyclopentene building block.  
 
5.8 Experimental Section 
5.8.1 Materials and Methods 
Unless otherwise stated, reactions were performed in flame-dried glassware under an argon or 
nitrogen atmosphere using dry, deoxygenated solvents. Reaction progress was monitored by thin-
layer chromatography (TLC). THF was distilled over sodium/fluoroenone and p-dioxane was 
distilled over sodium prior to use. Other solvents were dried by passage through an activated 
alumina column under argon. Diisopropylamine and triethylamine were distilled over CaH2 prior to 
use. Purified water was obtained using a Barnstead NANOpure Infinity UV/UF system. Brine 
solutions are saturated aqueous solutions of sodium chloride. Phosphinooxazoline ligands were 
prepared by methods described in our previous work.415,536 Tris(4,4’-methoxydibenzylidene-
acetone)dipalladium(0) was prepared according to the method of Ibers.556 Allyl cyanoformate was 
prepared according to the method of Rattigan.557 (Z)-2-Methyl-cyclooct-2-enone (5.127) was 
prepared according to the method of Conia.540 Starting materials were purchased from Aldrich or 
Alfa Aesar and used as received unless otherwise stated. Reaction temperatures were controlled by 
an IKAmag temperature modulater. TLC was performed using E. Merck silica gel 60 F254 
precoated glass plates (0.25 mm) and visualized by UV fluorescence quenching, anisaldehyde or 
KMnO4 staining. ICN silica gel (particle size 0.032-0.0653 mm) was used for flash chromatography. 
Silica gel impregnated AgNO3 was prepared as follows: AgNO3 (5.0 g) was dissolved in MeCN (15 
mL), SiO2 (15 g) was added the slurry was thoroughly mixed and dried under vacuum (2 h) to 
provide a free-flowing powder. 1H NMR spectra were recorded on a Varian Mercury 300 MHz or a 
Varian Inova 500 MHz spectrometer and are reported relative to residual CHCl3 (δ 7.26 ppm) or 
C6H6 (δ 7.16 ppm). 13C NMR spectra were recorded on a Varian Mercury 300 MHz or a Varian 
Inova 500 MHz spectrometer (at 75 MHz and 125 MHz respectively) and are reported relative to 
CDCl3 (δ 77.16 ppm) or C6D6 (δ 106 ppm). 31P NMR were recorded on a Varian Mercury 300 MHz 
spectrometer at 121 MHz, and are reported relative to the external standard H3PO4 (0.0 ppm). Data 
for 1H NMR are reported as follows: chemical shift (δ ppm) (multiplicity, coupling constant (Hz), 
integration). Multiplicities are reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, m 
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= multiplet, comp. m = complex multiplet, br s = broad singlet, app = apparent. Data for 13C and 31P 
NMR are reported in terms of chemical shifts (δ ppm). IR spectra were obtained by use of a Perkin 
Elmer Paragon 1000 spectrometer using thin films deposited on NaCl plates and reported in 
frequency of absorption (cm-1). Optical rotations were measured with a Jasco P-1010 polarimeter 
operating on the sodium D-line (254 nm), using a 100 mm path-length cell and are reported as: 
[α]DT (concentration in g/100 mL, solvent, ee). Melting points were measured using a Thomas-
Hoover capillary melting point apparatus and the reported values are uncorrected. Analytical chiral 
HPLC was performed with an Agilent 1100 Series HPLC utilizing a Chiralcel OD-H column (4.6 
mm x 25 cm) obtained from Daicel Chemical Industries Ltd. with visualization at 254 nm. 
Analytical chiral GC was performed with an Agilent 6850 GC utilizing a G-TA (30 m x 0.25 mm) 
column (1.0 mL/min carrier gas flow). High resolution mass spectra (HRMS) were obtained from 
the Caltech Mass Spectral Facility.  
5.8.2 Synthesis of the Variecolin D-Ring Fragment 
3-Isobutoxy-cyclohept-2-enone (5.114) 
 
1. TMSCl, Et3N, NaI
    CH3CN, 23 oC
2. Cl2CHCOCl, Et3N
    hexanes, 23 oC
3. Zn, AcOH, H2O, isopropyl alcohol
   -10 to 23 oC
4. PPTS (cat.), i-BuOH
    PhMe, 110 oC, Dean-Stark
O
O
Oi-Bu
(66% yield)
5.114
 
NaI (156.74 g, 1.05 mol) was placed in a 3-L 3-neck round  bottom flask and dried under high 
vacuum at 90 °C for 12 h and then allowed to cool to 23 °C under N2. CH3CN (1.3 L) was added to 
dissolve the NaI. To the solution was added cyclopentenone (70.7 g, 74.3 mL, 0.84 mol) followed 
by Et3N (106.25 g, 146.3 mL, 1.05 mol). The flask was fitted with an addition funnel, the funnel was 
charged with TMSCl (104.03 g, 122 mL), which was added dropwise over 30 min. The resulting 
suspension was stirred for an additional 1 h at 23 °C. Pentane (1.0 L) was added, and the biphasic 
system was stirred vigorously for 10 min. The layers were separated and the CH3CN layer was 
extracted with pentane (3 x 400 mL). The combined pentane phases were washed with H2O (2 x 500 
mL), brine (500 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to afford 
the desired product (131.4 g, quantitative) as a colorless oil. 
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The above trimethylsilylether (89.7 g, 0.57 mol) was placed in a flame-dried 3-L 3-neck round 
bottom flask fitted with a stopper, an addition funnel, and an overhead stirrer. Hexanes (900 mL) 
were added followed by Et3N (80.7 g, 111.2 mL, 0.798 mol). Dichloroacetyl chloride (101.70 g, 
66.4 mL, 0.69 mol) was dissolved in hexanes (400 mL) and added dropwise over 9.5 h. After 18 h 
stirring at 23 °C, the brown suspension was filtered, rinsing with EtOAc (3 x 500 mL). The clear 
brown solution was concentrated under reduced pressure and then filtered through a pad of Al2O3 (7 
x 18 cm, neutral) using EtOAc as eluent. The solution was concentrated under reduced pressure to 
afford the desired product (124.7 g, 82% yield) as a brown oil that crystallized in the freezer (-20 
°C). 
 
The above dichlorocyclobutanone (53.4 g, 0.2 mol) was placed in a 3-L 3-neck round bottom flask 
fitted with a thermometer, an addition funnel and an overhead stirrer. Isopropyl alcohol and purified 
water (170 mL each) were added, and the suspension was cooled to -10 °C (internally) by use of a 
MeOH/ice bath. Zn (58.8 g, 0.9 mol) was added in four portions (5 min between each) and AcOH 
(66.1 g, 63 mL, 1.1 mol) dissolved in H2O (130 mL) was added in a dropwise manner, keeping the 
internal temperature below 0 °C  (usually added over 1.5 h). The mixture was stirred for an 
additional 30 min at -10 °C (internally) then the cooling bath was removed and the mixture was 
allowed to warm to 23 °C. After 8.5 h, the reaction mixture was filtered, elution with isopropyl 
alcohol (100 mL). The mixture was cooled to 0 °C and neutralized by portionwise addition of 
K2CO3 (74.6 g, 0.54 mol). The viscous suspension was filtered, elution with H2O (100 mL) and 
EtOAc (300 mL). The biphasic system was concentrated under reduced pressure to ~200 mL and 
extracted with CH2Cl2. The combined organics were dried over MgSO4, filtered, and concentrated 
under reduced pressure to afford the desired product (24.2 g, 96% yield) as a pale orange oil. 
 
To a flask fitted with a Dean-Stark trap, a reflux condenser, and containing a solution of 1,3-
cycloheptanedione529 (35.8 g, 0.28 mol) in toluene (280 mL) was added i-butanol (168.3 g, 208 mL, 
2.27 mol) and PPTS (1.07 g, 4.26 mmol).  The solution was immersed into an oil bath at 130 °C and 
monitored by TLC.  When the starting material was consumed (typically within 4-6 h), the reaction 
was allowed to cool to room temperature.  The resulting dark orange solution was washed with 
saturated aqueous NaHCO3 (200 mL). The aqueous phase was extracted with EtOAc (3 x 150 mL), 
the combined organics were washed with brine, dried over MgSO4, filtered and concentrated under 
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reduced pressure to afford a thick dark orange oil. The crude oil was flushed through a plug of silica 
gel (7 x 9 cm SiO2, 1:4→3:7→1:1 Et2O-Hexanes) to afford the desired product 5.114 (43.5 g, 84% 
yield, 66% yield over 4 steps) as a pale orange oil; Rf  = 0.22 (2:1 Hexanes-EtOAc); 1H NMR (500 
MHz, CDCl3) δ 5.37 (s, 1H), 3.49 (d, J = 6.6 Hz, 2H), 2.60-2.56 (comp. m, 4H), 2.00 (septuplet, J = 
6.6 Hz, 1H), 1.88-1.77 (comp. m, 4H), 0.96 (d, J = 6.8 Hz, 6H); 13C NMR (125 MHz, CDCl3) δ 
202.5, 176.6, 106.0, 75.0, 41.9, 33.1, 27.9, 23.7, 21.5, 19.3; IR (Neat Film NaCl) 2958, 2872, 1646, 
1607, 1469, 1237, 1190, 1174 cm-1; HRMS (EI) m/z calc'd for C11H18O2 [M]+·: 182.1307; found 
182.1310. 
 
4-Isobutoxy-1-methyl-2-oxo-cyclohept-3-enecarboxylic acid allyl ester (5.52) 
O
Oi-Bu
O
Oi-Bu
O
O
1. LDA, THF, -78 oC
    then
2. MeI, Cs2CO3
    CH3CN, 80 oC
(79% yield)
NC O
O
5.114 5.52
 
Diisopropyl amine (4.66 g, 6.46 mL, 46.1 mmol) was placed in a 500-mL round bottom flask, 
dissolved in THF (180 mL) and cooled to 0 °C by use of an ice/water bath. n-BuLi (17.2 mL, 44.2 
mmol, 2.57 M in hexanes) was added dropwise over 15 min by use of syringe pump. After 15 min 
stirring at 0 °C, the mixture was cooled to -78 °C by use of an acetone/CO2(s) bath. Vinylogous 
ester 5.114 (7.01 g, 38.4 mmol) was dissolved in THF (20 mL) and added in a dropwise manner 
over 20 min by use of a syringe pump. After an additional 1 h stirring at -78 °C, allyl cyanoformate 
(4.69 g, 4.60 mL, 42.2 mmol) was added in a dropwise manner over 10 min. The mixture was stirred 
at -78 °C for 2.5 h, quenched with saturated aqueous NH4Cl and H2O (30 mL each) and then 
allowed to warm to ambient temperature. The reaction mixture was diluted with Et2O (100 mL) and 
the phases were separated. The aqueous phase was extracted with Et2O (2 x 100 mL) and the 
combined organic phases were dried over MgSO4, filtered, and concentrated under reduced pressure 
to afford a pale orange oil 10.5 g (>100%, some allyl cyanoformate left). The crude oil was placed 
in a 500 mL round bottom flask and dissolved in CH3CN (130 mL). MeI (16.35 g, 7.2 mL, 115 
mmol) was added to the reaction mixture followed by Cs2CO3 (16.76 g, 49.9 mmol), the flask was 
fitted with a condenser, immersed into an oil bath, and heated to 80 °C while stirring vigorously. 
After 12 h stirring at 80 °C, the reaction mixture was allowed to cool to ambient temperature, diluted 
with EtOAc (100 mL), dried over MgSO4, filtered, and concentrated under reduced pressure to 
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afford an orange oil. The crude product was purified by flash chromatography (5 x 15 cm SiO2, 19:1 
→ 9:1, Hexanes-EtOAc, dry-loaded using celite) to afford 5.51 (8.51 g, 79% yield) as a pale yellow 
oil; Rf = 0.43 (4:1 Hexanes-EtOAc); 1H NMR (500 MHz, CDCl3) δ 5.86 (dddd, J = 17.1, 10.7, 5.6, 
5.6 Hz, 1H), 5.39 (s, 1H), 5.29 (ddd, J = 17.1, 2.9, 1.5 Hz, 1H), 5.20 (app. d, J = 10.5 Hz, 1H), 4.64 
(ddt, J = 13.3, 5.6, 1.2 Hz, 1H), 4.56 (ddt, J = 13.4, 5.6, 1.2), 3.50 (dd, J = 9.3, 6.8 Hz, 2H), 3.47 
(dd, J = 9.3, 6.6 Hz, 1H), 2.59 (ddd, J = 17.8, 9.8, 3.9 Hz, 1H), 2.45-2.38 (comp. m, 2H), 2.02-1.94 
(m, 1H), 1.84-1.75 (m, 1H), 1.70 (ddd, J = 14.4, 7.3, 4.4 Hz, 1H), 1.43 (s, 3H), 0.94 (d, J = 6.6 Hz, 
6H); 13C NMR (125 MHz, CDCl3) δ 199.1, 174.0, 173.5, 132.0, 118.4, 105.2, 74.8, 65.8, 59.1, 34.3, 
33.9, 27.9, 24.2, 21.4, 19.3; IR (Neat Film NaCl) 2959, 2936, 2875, 1734, 1650, 1613, 1456, 1384, 
1233, 1170, 1115, 994 cm-1; HRMS (EI) m/z calc'd for C16H24O4 [M]+·: 280.1675; found 280.1686. 
 
(S)-7-Allyl-3-isobutoxy-7-methyl-cyclohept-2-enone (5.51) 
O
Oi-Bu
O
O Pd2(pmdba)3 (cat.)
(S)-t-BuPHOX (cat.)
PhMe, 30 oC
(98% yield, 88% ee)
O
Oi-Bu
5.52 5.51
 
Pd2(pmdba)3 (496 mg, 0.45 mmol) and (S)-t-BuPHOX 5.102 (439 mg, 1.13 mmol) were placed in a 
500-mL round bottom flask. The flask was evacuated and backfilled with N2 (3 cycles with 10 min 
evacuation per cycle). Toluene (150 mL, sparged with N2 for 1 h immediately before use) was added 
and the black suspension was immersed into an oil bath preheated to 30 °C. After 30 min stirring, 
the β-keto-ester 5.52 (10.16 g, 36.2 mmol) was added as a solution in toluene (31 mL sparged with 
N2 immediately before use) by use of positive pressure cannulation. The dark orange catalyst-
solution turned olive green immediately after the addition of β-keto-ester 5.52. The reaction mixture 
was stirred at 30 °C for 21 h, allowed to cool to ambient temperature, filtered through a plug of 
silica (5.5 x 2 cm SiO2, Et2O) and concentrated under reduced pressure. The crude oil was purified 
by flash chromatography (SiO2, 5 x 15 cm, 19:1 Hexanes-EtOAc, dry-loaded using SiO2) to afford 
5.51 (8.38 g, 98% yield) as a pale yellow oil; Rf  = 0.31 (3:1 Hexanes-Et2O); 1H NMR (500 MHz, 
CDCl3) δ 5.72 (dddd, J = 16.6, 10.5, 7.3, 7.3 Hz, 1H), 5.31 (s, 1H), 5.05-5.00 (m, 2H), 3.50 (dd, J = 
9.3, 6.6 Hz, 1H), 3.47 (dd, J = 9.3, 6.6 Hz, 1H), 2.53-2.42 (m, 2H), 2.38 (dd, J = 13.7, 7.1 Hz, 1H), 
2.20 (dd, J = 13.7, 7.8 Hz, 1H), 1.98 (app septuplet, J = 6.6 Hz, 1H), 1.86-1.70 (comp. m, 3H), 1.62-
1.56 (m, 1H), 1.14 (s, 3H), 0.95 (app d, J = 6.6 Hz, 6H); 13C NMR (125 MHz, CDCl3) δ 206.7, 
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171.3, 134.6, 117.9, 105.0, 74.5, 51.5, 45.4, 36.1, 35.2, 28.0, 25.2, 19.9, 19.3, 19.3; IR (Neat Film 
NaCl) 2960, 2933, 2873, 1614, 1470, 1387, 1192, 1171, 998, 912 cm-1; HRMS (EI) m/z calc'd for 
C15H24O2 [M]+·: 236.1776; found 236.1767; [α]D25.6 –69.04 ° (c 1.08, CHCl3, 88.0% ee). HPLC 
conditions: 1% IPA, OD-H column, tR (min): major = 6.30, minor = 7.26. 
 
(S)-4-Allyl-3-hydroxy-4-methyl-cycloheptanone (5.118) and (S)-4-Allyl-4-methyl-cyclohept-2-
enone (5.119) 
O
Oi-Bu
LiAlH4, Et2O
then 10% HCl
0 to oC
(5.118: 87% yield)
(5.119: 6% yield)
HO
O O
+
5.51
5.118 5.119
 
A 500-mL round bottom flask was charged with Et2O (150 mL) and cooled to 0 °C by use of an 
ice/water bath. LiAlH4 (806 mg, 21.2 mmol) was added in one portion. After 10 min was 5.51 (9.13 
g, 38.6 mmol) added in a dropwise manner as a solution in Et2O (43 mL) by use of positive pressure 
cannulation. The grey suspension was stirred for 40 min and LiAlH4 (148 mg, 3.9 mmol) was added 
in one portion. After an additional 30 min stirring at 0 °C, the reaction was quenched by slow 
addition of HCl (110 mL, 10% w/w). The resulting biphasic system was allowed to warm to ambient 
temperature and stirred vigorously for 8.5 h. The layers were separated and the aqueous phase was 
extracted with Et2O (3 x 100 mL). The combined organic phases were dried over Na2SO4, filtered 
and concentrated under reduced pressure. The crude product was azeotroped with toluene (3 x 20 
mL) and purified using flash chromatography (SiO2, 5 x 15 cm, 9:1→3:1 Hexanes-EtOAc, dry-
loaded using celite) to afford 5.118 (6.09 g, 87% yield) and 5.119 (387 mg, 6.1% yield) both as 
colorless oils.   
 
(5.118); Rf = 0.23 (7:3 Hexanes-EtOAc);1H NMR (500 MHz, CDCl3) δ major epimer; 5.88 (dddd, 
J = 15.1, 9.0, 7.6, 7.6 Hz, 1H), 5.12-5.08 (m, 2H), 3.70 (dd, J = 4.9, 3.9 Hz, 1H), 2.86 (dd, J = 15.6, 
1.7 Hz, 1H), 2.65 (dd, J = 15.6, 7.3 Hz, 1H), 2.54-2.43 (m, 2H), 2.24 (dd, J = 13.7, 7.8 Hz, 1H), 2.07 
(dd, J = 13.4, 7.3 Hz, 1H), 1.99 (dd, J = 15.9, 4.4 Hz, 1H), 1.82-1.69 (comp. m, 2H), 1.45-1.41 (m, 
1H), 0.96 (s, 3H); minor epimer 5.83 (dddd, J = 14.9, 10.3, 7.6, 7.6 Hz, 1H), 5.12-5.06 (m, 2H), 
3.68 (dd, J = 4.1, 2.4 Hz, 1H) 2.80 (dd, J = 15.4, 2.4 Hz, 1H), 2.74 (dd, J = 15.4, 8.1 Hz 1H), 2.46-
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2.38 (m, 2H), 2.18 (dd, J = 13.9, 7.3 Hz, 1H), 2.09 (dd, J = 12.9, 7.8 Hz, 1H), 1.82-1.65 (comp. m, 
3H) 1.50-1.47 (m, 1H), 1.02 (s, 3H); 13C NMR (75 MHz, CDCl3) δ major epimer; 213.2, 135.0, 
118.1, 72.9, 46.7, 44.9, 44.2, 41.0, 36.3, 21.9, 18.9; minor epimer; 212.6, 134.2, 118.3, 73.3, 47.2, 
42.8, 41.0, 35.9, 22.6, 18.7; IR (Neat Film NaCl) 3436, 3074, 2932, 1692, 1638, 1443, 1403, 1380, 
1352, 1318, 1246, 1168, 1106, 1069, 999, 913, 840 cm-1; HRMS (EI) m/z calc'd for C11H18O2 [M]+·: 
182.1313; found 182.1307. 
 
(5.119); Rf = 0.54 (7:3 Hexanes-EtOAc); 1H NMR (500 MHz, CDCl3) δ 6.04 (dd, J = 12.9, 0.7 Hz, 
1H), 5.82 (d, J = 12.9 Hz, 1H), 5.75 (dddd, J = 17.1, 10.3, 7.8, 7.1 Hz, 1H), 5.10 (dddd, J = 10.3, 
1.2, 1.2, 1.2 Hz, 1H), 5.08-5.03 (m, 1H), 2.65-2.52 (m, 2H), 2.19 (app dd, J = 13.7, 6.8 Hz, 1H), 
2.11 (app dd, J = 13.7, 8.1 Hz, 1H), 1.84-1.76 (m, 3H), 1.68-1.63 (m, 1H), 1.10 (s, 3H); 13C NMR 
(75 MHz, CDCl3) δ 204.7, 152.5, 133.8, 128.6. 118.6, 47.2, 45.1, 42.7, 38.2, 27.1, 18.4; IR (Neat 
Film NaCl) 3076, 3011, 2962, 2934, 2870, 1659, 1454, 1402, 1373, 1349, 1335, 1278, 1208, 1172, 
997, 916, 874, 822, 772 cm-1; HRMS (EI) m/z calc'd for C11H16O [M]+·: 164.1201; found 164.1209; 
[α]D21.0 –9.55 ° (c 1.07, CHCl3, 88.0% ee). 
 
1-((S)-3-Allyl-3-methyl-cyclopent-1-enyl)-ethanone (5.117) 
LiOH, CF3CH2OH
THF, 60 oC
(96% yield))
HO
O O
5.118 5.117  
β-Hydroxyketoester 5.118 (6.09 g, 33.4 mmol) was placed in a 500-mL round bottom flask and 
dissolved in THF (334 mL). 2,2,2-Trifluoroethanol (5.04 g, 3.67 mL, 50.1 mmol) and LiOH (1.20 g, 
50.1 mmol) were added, and the flask was fitted with a condenser, purged with N2, and heated to 60 
°C by use of an oil bath. After 18 h stirring, the suspension was allowed to cool to ambient 
temperature, diluted with Et2O (150 mL), dried over Na2SO4 (30 min stirring), filtered, and 
concentrated carefully under vacuum allowing for a film of ice to form on the outside of the flask. 
The crude product was purified using flash chromatography (SiO2, 5 x 15 cm, 15:1 Hexanes-Et2O) 
to afford 5.117 (5.29 g, 96% yield) as a colorless fragrant oil; Rf = 0.67 (8:2 Hexanes-EtOAc); 1H 
NMR (500 MHz, CDCl3) δ  6.45 (app t, J = 1.7 Hz, 1H), 5.76 (dddd, J = 16.4, 10.7, 7.3, 7.3 Hz, 
1H), 5.07-5.03 (comp. m, 2H), 2.59-2.48 (m, 2H), 2.21-2.14 (m, 2H), 2.30 (s, 3H), 1.85 (ddd, J = 
5 Studies Toward the Asymmetric Total Synthesis of Variecolin 
 178
12.9, 8.3, 6.3 Hz, 1H), 1.64 (ddd, J = 6.1, 8.5, 12.9 Hz), 1.11 (s, 3H);13C NMR (125 MHz, CDCl3) δ 
197.5, 151.9, 143.8, 134.9, 117.8, 50.0, 45.3, 36.0, 29.7, 26.8, 25.6; IR (Neat Film NaCl) 3077, 
2956, 2863, 1668, 1635, 1616, 1454, 1435, 1372, 1366,  1309, 1265, 1213, 1177, 993, 914, 862 cm-
1; HRMS (EI+) m/z calc'd for C11H17O [M+H] 165.1279; found 165.1281; [α]D21.4 +17.30 ° (c 
0.955, CHCl3, 88.0% ee).     
 
(1E)-1-(1-((S)-3-Allyl-3-methylcyclopent-1-enyl)ethylidene)semicarbazide (5.120) 
NaOAc
H2O, 60 oC
(92% yield)
O N
H
N
O
H2NNH
O
H2N NH2
HCl
5.117 5.120  
A 15-mL round bottom flask was charged with sodium acetate (150 mg, 1.83 mmol), semicarbazide 
hydrochloride (204 mg, 1.83 mmol), and a magnetic stirbar. Purified water (1.7 mL) was added and 
the mixture was stirred until all the solids had dissolved. Acylcyclopentene 5.117 (250 mg, 1.52 
mmol) was added neat and the mixture was heated to 60 °C for 4 h. The slurry was allowed to cool 
to ambient temperature while stirring and vacuum filtered (water aspirator). The white solid was 
dried under reduced pressure to afford 5.120 (311 mg, 92% yield). The ee of the semicarbazone at 
this point was found to be 91% (measured by hydrolysis to 5.117). The semicarbazone 5.120 (300 
mg, 1.36 mmol) was transferred to a round bottom flask, the solids were suspended in toluene-
hexanes (50:50), and the mixture was heated to 90 °C while stirring. After a few minutes stirring, 
the solids had dissolved completely to afford a clear colorless solution. Heating was discontinued 
and the stirring mixture was allowed to cool to 23 °C while still immersed in the oil bath. After 10 h 
had elapsed, the slurry was vacuum filtered to afford 5.120 (246 mg, 82% yield). The ee at this point 
was found to be 94.5 % (measured by hydrolysis to 5.117). A second recrystallization following the 
above procedure employing 5.120 (241 mg, 1.09 mmol) afforded 5.120 (201 mg, 83% yield). The ee 
at this point was found to be 97.9% (measured by hydrolysis to 5.117); Rf = 0.30 (9:1 CHCl3-
MeOH); 1H NMR (300 MHz, CDCl3) δ 8.52 (br s, 1H), 6.06 (br s, 1H), 5.85 (app t, J = 1.6 Hz, 1H), 
5.76 (dddd, J =  16.7, 9.3, 7.4, 7.4 Hz, 1H), 5.47 (br s, 1H), 5.06-4.98 (comp. m, 2H), 2.67-2.49 (m, 
2H), 2.15-2.12 (m, 2H), 1.98 (s, 3H), 1.82 (ddd, J = 12.8, 8.2, 6.9 Hz, 1H), 1.62 (ddd, J = 12.8, 8.5, 
6.4 Hz, 1H), 1.07 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 158.1, 145.0, 141.7, 141.2, 135.6, 117.2, 
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49.2, 45.9, 36.2, 30.8, 26.3, 12.8; IR (Neat Film NaCl) 3473, 3266, 3189, 2946, 2858, 1698, 1579, 
1478, 1437, 1377, 1349, 1321, 1130, 1109, 993, 910, 845, 768 cm-1; HRMS (TOF MS ES+) m/z 
calc'd for C12H20N3O [M+H]+: 222.1606; found; 222.1610; [α]D22.6 +39.80 ° (c 0.84, CHCl3, 97.9% 
ee); mp =145-146 °C (1:1 toluene-hexanes). 
 
1-((S)-3-Allyl-3-methyl-cyclopent-1-enyl)-ethanone (5.117) 
ON
H
N
O
H2N
6.0 M HCl aq
THF, H2O, 23 oC
(93% yield)5.120 5.117
98% ee  
Semicarbazone 5.120 (191.8 mg, 0.867 mmol) was dissolved in THF (1.92 mL) and HCl (3.84 mL, 
6.0 M, in H2O) was added. The resulting biphasic mixture was stirred vigorously at 23 °C for 30 h. 
The reaction mixture was diluted with Et2O (10 mL), the phases were separated, and the aqueous 
phase was extracted with Et2O (2 x 10 mL). The combined organics were dried over MgSO4, filtered 
and concentrated carefully under vacuum allowing for a film of ice to form on the outside of the 
flask. The residue was filtered through a short pad of silica (1 x 10 cm SiO2, 4:1 Hexanes:Et2O) to 
afford 5.117 132.6 mg (0.81 mmol, 93% yield); [α]D22.6 +39.80° (c 0.84, CHCl3, 97.9% ee). 
 
(1E)-4-(4-Iodobenzyl)-1-(1-((S)-3-allyl-3-methylcyclopent-1-enyl)ethylidene)semicarbazide 
(5.122) 
N
H
N
O
H2N N
H
N
O
H
N
I
I
NH2
m-xylene, 150 oC
(89% yield)
5.120 5.122  
To a solution of semicarbazone 5.120 (50 mg, 0.23 mmol, 91% ee) in m-xylene (2.2 mL) was added 
4-iodo-benzylamine (63 mg, 0.27 mmol). The resulting pale yellow solution was immersed in an oil 
bath and heated to 150 °C. After 9 h stirring at 150 °C, the mixture was allowed to cool to ambient 
temperature and concentrated under reduced pressure to afford a pale yellow solid. The crude solid 
was purified by flash chromatography (1.0 x 15 cm SiO2, 9:1 → 7:3 Hexanes:EtOAc) to afford 
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5.122 (88 mg, 89% yield) as a white solid. X-ray quality crystals were obtained by slow vapor 
diffusion of pentane into a chloroform solution of 5.122; Rf = 0.52 (9:1 CHCl3-MeOH); 1H NMR 
(500 MHz, CDCl3) δ 7.88 (s, 1H), 7.66-7.64 (m, 2H), 7.08 (d, J = 8.5 Hz, 2H), 6.50 (t, J = 6.1 Hz, 
1H), 5.86 (app t, J = 1.5 Hz, 1H), (dddd, J = 16.9, 9.0, 7.6,7.6 Hz, 1H), 5.04-5.01 (comp. m, 2H), 
4.46 (d, J = 6.3 Hz, 2H), 2.60-2.49 (m, 2H), 2.18-2.10 (m, 2H); 1.95 (s, 3H), 1.82 (ddd, J = 12.9, 
8.5, 6.3 Hz, 1H), 1.62 (ddd, J = 12.9, 8.5, 6.1 Hz, 1H), 1.07 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 
156.3, 144.5, 141.5, 141.4, 139.2, 137.8, 135.6, 129.4, 117.2, 92.6, 49.3, 45.9, 43.2, 36.2, 30.9, 26.3, 
12.5; IR (Neat Film NaCl) 3411, 3194, 3075, 2946, 2920, 2863, 1677, 1528, 1486, 1401, 1323, 
1259, 1142, 1114, 1057, 1000, 913, 845 cm-1; HRMS (FAB+) m/z calc'd for C19H25N3OI [M+H]+: 
438.1043; found 438.1036; [α]D22.2 +31.43 ° (c 0.36, CHCl3, 91.0% ee); mp = 123-124 °C (CHCl3-
n-pentane). 
 
2-(3-Allyl-3-methyl-cyclopent-1-enyl)-2-methyl-[1,3]dioxolane (5.123) 
O
HO
OH
PPTS
PhMe, 110 oC
(77% yield)
OO
5.117 5.123
 
Acylcyclopentene 5.117 (388.1 mg, 2.36 mmol) was placed in a 25-mL round bottom flask and 
dissolved in benzene (11.8 mL). Ethylene glycol (880 mg, 791 μL, 14.2 mmol) was added followed 
by PPTS (59.4 mg, 0.24 mmol), and the flask was fitted with a condenser and a Dean-Stark trap. 
The flask was immersed into an oil bath and heated to reflux (oil bath at 115 °C). After 18 h stirring 
at reflux, the mixture was allowed to cool to ambient temperature, diluted with Et2O (50 mL), and 
washed with brine (10 mL). The aqueous phase was extracted with Et2O (2 x 10 mL) and the 
combined organic phases were dried over Na2SO4, filtered and concentrated under reduced pressure 
to give a colorless oil. The crude product was purified by flash chromatography (2 x 20 cm SiO2, 
15:1→ 9:1 Hexanes:EtOAc) to afford 5.123 (381.4 mg, 77% yield); Rf = 0.49 (7:3 Hexanes-EtOAc); 
1H NMR (300 MHz, CDCl3) δ 5.76 (dddd, J = 17.1, 9.3, 7.6, 7.6 Hz, 1H), 5.50, (br s, 1H), 5.02-4.99 
(comp. m, 4H), 3.98-3.84 (comp. m, 2H), 2.36 (dddd, J = 10.3, 8.1, 5.9, 1.7 Hz, 1H), 2.30 (dddd, J = 
10.3, 8.1, 6.1, 1.7 Hz, 1H), 2.09 (d, J = 7.3 Hz, 2H), 1.82 (ddd, J = 12.9, 8.5, 6.1 Hz, 1H), 1.62 (ddd, 
J = 12.7, 8.8, 5.9 Hz, 1H), 1.48-1.47 (m, 3H), 1.03 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 142.9, 
5 Studies Toward the Asymmetric Total Synthesis of Variecolin 
 181
136.0, 135.7, 116.8, 107.4, 64.7, 64.7 (two peaks), 48.4, 46.1, 36.8, 30.6, 26.5, 24.0; IR (Neat Film 
NaCl) 2951, 2888, 1454, 1372, 1192, 1108, 1043, 996, 946, 912, 858 cm-1; HRMS (EI+) m/z calc'd 
for C12H17O2 [M - Me]+: 193.1229; found 193.1232.  
 
2-((S)-3-Allyl-3-methyl-cyclopent-1-enyl)-2,5,5-trimethyl-[1,3]dioxane (5.124) 
O
OOHO OH
PPTS
PhMe, 110 oC
(82% yield)5.117 5.124  
Acylcyclopentene 5.117 (5.29 g, 32.2 mmol) was placed in a 1-L round bottom flask and dissolved 
in toluene (322 mL). Neopentyl glycol (20.1 g, 193.2 mmol) was added followed by PPTS (809 mg, 
3.22 mmol) and the flask was fitted with a Dean-Stark trap and a condenser. The mixture was placed 
in an oil bath and heated to reflux (oil bath at 135 °C). After 25 h stirring, the mixture was allowed 
to cool to ambient temperature, diluted with Et2O (250 mL), and poured into saturated aqueous 
NaHCO3 (100 mL). The aqueous phase was extracted with Et2O (2 x 100 mL) and the combined 
organic phases were dried over Na2SO4, filtered, and concentrated under reduced pressure to afford 
a white semi-solid. The crude product was purified by flash chromatography (7.0 x 25 cm SiO2, 
hexanes → 99:1 → 98:2  Hexanes:EtOAc) to afford 5.124 (6.59 g, 82% yield) as a pale yellow oil; 
Rf = 0.62 (7:3 Hexanes-EtOAc); 1H NMR (300 MHz, CDCl3) δ 5.80 (dddd, J = 16.7, 9.3, 7.4, 7.4 
Hz, 1H), 5.52 (app t, J = 1.8 Hz, 1H), 5.06-4.99 (comp. m, 2H), 3.59 (dd, J = 11.2, 0.8 Hz, 1H), 3.51 
(dd, J = 11.2, 0.8 Hz, 1H), 3.31 (d, J = 11.2 Hz, 2H), 2.37-2.19 (m, 2H), 2.13 (app dt, J = 7.4, 1.1 
Hz, 2H), 1.853 (ddd, J = 12.8, 8.2, 6.4 Hz, 1H), 1.63 (ddd, J = 12.8, 8.8, 6.1 Hz, 1H), 1.41 (s, 3H), 
1.17 (s, 3H), 1.07 (s, 3H), 0.69 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 141.1, 138.2, 136.1, 116.9, 
98.8, 71.8, 71.7, 49.0, 46.2, 36.4, 31.4, 29.8, 27.8, 26.9, 22.8, 22.2; IR (Neat Film NaCl) 3075, 2952, 
2906, 2868, 1640, 1472, 1455, 1182, 1118, 1041, 996, 950, 911, 862 cm-1; HRMS (EI+) m/z calc'd 
for C16H27O2 [M+H]+: 251.2011; found 251.2011; [α]D20.9 +11.48 ° (c 1.01, CHCl3, 88.0% ee). 
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2-[(S)-1-Methyl-3-(2,5,5-trimethyl-[1,3]dioxan-2-yl)-cyclopent-2-enyl]-ethanol (5.125) 
OO
1. OsO4, NaIO4, 2,6-lutidine
    p-dioxane/H2O (3:1), 0 oC
2. NaBH4
    EtOH, 0 oC OH
OO
(77% yield)
5.1255.124
 
Dioxane 5.124 (1.51 g, 6.0 mmol) was dissolved in 1,4-dioxane (45 mL) and purified H2O (15 mL) 
was added followed by 2,6-lutidine (1.29 g, 1.40 mL, 12.0 mmol). The mixture was cooled to 0 °C 
by use of an ice/water bath and then NaIO4 (5.13 g, 24.0 mmol) was added followed  by OsO4 (30.5 
mg, 0.12 mmol). The resulting suspension was stirred for 4.5 h at 0 °C and then filtered, rinsing with 
EtOAc (100 mL). The aqueous phase was separated and extracted with EtOAc (2 x 25 mL). The 
combined organic phases were dried over Na2SO4, filtered, and concentrated under reduced pressure 
to afford the desired product 1.82 g (>100 %, contains some 2,6-lutidine) as a clear brown oil. The 
crude product was dissolved in EtOH (7.5 mL) and cooled to -21 °C by use of a MeOH/ice bath. 
NaBH4 (227.0 mg, 6.0 mmol) was dissolved in EtOH (7.5 mL), precooled to 0 °C, and added 
dropwise over 25 min to the reaction mixture by use of positive pressure cannulation. After an 
additional 1 h stirring at -21 °C, the reaction was quenched by slow addition of H2O (4.5 mL). The 
reaction mixture was allowed to warm to 0 °C, concentrated under reduced pressure to ~10 mL and 
extracted with CH2Cl2 (3 x 25 mL), dried over Na2SO4, filtered and concentrated under reduced 
pressure to afford a pale brown oil. The crude product was purified by flash chromatography (3.0 x 
15 cm SiO2, 19:1 → 9:1 → 4:1  Hexanes:EtOAc) to afford 5.125 1.18 g (4.6 mmol, 77% yield) as a 
pale yellow oil. Rf = 0.38 (7:3 Hexanes-EtOAc); 1H NMR (500 MHz, CDCl3) δ 5.57 (app t, J = 1.7 
Hz, 1H), 3.71 (ddd, J = 7.3, 7.3, 5.4 Hz, 2H), 3.52 (app t, J = 11.0 Hz, 2H), 3.34 (11.0 Hz, 2H), 
2.38-2.26 (m, 2H), 1.88 (ddd, J = 12.9, 8.5, 6.1 Hz, 1H), 1.71 (t, J = 7.3 Hz, 2H), 1.69 (ddd, J = 
12.9, 8.5, 5.9 Hz, 1H), 1.42 (s, 3H), 1.21 (t, J = 5.1 Hz, 1H), 1.16 (s, 3H), 1.09 (s, 3H). 0.71 (s, 3H); 
13C NMR (75 MHz, CDCl3) δ 141.1, 138.1, 98.6, 71.7, 60.2, 47.3, 44.1, 36.9, 31.1, 29.5, 29.5, 27.4, 
27.1, 22.7, 22.2; IR (Neat Film NaCl) 3428, 3041, 2951, 2868, 1472, 1456, 1396, 1370, 1353, 1321, 
1259, 1242, 1181, 1117, 1082, 1040, 1015, 950, 911, 862, 809, 793 cm-1; HRMS (EI+) m/z calc'd 
for C15H27O3 [M]+: 255.1960; found 255.1951; [α]D19.9 –3.23 ° (c 0.99, CHCl3, 88.0% ee). 
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2-[(S)-3-(2-Iodo-ethyl)-3-methyl-cyclopent-1-enyl]-2,5,5-trimethyl-[1,3]dioxane (5.126) 
I2, Ph3P, imidazole
CH2Cl2, 0 to 23 oC
(92% yield)
I
OO
OH
OO
5.125 5.126  
PPh3 (881.3 mg, 3.36 mmol) and imidazole (457.5 mg, 6.72 mmol) were placed in a 25-mL round 
bottom flask. The flask was evacuated and backfilled with Ar (x 3). CH2Cl2 (8.0 mL) was added and 
the mixture was stirred at 23 °C until all the solids had dissolved (typically within 10 min). The flask 
was wrapped in aluminum foil and I2 (869.6 mg, 3.36 mmol) was added. After 10 min stirring, the 
mixture was cooled to 0 °C by use of an ice/water bath and alcohol 5.125 (571.2 mg, 2.24 mmol) 
was added as a solution in CH2Cl2 (3.0 mL) by use of a syringe. The reaction mixture was stirred at 
0 °C for 1 h and then allowed to warm to 23 °C. After an additional 3 h stirring, hexanes (11 mL) 
were added and the resulting slurry was filtered through a plug of celite (5 x 1 cm) using hexanes-
Et2O (1:1, 100 mL) as eluent. The filtrate was concentrated under reduced pressure, resuspended in 
hexanes (50 mL), filtered, and concentrated under reduced pressure. The crude product was purified 
by flash chromatography (2.0 x 16 cm SiO2, hexanes → 99:1 → 98:2 → 90:10 Hexanes:Et2O, dry-
loaded using celite) to afford 5.126 753 mg (2.1 mmol, 92% yield); Rf = 0.71 (7:3 Hexanes-EtOAc); 
1H NMR (500 MHz, CDCl3) δ 5.51 (s, 1H), 3.50 (app t, 11.5 Hz, 2H), 3.34 (d, J = 11.2 Hz, 2H), 
3.19-3.06 (m, 2H), 2.38-2.25 (m, 2H), 2.12-2.02 (m, 2H), 1.84 (ddd, J = 13.2, 8.8, 5.9 Hz, 1H), 1.67 
(ddd, J =  13.2, 8.8, 5.6 Hz, 1H), 1.41 (s, 3H), 1.16 (s, 3H), 1.07 (s, 3H), 0.71 (s, 3H); 13C NMR 
(125 MHz, CDCl3) δ 142.5, 136.6, 98.6, 71.9, 71.9 (two peaks), 51.2, 46.8, 36.1, 31.4, 29.8, 27.5, 
26.4, 22.8, 22.3, 1.1; IR (Neat Film NaCl) 3039, 2956, 2863, 1470, 1450, 1390, 1365, 1315, 1254, 
1173, 1119, 1083, 1039, 1011, 944, 915, 866, 814 cm-1; HRMS (EI+) m/z calc'd for C15H26O2I 
[M+H]+: 365.0978; found 365.0980; [α]D20.3 +31.24 ° (c 1.03, CHCl3, 88.0% ee). 
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5.8.3 Model Study for the Radical Cyclization 
2-Methyl-cyclooctanone 558 
O O
LDA, MeI
THF, -78 oC
(59% yield)  
A 250-mL 3-neck flask was charged with diisopropylamine (4.26 g, 5.7 mL, 33.0 mmol), THF (50 
mL) was added, and the solution was cooled to 0 °C by use of an ice/water bath. n-BuLi (14.8 mL, 
33.0 mmol, 2.23 M in hexanes) was added in a dropwise manner keeping the internal temperature 
below 5 °C. The mixture was stirred for an additional 30 min at 0 °C and then cooled to –78 °C by 
immersion into a dry ice/acetone bath. Cyclooctanone (3.79g, 30.0 mmol) was dissolved in THF 
(5.0 mL) and added to the reaction mixture in a dropwise manner over 1 h. After an additional 30 
min of stirring at –78 °C, MeI (5.54 g, 2.4 mL, 39.0 mmol) was added in a dropwise manner and the 
mixture was allowed to warm gradually to 22 °C. After 14 h stirring, the reaction was quenched with 
saturated aqueous NH4Cl (25 mL) and diluted with Et2O (250 mL). The phases were separated and 
the aqueous phase was extracted with Et2O (3 x 50 mL). The combined organics were washed with 
brine (50 mL), dried over MgSO4, and concentrated under reduced pressure afford a clear pale 
yellow oil. The crude oil was purified by flash chromatography (5.0 x 15 cm SiO2, Hexanes → 98:2 
Hexanes:Et2O) to afford 2-methyl-cyclooctanone (2.47 g, 59% yield) as a colorless oil; Rf = 0.79 
(9.5:0.5 Hexanes-EtOAc); 1H NMR (300 MHz, CDCl3) δ 2.61 (ddq, J = 10.1, 6.9, 3.5 Hz, 1H), 
2.43-2.38 (comp. m, 2H), 2.00-1.16 (comp. m, 10H), 1.05 (d, J = 6.9 Hz, 3H); 13C NMR (125 MHz, 
CDCl3) δ 220.5, 45.4, 40.5, 33.2, 27.0, 26.7, 25.8, 24.7, 17.0; IR (Neat Film NaCl) 2925, 2858, 
1703, 1463, 1447, 1409, 1375, 1362, 1328, 1197, 1161, 1137, 1096, 1080, 1049, 1008, 962, 933, 
905, 858, 830 cm-1; HRMS (EI+) m/z calc'd for C9H16O [M]+: 140.1201; found 140.1192. Spectral 
data in accordance with literature values.559  
 
5 Studies Toward the Asymmetric Total Synthesis of Variecolin 
 185
Trimethyl-((E)-2-methyl-cyclooct-1-enyloxy)-silane415 
 
O OTMS1. TMSCl, NaI, Pyr
    CH3CN, 23 oC
2. Pd(OAc)2 (cat.), O2
    DMSO, 23 oC
(65% yield)  
A 100-mL round bottom flask was charged with NaI (2.52 g, 16.8 mmol) and CH3CN (15 mL). 
When all the solids had dissolved, 2-methyl-cyclooctanone (1.90 g, 13.6 mmol) in CH3CN (2.0 mL) 
and pyridine (1.31 g, 1.33 mL, 16.5 mmol) were added followed by dropwise addition (over 8 min) 
of TMSCl (1.68 g, 1.96 mL, 15.4 mmol). The resulting pale yellow suspension was stirred at 23 °C 
for 12 h and then diluted with pentane (40 mL). The biphasic mixture was stirred vigorously for 10 
min and the layers were separated. The CH3CN layer was extracted with pentane (3 x 40 mL). The 
combined pentane phases were washed with H2O (2 x 25 mL), brine (25 mL), dried over Na2SO4, 
and concentrated under reduced pressure to afford the crude silyl enol ether 2.70 g (12.6 mmol, 93% 
yield) as a 96:4 mixture (1H NMR) of regioisomers favoring the tetrasubstituted silyl enol ether. An 
oxygen balloon was affixed to a flask charged with the crude silyl enol ether (2.70 g, 12.6 mmol), 
Pd(OAc)2 (153 mg, 0.68 mmol, 5 mol%) and DMSO (100 mL).  The reaction mixture turned dark 
and became heterogeneous within 5 min. After 3 h stirring at 23 °C, 1H NMR analysis of an aliquot 
indicated less than 2% of the undesired isomer. The reaction mixture was poured into a separation 
funnel containing pentane (100 mL), H2O (50 mL), and ice (50 g). The layers were separated and 
the aqueous phase was extracted with pentane (3 x 100 mL). The combined pentane phases were 
washed with H2O (2 x 100 mL), brine (100 mL), dried over Na2SO4, and concentrated under 
reduced pressure to give a colorless oil. The crude product was purified using flash chromatography 
(3 x 15 cm MgO3Si, 98:2 Pentane-Et2O) to afford trimethyl-((E)-2-methyl-cyclooct-1-enyloxy)-
silane (1.82 g, 63% yield) as a colorless oil; Rf = 0.78 (9.5:0.5 Hexanes-Et2O); 1H NMR (500 MHz, 
C6D6) δ 2.24-2.22 (m, 2H), 2.06-2.04 (m, 2H), 1.7 (s, 3H), 1.64-1.59 (m, 2H), 1.52-1.43 (comp. m, 
6H), 0.18 (s, 9H); 13C NMR (125 MHz, C6D6) δ 145.6, 113.3, 32.1, 32.0, 29.3, 29.2, 27.0, 26.8, 
16.1, 0.9; IR (Neat Film NaCl) 2956, 2925, 2848, 1680, 1473, 1447, 1372, 1349, 1282, 1269, 1251, 
1210, 1186, 1135, 1091, 1052, 1018, 993, 951, 882, 845, 755 cm-1; HRMS (EI+) m/z calc'd for 
C12H24OSi [M]+: 212.1596; found 212.1605. Spectral data in accordance with literature values.415 
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Dimethyl-((E)-2-methyl-cyclooct-1-enyloxy)-phenyl-silane (5.129) 
O OSiMe2Ph
HRh(PPh3)4 (2.5 mol%)
PhMe2SiH (5.0 equiv)
THF, 0.5 M, 22 oC
(76% yield) 5.1295.127  
Enone 5.127 (100 mg, 0.724 mmol) was placed in a 1-dram vial. The vial was evacuated and 
backfilled with N2 (x 3) and THF (350 μL) was added.  HRh(PPh3)4 (20.9 mg, 0.0181 mmol) was 
placed in a 10-mL round bottom flask. The flask was evacuated and backfilled with N2 (3 cycles 
with 5 min evacuation per cycle) and then THF (1.1 mL) was added. An excess of PhMe2SiH was 
placed in a 1-dram vial. The vial was evacuated and backfilled with N2 (x 3). The required amount 
of PhMe2SiH (631 mg, 720 μL, 4.63 mmol) was added to the catalyst mixture by use of a syringe. 
The resulting clear orange solution was immersed into an oil bath preheated to 30 °C. After 10 min 
stirring at 30 °C, the solution of enone 5.127 was added by use of positive pressure cannulation. The 
mixture was stirred at 30 °C for 25 h, allowed to cool to ambient temperature, filtered through a plug 
of SiO2 (2 x 1 cm, Et2O) and concentrated under reduced pressure to afford a pale orange oil. The 
crude oil was purified by flash chromatography (2 x 16 cm, 99:1 → 98:2 Hexanes-Benzene) to 
afford 5.129 (150.2 mg, 76% yield) as a colorless oil: Rf = 0.52 (Hexanes); 1H NMR (300 MHz, 
CDCl3) δ 7.65-7.61 (m, 2H), 7.42-7.34 (m, 3H), 2.18-2.14 (m, 2H), 2.06-2.02 (m, 2H), 1.59 (s, 3H), 
1.55-1.38 (comp. m, 8H), 0.44 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 145.1, 138.7, 133.5, 129.6, 
127.9, 113.9, 31.9, 31.6, 29.0, 28.7, 26.8, 26.5, 16.1, -0.4; IR (Neat Film NaCl) 3075, 2951, 2863, 
1638, 1468, 1450, 1393, 1370, 1254, 1241, 1179, 1117, 1080, 1037, 1011, 995, 949, 910, 861, 809 
cm-1; HRMS (FAB+) m/z calc'd for C17H26OSi [M]+ ·: 274.1753; found 274.1752.  
 
2-Methyl-2-(2-[1-methyl-3-(2,5,5-trimethyl-[1,3]dioxan-2-yl)-cyclopent-2-enyl]-ethyl)-
cyclooctanone (5.130) 
OSiMe2Ph
MeLi, Me2Zn
THF, HMPA, -78 oC
then 5.126, -78oC to 23oC
(71% yield)
O
OO
5.129 5.130
 
Silylether 5.129 (39.7 mg, 0.145 mmol) was placed in a 10-mL round bottom flask. The flask was 
evacuated and backfilled with N2 (x 3), THF (1.45 mL) was added and the solution was cooled to 0 
°C by use of an ice/water bath. MeLi (57 μL, 0.15 mmol, 2.66 M in dimethoxymethane) was added 
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in a dropwise manner over 5 min. After an additional 1 h stirring at 0 °C, HMPA (260 mg, 252 μL, 
1.45 mmol) was added in a dropwise manner over 5 min and then the mixture was cooled to -78 °C 
by use of an acetone/CO2 (s) bath. The resulting clear solution mixture was stirred for 10 min 
followed by addition of Me2Zn (145 μL, 0.145 mmol, 1.0 M in heptane) in a dropwise manner. 
After an additional 10 min stirring, alkyl iodide 5.126 (63.4 mg, 0.0174 mmol) in THF (200 μL) was 
added in a dropwise manner (over 2 min). The mixture was stirred at -78 °C for 1 h and then 
allowed to warm gradually to ambient temperature. After 21 h stirring at 23 °C, the reaction mixture 
was diluted with Et2O and washed with H2O (10 mL). The aqueous phase was extracted with Et2O 
(2 x 10 mL) and the combined organic phases were dried over Na2SO4, filtered, and concentrated 
under reduced pressure. The crude oil was purified by flash chromatography (1 x 19 cm SiO2, 99:1 
→ 98:2 → 95:5 → 90:10 Hexanes-Et2O) to afford 5.130 (43.9 mg, 79% yield) as a 1:1.25 mixture of 
diastereomers; Rf = 0.70 (3:7 Hexanes-Et2O); 1H NMR (500 MHz, C6D6) δ major diastereomer: 
5.58 (app t, J = 1.7 Hz, 1H), 3.55 (d, J = 11.0 Hz, 1H), 3.48 (d, J = 11.0 Hz, 1H), 3.31 (d, J = 11.0 
Hz, 2H), 2.40-2.36 (m, 3H), 2.03 (ddd, J = 10.7, 7.1, 3.4 Hz, 1H), 1.81-1.69 (comp. m, 3H), 1.62 (s, 
3H), 1.60-1.50 (comp. m, 3H), 1.42-1.22 (comp. m, 8H), 1.19 (s, 3H), 1.18-1.10 (comp. m, 3H), 
1.02 (s, 3H), 1.00 (s, 3H), 0.53 (s, 3H); minor diastereomer: 5.56 (app t, J = 1.7 Hz, 1H), 3.52 (d, J 
= 11.0 Hz, 1H), 3.48 (d, J = 10.7 Hz, 1H), 3.30 (d, J = 11.0 Hz, 2H), 2.40-2.36 (m, 3H), 2.02 (ddd, J 
= 10.7, 7.1, 3.4 Hz, 1H), 1.81-1.69 (comp. m, 3H), 1.62 (s, 3H), 1.62 (s, 3H),  1.60-1.50 (comp. m, 
3H), 1.42-1.22 (comp. m, 8H), 1.19 (s, 3H), 1.18-1.10 (comp. m, 3H), 1.03 (s, 3H), 1.00 (s, 3H), 
0.52 (s, 3H); Mixture of two diastereomers: 13C NMR (125 MHz, C6D6) δ 218.1, 218.1, 142.4, 
142.4, 137.9, 137.8, 98.9, 98.9, 71.9, 71.8, 71.8, 71.8, 49.8, 49.8, 48.7, 48.7, 36.9, 36.8, 36.5, 36.5, 
35.9, 35.8, 34.6, 34.5, 34.2, 34.1, 31.9, 31.9, 30.4, 30.4, 29.7, 28.1, 28.0, 27.2, 27.1, 26.2, 26.2, 25.3, 
25.3, 24.5, 22.9, 22.2, 22.1, 19.2, 19.1; IR (Neat Film NaCl) 2932, 2858, 1698, 1469, 1448, 1396, 
1368, 1254, 1239, 1180, 1117, 1083, 1040, 950, 911, 863, 810, 793 cm-1; HRMS (FAB+) m/z calc'd 
for C24H41O3 [M+H]+: 377.3305; found 377.3043.  
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1-(3-[2-(2-Hydroxy-1-methyl-cyclooctyl)-ethyl]-3-methyl-cyclopent-1-enyl)-ethanone (5.132) 
O
OO
OH
O
LiAlH4, THF, 0 oC
then 10% HCl
0 to 21 oC
81% yield
5.1325.130
 
THF (12.5 mL) was added to a 50-mL round bottom flask and cooled to 0 °C by use of an ice/water 
bath. LiAlH4 (56.9 mg, 1.50 mmol) was added followed by dropwise addition of ketone 5.130 (472 
mg, 1.25 mmol) dissolved in THF (4.7 mL). The suspension was stirred at 0 °C for 1.5 h and then 
the reaction was quenched by dropwise addition of HCl (10 mL, 10% w/w). The suspension was 
stirred at 0 °C for 2 h, allowed to warm to 23 °C and stirred for an additional 30 min. The reaction 
mixture was diluted with Et2O (25 mL), the phases were separated and the aqueous phase was 
extracted with CH2Cl2 (2 x 25 mL). The combined organic phases were dried over MgSO4, filtered 
and concentrated under reduced pressure. The crude product was purified by flash chromatography 
(2 x 15 cm SiO2, 7:3 Hexanes-EtOAc) to afford 5.132 (296 mg, 81% yield) as a colorless viscous 
oil; Rf = 0.22 (7:3 Hexanes-Et2O); Mixture of diastereomers: 1H NMR (500 MHz, CDCl3) δ major 
set of diastereomers: 6.48 (q, J = 1.7, 2H), 3.69 (app d, J = 7.1 Hz, 1H), 3.68 (app d, J = 7.1 Hz, 
1H), 2.56-2.52 (comp. m, 4H), 2.30 (s, 6H), 1.95-1.20 (comp. m, 36 H), 1.10 (s, 6H), 1.09 (s, 6H); 
minor set of diastereomers: 6.47 (q, J = 2.2 Hz, 2H), 3.76 (app d, J = 8.8 Hz, 2H), 2.56-2.52 
(comp. m, 4H), 2.30 (s, 6H), 1.95-1.20 (comp. m, 36 H), 0.96 (s, 3H), 0.95 (s, 3H), 0.78 (s, 3H), 
0.78 (s, 3H); Mixture of four diastereomers: 13C NMR (125 MHz, CDCl3) δ 197.7, 197.7, 152.9, 
152.9, 152.8, 143.4, 143.4, 78.2, 78.2, 77.5, 50.1, 50.1, 50.0, 50.0, 40.3, 40.3, 39.6, 39.6, 36.3, 36.2, 
35.3, 35.2, 34.7, 34.7, 34.7, 34.5, 34.5, 33.6, 33.6, 32.3, 32.3, 32.3, 32.1, 29.7, 29.6, 29.1, 29.1, 28.1, 
28.1, 27.9, 27.9 26.8, 26.6, 26.6, 26.0, 25.8, 25.6, 25.6, 25.5, 25.4, 23.7, 22.7, 22.2, 22.2, 19.3; IR 
(Neat Film NaCl) 3468, 3039, 2925, 2853, 1667, 1618, 1468, 1447, 1377, 1365, 1305, 1269, 1204, 
1044, 964, 944, 871 cm-1; HRMS (EI+) m/z calc'd for C19H32O2 [M]+: 292.2402; found 292.2401.  
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Imidazole-1-carbothioic acid O-(2-[2-(3-acetyl-1-methyl-cyclopent-2-enyl)-ethyl]-2-methyl-
cyclooctyl) ester (5.131) 
OH
O
O
ON S
N
DMAP (30 mol%)
TCDI
 CH2Cl2, 23 oC
(98% yield) 5.131
5.132
 
Alcohol 5.132 (66.0 mg, 0.226 mmol) was placed in a 25-mL round bottom flask and dissolved in 
CH2Cl2 (4.7 mL). 4-Dimethylaminopyridine (8.28 mg, 0.068 mmol) and 1,1’-
thiocarbonyldiimidazole (201.4 mg, 1.13 mmol) were added and the resulting yellow solution was 
stirred at 23 °C for 29 h. The reaction mixture was concentrated under reduced pressure and the 
crude product was purified using flash chromatography (2 x 15 cm SiO2, 9:1→4:1 Hexanes-EtOAc) 
to afford 5.131 (89.2 mg, 98% yield) as a sticky colorless oil; Rf = 0.19 (7:3 Hexanes-EtOAc); 1H 
NMR (500 MHz, CDCl3) δ major set of diastereomers: 8.32 (s, 1H), 8.30 (s, 1H), 7.60 (s, 2H), 
7.03 (s, 2H), 6.37 (s, 1H), 6.34 (s, 1H), 5.65 (app d, J = 8.5 Hz, 2H), 2.63-2.53 (m, 2H), 2.53-2.42 
(m, 2H), 2.23 (s, 3H), 2.21 (s, 3H), 2.09-2.03 (m, 2H), 1.84-1.22 (comp. m, 34 H), 1.03 (s, 6H), 1.02 
(s, 3H), 1.02 (s, 3H) (two peaks); minor set of diastereomers: 8.30 (s, 1H), 8.29 (s, 1 H), 7.59 (s, 
1H), 7.55 (s, 1H), 7.03 (s, 2H), 6.45 (s, 1H), 6.44 (s, 1H), 5.77 (app d, J = 9.3 Hz, 2H), 2.63-2.53 (m, 
2H), 2.53-2.42 (m, 2H), 2.31 (s, 3H), 2.31 (s, 3H), 2.09-2.03 (m, 2H), 1.84-1.22 (comp. m, 34 H), 
1.13 (s, 3H), 1.13 (s, 3H), 0.95 (s, 3H), 0.94 (s, 3H) ; Mixture of four diastereomers: 13C NMR (125 
MHz, CDCl3) δ 197.5, 197.4, 197.4, 184.1, 152.0, 151.9, 151.9, 151.8, 143.8, 143.7, 143.6, 143.6, 
136.8, 136.7, 130.9, 130.9, 118.0, 117.9, 117.8, 91.7, 91.6, 91.3, 91.2 50.0, 49.9, 49.7, 49.7, 40.2, 
40.2, 39.9, 39.9, 36.3, 36.1, 36.1, 36.0, 35.2, 34.8, 34.7, 34.6, 34.5, 34.4, 32.5, 32.4, 32.3, 31.3, 30.5, 
30.5, 29.9, 29.8, 29.7, 29.6, 28.7, 28.6, 27.6, 27.4, 27.4, 26.8, 26.8, 26.7, 26.4, 26.2, 25.7, 25.6, 25.3, 
25.3, 25.1, 25.1, 23.3, 23.3, 22.6, 22.6, 22.1, 22.1, 21.5, 21.4; IR (Neat Film NaCl) 3158, 3121, 
2930, 2853, 1664, 1618, 1530, 1460, 1383, 1328, 1282, 1228, 1099, 1037, 1013, 967, 889, 871, 830, 
734; HRMS (EI+) m/z calc'd for C23H34N2O2S [M]+: 402.2341; found 402.2354.  
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1-(3a,5a-Dimethyl-tetradecahydro-cycloocta[e]inden-1-yl)-ethanone (5.131) and 1-(3-methyl-3-
[2-(1-methyl-cyclooctyl)-ethyl]-cyclopent-1-enyl)-ethanone (5.133) 
O
ON S
N
O
O
+
83% yield 9% yield
AIBN (25 mol%)
n-Bu3SnH
PhH, reflux
5.131 5.134 5.133
 
Thiocarbonate 5.131 (41.2 mg, 0.102 mmol) was placed in a 50-mL round bottom 2-neck flask fitted 
with a condenser, benzene (18.4 mL) was added, and the solution was sparged with N2 for 1 h. The 
reaction mixture was immersed into an oil bath and heated to reflux (oil bath at 85 °C. AIBN (4.19 
mg, 0.026 mmol) was placed in a 10-mL flask. The flask was evacuated and backfilled with N2 (x 
3). Benzene (2.0 mL, sparged with N2 for 1 h prior to use) was added followed by n-Bu3SnH (59.4 
mg, 54 μL, 0.204 mmol). The solution was added dropwise to the reaction mixture over 5 h by use 
of syringe pump. The mixture was stirred for an additional 12 h at reflux, allowed to cool to ambient 
temperature, and concentrated under reduced pressure to afford a pale yellow oil. The crude oil was 
purified by flash chromatography (1 x 15 cm, SiO2 impregnated with AgNO3, Hexanes) to afford a 
mixture of diastereomers of the desired ketone 5.134 (23.4 mg, 83% yield) and deoxygenated 
product 5.133 (2.5 mg, 9% yield) (ratio judged by 1H NMR). Samples of sufficient purity for NMR 
were obtained by flash chromatography (1 x 10 cm SiO2, Hexanes → 99:1 → 98:1 Hexanes-Et2O) 
and subsequent preparative TLC (20 x 20 cm, compound applied 2 cm from bottom, Toluene, 
developed x 3) of the fractions containing mainly the desired set of diastereomers. 
 
Major diastereomer (5.134):Rf = 0.52 (4:1 Hexanes-Et2O); 1H NMR (600 MHz, CDCl3) δ 3.27 
(ddd, J = 10.8, 7.3, 7.3 Hz, 1H), 2.38 (app dt, J = 7.0, 1.2 Hz, 1H), 2.27-2.22 (m, 1H), 2.20 (s, 3H), 
1.78-1.74 (m, 2H), 1.67-1.10 (comp. m, 12H), 0.98 (s, 3H), 0.96 (s, 3H), 0.89-0.81 (comp. m, 6H); 
13C NMR (125 MHz, CDCl3) δ 210.3, 56.9, 49.5, 42.7, 42.0, 37.9, 36.4, 34.6, 31.7, 31.6, 31.5, 30.9, 
30.4, 26.8, 26.0, 25.6, 23.3, 23.0, 22.4; IR (Neat Film NaCl) 2920, 2853, 1708, 1460, 1377, 1199, 
1179 cm-1; HRMS (EI+) m/z calc'd for C19H32O [M]+ : 276.2453; found 276.2450. 
 
Minor set of diastereomers (5.134): Rf = 0.58 (4:1 Hexanes-Et2O); 1H NMR (500 MHz, CDCl3) δ 
2.90 (ddd, J = 10.0, 8.3, 5.6 Hz, 1H), 2.71-2.64 (m, 1H), 2.35 (app t, J = 7.3 Hz, 1H), 2.17 (s, 3H), 
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2.16 (s, 3H), 2.07-1.85 (comp. m, 4H), 1.76-1.06 (comp. m, 33H), 1.04 (s, 3H), 1.03 (s, 3H), 1.00-
0.82 (comp. m, 6H), 0.77 (s, 3H), 0.76 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 211.5, 211.2, 58.8, 
55.9, 44.6, 44.5, 41.3, 40.9, 40.9, 39.6, 36.4, 35.2, 34.6, 34.0, 33.1, 32.1, 32.0, 30.7, 29.9, 29.9, 29.5, 
29.4, 29.2, 29.0, 28.8, 28.7, 27.9, 27.2, 26.4, 26.2, 25.8, 25.4, 24.6, 24.5, 24.3, 22.8, 22.1, 19.8; IR 
(Neat Film NaCl) 2919, 2848, 1737, 1711, 1460, 1383, 1352, 1261, 1173 cm-1; HRMS (EI+) m/z 
calc'd for C19H32O [M]+: 276.2453; found 276.2441. 
5.8.4 Ligand Synthesis 
2-(2-Bromo-phenyl)-4,5-dihydro-oxazole 
 
Br
Cl
O
1. H2N(CH)2OH, Na2CO3
    CH2Cl2, H2O, 23 oC
2. MsCl, Et3N
    CH2Cl2, 0 to 40 oC
(64% yield)
Br N
O
 
Ethanolamine (1.34 g, 1.32 mL, 21.9 mmol) was placed in a 250-mL round bottom flask and 
dissolved in CH2Cl2 (60 mL) and a solution of Na2CO3 (5.80 g, 54.7 mmol) in H2O (45 mL) was 
added. To the vigorously stirred biphasic system was added neat 2-bromobenzoyl chloride (4.00 g, 
2.38 mL, 18.2 mmol) dropwise via syringe. The reaction flask was capped with a yellow plastic 
stopper and stirred for 7.5 h at 23 °C. The layers were separated and the aqueous phase was 
extracted with CH2Cl2 (2 x 25 mL). The combined organics were dried over Na2SO4, filtered, and 
concentrated under reduced pressure to afford a white solid. The crude product was dissolved in 
CH2Cl2 (50 mL) and hexanes (10 mL) were added. The solution was concentrated to ~ 25 mL under 
reduced pressure resulting in precipitation of the desired amide 4.02 g (16.4 mmol, 90% yield) as a 
white solid.  
 
The above amide (2.0 g, 8.2 mmol) was placed in a 100-mL round bottom flask equipped with a 
reflux condenser and dissolved in CH2Cl2 (62 mL). Et3N (2.49 g, 3.43 mL, 24.5 mmol) was added 
and the solution was cooled to 0 °C by use of an ice/water bath followed by dropwise addition of 
MsCl (1.41 g, 952 μL, 12.3 mmol). The reaction mixture was stirred at 0 °C for 30 min, then 
transferred to an oil bath and heated to 40 °C. After 5 h stirring, the resulting yellow solution was 
allowed to cool to ambient temperature, diluted with CH2Cl2 (25 mL), washed with H2O (2 x 25 
mL), brine (25 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to afford a 
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thick, pale yellow oil. The crude oil was purified by flash chromatography (5 x 10 cm SiO2, 6:2:2 
Hexanes-EtOAc-Toluene) to afford 2-(2-bromo-phenyl)-4,5-dihydro-oxazole (1.31 g, 71% yield); Rf 
= 0.45 (9.0:1.0 CHCl3-MeOH); 1H NMR (500 MHz, CDCl3) δ 7.72 (dd, J = 7.8, 2.0 Hz 1H), 7.65 
(dd, J = 8.1, 1.0 Hz, 1H), 7.35 (app dt, J = 7.6, 1.2 Hz, 1H), 7.29 (app dt, J = 7.6, 1.7 Hz, 1H), 4.46 
(t, J = 9.6 Hz, 2H), 4.12 (t, J = 9.6 Hz, 2H); 13C NMR (125 MHz, CDCl3) δ 164.0, 134.1, 131.8, 
131.5, 129.8, 127.2, 122.0, 67.8, 55.5; IR (Neat Film NaCl)  cm-1 3390, 3070, 2966, 2904, 2868, 
1729, 1646, 1589, 1432, 1362, 1328, 1272, 1243, 1093, 1026, 938: HRMS (EI+) m/z calc’d for 
C9H8BrNO [M]+: 224.9789; found 224.9779. 
 
2-(2-Diphenylphosphanyl-phenyl)-4,5-dihydro-oxazole 
Br N
O
PPh2 N
O
CuI, Ph2PH
N,N'-dimethylethylenediamine
Cs2CO3, PhMe, 110 oC
(86% yield)  
A 250-mL Schlenk flask was charged with CuI (66.7 mg, 0.35 mmol), Ph2PH (4.12g, 3.85 mL, 22.1 
mmol) and then N,N’-dimethylethylenediamine (156 mg, 191 μL, 1.77 mmol) followed by toluene 
(18 ml). The solution was stirred at 23 °C for 20 min. 2-(2-Bromo-phenyl)-4,5-dihydro-oxazole (4.0 
g, 17.7 mmol) was azeotroped with toluene (2 x 5 ml) under reduced pressure, then dissolved in 
toluene (18 mL) and transferred quantitatively to the Schlenk flask by use of positive pressure 
cannulation. Cs2CO3 (8.65 g, 26.5 mmol) was added in one portion, the flask was evacuated, and 
backfilled with Ar (x 3). The Teflon valve was sealed and the yellow heterogeneous reaction 
mixture was placed in an oil bath, heated to 110 °C, and stirred vigorously. After 20 h stirring at 110 
°C, the mixture was allowed to cool to ambient  temperature and filtered through a pad of celite 
using CH2Cl2 (2 x 50 mL). The filtrate was concentrated under reduced pressure to afford a clear 
orange oil. The crude oil was flushed through a plug of silica gel (5.0 x 10 cm SiO2, hexanes → 9:1 
dichloromethane:Et2O) to afford 2-(2-diphenylphosphanyl-phenyl)-4,5-dihydro-oxazole (5.03 g, 
86% yield) as a colorless viscous oil that crystallized upon standing; Rf = 0.50 (7:3 Hexanes-
EtOAc); 31P NMR (121 MHz, CDCl3) δ -3.99 (s); 1H NMR (500 MHz, CDCl3) δ 7.85 (dd, J = 7.6, 
3.4 Hz, 1H), 7.37-7.26 (comp. m, 12H), 6.89 (dd, J = 4.1, 7.6 Hz, 1H), 4.08 (t, J = 9.5 Hz, 2H), 3.78 
(t, J = 9.5 Hz, 2H); 13C NMR (125 MHz, CDCl3) δ 164.5 (d, JCP = 2.8 Hz), 139.1 (d, JCP = 24.9 
Hz), 138.0 (d, JCP = 11.5 Hz), 134.1 (d, JCP = 20.7 Hz), 133.7 (d, JCP = 1.8 Hz), 131.9 (d, JCP = 18.9 
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Hz), 130.5, 129.9 (d, JCP = 2.8 Hz), 128.7, 128.5 (d, JCP = 7.4 Hz), 128.1, 67.2, 55.0; IR (Neat Film 
NaCl) 3053, 3000, 2971, 2901, 2876, 1650, 1585, 1562, 1478, 1434, 1354, 1326, 1248, 1133, 1089, 
1070, 1041, 974, 942, 898, 743 cm-1; HRMS (FAB+) m/z calc'd for C21H19NOP [M+H]+: 332.1204; 
found 332.1218; mp = 99-101 °C. 
 
(S)-2-(1-Bromo-naphthalen-2-yl)-4-tert-butyl-4,5-dihydro-oxazole (5.116A) 
H2N OH
1. Na2CO3
    CH2Cl2, H2O, 23 oC
2. MsCl, Et3N
    CH2Cl2, 0 to 40 oC
(82% yield)
Br
O
Cl
Br N
O
5.116A  
(S)-tert-Leucinol (1.02 g, 8.66 mmol) was placed in a 250-mL round bottom flask and dissolved in 
CH2Cl2 (14.0 mL). Na2CO3 (2.75 g, 26.0 mmol) was added as a solution in H2O (27.0 mL). To the 
biphasic mixture was added a solution of 1-bromonaphthalene-2-carbonyl chloride (2.68 g, 9.96 
mmol) in CH2Cl2 (15.0 mL). The biphasic system was stirred vigorously at 23 °C for 9.5 h. The 
phases were separated and the aqueous phase was extracted with CH2Cl2 (4 x 50 mL). The 
combined organics were stirred with KOH (10 mL, 10 mmol, 1.0 N in MeOH) for 30 min then 
transferred to a separation funnel. H2O (10 mL) was added and the mixture was neutralized with 
HCl (6.0 M, in H2O). The phases were separated and the aqueous phase was extracted with CH2Cl2 
(4 x 50 mL). The combined organics were dried over MgSO4 and concentrated under reduced 
pressure to afford the desired amide as a pale yellow solid 3.03 g (9.96 mmol, quantitative).  
 
The above amide (3.03 g, 9.96 mmol) was placed in a 100-mL 3-neck round bottom flask fitted with 
a condenser and dissolved in CH2Cl2 (43.3 mL). The solution was cooled to 0 °C by use of an 
ice/water bath and Et3N (2.10 g, 2.90 mL, 20.8 mmol) was added followed by dropwise addition of 
methanesulfonyl chloride (1.14 g, 0.77 mL, 9.96 mmol). Following consumption of the starting 
material as indicated by TLC (typically 15 min stirring), the reaction mixture was warmed to 40 °C 
in a water bath. After 21 h stirring at 40 °C the mixture was allowed to cool to room temperature and 
saturated aqueous NaHCO3 was added. The biphasic system was stirred vigorously for 5 min and 
then the layers were separated. The aqueous phase was extracted with CH2Cl2 (2 x 50 mL). The 
combined organics were washed with brine (50 mL), dried over MgSO4, and concentrated under 
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reduced pressure to afford a pale yellow oil. The crude oil was purified by flash chromatography 
(SiO2 3 x 15 cm, 9:1 Hexanes-EtOAc) to afford 5.116A (2.36 g, 82% yield over two steps) as a pale 
yellow oil that solidifies when placed in a –20 °C freezer; Rf = 0.73 (9.0:1.0 CHCl3-MeOH); 1H 
NMR (300 MHz, CDCl3) δ 8.41 (dd, J = 7.7, 0.5 Hz, 1H), 7.85-7.81 (m, 2H), 7.64 (d, J = 8.5 Hz, 
1H), 7.60 (app dt, J = 8.2, 1.3 Hz, 1H), 7.56 (app dt, J = 6.9, 1.3 Hz, 1H), 4.46 (dd, J = 8.5, 10.4 Hz, 
1H), 4.33 (dd, 8.5, 8.0 Hz, 1H), 4.17 (dd, 8.2, 10. 4 Hz, 1H), 1.05 (s, 9H); 13C NMR (125 MHz, 
CDCl3) δ 163.8, 134.9, 132.3, 128.8, 128.3, 128.3, 128.0, 127.8, 127.7, 126.9, 123.2, 76.9, 69.2, 
34.1, 26.1; IR (Neat Film NaCl) 3065, 2956, 2899, 2863, 1667, 1620, 1594, 1556, 1499, 1476, 1463, 
1393, 1372, 1362, 1339, 13212, 1300, 1238, 1264, 1210, 1161, 1104, 1024, 977, 956, 920, 817, 752 
cm-1; HRMS (EI+) m/z calc'd for C17H18ONBr [M]+: 331.0572; found 331.0583; [α]D20.0 –63.95 ° 
(c 0.92, CHCl3); mp = 66-68 °C.  
 
(S)-4-tert-Butyl-2-(1-diphenylphosphanyl-naphthalen-2-yl)-4,5-dihydro-oxazole (5.116) 
Br N
O
5.116A
PPh2 N
O
CuI (2 mol%), Ph2PH
N,N'-dimethylethylenediamine
Cs2CO3, PhMe, 110 oC
(87% yield) 5.116  
Prepared by the typical method employing 5.116A (830.6 mg, 2.50 mmol). After 24 h stirring, the 
reaction mixture was filtered through a plug of celite washing with CH2Cl2 (2 x 25 mL) and 
concentrated under reduced pressure. The crude oil was flashed through a short path of silica (2.5 x 
8 cm SiO2, Hexanes → 9:1 dichloromethane:Et2O) to afford a bright yellow oil containing the 
desired product. The oil was purified by flash chromatography (2.5 x 25 cm SiO2, 19:1 Hexanes-
Acetone and then 2.5 x 21 cm SiO2, 9:1 → 6:1 Hexanes-EtOAc) to afford 5.116 (950.8 mg, 87% 
yield) as a bright yellow foam; 31P NMR (121 MHz, CDCl3) δ -9.33(s); 1H NMR (500 MHz, 
CDCl3) δ 7.97 (d, J = 8.1 Hz, 1H), 7.96 (d, J = 8.0 Hz, 2H), 7.72 (dd, J = 8.3, 2.9 Hz, 1H), 7.45 (app 
dt, J = 7.8, 1.7 Hz, 2H); 7.41-7.38 (m, 3H), 7.29-7.22 (comp. m, 6H). 7.16 (ddd, J = 8.3, 6.9, 1.0 Hz, 
1H), 4.17-4.15 (m, 2H), 3.91 (dd, J = 9.8, 8.8 Hz, 1H), 0.97 (s, 9H); 13C NMR (125 MHz, CDCl3) 
δ 165.6 (d, JCP = 5.1 Hz), 137.5 (d, JCP = 33.1 Hz), 136.8, (d, JCP = 14.7 Hz), 136.5 (d, JCP = 14.7), 
134.9, 134.7 (d, JCP = 33.6 Hz), 133.1 (d, JCP = 26.7 Hz), 132.2 (d, JCP = 17.5 Hz), 132.1 (d, JCP = 
17.5 Hz), 131.5 (d, JCP = 0.9 Hz), 129.1 (d, JCP = 7.4 Hz), 129.0, 128.4 (d, JCP = 6.0 Hz), 127.8 (d, 
JCP = 8.3 Hz), 126.6 (d, JCP = 8.7 Hz), 126.4 (d, JCP = 40.5 Hz), 76.8, 69.0, 34.1, 26.3; IR (Neat Film 
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NaCl) 3054, 2954, 2867, 1665, 1584, 1478, 1434, 1364, 1244, 1094, 1026, 986, 962, 922, 824 cm-1; 
HRMS (FAB+) m/z calc'd for C29H28NOP [M]+: 437.1908; found 437.1908; [α]D26.1 –38.2 ° (c 
1.59, n-Hexane). 
 
Table 5.5 Methods for the determination of enantiomeric excess. 
 
a Suitable assay conditions were developed utilizing racemic material.
entry product assayconditionsa
retention time of
major isomer (min)
retention time of
minor isomer (min) %ee
1
O
Oi-Bu
5.51
HPLC
Chiralcel OD-H
1% IPA in n-hexane
isocratic, 1.0 mL/min
6.30 7.26 88
2
O
5.117
GC
G-TA
80 oC isotherm
54.98 61.35 88
3
O
5.117
GC
G-TA
80 oC isotherm
54.74 60.24 98
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6 Concluding Remarks 
The importance of transition metal-catalyzed C-C bond formation within the area of synthetic 
organic chemistry can hardly be overestimated. The development of transition-metal-catalyzed 
regio-, chemo-, and enantioselective C-C bond forming reactions continues to be a central research 
area, which has a widespread impact on organic synthesis. The ability to construct C-C bonds by 
novel and more efficient means greatly influences our ability to construct complex molecules. The 
present work has evolved around four projects within the general area of organic synthesis and 
method development. Crucial to these projects was the development or application of ruthenium- or 
palladium-catalyzed C-C bond forming reactions.   
 
A concise synthesis of (+)-castanospermine starting from methyl α-D-glucopyranoside has been 
developed. The octahydroindolizidine skeleton of (+)-castanospermine was constructed be 
sequential use of a medium ring metathesis reaction, a diastereoselective epoxidation, and a strain-
releasing transannular cyclization. The second project has culminated in an efficient synthetic 
strategy to the (−)-pladienolide B core. The synthesis relied on chiral auxiliary-mediated aldol 
addition and Sharpless asymmetric dihydroxylation to install the three oxygen substituted 
stereocenters of the macrocycle. (E)-Selective cross metathesis combined with Yamaguchi-
macrolactonization afforded the 12-membered lactone. This approach constitutes a flexible and 
excellent starting point for future analog synthesis of the very promising anticancer lead structure 
pladienolide B. The third project was directed toward the development of an efficient and atom-
economical protocol to directly alkylate the 3-position of oxindoles utilizing alcohols. This was 
achieved employing cheap and commercially available [RuCl3·xH2O] as catalyst. The reaction was 
highly selective for the formation of C(3) substituted oxindoles. Moreover, this transformation was 
tolerant to a wide range of functional groups and could be applied to a range of different alcohols. 
The final project was concerned with synthetic studies toward the sesterterpenoid variecolin. 
Synthetic routes to two main fragments were developed. Key to these achievements was the 
implementation of the tandem Wolff-Cope rearrangement and the palladium-catalyzed 
enantioselective decarboxylative allylation. In addition model studies revealed that these fragments 
could be convergently combined through a 1,4-hydrosilylation-alkylation sequence followed by 
conjugate radical cyclization. 
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7 Abbreviations 
 
Ac Acetyl 
acac Acetylacetonate  
AD Asymmetric dihydroxylation 
(Sharpless) 
AIBN 2,2’-Azobisisobutyronitrile 
aq Aqueous 
app Apparent (NMR) 
AQN Anthraquinone 
BHT 2,6-Di-tert-butyl-4-
methylphenol 
Bn Benzyl 
Boc tert-Butoxycarbonyl 
bp Base pair 
bp Boiling point 
br s Broad singlet (NMR) 
i-Bu iso-Butyl 
n-Bu normal-Butyl 
t-Bu tert-Butyl 
Bz Benzoyl 
Caltech California Institute of 
Technology 
CAN Cerium(IV) ammonium nitrate 
cat Catalyst / catalytic amount 
Cbz Benzyloxocarbonyl 
CCR5 Chemokine receptor 5 
CD4 Cluster of differentiation 4 
CM Cross metathesis 
CNS Central nervous system 
cod 1,5-Cyclooctadiene 
Con A Concanavalin A 
Cp* Pentamethylcyclopentadienyl 
mCPBA meta-Chloroperbenzoic acid 
CSA  Camphorsulfonic acid 
CXCR5 CXC chemokine receptor 5 
Cy Cyclohexyl 
d Doublet (NMR) 
dba Dibenzylidene acetone 
DBU 1,8-Diazabicyclo[5.4.0]undec-7-
ene 
DDQ 2,3-Dichloro-5,6-dicyano-1,4-
benzoquinone 
de Diastereomeric excess 
DEAD Diethyl azodicarboxylate 
DEIPS Diethylisopropylsilyl 
DHQD Dihydroquinidine 
DIAD Diisopropyl azodicarboxylate 
DIBAL Diisobutylaluminium hydride 
DIPEA N,N-Diisopropylethylamine, 
Hünigs base 
DIPHOS Dithylenebis(diphenylphosphine) 
(+)-DIPT (+)-Diisopropyl tartrate 
dmdba Bis(3,5-dimethoxybenzylidene)-
acetone 
DMAC Dimethyl acetamide 
DMAP 4-(Dimethylamino)pyridine 
DMDO Dimethyldioxirane 
DMF N,N-Dimethylformamide 
DMP Dess-Martin periodinane 
DMPU 1,3-dimethyl-3,4,5,6-tetrahydro-
2(1H)-pyrimidone 
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DMS Dimethyl sulfide 
DMSO Dimethylsulfoxide 
dr Diastereomeric ratio 
DTS Diverted total synthesis 
E Entgegen 
EC50 Half maximal effective 
concentration 
EDTA Ethylenediamine tetraacetic 
acid 
ee Enantiomeric excess 
Et Ethyl 
EWG Electron-withdrawing group 
FOS Function oriented synthesis 
GC Gas chromatography 
h Hour(s) 
HCV Hepatitis C virus 
HIV Human immunodeficiency 
virus 
HMBC Heteronuclear multiple bond 
connectivity 
HMPA Hexamethylphosphoramide 
HPLC High performance liquid 
chromatography 
5-HT7 5-Hydroxytryptamine receptor 
7 
IC50 Half maximal inhibitory 
concentration 
IDCP Iodonium dicollidine 
perchlorate 
IR Infrared 
KDA Potassium diisopropylamide 
KHMDS Potassium bis(trimethylsilyl) -
amide 
L Ligand 
LDA Lithium diisopropylamide 
LiHMDS Lithium bis(trimethylsilyl) -amide 
m meta 
m Mulitplet (NMR) 
M Molar 
MAPh Methylaluminum bis(2,6-
diphenyloxide) 
Me Methyl 
Mes Mesityl 
MIT Massachusetts Institute of 
Technology 
MOM Methoxymethyl 
Ms Methanesulfonyl 
MS Mass spectrometry 
MS Molecular sieves 
MSH ortho-Mesitylenesulfonyl-
hydroxylamine 
NaHMDS Sodium bis(trimethylsilyl) -amide  
NBD Norbornadiene 
NHC N-Heterocyclic carbene 
NMO N-Methylmorpholine N-oxide 
NMR Nuclear magnetic resonance 
NOE Nuclear Overhauser effect 
o Ortho 
p Para 
PCC Pyridinium chlorochromate 
Pf 9-Phenylfluorenyl 
Pg Protection group 
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Ph Phenyl 
PHAL Phtalazine 
PHOX Phosphinooxazoline 
Piv Pivaloyl 
PKC Protein kinase C 
PLAP Placental alkaline phosphatase 
PMB para-Methoxybenzyl 
pmdba bis(4-methoxy-
benzylidene)acetone 
PP Diphosphate 
PPTS Pyridinium para-
toluenesulfonate 
i-Pr iso-Propyl 
pyr Pyridine 
q Quartet (NMR) 
Rf Retention factor 
RCM Ring-closing olefin metathesis 
RNA Ribonucleic acid 
ROMP Ring-opening olefin metathesis 
polymerization 
s Singlet (NMR) 
SN2 Bimolecular nucleophilic 
substitution 
t Triplet (NMR) 
TBAF Tetrabutylammonium fluoride 
TBAI Tetrabutylammonium iodide 
TBDPS tert-Butyldiphenylsilyl 
TBHP tert-Butyl hydroperoxide 
TBS tert-Butyldimethylsilyl 
TCDI 1,1’-Thiocarbonyldiimidazole 
Tf Trifluoromethanesulfonyl 
TFA Trifluoroacetic acid 
TFAA Trifluoroacetic anhydride 
THF Tetrahydrofuran 
TIPS Triisopropylsilyl 
TLC Thin layer chromatography 
TMS Trimethylsilyl 
o-Tol ortho-Tolyl 
TPAP Tetra-N-propylammonium 
perruthenate 
Tr Trityl, triphenylmethyl 
Ts p-Toluenesulfonyl, tosyl 
X Halogen, oxygen or sulfur 
Xantphos 9,9-Dimethyl-4,5-bis(diphenyl-
phosphino)xanthene 
Xphos 2’,4’,6’-Triisopropyl-2-
dicyclohexylphosphinobiphenyl 
UHP Urea hydrogen peroxide 
UV Ultraviolet 
VEGF Vascular endothelial growth 
factor 
Z Zusammen 
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Table 1.  Crystal data and structure refinement for 3.38. 
Empirical formula  C15H24O6 
Formula weight  300.34 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 5.563(2) Å α = 90° 
 b = 9.190(2) Å β = 90° 
 c = 30.584(6) Å γ = 90° 
Volume 1563.6(7) Å3 
Z 4 
Density (calculated) 1.276 g/cm3 
Absorption coefficient 0.816 mm-1 
F(000) 648 
Crystal size 0.31 x 0.15 x 0.14 mm3 
Theta range for data collection 2.89 to 68.23° 
Index ranges -6<=h<=6, -10<=k<=11, -36<=l<=36 
Reflections collected 22545 
Independent reflections 2844 [R(int) = 0.0325] 
Completeness to theta = 68.23° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.8944 and 0.7861 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2844 / 0 / 201 
Goodness-of-fit on F2 1.087 
Final R indices [I>2sigma(I)] R1 = 0.0271, wR2 = 0.0673 
R indices (all data) R1 = 0.0278, wR2 = 0.0679 
Absolute structure parameter 0.06(13) 
Largest diff. peak and hole 0.146 and -0.297 e.Å-3 
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Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for 3.38.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
 x y z U(eq) 
C(1) 9576(2) 1969(1) 8632(1) 16(1) 
C(2) 9430(2) 924(1) 8244(1) 18(1) 
C(3) 7046(2) 917(1) 7996(1) 18(1) 
C(4) 7046(2) -148(1) 7611(1) 19(1) 
C(5) 7448(2) -1744(1) 7748(1) 18(1) 
C(6) 5551(2) -2217(1) 8067(1) 17(1) 
O(7) 6469(2) -2885(1) 8418(1) 19(1) 
C(8) 4827(2) -3248(1) 8768(1) 21(1) 
C(9) 5590(2) -2434(1) 9182(1) 18(1) 
C(10) 5718(2) -826(1) 9091(1) 17(1) 
C(11) 7680(2) -6(1) 9111(1) 18(1) 
C(12) 7687(2) 1564(1) 8983(1) 16(1) 
O(13) 8339(2) 2430(1) 9371(1) 18(1) 
C(14) 6730(2) 3351(1) 9538(1) 17(1) 
O(15) 4707(2) 3517(1) 9399(1) 23(1) 
C(16) 7739(3) 4152(1) 9924(1) 24(1) 
C(17) 3753(2) -2775(1) 9542(1) 22(1) 
O(18) 3426(2) -1973(1) 8017(1) 24(1) 
O(19) 4865(2) -21(1) 7366(1) 25(1) 
O(20) 11926(2) 1728(1) 8809(1) 20(1) 
C(21) 9320(2) 3556(1) 8496(1) 21(1) 
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Table 3.   Bond lengths [Å] and angles [°] for  3.38. 
C(1)-O(20)  1.4314(15) 
C(1)-C(21)  1.5233(17) 
C(1)-C(2)  1.5307(16) 
C(1)-C(12)  1.5458(16) 
C(2)-C(3)  1.5277(17) 
C(2)-H(2A)  0.9900 
C(2)-H(2B)  0.9900 
C(3)-C(4)  1.5302(16) 
C(3)-H(3A)  0.9900 
C(3)-H(3B)  0.9900 
C(4)-O(19)  1.4315(16) 
C(4)-C(5)  1.5416(17) 
C(4)-H(4)  1.0000 
C(5)-C(6)  1.5017(17) 
C(5)-H(5A)  0.9900 
C(5)-H(5B)  0.9900 
C(6)-O(18)  1.2126(16) 
C(6)-O(7)  1.3372(15) 
O(7)-C(8)  1.4461(15) 
C(8)-C(9)  1.5320(17) 
C(8)-H(8A)  0.9900 
C(8)-H(8B)  0.9900 
C(9)-C(10)  1.5056(17) 
C(9)-C(17)  1.5336(17) 
C(9)-H(9)  1.0000 
C(10)-C(11)  1.3281(18) 
C(10)-H(10)  0.9500 
C(11)-C(12)  1.4956(17) 
C(11)-H(11)  0.9500 
C(12)-O(13)  1.4752(13) 
C(12)-H(12)  1.0000 
O(13)-C(14)  1.3328(15) 
C(14)-O(15)  1.2121(17) 
C(14)-C(16)  1.5006(17) 
C(16)-H(16A)  0.9800 
C(16)-H(16B)  0.9800 
C(16)-H(16C)  0.9800 
C(17)-H(17A)  0.9800 
C(17)-H(17B)  0.9800 
C(17)-H(17C)  0.9800 
O(19)-H(19)  0.863(19) 
O(20)-H(20)  0.790(19) 
C(21)-H(21A)  0.9800 
C(21)-H(21B)  0.9800 
C(21)-H(21C)  0.9800 
O(20)-C(1)-C(21) 109.70(10) 
O(20)-C(1)-C(2) 104.10(9) 
C(21)-C(1)-C(2) 112.50(10) 
O(20)-C(1)-C(12) 108.81(9) 
C(21)-C(1)-C(12) 110.93(10) 
C(2)-C(1)-C(12) 110.53(9) 
C(3)-C(2)-C(1) 115.75(10) 
C(3)-C(2)-H(2A) 108.3 
C(1)-C(2)-H(2A) 108.3 
C(3)-C(2)-H(2B) 108.3 
C(1)-C(2)-H(2B) 108.3 
H(2A)-C(2)-H(2B) 107.4 
C(2)-C(3)-C(4) 112.61(10) 
C(2)-C(3)-H(3A) 109.1 
C(4)-C(3)-H(3A) 109.1 
C(2)-C(3)-H(3B) 109.1 
C(4)-C(3)-H(3B) 109.1 
H(3A)-C(3)-H(3B) 107.8 
O(19)-C(4)-C(3) 110.53(10) 
O(19)-C(4)-C(5) 110.07(10) 
C(3)-C(4)-C(5) 113.53(9) 
O(19)-C(4)-H(4) 107.5 
C(3)-C(4)-H(4) 107.5 
C(5)-C(4)-H(4) 107.5 
C(6)-C(5)-C(4) 110.49(10) 
C(6)-C(5)-H(5A) 109.6 
C(4)-C(5)-H(5A) 109.6 
C(6)-C(5)-H(5B) 109.6 
C(4)-C(5)-H(5B) 109.6 
H(5A)-C(5)-H(5B) 108.1 
O(18)-C(6)-O(7) 123.98(11) 
O(18)-C(6)-C(5) 123.31(11) 
O(7)-C(6)-C(5) 112.67(10) 
C(6)-O(7)-C(8) 117.27(10) 
O(7)-C(8)-C(9) 108.95(10) 
O(7)-C(8)-H(8A) 109.9 
C(9)-C(8)-H(8A) 109.9 
O(7)-C(8)-H(8B) 109.9 
C(9)-C(8)-H(8B) 109.9 
H(8A)-C(8)-H(8B) 108.3 
C(10)-C(9)-C(8) 109.80(10) 
C(10)-C(9)-C(17) 111.41(10) 
C(8)-C(9)-C(17) 108.05(10) 
C(10)-C(9)-H(9) 109.2 
C(8)-C(9)-H(9) 109.2 
C(17)-C(9)-H(9) 109.2 
C(11)-C(10)-C(9) 125.99(11) 
C(11)-C(10)-H(10) 117.0 
C(9)-C(10)-H(10) 117.0 
C(10)-C(11)-C(12) 122.53(11) 
C(10)-C(11)-H(11) 118.7 
C(12)-C(11)-H(11) 118.7 
O(13)-C(12)-C(11) 108.01(9) 
O(13)-C(12)-C(1) 105.15(9) 
C(11)-C(12)-C(1) 114.60(10) 
O(13)-C(12)-H(12) 109.6 
C(11)-C(12)-H(12) 109.6 
C(1)-C(12)-H(12) 109.6 
C(14)-O(13)-C(12) 119.04(9) 
O(15)-C(14)-O(13) 124.72(11) 
O(15)-C(14)-C(16) 124.11(12) 
O(13)-C(14)-C(16) 111.16(11) 
C(14)-C(16)-H(16A) 109.5 
C(14)-C(16)-H(16B) 109.5 
H(16A)-C(16)-H(16B) 109.5 
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C(14)-C(16)-H(16C) 109.5 
H(16A)-C(16)-H(16C) 109.5 
H(16B)-C(16)-H(16C) 109.5 
C(9)-C(17)-H(17A) 109.5 
C(9)-C(17)-H(17B) 109.5 
H(17A)-C(17)-H(17B) 109.5 
C(9)-C(17)-H(17C) 109.5 
H(17A)-C(17)-H(17C) 109.5 
H(17B)-C(17)-H(17C) 109.5 
C(4)-O(19)-H(19) 106.3(12) 
C(1)-O(20)-H(20) 108.7(13) 
C(1)-C(21)-H(21A) 109.5 
C(1)-C(21)-H(21B) 109.5 
H(21A)-C(21)-H(21B) 109.5 
C(1)-C(21)-H(21C) 109.5 
H(21A)-C(21)-H(21C) 109.5 
H(21B)-C(21)-H(21C) 109.5 
 
Symmetri transformations used to generate equivalent atoms.    
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Table 4.   Anisotropic displacement parameters  (Å2x 103) for 3.38.  The anisotropic 
displacement factor exponent takes the form:  -2π2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
 U11 U22  U33 U23 U13 U12 
C(1) 13(1)  17(1) 19(1)  -1(1) -1(1)  0(1) 
C(2) 17(1)  18(1) 18(1)  -1(1) 1(1)  0(1) 
C(3) 20(1)  17(1) 19(1)  0(1) -2(1)  1(1) 
C(4) 21(1)  21(1) 16(1)  -1(1) -2(1)  -1(1) 
C(5) 19(1)  18(1) 17(1)  -3(1) -1(1)  1(1) 
C(6) 20(1)  13(1) 19(1)  -3(1) -2(1)  3(1) 
O(7) 19(1)  20(1) 18(1)  0(1) 0(1)  2(1) 
C(8) 24(1)  19(1) 21(1)  1(1) 2(1)  -3(1) 
C(9) 18(1)  17(1) 20(1)  2(1) 1(1)  2(1) 
C(10) 18(1)  19(1) 15(1)  0(1) 1(1)  3(1) 
C(11) 18(1)  20(1) 15(1)  -1(1) -2(1)  3(1) 
C(12) 15(1)  18(1) 15(1)  -4(1) -2(1)  0(1) 
O(13) 18(1)  20(1) 17(1)  -5(1) -3(1)  1(1) 
C(14) 22(1)  14(1) 17(1)  3(1) 0(1)  -2(1) 
O(15) 21(1)  22(1) 26(1)  -6(1) -3(1)  3(1) 
C(16) 28(1)  22(1) 22(1)  -5(1) -4(1)  1(1) 
C(17) 25(1)  18(1) 24(1)  2(1) 3(1)  1(1) 
O(18) 18(1)  26(1) 29(1)  4(1) -1(1)  3(1) 
O(19) 30(1)  23(1) 22(1)  1(1) -10(1)  -1(1) 
O(20) 14(1)  21(1) 24(1)  -7(1) -4(1)  1(1) 
C(21) 22(1)  19(1) 22(1)  -1(1) -1(1)  0(1) 
 
Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for 3.38. 
 
 x  y  z  U(eq) 
H(2A) 10728 1174 8036 21 
H(2B) 9745 -75 8351 21 
H(3A) 6715 1909 7885 22 
H(3B) 5736 650 8200 22 
H(4) 8401 132 7413 23 
H(5A) 7395 -2377 7486 21 
H(5B) 9055 -1846 7884 21 
H(8A) 4855 -4311 8821 25 
H(8B) 3170 -2967 8686 25 
H(9) 7210 -2787 9276 22 
H(10) 4262 -355 9011 21 
H(11) 9135 -433 9211 21 
H(12) 6050 1852 8879 19 
H(16A) 6967 5107 9947 36 
H(16B) 9475 4280 9885 36 
H(16C) 7435 3592 10191 36 
H(17A) 4299 -2353 9819 33 
H(17B) 3596 -3831 9574 33 
H(17C) 2192 -2357 9463 33 
H(19) 3770(30) -470(20) 7515(6) 33(5) 
H(20) 12190(30) 2330(20) 8988(6) 31(5) 
H(21A) 9523 4184 8752 32 
H(21B) 7722 3712 8369 32 
H(21C) 10550 3792 8278 32 
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Table 6.  Torsion angles [°] for 3.38. 
O(20)-C(1)-C(2)-C(3) 178.44(9) 
C(21)-C(1)-C(2)-C(3) -62.86(14) 
C(12)-C(1)-C(2)-C(3) 61.75(13) 
C(1)-C(2)-C(3)-C(4) 179.67(10) 
C(2)-C(3)-C(4)-O(19) -174.74(10) 
C(2)-C(3)-C(4)-C(5) 61.01(14) 
O(19)-C(4)-C(5)-C(6) -66.46(12) 
C(3)-C(4)-C(5)-C(6) 58.04(13) 
C(4)-C(5)-C(6)-O(18) 45.99(15) 
C(4)-C(5)-C(6)-O(7) -131.72(10) 
O(18)-C(6)-O(7)-C(8) -4.06(17) 
C(5)-C(6)-O(7)-C(8) 173.63(9) 
C(6)-O(7)-C(8)-C(9) -118.15(11) 
O(7)-C(8)-C(9)-C(10) 55.48(13) 
O(7)-C(8)-C(9)-C(17) 177.17(9) 
C(8)-C(9)-C(10)-C(11) -116.88(13) 
C(17)-C(9)-C(10)-C(11) 123.46(13) 
C(9)-C(10)-C(11)-C(12) 175.29(11) 
C(10)-C(11)-C(12)-O(13) 118.24(12) 
C(10)-C(11)-C(12)-C(1) -124.95(12) 
O(20)-C(1)-C(12)-O(13) 54.68(11) 
C(21)-C(1)-C(12)-O(13) -66.09(12) 
C(2)-C(1)-C(12)-O(13) 168.41(9) 
O(20)-C(1)-C(12)-C(11) -63.76(12) 
C(21)-C(1)-C(12)-C(11) 175.46(10) 
C(2)-C(1)-C(12)-C(11) 49.96(13) 
C(11)-C(12)-O(13)-C(14) -115.67(11) 
C(1)-C(12)-O(13)-C(14) 121.54(11) 
C(12)-O(13)-C(14)-O(15) 1.77(17) 
C(12)-O(13)-C(14)-C(16) -178.73(10) 
Symmetri transformations used to generate equivalent atoms. 
 
Table 7.  Hydrogen bonds for 3.38  [Å and °]. 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
O(20)-H(20)...O(15)#1 0.790(19) 2.178(19) 2.8910(13) 150.3(17) 
O(19)-H(19)...O(18) 0.863(19) 2.077(19) 2.7978(14) 140.5(16) 
Symmetry transformations used to generate equivalent atoms:  
#1 x+1,y,z    
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Table 1.  Crystal data and structure refinement for 5.122 (CCDC 686849). 
Empirical formula  C19H24N3OI 
Formula weight  437.31 
Crystallization Solvent  Dichloromethane/pentane 
Crystal Habit  Needle 
Crystal size 0.28 x 0.11 x 0.07 mm3 
Crystal color  Colorless  
 Data Collection  
Type of diffractometer  Bruker KAPPA APEX II 
Wavelength  0.71073 Å MoKα  
Data Collection Temperature  100(2) K 
θ range for 9911 reflections used 
in lattice determination  2.57 to 28.78° 
Unit cell dimensions a = 17.160(4) Å 
 b = 5.5921(14) Å β= 90.689(6)° 
 c = 19.984(5) Å 
Volume 1917.6(8) Å3 
Z 4 
Crystal system  Monoclinic 
Space group  P21 
Density (calculated) 1.515 Mg/m3 
F(000) 880 
Data collection program Bruker APEX2 v2.1-0 
θ range for data collection 1.55 to 29.84° 
Completeness to θ = 29.84° 88.9 %  
Index ranges -23 ≤ h ≤ 23, -7 ≤ k ≤ 7, -26 ≤ l ≤ 25 
Data collection scan type  ω scans; 16 settings 
Data reduction program  Bruker SAINT-Plus v7.34A 
Reflections collected 8962 
Independent reflections 8962 [Rint= 0.0000] 
Absorption coefficient 1.680 mm-1 
Absorption correction Semi-empirical from equivalents (TWNABS) 
Max. and min. transmission 0.7460 and 0.5010
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Table 1 (cont.) 
 Structure solution and Refinement  
Structure solution program  SHELXS-97 (Sheldrick, 2008) 
Primary solution method  Direct methods 
Secondary solution method  Difference Fourier map 
Hydrogen placement  Geometric positions 
Structure refinement program  SHELXL-97 (Sheldrick, 2008) 
Refinement method Full matrix least-squares on F2 
Data / restraints / parameters 8962 / 1 / 437 
Treatment of hydrogen atoms  Riding 
Goodness-of-fit on F2 1.609 
Final R indices [I>2σ(I),  7203 reflections] R1 = 0.0409, wR2 = 0.0481 
R indices (all data) R1 = 0.0619, wR2 = 0.0493 
Type of weighting scheme used Sigma 
Weighting scheme used w=1/σ2(Fo2) 
Max shift/error  0.002 
Average shift/error  0.000 
Absolute structure determination Anomalous differences 
Absolute structure parameter 0.003(11) 
Largest diff. peak and hole 0.807 and -0.967 e.Å-3 
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Special Refinement Details  
The structure was refined as a single component, although the crystals were twins, using an HKLF4 format 
reflection file prepared with TWINABS (see below). The two orientations were separated using CELL_NOW as 
follows. 
Rotated from first domain by 178.9 degrees about reciprocal axis -0.032  1.000  0.104  and real axis -0.001  
1.000  0.007. Twin law to convert hkl from first to this domain (SHELXL TWIN matrix): 
 
 -1.000  -0.065   0.016 
 -0.003   0.998   0.014 
 -0.022   0.207  -0.999 
 
From Saint integration; Twin Law, Sample 1 of 1 transforms h1.1(1)->h1.2(2) 
 
 -0.99897 -0.07583  0.01646 
 -0.00750  0.99693  0.01538 
 -0.02464  0.19596 -0.99910 
 
Twinabs; 
 
PART 1 - Refinement of parameters to model systematic errors 
 
18757 data (   4443 unique ) involve domain  1 only,  mean I/sigma  13.7 
18551 data (   4364 unique ) involve domain  2 only,  mean I/sigma   7.1 
10342 data (   4106 unique ) involve   2 domains,  mean I/sigma  19.2 
 
HKLF 4 dataset constructed from all observations involving domains 1..2 
    8970 Corrected reflections written to file twin4.hkl 
 Reflections merged according to point-group 2 
 Minimum and maximum apparent transmission:  0.501007  0.745969 
 Additional spherical absorption correction applied with mu*r =  0.2000 
 
Crystals were mounted on a glass fiber using Paratone oil then placed on the diffractometer under a nitrogen 
stream at 100K. 
Refinement of F2 against ALL reflections.  The weighted R-factor (wR) and goodness of fit (S) are based on F2, 
conventional R-factors (R) are based on F, with F set to zero for negative F2. The threshold expression of F2 > 2σ( F2) is 
used only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement.  R-factors 
based on F2 are statistically about twice as large as those based on F, and R-factors based on ALL data will be even 
larger. 
All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance 
matrix.  The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion 
angles; correlations between esds in cell parameters are only used when they are defined by crystal symmetry.  An 
approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. planes. 
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Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 
103) for 5.122 (CCDC 686849).  U(eq) is defined as the trace of the orthogonalized Uij tensor.  
________________________________________________________________________________ 
 x y z Ueq 
________________________________________________________________________________ 
I(1) 9525(1) 8297(1) 6590(1) 36(1) 
O(1A) 7955(1) 941(3) 3051(1) 30(1) 
N(1A) 7500(2) 3872(4) 3727(1) 30(1) 
N(2A) 6670(2) 1070(4) 3270(1) 28(1) 
N(3A) 6059(2) 2296(4) 3562(1) 28(1) 
C(1A) 8489(2) 4383(5) 4938(2) 26(1) 
C(2A) 8786(2) 5006(6) 5555(2) 27(1) 
C(3A) 9158(2) 7186(5) 5637(2) 24(1) 
C(4A) 9240(2) 8700(6) 5094(2) 23(1) 
C(5A) 8934(2) 8049(6) 4481(2) 24(1) 
C(6A) 8541(2) 5886(5) 4389(2) 21(1) 
C(7A) 8214(2) 5251(6) 3716(2) 29(1) 
C(8A) 7411(2) 1915(5) 3335(2) 24(1) 
C(9A) 5356(2) 1676(5) 3411(2) 25(1) 
C(10A) 5153(2) -221(5) 2912(2) 34(1) 
C(11A) 4738(2) 3016(6) 3736(2) 25(1) 
C(12A) 4902(2) 5012(5) 4229(2) 30(1) 
C(13A) 4096(2) 6199(5) 4302(2) 34(1) 
C(14A) 3501(2) 4222(5) 4130(2) 33(1) 
C(15A) 3985(2) 2625(5) 3693(2) 32(1) 
C(16A) 3271(2) 2838(6) 4771(2) 47(1) 
C(17A) 2751(2) 5160(6) 3793(2) 36(1) 
C(18A) 2864(2) 6198(6) 3116(2) 39(1) 
C(19A) 2612(2) 8233(8) 2900(2) 51(1) 
I(2) 5760(1) 351(1) -1541(1) 52(1) 
O(1B) 6661(1) 7118(3) 2275(1) 34(1) 
N(1B) 7173(2) 4167(4) 1625(1) 34(1) 
N(2B) 7955(2) 7040(4) 2098(1) 27(1) 
N(3B) 8578(2) 5882(4) 1807(1) 26(1) 
C(1B) 6496(2) 3858(5) 289(2) 33(1) 
C(2B) 6341(2) 3322(8) -374(2) 35(1) 
C(3B) 5958(2) 1240(6) -534(2) 29(1) 
C(4B) 5742(2) -303(6) -40(2) 31(1) 
C(5B) 5895(2) 235(6) 618(2) 28(1) 
C(6B) 6287(2) 2329(5) 795(2) 26(1) 
C(7B) 6454(2) 2863(6) 1519(2) 32(1) 
C(8B) 7233(2) 6143(5) 2016(2) 25(1) 
C(9B) 9266(2) 6619(5) 1925(2) 24(1) 
C(10B) 9471(2) 8670(6) 2382(2) 33(1) 
C(11B) 9892(2) 5325(6) 1586(2) 25(1) 
C(12B) 9704(2) 3469(7) 1051(2) 34(1) 
C(13B) 10499(2) 2401(6) 903(2) 54(1) 
C(14B) 11131(2) 4019(5) 1204(2) 33(1) 
C(15B) 10659(2) 5558(6) 1666(2) 30(1) 
C(16B) 11736(3) 2543(7) 1600(2) 67(2) 
C(17B) 11522(2) 5571(7) 690(2) 58(1) 
C(18B) 12017(3) 4302(6) 194(2) 52(1) 
C(19B) 11859(3) 3982(7) -416(2) 77(2_______ 
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Table 3.   Bond lengths [Å] and angles [°] for 5.122 (CCDC 686849). 
I(1)-C(3A)  2.092(3) 
O(1A)-C(8A)  1.226(4) 
N(1A)-C(8A)  1.354(4) 
N(1A)-C(7A)  1.449(4) 
N(2A)-C(8A)  1.361(4) 
N(2A)-N(3A)  1.388(3) 
N(3A)-C(9A)  1.289(4) 
C(1A)-C(2A)  1.375(5) 
C(1A)-C(6A)  1.386(4) 
C(2A)-C(3A)  1.385(4) 
C(3A)-C(4A)  1.384(4) 
C(4A)-C(5A)  1.376(4) 
C(5A)-C(6A)  1.397(5) 
C(6A)-C(7A)  1.494(4) 
C(9A)-C(11A)  1.457(4) 
C(9A)-C(10A)  1.494(4) 
C(11A)-C(15A)  1.312(4) 
C(11A)-C(12A)  1.514(5) 
C(12A)-C(13A)  1.542(4) 
C(13A)-C(14A)  1.542(5) 
C(14A)-C(15A)  1.505(4) 
C(14A)-C(17A)  1.538(5) 
C(14A)-C(16A)  1.552(5) 
C(17A)-C(18A)  1.487(5) 
C(18A)-C(19A)  1.290(5) 
I(2)-C(3B)  2.096(3) 
O(1B)-C(8B)  1.242(4) 
N(1B)-C(8B)  1.356(4) 
N(1B)-C(7B)  1.447(4) 
N(2B)-C(8B)  1.346(4) 
N(2B)-N(3B)  1.383(3) 
N(3B)-C(9B)  1.270(4) 
C(1B)-C(6B)  1.376(4) 
C(1B)-C(2B)  1.380(5) 
C(2B)-C(3B)  1.373(5) 
C(3B)-C(4B)  1.366(4) 
C(4B)-C(5B)  1.372(4) 
C(5B)-C(6B)  1.394(5) 
C(6B)-C(7B)  1.501(5) 
C(9B)-C(11B)  1.467(4) 
C(9B)-C(10B)  1.504(4) 
C(11B)-C(15B)  1.330(4) 
C(11B)-C(12B)  1.522(4) 
C(12B)-C(13B)  1.521(5) 
C(13B)-C(14B)  1.530(5) 
C(14B)-C(15B)  1.505(4) 
C(14B)-C(17B)  1.509(5) 
C(14B)-C(16B)  1.537(6) 
C(17B)-C(18B)  1.493(5) 
C(18B)-C(19B)  1.260(5) 
C(8A)-N(1A)-C(7A) 120.7(3) 
C(8A)-N(2A)-N(3A) 119.8(3) 
C(9A)-N(3A)-N(2A) 118.6(3) 
C(2A)-C(1A)-C(6A) 122.1(3) 
C(1A)-C(2A)-C(3A) 119.6(3) 
C(2A)-C(3A)-C(4A) 119.8(3) 
C(2A)-C(3A)-I(1) 120.1(2) 
C(4A)-C(3A)-I(1) 119.9(2) 
C(5A)-C(4A)-C(3A) 119.7(3) 
C(4A)-C(5A)-C(6A) 121.7(3) 
C(1A)-C(6A)-C(5A) 117.2(3) 
C(1A)-C(6A)-C(7A) 122.8(3) 
C(5A)-C(6A)-C(7A) 120.1(3) 
N(1A)-C(7A)-C(6A) 115.0(3) 
O(1A)-C(8A)-N(1A) 123.1(3) 
O(1A)-C(8A)-N(2A) 121.2(3) 
N(1A)-C(8A)-N(2A) 115.8(3) 
N(3A)-C(9A)-C(11A) 116.2(3) 
N(3A)-C(9A)-C(10A) 123.9(3) 
C(11A)-C(9A)-C(10A) 119.8(3) 
C(15A)-C(11A)-C(9A) 127.4(3) 
C(15A)-C(11A)-C(12A) 109.9(3) 
C(9A)-C(11A)-C(12A) 122.6(3) 
C(11A)-C(12A)-C(13A) 102.6(3) 
C(12A)-C(13A)-C(14A) 105.2(2) 
C(15A)-C(14A)-C(17A) 114.4(3) 
C(15A)-C(14A)-C(13A) 100.7(3) 
C(17A)-C(14A)-C(13A) 113.7(3) 
C(15A)-C(14A)-C(16A) 109.3(3) 
C(17A)-C(14A)-C(16A) 108.2(3) 
C(13A)-C(14A)-C(16A) 110.3(3) 
C(11A)-C(15A)-C(14A) 114.4(3) 
C(18A)-C(17A)-C(14A) 114.4(3) 
C(19A)-C(18A)-C(17A) 127.0(3) 
C(8B)-N(1B)-C(7B) 123.6(3) 
C(8B)-N(2B)-N(3B) 119.3(3) 
C(9B)-N(3B)-N(2B) 119.4(3) 
C(6B)-C(1B)-C(2B) 121.4(3) 
C(3B)-C(2B)-C(1B) 119.6(3) 
C(4B)-C(3B)-C(2B) 120.0(3) 
C(4B)-C(3B)-I(2) 120.1(3) 
C(2B)-C(3B)-I(2) 119.8(2) 
C(3B)-C(4B)-C(5B) 120.3(3) 
C(4B)-C(5B)-C(6B) 120.9(3) 
C(1B)-C(6B)-C(5B) 117.7(3) 
C(1B)-C(6B)-C(7B) 122.4(3) 
C(5B)-C(6B)-C(7B) 119.8(3) 
N(1B)-C(7B)-C(6B) 113.3(3) 
O(1B)-C(8B)-N(2B) 121.1(3) 
O(1B)-C(8B)-N(1B) 123.0(3) 
N(2B)-C(8B)-N(1B) 115.9(3) 
N(3B)-C(9B)-C(11B) 116.0(3) 
N(3B)-C(9B)-C(10B) 124.7(3) 
C(11B)-C(9B)-C(10B) 119.3(3) 
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C(15B)-C(11B)-C(9B) 128.7(3) 
C(15B)-C(11B)-C(12B) 110.6(3) 
C(9B)-C(11B)-C(12B) 120.7(3) 
C(13B)-C(12B)-C(11B) 102.9(3) 
C(12B)-C(13B)-C(14B) 108.9(3) 
C(15B)-C(14B)-C(17B) 109.6(3) 
C(15B)-C(14B)-C(13B) 101.3(3) 
C(17B)-C(14B)-C(13B) 112.9(3) 
C(15B)-C(14B)-C(16B) 110.9(3) 
C(17B)-C(14B)-C(16B) 110.8(3) 
C(13B)-C(14B)-C(16B) 110.9(3) 
C(11B)-C(15B)-C(14B) 114.2(3) 
C(18B)-C(17B)-C(14B) 116.1(3) 
C(19B)-C(18B)-C(17B) 126.3(5) 
 
 
Table 4.   Anisotropic displacement parameters (Å2x 104) for 5.122 (CCDC 686849).  The 
anisotropic displacement factor exponent takes the form: -2π2[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
I(1) 340(2)  433(1) 310(1)  1(1) -116(1)  -2(1) 
O(1A) 177(14)  294(13) 431(15)  -131(10) -15(11)  35(10) 
N(1A) 166(17)  377(19) 352(17)  -168(12) 3(13)  -6(12) 
N(2A) 150(17)  315(15) 378(18)  -133(12) -22(13)  22(12) 
N(3A) 186(19)  310(15) 328(18)  -35(12) -35(15)  38(13) 
C(1A) 190(20)  176(16) 420(20)  13(15) -22(18)  9(13) 
C(2A) 250(20)  237(18) 320(20)  88(15) -7(16)  -4(16) 
C(3A) 170(20)  261(17) 270(20)  -18(14) -7(16)  69(14) 
C(4A) 180(20)  200(20) 310(20)  -23(14) -29(15)  -13(14) 
C(5A) 240(20)  201(19) 275(19)  26(16) 5(15)  34(16) 
C(6A) 171(19)  195(18) 269(19)  -26(14) -8(15)  64(14) 
C(7A) 260(20)  280(18) 330(20)  -40(17) -16(16)  -38(18) 
C(8A) 200(20)  257(18) 260(20)  -33(14) -61(17)  19(16) 
C(9A) 200(20)  231(17) 330(20)  -9(14) -9(18)  -26(15) 
C(10A) 200(20)  410(20) 430(20)  -69(17) 3(18)  -44(17) 
C(11A) 190(20)  240(20) 330(20)  21(16) -31(15)  -26(17) 
C(12A) 250(20)  283(18) 360(20)  -23(16) -60(16)  -30(16) 
C(13A) 260(20)  305(19) 440(20)  -99(15) -50(18)  42(16) 
C(14A) 190(20)  305(19) 490(30)  -7(15) 9(19)  19(15) 
C(15A) 260(20)  240(20) 460(20)  -48(14) -26(19)  -18(15) 
C(16A) 360(30)  500(30) 540(30)  114(18) 30(20)  88(19) 
C(17A) 250(20)  390(20) 450(20)  -34(18) 9(18)  40(20) 
C(18A) 270(20)  480(20) 420(30)  -75(18) -70(20)  77(18) 
C(19A) 410(30)  600(20) 510(20)  40(20) -88(19)  120(30) 
I(2) 431(2)  791(2) 333(2)  -69(1) -57(1)  -30(2) 
O(1B) 227(16)  346(12) 447(16)  -105(10) 2(13)  9(11) 
N(1B) 220(19)  350(17) 440(20)  -151(12) -38(16)  9(12) 
N(2B) 230(20)  301(15) 272(17)  -106(12) -29(14)  3(13) 
N(3B) 208(18)  309(16) 277(16)  -57(12) -23(14)  26(14) 
C(1B) 340(30)  190(20) 470(30)  -9(15) -50(20)  -62(15) 
C(2B) 310(20)  404(19) 350(20)  130(20) -22(16)  20(20) 
C(3B) 190(20)  370(20) 310(20)  -17(16) -51(17)  17(16) 
C(4B) 200(20)  270(20) 450(30)  -58(16) -50(18)  -39(15) 
C(5B) 270(20)  236(18) 340(20)  71(16) -20(16)  -10(17) 
C(6B) 170(20)  246(18) 350(20)  8(15) -46(17)  -2(14) 
C(7B) 300(20)  310(20) 360(20)  -12(15) -23(17)  -59(16) 
C(8B) 200(20)  282(19) 270(20)  -34(14) -76(16)  -6(16) 
C(9B) 250(20)  257(18) 220(20)  11(14) 2(17)  11(16) 
C(10B) 260(20)  400(20) 330(20)  -104(16) 37(16)  -60(18) 
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C(11B) 250(20)  241(17) 253(19)  -25(16) -45(15)  -52(18) 
C(12B) 340(20)  341(18) 330(20)  -105(19) -60(16)  10(20) 
C(13B) 450(30)  450(20) 730(30)  -310(20) 70(30)  -4(19) 
C(14B) 250(20)  350(20) 390(20)  -54(15) 20(19)  25(15) 
C(15B) 340(20)  290(18) 266(19)  -75(16) -25(16)  33(18) 
C(16B) 720(40)  680(30) 610(30)  -170(20) -50(30)  380(30) 
C(17B) 840(30)  400(20) 510(30)  -150(20) 330(20)  -90(20) 
C(18B) 500(30)  540(30) 520(30)  -104(19) 110(30)  -49(19) 
C(19B) 1060(50)  830(40) 420(30)  40(20) 60(30)  500(30) 
______________________________________________________________________________ 
 
 
Table 5.  Hydrogen bonds for 5.122 (CCDC 686849) [Å and °]. 
____________________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________ 
 N(2A)-H(2A)...O(1B)#1 0.88 2.13 2.972(3) 159.7 
 N(2B)-H(2B)...O(1A)#2 0.88 2.04 2.895(3) 163.1 
____________________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
#1 x,y-1,z     
#2 x,y+1,z 
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ABSTRACT
An efficient synthesis of the macrocyclic core of (-)-pladienolide B is disclosed. The concise route relies on a chiral auxiliary-mediated
asymmetric aldol addition and an osmium-catalyzed asymmetric dihydroxylation to install the three oxygenated stereocenters of the macrocycle.
This purely reagent-controlled and flexible strategy sets the stage for future analogue syntheses and structure-activity relationship plotting
of the appealing anticancer lead structure pladienolide B.
The identification of new targets of clinical relevance is a
cornerstone in improving the level of existing disease
remedies and for developing new therapies for hitherto
untreatable diseases.1 Recently, it has been indicated that
splicing factors are important potential targets for the
development of new cancer therapies.2 The natural product
pladienolide B (1, Figure 1) potently inhibits cancer cell
proliferation, and biological studies aimed at elucidating its
mode of action have led to a proposed mechanism involving
binding to the splicing factor SF3b.3 Pladienolide B was
isolated by Sakai and co-workers in 2004 from the fermenta-
tion broth of Streptomyces platensis Mer-11107 using a
screen designed to identify compounds that inhibit cell
signaling pathways in a tumor-specific microenvironment.4a–c
Significantly, pladienolide B inhibts hypoxia-induced VEGF
expression and proliferation of human cancer cell lines with
low to subnanomolar IC50 values.4a,c Moreover, pladienolide
B displays unchanged inhibitory activity against drug-
resistant cancer cells, as compared to their parental cell lines,
and has demonstrated complete regression of BSY-1 tumors
in xenograft mice models.4c This unique biological profile
has inspired considerable interest from the scientific com-
munity5,6 leading to elucidation of the absolute stereochem-
istry5 (1, Figure 1) and the first total synthesis by Kotake
and co-workers.6a,c Despite these noteworthy efforts, little
is known about the structural basis for pladienolide B’s
modulation of spliceosomal activity and potential interaction
with other targets.
At the outset of our synthetic efforts in April 2005, only
the planar structure of pladienolide B had been reported.4b,7
Interestingly, the 12-membered core and the side chain of
pladienolide B resemble the macrocyclic core of 10-
† Technical University of Denmark.
‡ Novartis Institutes for BioMedical Research.
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Pool, M.; Darcy, K. M.; Lim, S. B.; Auersperg, N.; Coon, J. S.; Beck,
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deoxymethynolide8 (2, Figure 1) and the side chain of
herboxidiene9 (3). From an evolutionary point of view, it is
conceivable that pladienolide B and other secondary me-
tabolites produced by Streptomyces strains, such as herboxi-
diene and 10-deoxymethynolide, could be synthesized by
polyketide synthases encoded by related gene clusters.10
Consistent with a common biogenesis for these three
polyketides, we projected that the absolute configuration of
1 would correlate to that of 2 and 3. Hence, we focused our
synthetic studies on the asymmetric synthesis of core
structure 4, the enantiomer of the (+)-pladienolide B core
(Figure 1). Herein, we wish to report a convergent synthesis
of 4 and its crystal structure.
Structurally, the core structure 4 consists of a 12-membered
macrolactone bearing four stereocenters with an O-acetylated
secondary alcohol adjacent to a tertiary hydroxyl group. The
macrolactone also contains a disubstituted trans olefin, a
tertiary stereocenter, and a second hydroxyl group stereo-
center. Toward our synthetic target 4 we envisioned a
strategy with maximum flexibility that would provide access
to all sixteen stereoisomers of the core structure. Specifically,
we envisioned an orthoester formation and ring-opening
sequence to selectively acetylate the desired secondary
alcohol and complete the synthesis of 4. Macrolactonization
and (E)-selective cross metathesis between olefins 5 and 6
could construct the 12-membered lactone. 5 would in turn
be available from commercial (S)-Roche ester and 6 was
anticipated to arrive from sequential olefination and osmium-
catalyzed asymmetric dihydroxylation thereby installing the
vicinal oxygen-substituted stereocenters of the macrocycle.
Finally, key intermediate 7 would result from chiral auxiliary-
mediated asymmetric aldol addition of known acetylthiazo-
lidine-thione 9 and aldehyde 8 (Scheme 1).
The synthesis takes advantage of the easily obtainable
building blocks 5 and 8 (Scheme 2). Tritylation of (S)-Roche
ester 10 followed by LAH reduction, Swern oxidation,11 and
Wittig methylenation afforded alkene 5 smoothly over this
four-step sequence (Scheme 2a). Prilezhaev epoxidation12
of commercial acetate 11 and subsequent epoxide cleavage
(6) (a) Kanada, R. M.; Itoh, D.; Nagai, M.; Niijima, J.; Asai, N.; Mizui,
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Figure 1. Metabolites of the Streptomyces family 1-3 and target structure 4.
Scheme 1. Retrosynthesis of (-)-Pladienolide B Core Structure
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using periodic acid provided aldehyde 8.13 Secondary alcohol
12a was available via an asymmetric aldol reaction of
aldehyde 8 with a chiral acetylthiazolidinethione enolate
generated from 9 using Vilarrasa’s conditions.14 The selec-
tivity of the aldol reaction could be tuned to give either 12a
or 12b as the major product even when the same acetylthi-
azolidinethione was employed. The titanium enolate gener-
ated with titanium tetrachloride and Hu¨nig’s base gave
predominantly the desired isomer 12a in excellent yield. If
the enolate was generated from dichlorophenylborane and
(-)-sparteine, 12b was formed as the major product.15
Additionally, the valine and tert-leucine-derived auxiliaries
gave slightly improved product ratios of 5:1 to 6:1. However,
we chose to use the phenylalanine-derived auxiliary because
all intermediates leading to 9 are crystalline and can be
obtained easily in analytically pure form. The aldol product
was then protected as the TBS ether to give 7 in 92% yield
(Scheme 2b).
The oxygenated functionality at the northern portion of
the target molecule was installed by Sharpless’s asymmetric
dihydroxylation protocol.16 From the well-defined olefin
geometry of the substrate, which relates back to nerol and
using the (DHQD)2PHAL ligand, diol 13a was produced in
good yield and selectivity greater than 20:1 at the newly
formed stereocenters (Scheme 3). Acetate 13b was also
formed in equal diastereomeric ratio and is the likely product
of intramolecular acetyl migration. All attempts to convert
13b into 13a were unsuccessful. The key alkene fragment 6
was prepared from 13a in a four-step sequence initially
involving acetonide formation and treatment with K2CO3 in
methanol to concomitantly cleave the acetate and convert
the chiral auxiliary into a methyl ester.17 Parikh-Do¨ering
oxidation18 followed by Wittig methylenation provided
alkene 6 in 71% yield over these four steps. With compound
6 in hand, we set out to identify reaction conditions that
would furnish (E)-alkene 14 efficiently. Initial attempts to
mediate the cross-metathesis between olefins 5 and 6 with
10 mol% of either Grubbs’ second-generation catalyst,19
Hoveyda-Grubbs’ second-generation catalyst,20 or Grubbs’
third-generation catalyst21 gave the desired alkene 14 in less
than 30% yield.22 Interestingly, only the (E)-alkene was
observed by 1H NMR. Following optimization the yield of
14 could be improved to 76% using Hoveyda-Grubbs’
second-generation catalyst and by adding 5 in two portions
over the course of the reaction (Scheme 3). Selective
deprotection of the trityl ether using a solution of BCl323
followed by methyl ester hydrolysis successfully gave seco-
acid 15 in 84% yield for this two-step sequence (Scheme
4).
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(14) Gonza´lez, A´ .; Aiguade´, J.; Urpı´, F.; Vilarrasa, J. Tetrahedron Lett.
1996, 49, 8949–8952.
(15) Zhang, Y.; Phillips, A. J.; Sammakia, T. Org. Lett. 2004, 6, 23–
25.
(16) (a) Jacobsen, E. N.; Marko´, I.; Mungall, W. S.; Schro¨der, G.;
Sharpless, K. B. J. Am. Chem. Soc. 1988, 110, 1968–1970. For a recent
review, see: (b) Zaitsev, A. B.; Adolfsson, H. Synthesis 2006, 11, 1725–
1756.
(17) Crimmins, M. T.; Chaudhary, K. Org. Lett. 2000, 2, 775–777.
(18) Parikh, J. R.; Doering, W. von E. J. Am. Chem. Soc. 1967, 89,
5505–5507.
(19) Scholl, M.; Ding, S.; Lee, C. W.; Grubbs, R. H. Org. Lett. 1999,
1, 953–956.
(20) Garber, S. B.; Kingsbury, J. S.; Gray, B. L.; Hoveyda, A. H. J. Am.
Chem. Soc. 2000, 122, 8168–8179.
(21) Stewart, I. C.; Ung, T.; Pletnev, A. A.; Berlin, J. M.; Grubbs, R. H.;
Schrodi, Y. Org. Lett. 2007, 9, 1589–1592.
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Scheme 2. Synthesis of Intermediates 5, 8, and 7 Scheme 3. Synthesis of (E)-Olefin 14
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Attempts to close the macrocycle under modified Yamagu-
chi conditions24 at room temperature produced 16 in 34%
yield. However, by increasing the reaction temperature to
80 °C and adding the preformed mixed anhydride slowly to
a DMAP-benzene solution,25 the yield improved consider-
ably, and macrocycle 16 could be isolated in 63% yield. The
TBS and acetonide groups were then effectively removed
through the action of aqueous HF in MeCN.26 Finally, the
secondary allylic alcohol was acetylated selectively by
treating the diol with trimethyl orthoacetate and CSA
followed by cleavage of the resulting orthoester with aqueous
AcOH to give the macrocyclic core structure 4 in 86% yield
(Scheme 4).
The structure and absolute stereochemistry of macrolactone
4 were unambiguously established by single-crystal X-ray
crystallography (Figure 2).27
In summary, the macrocyclic core of (-)-pladienolide B
(4) has been synthesized in 8.1% overall yield starting from
10 and 11 using a total number of 19 steps (longest linear )
15 steps). The achieved synthesis, with full control of all
four stereocenters of the macrocyclic core structure, illustrates
the flexibility of our approach. Through cross metathesis
reactions between olefin 6 and homoallylic alcohols, as a
readily available source of chemical diversity, our method
sets the stage for rapid synthesis of new pladienolide
analogues.30 Our ongoing efforts are focused on using this
strategy to synthesize new side-chain analogues and to study
the structural basis for pladienolide B’s anticancer activity.
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Scheme 4. Macrolactonization and Completion of 4
Figure 2. Structure of 4 in the crystal.28 The ellipsoids are drawn
at the 50% probability level, and the hydrogen atoms are drawn
with an arbitrary radius. For the enantiomer shown, the Flack x
parameter refined to 0.03(4).29
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An atom-economical and solvent-free catalytic procedure for
the mono-3-alkylation of oxindole with alcohols is described.
The reaction is mediated by the in situ generated catalyst
from RuCl3 · xH2O and PPh3 in the presence of sodium
hydroxide. The reactions proceed in good to excellent yields
with a wide range of aromatic, heteroaromatic, and aliphatic
alcohols.
The oxindole ring system is found in many natural products1
and biologically active molecules.2 Usually, the 3-position is
substituted with one or two substituents which can be introduced
from the parent molecule by alkylation with alkyl halides2/allylic
esters3 or by arylation with aryl halides.4 Recently, alcohols
have been used for alkylation of activated methylene compounds
such as malonates,5 barbiturates,6 ketones,7 and certain nitriles8
where water is produced as the only byproduct. In all cases,
the pKa value of the methylene group is less than ∼20 and the
alkylation is achieved with a transition-metal catalyst and a base.
The mechanism involves dehydrogenation of the alcohol to the
carbonyl compound followed by addition of the activated
methylene compound, elimination of water, and hydrogenation
of the resulting C-C double bond.9 Since the pKa of the
methylene group in oxindole is 18.2,10 we speculated that this
environmentally friendly alkylation reaction could also be used
for introducing substituents in the 3-position of this motif.11
Herein, we describe an expedient ruthenium-catalyzed procedure
for alkylation of oxindoles with alcohols.
The studies began with investigating the direct catalytic
alkylation of oxindole (1) with pentan-1-ol (2) (Table 1). We
(1) (a) Reisman, S. E.; Ready, J. M.; Weiss, M. M.; Hasuoka, A.; Hirata,
M.; Tamaki, K.; Ovaska, T. V.; Smith, C. J.; Wood, J. L. J. Am. Chem. Soc.
2008, 130, 2087–2100. (b) Yamada, Y.; Kitajima, M.; Kogure, N.; Takayama,
H. Tetrahedron 2008, 64, 7690–7694. (c) Galliford, C. V.; Scheidt, K. A. Angew.
Chem., Int. Ed. 2007, 46, 8748–8758. (d) Kagata, T.; Saito, S.; Shigemori, H.;
Ohsaki, A.; Ishiyama, H.; Kubota, T.; Kobayashi, J. J. Nat. Prod. 2006, 69,
1517–1521.
(2) (a) Volk, B.; Barko´czy, J.; Hegedus, E.; Udvari, S.; Gacsa´lyi, I.; Mezei,
T.; Pallagi, K.; Kompagne, H.; Le´vay, G.; Egyed, A.; Ha´rsing, L. G., Jr.;
Spedding, M.; Simig, G. J. Med. Chem. 2008, 51, 2522–2532. (b) Fensome, A.;
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Bioorg. Med. Chem. Lett. 2007, 17, 6270–6273. (d) Jiang, T.; Kuhen, K. L.;
Wolff, K.; Yin, H.; Bieza, K.; Caldwell, J.; Bursulaya, B.; Wu, T. Y.-H.; He, Y.
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7415.
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Chem. Commun. 2006, 5000–5002.
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Soc. 2004, 126, 5662–5663.
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TABLE 1. Catalyst Screening for the Alkylation of Oxindole (1)
with Pentan-1-ol (2)a
entry catalyst
catalyst loading
(mol %) ligand 3b (%)
1 [Cp*IrCl2]2 1.0 >95
2 [IrCl(cod)]2 1.0 PPh3 32c
3 [RuCl3 ·xH2O] 2.0 PPh3 >95c
4 [RuCl3 ·xH2O] 2.0 0
5 [RuCl2(PPh3)3] 2.0 >95
6 [Ru(p-cymene)Cl2]2 1.0 47
7 [Ru(p-cymene)Cl2]2 1.0 Xantphos >95d
8 [Ru(PPh3)3(CO)H2] 2.0 53
9 [Ru(PPh3)3(CO)H2] 2.0 Xantphos 81d
10 Shvo’s14 1.0 >95
11 [Ru(acac)3] 1.0 0
a 1 (2.0 mmol) was reacted with 2 (2.2 mmol) under the influence of
catalyst (1.0-2.0 mol %) and NaOH (10 mol %) at 110 °C for 20 h.
b Conversion was estimated by 1H NMR spectroscopy based on 1.
c PPh3 (4.0 mol %). d Xantphos (2.0 mol %).
10.1021/jo900341w CCC: $40.75  2009 American Chemical Society3990 J. Org. Chem. 2009, 74, 3990–3992
Published on Web 04/16/2009
decided to employ the commercially available trivalent iridium
complex [Cp*IrCl2]212 for the first experiments since this catalyst
has previously shown high reactivity in the alkylation of
barbiturates and arylacetonitriles with primary alcohols.6,8a After
surveying a small range of bases and reaction temperatures, it
was found that the alkylation of 1 with 2 proceeded cleanly to
provide the 3-alkylation product in almost quantitative yield
when the reaction was performed under neat conditions at 110
°C. Surprisingly, the catalyst system based on [IrCl(cod)]2 and
PPh3 only provided the desired product in low yield (Table 1,
entries 1 and 2). With these encouraging results in hand, we
decided to examine the performance of a range of different
catalysts in the alkylation reaction in order to find a cheaper
ruthenium-based catalyst system. The in situ generated catalyst
based on [RuCl3 · xH2O] and PPh3 as well as the preformed
[RuCl2(PPh3)3] complex afforded the desired product in high
yield (entries 3 and 5). The addition of PPh3 proved to be
essential since the absence of PPh3 resulted in complete recovery
of the starting materials. A selection of other ruthenium-based
catalysts were tested in the reaction. [Ru(p-cymene)Cl2]2 and
[Ru(PPh3)3(CO)H2] in combination with Xantphos13 as well as
Shvo’s catalyst14 provided the product in high yields while
[Ru(acac)3] and [Ru(p-cymene)Cl2]2 with no additional ligand
added gave either no reaction or low conversion (entries 6-11).
We did not in any case observe dialkylation of the C-3-position,
nor did we observe any N- or O-alkylation. Based on this initial
screening, we decided to use [RuCl3 · xH2O] in combination with
PPh3 for the further studies.
A number of experiments were carried out to investigate the
influence of the base and the solvent (Table 2). Sodium
hydroxide and potassium hydroxide seemed to perform equally
well leading to complete conversion of the starting material
(entries 1 and 2). Lower yields were observed when sodium or
potassium carbonate as well as triethylamine were employed,
while cesium carbonate afforded full conversion of 1 (entries
3-6). Not surprisingly no reaction was observed in the absence
of a base, and the starting materials were recovered quantita-
tively (entry 7). The reaction performed very well in toluene or
dioxane while water gave a slightly lower yield (entries 8-10).
However, for general use we decided to use sodium hydroxide
as the additive under neat reaction conditions.
(12) Fujita, K.-i.; Yamaguchi, R. Synlett 2005, 560–571.
(13) Slatford, P. A.; Whittlesey, M. K.; Williams, J. M. J. Tetrahedron Lett.
2006, 47, 6787–6789.
(14) Shvo, Y.; Czarkie, D.; Rahamim, Y.; Chodosh, D. F. J. Am. Chem.
Soc. 1986, 108, 7400–7402.
TABLE 3. Catalytic Alkylation of Oxindole (1) with Various
Alcoholsa
a 1 (2.0 mmol) was reacted with 2 (2.2 mmol) under the influence of
RuCl3 · xH2O (2.0 mol %), PPh3 (4.0 mol %), and base (10 mol %) at
110 °C for 20 h. b Isolated yield. c Toluene (1.0 mL) used as cosolvent.
d Stirred for 48 h with 5 equiv (10 mmol) of the alcohol.
TABLE 2. Influence of Base and Solvent on the Catalytic
Alkylation of Oxindole (1) with Pentan-1-ol (2)a
entry base solvent 3b (%)
1 NaOH >95
2 KOH >95
3 Na2CO3 58
4 K2CO3 80
5 Cs2CO3 >95
6 Et3N 39
7 0
8 NaOH toluene >95c
9 NaOH p-dioxane 92c
10 NaOH water 58c
a 1 (2.0 mmol) was reacted with 2 (2.2 mmol) under the influence of
RuCl3 · xH2O (2.0 mol %), PPh3 (4.0 mol %), and base (10 mol %) at
110 °C for 20 h. b Conversion was estimated by 1H NMR spectroscopy
based on 1. c Solvent (1.0 mL) added.
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We then turned our attention to other alcohols in order to
investigate the scope of the 3-alkylation procedure (Table 3).
The reaction proceeded in high yield when benzylic alcohols
with either electron-donating or electron-withdrawing groups
present in the 2-, 3-, or 4-position were employed (entries 2-8
and 11-15). It is interesting that chloro substituents are tolerated
under the reactions conditions (entries 5 and 12) since they will
allow for further functionalization of the alkylated product
through cross-coupling chemistry. The use of 4-bromobenzyl
alcohol or 4-(hydroxymethyl)benzonitrile led to complex product
mixtures probably due to hydrodehalogenation and hydrolysis,
respectively. It should be noted that several protecting groups
such as amide, benzyl, and p-methoxybenzyl were compatible
with the reaction conditions (entries 8-10). Some steric
hindrance ortho to the benzyl alcohol is well-tolerated (entries
11-14 and 16), while the highly congested 2,4,6-trimethylben-
zyl alcohol and 2,6-dimethoxybenzyl alcohol afforded the
desired alkylated product in less than 25% yield as judged by
1H NMR. A variety of pharmacophoric functionalities such as
catechol, thiophene, furan, and unprotected indole also proved
successful in the catalytic alkylation (entries 17-20). Notably,
the attempt to alkylate 1 with 2-hydroxymethylfuran under neat
conditions mainly led to decomposition while the addition of
toluene provided a clean alkylation (entry 18).
The reaction in entry 21 required longer reaction time and
excess alcohol (5 equiv) to reach full conversion of the oxindole
which shows that secondary alcohols react significantly slower
than the corresponding primary alcohols. Attempts to use
cyclohexanol and cyclopentanol gave inseparable mixtures of
the R,-unsaturated aldol product and the desired product. Thus
for secondary alcohols the reduction of the putative intermediate
R,-unsaturated carbonyl species seems to be the rate-limiting
step. When 4-penten-1-ol was employed in the alkylation
procedure, a 2:1 mixture of 3 and the corresponding R,-
unsaturated oxindole was obtained in a modest 27% yield.
In conclusion, we have developed a convenient, cheap, and
very effective catalytic system for the selective mono 3-alky-
lation of unprotected and protected oxindoles with a range of
aromatic, heteroaromatic, and aliphatic alcohols. This catalytic
hydrogen transfer reaction constitutes a highly atom-economical
transformation that can be performed under neat conditions and
only produces water as the byproduct.
Experimental Section
General Procedure for 3-Alkylation of Oxindole.
[RuCl3 · xH2O] (8.3 mg, 0.04 mmol), PPh3 (21.0 mg, 0.08 mmol),
NaOH (8.0 mg, 0.2 mmol), oxindole (266 mg, 2.0 mmol), and the
alcohol (2.2 mmol) were placed in a 7-mL thick-walled screw-cap
vial. The vial was purged with Ar and sealed with a screw-cap.
The mixture was placed in an aluminum block preheated to 110
°C and stirred for 20 h or until 1H NMR of the crude reaction
mixture showed complete consumption of the oxindole. The reaction
mixture was allowed to cool to room temperature followed by
dilution with CH2Cl2 (10 mL). SiO2 was added, and the suspension
was concentrated under reduced pressure to afford a powder that
was purified by use of silica gel chromatography (3 × 15 cm SiO2,
9:1 f 4:1 f 3:7 n-hexane/EtOAc).
3-Pentyl-1,3-dihydroindol-2-one (3) (Table 3, entry 1). Isolated
yield 89%; colorless oil; Rf ) 0.18 (heptane/EtOAc ) 7:3); 1H
NMR (300 MHz, CDCl3) δ 8.99 (bs, 1H), 7.26-7.17 (m, 2H),
7.08-6.98 (m, 1H), 6.92 (d, J ) 7.6 Hz, 1H), 3.48 (t, J ) 5.9,
1H), 2.28-1.86 (m, 2H), 1.55-1.16 (m, 6H), 0.88 (t, J ) 6.9 Hz,
3H); 13C NMR (75 MHz, CDCl3) δ 180.8, 141.6, 129.9, 127.7,
124.1, 122.2, 109.7, 46.1, 31.8, 30.5, 25.4, 22.4, 14.0; IR (neat)
3211, 3094, 3060, 3031, 2955, 2928, 2858, 1701, 1620, 1470, 1338,
1219, 1100, 749 cm-1; HRMS (ESI+) calcd for C15H21N2O ([M
+ H + MeCN]+) 245.1654, found 245.1649.
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